

# BIENNIAL REPORT



14/15

# BIENNIAL REPORT

## 2014–2015

INTERNATIONAL AGENCY FOR RESEARCH ON CANCER

LYON, FRANCE

2015

ISBN 978-92-832-1101-3  
ISSN 0250-8613

# TABLE OF CONTENTS

Introduction .....	1
Scientific Structure .....	3
IARC Medals of Honour .....	4
Section of Cancer Surveillance .....	7
Section of IARC Monographs .....	15
Section of Mechanisms of Carcinogenesis .....	21
Epigenetics Group .....	23
Molecular Mechanisms and Biomarkers Group .....	29
Section of Molecular Pathology .....	35
Section of Infections .....	41
Infections and Cancer Biology Group .....	43
Infections and Cancer Epidemiology Group .....	47
Section of Environment and Radiation .....	53
Section of Nutrition and Metabolism .....	61
Biomarkers Group .....	63
Dietary Exposure Assessment Group .....	67
Nutritional Epidemiology Group .....	71
Section of Genetics .....	77
Biostatistics Group .....	79
Genetic Cancer Susceptibility Group .....	81
Genetic Epidemiology Group .....	85
Section of Early Detection and Prevention .....	89
Prevention and Implementation Group .....	91
Screening Group .....	95
Office of the Director .....	103
Communications Group .....	105
Education and Training Group .....	109
Laboratory Services and Biobank Group .....	115
The Gambia Hepatitis Intervention Study .....	119
Section of Support to Research .....	121
Committees .....	125
Laboratory Steering Committee .....	125
Biobank Steering Committee .....	125
Bioinformatics Steering Committee .....	126
Ethics Committee .....	126
Occupational Health and Safety Committee .....	126
Governing and Scientific Councils .....	127
Staff Publications .....	135



## INTRODUCTION



Dr Christopher Wild. © Jason Harris.

I AM PLEASED TO PRESENT THIS BIENNIAL REPORT, WHICH PROVIDES A SUMMARY OF THE ACTIVITIES OF THE INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (IARC) OVER THE PERIOD 2014–2015. THIS HAS BEEN A HISTORIC PERIOD, MARKING 50 YEARS SINCE THE CREATION OF THE ORGANIZATION IN 1965.

Several events marked the 50th anniversary, starting with a celebration at the City Hall in Lyon on 15 May 2015 in the presence of Her Royal Highness Princess Lalla Salma of Morocco, Her Royal Highness Princess Dina Mired of Jordan, and Mr Gérard Collomb, Mayor of Lyon, Senator, and President of the Lyon Métropole, together with other dignitaries. Agency personnel were joined by former IARC staff members as well as colleagues and collaborators from the city and region, and from across France and worldwide. The celebration was the occasion to launch a new publication, *International Agency for Research on Cancer: The First 50 Years, 1965–2015*, which charts the creation of IARC and the Agency's activities over the past five decades.

The 50th anniversary also marked a turning point in relation to several other key aspects of the Agency's future. The Governing Council adopted the IARC Medium-Term Strategy for 2016–2020, which is built on three major themes: describing the occurrence of cancer, understanding the causes, and evaluating preventive interventions and their implementation. Training new generations of cancer researchers remains as a core responsibility. Catalysing international collaboration is an underlying principle that is as relevant today as ever before.

In addition, the opportunities for interdisciplinary research, notably integrating laboratory science into epidemiological research, continue to grow. The 50th anniversary also coincided with a major commitment from the local and national governments of our host country, France, to provide a new, purpose-built centre for the Agency, confirming its presence in Lyon for the coming decades. Morocco became the first country from the African continent to join IARC as a Participating State, a further important step in expanding the geographical representation on the Governing Council as the demands on the Agency continue to grow along with the increasing cancer burden globally.

Fifty years on from 1965, IARC is an internationally recognized centre of excellence, respected and appreciated for its mission, its research, its independence, its leadership, and its cooperation. While some core commitments have remained, the Agency has constantly adapted to the changing knowledge about cancer and the evolving international cancer research landscape. Its unique role as the cancer agency of the World Health Organization (WHO) provides the foundation both to conduct novel research and to produce the authoritative evidence base for cancer control, which is provided by programmes such as the IARC Monographs, the IARC Handbooks of Cancer Prevention, the

WHO Classification of Tumours, and the global cancer statistics contained in *Cancer Incidence in Five Continents* and GLOBOCAN. The Agency's overall research portfolio has increasing relevance to policy, with implementation research becoming a theme across a number of the research Sections.

The current Report presents a spectrum of research contributing in different ways to cancer control. It is an ambitious programme in line with the ambitions expressed in the new IARC Medium-Term Strategy. However, through the list of collaborators recorded herein, the Report reveals the secret of how IARC is able to achieve so much with so little: by joining with the international cancer research community to achieve common goals.

Generosity in collaboration, working in partnership with others as equals, is surely one major reason why there remains a strong desire of scientists across the world to work with IARC. Coupled with excellent science, this is a powerful model for success – through cooperation rather than competition, through emphasis on the group rather than the individual. That much has not changed over the past 50 years and is unlikely to over the next 50.

The Agency's year of celebrations will conclude with a major scientific conference in Lyon on 7–10 June 2016, structured around the main areas of IARC's research strategy: Global Cancer: Occurrence, Causes, and Avenues to Prevention. This conference will serve to launch the next phase of IARC's work.

In addition, it will feature the IARC "50 for 50" initiative, whereby the Agency will invite 50 future leaders in cancer research from low- and middle-income countries to attend the conference and participate in an associated programme of leadership training. We hope this will be an additional legacy of the vision shown by the leaders who, 50 years ago, had the foresight to create an international cancer agency to "fight for life".

I commend the work of all IARC personnel to you and trust that the contents of this Biennial Report provide a clear illustration of the value of the Agency's research as it seeks to fulfil its mission to reduce the global burden of cancer.







## IARC MEDALS OF HONOUR

THE IARC MEDALS OF HONOUR ARE AWARDED TO ACKNOWLEDGE AND REWARD THE WORK OF SCIENTISTS WHOSE RESEARCH HAS MADE AN OUTSTANDING CONTRIBUTION TO ADVANCING OUR UNDERSTANDING OF THE BIOLOGY OR OF THE EPIDEMIOLOGY OF CANCER.



**Her Royal Highness Princess Dina Mired of Jordan**



**Her Royal Highness Princess Lalla Salma of Morocco**

On the occasion of the celebrations of the 50th anniversary of the establishment of IARC, on 15 May 2015, the IARC Medals of Honour were awarded to Her Royal Highness Princess Dina Mired of Jordan and to Her Royal Highness Princess Lalla Salma of Morocco. The awards were made in recognition of their outstanding leadership and advocacy for cancer control worldwide. Princess Dina Mired presented a speech on “Caring for cancer patients in developing countries”, and Princess Lalla Salma presented a speech on “La lutte contre le cancer en Afrique du Nord”.

The Agency also invites outstanding speakers to present the IARC Cancer and Society Lecture to address the ways in which cancer research has a broad relevance for society, in a style that is accessible to all IARC personnel, both scientists and non-scientists. Professor Sir Michael G. Marmot (University College London, United Kingdom) presented the second IARC Cancer and Society Lecture, on “Fair society, healthy lives”, on 4 February 2014 (World Cancer Day). Professor W. Philip T. James (London School of Hygiene & Tropical Medicine, United Kingdom) presented the third IARC Cancer and Society Lecture, on “Cancer prevention: the challenge of dietary change and obesity”, on 5 February 2015, again timed to mark World Cancer Day.

## IARC MEDALS OF HONOUR

### ROGER SOHIER LECTURE

- 1993 Gérard Orth (Institut Pasteur, Paris) – Papilloma virus and human cancer
- 1994 Guy Blaudin de Thé (Institut Pasteur, Paris) – Epidémiologie moléculaire des retrovirus oncogènes
- 1995 Richard Peto (Oxford University, United Kingdom) – Avoidance of premature death
- 1996 Dirk Bootsma (Erasmus University, Rotterdam, The Netherlands) – DNA repair: maintaining nature's perfection
- 1997 Luca Cavalli-Sforza (Stanford University, USA) – Gènes, peuples, langues, cultures
- 1998 Charles Weissmann (University of Zurich, Switzerland) – Biology and transmission of prion diseases
- 1999 Jan Pontén (Uppsala University, Sweden) – Sunlight and skin cancer: new insights
- 2000 Richard Klausner (National Cancer Institute, Bethesda, USA) – The war on cancer: where we are and where research is taking us
- 2001 Oliver Brüstle (Institut für Neuropathologie, University of Bonn, Germany) – Embryonic stem cells: basic concepts and therapeutic applications
- 2002 Jeffrey Koplan (Centers for Disease Control, Atlanta, USA) – Bioterrorism and public health preparedness
- 2003 Paul Kleihues (Director, IARC) – Poverty, affluence and the global burden of cancer
- 2004 Umberto Veronesi (European Institute of Oncology, Milan, Italy) – Breast cancer management and care: current results and future perspectives
- 2005 David Lane (University of Dundee, United Kingdom) – p53 and human cancer: the next 25 years
- 2006 Georg Klein (Karolinska Institutet, Sweden) – Viral contributions to tumorigenesis
- 2007 Mariano Barbacid (Centro Nacional de Investigaciones Oncológicas, Spain) – Ras genes, Ras oncogenes and cancer
- 2008 Jan Hoeijmakers (Rotterdam, The Netherlands) – Genome maintenance and the link with cancer and ageing
- 2009 Harald zur Hausen (German Cancer Research Center, Heidelberg) – The search for infectious agents in human cancers
- 2010 Gerald N. Wogan (Massachusetts Institute of Technology, Cambridge, USA) – Aflatoxins and human liver cancer
- 2011 Robert A. Smith (American Cancer Society, USA) – The challenge and potential of early detection to reduce the global burden of cancer
- 2012 John D. Potter (University of Washington, Seattle, USA and Massey University, Wellington, New Zealand) – Nutrition, environment, development, and cancer: casting a wider net
- 2013 Harold Varmus (National Cancer Institute, Maryland, USA) – Promoting the discovery and application of knowledge about cancer

### RICHARD DOLL LECTURE

- 2004 Richard Doll (London, United Kingdom) – Fifty years follow-up of British doctors
- 2005 Brian MacMahon (Needham, Massachusetts, USA) – Epidemiology and the causes of breast cancer
- 2006 Joseph Fraumeni Jr (National Institutes of Health, USA) – Genes and the environment in cancer causation: an epidemiologic perspective
- 2007 Dimitrios Trichopoulos (Harvard School of Public Health, USA) – Breast cancer: epidemiology and etiology
- 2008 Sir Richard Peto (Oxford, United Kingdom) – Halving premature death
- 2009 Nubia Muñoz (National Cancer Institute of Colombia) – From etiology to prevention: the case of cervical cancer
- 2010 Julian Peto (London School of Hygiene & Tropical Medicine and the Institute of Cancer Research, United Kingdom) – Future cancer mortality due to past and continuing worldwide asbestos use
- 2011 You-Lin Qiao (Chinese Academy of Medical Sciences & Peking Union Medical College, China) – Implementation of cancer screening and prevention in China – evidence and reality
- 2012 Walter C. Willett (Harvard School of Public Health, USA) – Diet and cancer: a three-decade follow-up
- 2013 Pelayo Correa (Vanderbilt University Medical Center, Nashville, USA) – The gastric precancerous cascade

### IARC LECTURE

- 2005 Tadao Kakizoe (National Cancer Center, Tokyo, Japan) – Bladder cancer: a model of human cancer determined by environmental factors and genetics
- 2006 Ketayun Dinshaw (Tata Memorial Hospital, India) – Cancer treatment and control
- 2007 LaSalle D. Leffall on behalf of Ambassador Nancy G. Brinker (Komen Foundation, USA)
- 2008 Maurice Tubiana (Paris, France) – La prévention des cancers, de l'analyse scientifique des données à la prise en compte des facteurs psychosociologiques


### IARC CANCER AND SOCIETY LECTURE

- 2012 David Michaels (Department of Labor and Occupational Safety and Health Administration, USA) – Research is necessary but not sufficient: challenges in preventing occupational and environmental cancer
- 2014 Michael G. Marmot (University College London, United Kingdom) – Fair society, healthy lives
- 2015 W. Philip T. James (London School of Hygiene & Tropical Medicine, United Kingdom) – Cancer prevention: the challenge of dietary change and obesity

### IARC 50TH ANNIVERSARY CELEBRATIONS, 15 MAY 2015

Her Royal Highness Princess Dina Mired of Jordan (King Hussein Cancer Center, Jordan) – Caring for cancer patients in developing countries

Her Royal Highness Princess Lalla Salma of Morocco (Fondation Lalla Salma, Morocco) – La lutte contre le cancer en Afrique du Nord



## SECTION OF CANCER SURVEILLANCE (CSU)

### Section head

Dr Freddie Bray  
Dr David Forman  
(until July 2014)

### Deputy section head

Dr Freddie Bray  
(until July 2014)

### Professional staff

Mr Morten Ervik  
Mr Jacques Ferlay  
Mr Les Mery  
Dr Marion Piñeros  
Ms Stella de Sabata  
(until June 2014)  
Dr Isabelle Soerjomataram  
Dr Eva Steliarova-Foucher  
Dr Ariana Znaor

### Technical and administrative staff

Mr Sébastien Antoni  
Ms Anastasia Dolya  
Ms Murielle Colombet  
Ms Sarah Dunbar-Khelifi  
Mr Frédéric Lam  
Mr Mathieu Laversanne  
(until October 2015)  
Mr Eric Masuyer  
Ms Isabelle Savage  
(until December 2014)

### Secretariat

Ms Fatiha Louled  
Ms Katuska Veselinović

### Visiting scientists

Dr Esther De Vries  
(until September 2014)  
Dr Leticia Fernandez Garrote  
(until September 2014)

Dr Yelda Leal Herrera  
(until April 2014)  
Dr D. Max Parkin  
Dr Donsuk Pongnikorn  
(until November 2015)  
Dr Brian Rous  
Dr Chiranthika Vithana  
(until September 2015)

### Postdoctoral fellows

Dr Melina Arnold  
Dr Bochen Cao  
Dr Tuvshinjargal Chimed  
Dr Olivier Collignon  
(until April 2014)  
Ms Amy Colquhoun  
(until August 2014)  
Dr Miranda Fidler  
Dr Ivana Kulhanova  
Dr Claire Marant Micallef  
Dr Elisenda Rentería  
(until June 2014)  
Dr Monica Sierra  
(until March 2015)  
Dr Kevin Shield

### Students

Ms Louise Ekobena Ekobo  
(until April 2014)  
Ms Miroslava Makohusova  
Ms Marie-Claire Meinecke  
(until May 2014)  
Mr Adalberto Miranda Filho  
(until October 2015)  
Ms Aminata Ndiaye  
(until September 2015)  
Mr Kennedy Opondo  
(until April 2014)  
Mr Tomasz Szmigiel  
(until September 2014)

THE SECTION OF CANCER SURVEILLANCE (CSU) COMPILES, ANALYSES, INTERPRETS, AND DISSEMINATES GLOBAL CANCER INDICATORS THAT DOCUMENT THE CHANGING SCALE, PROFILE, AND IMPACT OF THE DISEASE WORLDWIDE. THREE CORE AREAS OF INTERRELATED ACTIVITY AIM TO SUPPORT NATIONAL AS WELL AS GLOBAL CANCER PLANNING.

### CANCER REGISTRY SUPPORT AND DEVELOPMENT

Close cooperation with population-based cancer registries (PBCRs) worldwide is an essential aspect of the Section's work, and CSU serves as the secretariat for the International Association of Cancer Registries (IACR), working closely with the umbrella organization and individual registries in collaborative studies, including *Cancer Incidence in Five Continents* (C15). With cancer incidence set to rise to 20 million by 2025, and increasing by 70% in low- and middle-income countries (LMICs), cancer planning is critical but is currently impeded by the fact that only one third of countries (mostly high-income countries) are able to report high-quality cancer incidence data. The clear need for investment in PBCRs in LMICs led to the launch of the Global Initiative for Cancer Registry Development (GICR, <http://gicr.iarc.fr>). The goal is to inform cancer control through defined improvements in the coverage, quality, and usage of PBCRs worldwide. Operating to integrate activities at the global, regional, and national levels, partners share

**Table 1. GICR IARC Regional Hubs**

IARC Regional Hub (year established)	Area of coverage	Principal investigator	Main collaborators
Mumbai (2012)	South, East, and South-East Asia	Dr Rajesh Dikshit, Tata Memorial Hospital, India	Tata Memorial Hospital, Mumbai, India
African Cancer Registry Network (2012)	Sub-Saharan Africa	Dr Max Parkin, University of Oxford, United Kingdom	International Network for Cancer Treatment and Research
Izmir (2013)	North Africa, Central and West Asia	Dr Sultan Eser, Izmir Cancer Registry, Turkey	Cancer Control Department, Ministry of Health, Turkey Center for Global Health, National Cancer Institute, USA
Argentina (2014)	Latin America	Dr Graciela Abriata, National Cancer Institute, Argentina	National Cancer Institute, Buenos Aires, Argentina Brazil National Cancer Institute, Rio de Janeiro, Brazil Colombia National Cancer Institute, Bogotá, Colombia Uruguay Cancer Registry, Honorary Commission for the Fight Against Cancer, Montevideo, Uruguay
Caribbean (2015)	Caribbean	To be determined	Caribbean Public Health Agency, Port of Spain, Trinidad and Tobago Center for Global Health, Centers for Disease Control and Prevention, USA Center for Global Health, National Cancer Institute, USA
Pacific Islands (2015)	Oceania	To be determined	Cancer Institute New South Wales, Australia Cancer Council Victoria, Australia Cancer Council Queensland, Australia South Australian Health and Medical Research Institute, Australia

knowledge and adopt proven methods effectively across settings. Six IARC Regional Hubs have been established to deliver localized programmes of training, consultancy support, research, and advocacy (Table 1). Collectively, the IARC Regional Hubs target more than 6 billion people (85% of the world's population) in more than 150 underserved countries in Africa, the Americas, Asia, and Oceania. IARC Technical Publication No. 43, which is available in English, French, and Spanish, serves as a reference for health planners seeking to plan and develop PBCRs in LMICs.

During 2014–2015, several key activities of the GICR were achieved. Globally, the commitment of international partners to work together was secured, resulting in a unified solution to address disparities in cancer registration. The resulting GICR strategic plan was endorsed by the World Health Organization (WHO) as an official tool to support Member States in addressing cancer-related targets and indicators within the Global Monitoring Framework for the Prevention and Control of Noncommunicable Diseases (NCDs). Building on this, a group of initial focus countries have been identified to develop a mutual programme of activities

among GICR global partners to increase the effectiveness of capacity-building in cancer registration. Highlights of the regional and national activities are listed in Table 2; key GICR collaborative partners are listed below.

#### GLOBAL CANCER INDICATORS: DEVELOPMENT AND DISSEMINATION

CSU's two-tiered approach to global estimation involves validating estimates against recorded data of high quality where available and, where not, supporting in-country investments in data collection through the GICR, where feasible. The reporting of cancer statistics is generated through flagship projects, including CI5 and GLOBOCAN. After the computation of national estimates in 184 countries for 2012 and the launch of the GLOBOCAN 2012 website at the end of 2013, the 2014–2015 biennium has been devoted to documenting the source disparities, methods, and results (Ferlay et al., 2015a) and extending the use of GLOBOCAN to high-profile international collaborations. These include chapters in *World Cancer Report 2014*, the second edition of *The Cancer Atlas* (Jemal et al., 2014), and the cancer volume of the third edition of

*Disease Control Priorities* (DCP3) (Bray and Soerjomataram, 2015), alongside peer-reviewed articles, including the Lancet Oncology Commission on Global Radiotherapy (Atun et al., 2015) and a JNCI Commentary on the importance of integrating primary prevention into cancer control strategies worldwide (Bray et al., 2015b).

Validation exercises include a comparative study of estimates derived from the nine methods used in GLOBOCAN versus high-quality recorded incidence data in Norway. The results broadly emphasize the high performance of trends-based estimation approaches and the need for population-based data to accurately estimate incidence. The development of national estimates that capture the uncertainty in source information is also a priority for the next iteration of GLOBOCAN, and collaborative work with the University of Washington (USA) is ongoing; a study examining the derivation of credible intervals using Bayesian models in estimating national breast cancer in Europe is under way.

GLOBOCAN estimation relies heavily on the collaboration of PBCRs worldwide

**Table 2. GICR activities by region, 2014–2015**

Activity	Total number	Region [number] <sup>a</sup>			
		Africa	Asia	Caribbean	Americas
Site visits <sup>b</sup>	36	Algeria, Angola, Egypt, The Gambia, Madagascar, Malawi, Mali, Morocco, Namibia, Réunion, Senegal, Uganda, Zimbabwe [13]	Cambodia, India, Indonesia, Islamic Republic of Iran, Kyrgyzstan, Lao People's Democratic Republic, Philippines, Turkey, West Bank and Gaza Strip [9]	Aruba, Barbados, Grenada, Trinidad and Tobago [4]	Argentina, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru [10]
Courses	28	Côte d'Ivoire (Abidjan, August 2014); Egypt (Cairo, September 2014); Ethiopia (Addis Ababa, August 2015); Guinea (Conakry, August 2014); Kenya (Eldoret, March 2015); Kenya (Nairobi, August 2015); Mozambique (Beira, July 2014); Mozambique (Maputo, July 2014); Namibia (Windhoek, June 2014); Namibia (Windhoek, February 2015); Sudan (Khartoum, November 2014); Uganda (Kampala, June 2014) [12]	Cambodia (Phnom Penh, February 2014); China (Shanghai, September 2014); India (Chennai, March 2014); India (Chennai, October 2014); India (Mumbai, July 2014); Kazakhstan (Astana, September 2014); Myanmar (Yangon, September 2014); Russian Federation (Saint Petersburg, September 2015); Thailand (Bangkok, June 2015); Turkey (Ankara, October 2014); West Bank and Gaza Strip (Gaza City, July 2015); West Bank and Gaza Strip (Ramallah, July 2015) [12]	—	Canada (Ottawa, June 2014); Chile (Santiago, July 2014); El Salvador (San Salvador, October 2014); Panama (Panama City, November 2015) [4]
Signed agreements <sup>c</sup>	17	Congo, Côte d'Ivoire, Kenya, Mauritius, Mozambique, Senegal, South Africa, Uganda, Zimbabwe [9]	India, Islamic Republic of Iran, Turkey [3]	—	Argentina, Colombia, Guatemala, Mexico, Uruguay [5]

<sup>a</sup> Classified into continents according to IARC Regional Hub involvement; activities in Oceania will commence in 2016.

<sup>b</sup> Only initial visits to countries are listed.

<sup>c</sup> Includes agreements signed by the African Cancer Registry Network to provide the IARC Regional Hub for Sub-Saharan Africa.

and the high-quality registry data compiled in successive CI5 volumes. Volume X, released in late 2014, comprises cancer incidence data from 290 registries in 68 countries for 2003–2007. The increase in the number of high-quality PBCRs included in Volume X is offset by challenges in ensuring that data from more registries in LMICs are accepted in subsequent volumes. A recent paper documented the status of PBCRs worldwide (linking the registry capacity-building approaches of the GICR) and the techniques used in CI5 to evaluate quality (Bray et al., 2015a). The paper also highlighted the variability in cancer risk: a ratio of 3 to 45 was observed in the lowest versus highest rates for specific cancers worldwide (Figure 1). The call for data for the next volume (Volume XI) has been launched.

Childhood cancer surveillance is a major component of CSU's activities, and preparation of the third volume of *International Incidence of Childhood Cancer* (IICC3, <http://iicc.iarc.fr/>) is

nearing completion. Data on cancer incidence in children and adolescents (ages 0–19 years) are being compiled in collaboration with more than 350 cancer registries. A European study undertaken within the EURO COURSE project has estimated population coverage of children in the European Union by PBCRs at 80%; the growing formation of paediatric cancer registries was noted, as well as a merging of existing registries (Steliarova-Foucher et al., 2015a).


In supporting the development of cancer survival statistics in LMICs for benchmarking purposes, CSU is developing a third volume of the benchmark series *Cancer Survival in Africa, Asia, the Caribbean and Central America* (SURVCAN-3). Linked to local capacity-building, Module 1 of the IARC Summer School in 2015 focused on the training of registry staff in LMICs wishing to develop survival statistics at their registry (Figure 2). Finally, the Global Cancer Observatory (GCO) is under development by CSU following the

recruitment of a web programmer in 2015. The GCO will serve as an interactive, user-friendly, and data-driven online interface to examine and interpret global and regional cancer statistics based on the key databases held at CSU.

#### DESCRIPTIVE EPIDEMIOLOGY OF CANCER: CORE ACTIVITIES AND INNOVATION

A diverse set of research collaborations aim to interpret the changing magnitude and the transitional nature of cancer profiles. As well as the continued provision of global and regional cancer statistics with collaborators worldwide based on the GLOBOCAN estimates (Parkin et al., 2014; Torre et al., 2015), data from successive CI5 volumes continue to provide critical insights into changing trends and profiles of specific cancers, their determinants, and priorities for cancer control. Ad hoc collaborative studies have been published that describe the regional and global trends in, for example, female breast cancer (DeSantis et al., 2015),

**Figure 1. Absolute and relative global variations in age-standardized incidence rates (world) of registry populations included in CI5 Volume X. The variability in the age-standardized rates for 27 cancer sites is according to the 10th and 90th percentiles for males, other than for female breast and three female-specific cancers (cervix uteri, corpus uteri, and ovary). Reprinted with permission from Bray et al. (2015a). Copyright © 2015, John Wiley and Sons.**



testicular cancer (Le Cornet et al., 2014; Trabert et al., 2015; Znaor et al., 2014, 2015a), bladder cancer (Chavan et al., 2014), renal cell carcinoma (Znaor et al., 2015b, 2015c), and bone cancer (Valery et al., 2015).


More specific studies in collaboration with the Infections and Cancer Epidemiology Group (ICE) have looked at international

trends in thyroid cancer incidence and mortality in light of enhanced surveillance of the thyroid gland (Vaccarella et al., 2015), as well as the impact of screening on the burden of cervical cancer in the Nordic countries (Vaccarella et al., 2014). In the latter study, models predicted that up to 49% of the expected cervical cancer cases may have been prevented by the introduction of screening in the


late 1960s and early 1970s (Figure 3). In a study describing the major decrease in incidence rates of upper urinary tract cancer in Australia in 1983–2007, Antoni et al. hypothesized that the ban on phenacetin, an analgesic that was marketed widely for pain relief until the late 1970s, explained the observed decline (Antoni et al., 2014).

Approaches to global cancer surveillance research include the assessment of cancer in Indigenous peoples (Moore et al., 2014a, 2014b), who have disproportionately worse health and lower life expectancy than their non-Indigenous counterparts in high-income countries. As part of an IARC-Australia Fellowship, a recent study compared, for the first time, the cancer burden among Indigenous populations in Australia, New Zealand, Canada, and the USA, based on incidence data derived from PBCRs (Moore et al., 2015). Of note were the high rates of lung cancer among Indigenous men in all Australian regions, and in Alberta, Canada, and in the USA among Alaska Natives. Among women, lung cancer rates were considerably higher in Māori women in New Zealand and in

**Figure 2. IARC Summer School 2015, Module 1: Cancer Survival Methods for Cancer Registries. © IARC/Roland Dray.**



**Figure 3. Effect of age, period, and cohort on observed and projected rates of incident cervical cancer in the Nordic countries. Reprinted with permission from Vaccarella et al. (2014).**



Alaska Natives, whereas cervical cancer incidence was higher among Indigenous women in most areas.

Studies also aim to increasingly capture the broader context of NCDs, as well as the continuum of cancer progression from a healthy state to end of life. Recent methodological research areas include the systematic development of population attributable fractions (PAFs) for various major risk determinants of cancer. An estimated half a million new cancer cases (or 3.6% of all new cancer cases) could be attributed to excess body weight (Figure 4) (Arnold et al., 2015a); further work will assess the time-specific risk of cancer after cumulative exposure to excess body weight over the life course. Worldwide PAF estimates for tobacco, alcohol, infection, and


other major risk factors are under development. CSU is also embarking on major PAF projects in France (partnering with Institut national du Cancer [INCa]) and the Eastern Mediterranean region (with the WHO Regional Office for the Eastern Mediterranean) that will estimate the proportion of cancers attributable to key lifestyle and environmental determinants. These projects rely heavily on collaboration and multidisciplinary groups of experts.

Several studies link the changing demographic, epidemiological, and cancer transitions to the evolving NCD agenda. For example, an average loss of life expectancy of 2.4 years in men and 1 year in women, associated with tobacco smoking, has recently been reported. With rates of cardiovascular

disease declining due to the success of preventing and treating the disease, cancer contributed to a larger portion of the total mortality in 1980–2010. Hanly et al. have examined the societal loss related to premature mortality from cancer among the workforce of Europe (Hanly et al., 2015). The average cost of productivity lost due to premature mortality was estimated at 0.58% of the 2008 European gross domestic product, highest in central and eastern Europe (0.81%) and lowest in northern Europe (0.51%). The analysis highlighted the potential advantages of implementing prevention strategies for stomach, pancreatic, and cervical cancer and melanoma of the skin, and of improving access to treatment for Hodgkin lymphoma and testicular cancer.



Figure 4. Population attributable fraction (PAF) of new cancer cases in 2012 due to excess body mass index in (A) men and (B) women, by country. Reprinted from Arnold et al. (2015a). Copyright 2015, with permission from Elsevier.



**CSU is grateful to the following for their collaboration:**

Graciela Abriata, Florencia Moreno, Argentina; Jeff Dunn, Suzanne Moore, David Roder, Australia; Nelly Enwerem-Bronson, Luca Li-Bassi, Austria; Marc Arbyn, Belgium; Walter Zoss, Brazil; Mary Gospodarowicz, Ophira Ginsburg, Prabhat Jha, Brian O'Sullivan, Juergen Rehm, Canada; Wanqing Chen, China; Esther de Vries, Colombia; Ibithal Fadhil, Egypt; Jacqueline Clavel, Brigitte Lacour, Gwenn Menvielle, France; Peter Kaatsch, Germany; Rajesh Dikshit, Rajamaram Swaminathan, India; Kazem Zendehele, Islamic Republic of Iran; Roberto Zanetti, Italy; Sabine Siesling, The Netherlands; Bjorn Moller, Elisabete Weiderpass, Norway; Hee Young Shin, Republic of Korea; Paul Dickman, Lars Hjorth, Sweden; Robert Jakob, Colin Mathers, Gretchen Stevens, Julie Torode, Andreas Ullrich, Switzerland; Malcolm Moore, Suleeporn Sangrajrang, Thailand; Sultan Eser, Murat Gultekin, Turkey; Anton Ryzhov, Ukraine; David Conway, Majid Ezzati, Paul Lambert, Max Parkin, Kathy Pritchard-Jones, Andrew Renehan, Brian Rous, Mark Rutherford, Linda Sharp, Charles Stillier, Paolo Vineis, United Kingdom; Enrique Barrios, Uruguay; Hoda Anton-Culver, Brenda Edwards, Susan Devesa, Lindsay Frazier, Ahmedin Jemal, Katherine McGlynn, Angela Mariotto, Mona Saraiya, Silvana Luciani, Lisa Stevens, Jon Wakefield, Kevin Ward, USA.

**Financial support from the following bodies is gratefully acknowledged:**

Institut national du Cancer (France) – convention 2013-222, 2015-002  
Medical Research Council, United Kingdom  
Seventh Framework Programme (FP7/2007–2013) of the European Commission,  
grant agreement LSSH–CT–2008–21 9453 (EUROCOURSE)  
Seventh Framework Programme (FP7/2007–2013) of the European Commission,  
grant agreement HEALTH.2010.2.4.1-7257505 (PanCareSurFup)  
Seventh Framework Programme (FP7/2007–2013) of the European Commission,  
grant agreement HEALTH.2010.2.4.1-3 261474 (ENCCA)  
Marie Curie Action Intra-European Fellowship, contract number 302050  
World Cancer Research Fund, grant agreement SG 2012/619  
GAVI Alliance  
National Cancer Institute, National Institutes of Health, USA  
American Cancer Society, USA  
Centers for Disease Control and Prevention, USA  
Union for International Cancer Control (UICC)  
Dutch Cancer Society  
WHO Regional Office for the Eastern Mediterranean, for support to the GICR



## SECTION OF IARC MONOGRAPHS (IMO)

### Section head

Dr Kurt Straif

### Deputy section head

Dr Dana Loomis

### Scientists

Dr Lamia Benbrahim-Tallaa

Dr Véronique Bouvard

Dr Fatiha El Ghissassi

Dr Yann Grosse

Dr Neela Guha

Dr Kathryn Guyton

Dr Béatrice Lauby-Secretan

Dr Chiara Scoccianti

### Editor

Dr Heidi Mattock

### Secretary

Ms Helene Lorenzen-Augros

### Technical assistants

Ms Sandrine Egraz

Ms Elisabeth Elbers

Ms Brigitte Kajo

(until September 2015)

Ms Annick Leroux

(until November 2014)

Ms Anne-Magali Maillol

Ms Solène Quennehen

Ms Dorothy Russell

(until July 2014)

### Visiting scientists

Dr Bruce Armstrong  
(until November 2014)

Dr James Gomes  
(until October 2015)

Dr Sang Gil Lee  
(until February 2015)

Dr Christopher Portier  
(until October 2014)

Mr Andrew Shapiro  
(until September 2015)

Dr Kyle Steenland  
(until August 2014)

### Students

Ms Wiebke Mohr  
(until May 2014)

Ms Fatoumata Sylla  
(until June 2014)

THE FIRST STEP IN CANCER PREVENTION IS TO IDENTIFY THE CAUSES OF HUMAN CANCER. THE IARC MONOGRAPHS PROGRAMME ([HTTP://MONOGRAPHS.IARC.FR/](http://monographs.iarc.fr/)) IS AN INTERNATIONAL, INTERDISCIPLINARY APPROACH TO CARCINOGENIC HAZARD IDENTIFICATION. ITS PRINCIPAL PRODUCT IS THE SERIAL PUBLICATION OF THE IARC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS, WHICH BEGAN IN 1971 IN ACCORDANCE WITH ONE OF THE FUNDAMENTAL MISSIONS OF THE AGENCY: TO PREPARE AND DISTRIBUTE AUTHORITATIVE INFORMATION ON HUMAN CANCER AND ESPECIALLY ON ITS CAUSES AND PREVENTION.

Each Monograph consists of a comprehensive, critical summary and review of the published scientific literature and an evaluation of the overall evidence of carcinogenicity to humans. The IARC Monographs are a worldwide endeavour that has involved more than 1300 scientists from more than 50 countries. Reviews and evaluations of nominated agents and exposures are carried out by Working Groups of scientific experts who are invited to participate on the basis of their expertise in the topic. Since 1971, more than 950 chemicals, complex mixtures, occupational exposures, physical agents, biological agents, personal habits, and household exposures have been reviewed, some of them several times as new information has become available. More than 100 of these agents have been identified as carcinogenic to humans (Group 1), and

more than 350 as probably carcinogenic or possibly carcinogenic to humans (Groups 2A and 2B).

The IARC Monographs have evolved into the World Health Organization's encyclopaedia on the roles of environmental agents in human cancer causation. National and international health agencies use the Monographs as a source of scientific information, and as scientific support for their actions to prevent exposure to these agents. A recent example was the reference to the Monographs in developing the fourth edition of the European Code Against Cancer. Individuals, too, use the conclusions from the Monographs to inform their choices to reduce their exposure to potential carcinogens. In this way, the IARC Monographs contribute to cancer prevention and the improvement of public health.

In 1995, the IARC Handbooks of Cancer Prevention were launched to complement the IARC Monographs by providing evaluations of approaches to cancer prevention. The same rigorous procedures of critical review and evaluation as for the IARC Monographs are used. Evaluations have included chemopreventive agents, preventive actions, effectiveness of screening, and effectiveness of tobacco control. The IARC Handbooks of Cancer Prevention programme has now been relaunched, with a focus on primary and secondary prevention.

ADVISORY GROUP TO RECOMMEND  
PRIORITIES FOR THE IARC  
MONOGRAPHS DURING 2015–2019  
(7–9 APRIL 2014)

An Advisory Group of 21 scientists from 13 countries met at IARC in April 2014 to recommend evaluation topics for 2015–2019 and to discuss strategic matters for the IARC Monographs Programme. The Advisory Group considered responses to a call for nominations on the IARC website and recommended a broad range of agents and exposures with high or medium priority (Table 1); IARC will use this advice in making decisions on agents for future evaluations.

**Table 1. Agents recommended for evaluation by the IARC Advisory Group with high priority**

---

Acrylamide, Furan, 5-Hydroxymethyl-2-furfural
2-Amino-4-chlorophenol, 2-Chloronitrobenzene, 4-Chloronitrobenzene, 1,4-Dichloro-2-nitrobenzene, 2,4-Dichloro-1-nitrobenzene
Aspartame and sucralose
Bisphenol A
1-Bromopropane
Carbon nanotubes, multi-walled
Beta-carotene
3-Chloro-2-methylpropene
Coffee
Dietary iron and iron used as supplements or for medical purposes
Dimethylformamide
<i>N,N</i> -Dimethyl- <i>p</i> -toluidine
Disinfected water used for drinking, showering, bathing, or swimming
Electronic cigarettes and nicotine
Ethyl acrylate
Ethyl tertiary butyl ether (ETBE), Methyl tertiary butyl ether (MTBE), <i>tert</i> -Butyl alcohol (TBA)
Hot mate drinking
Human cytomegalovirus (HCMV)
Indium-tin oxide
Isobutyl nitrite
2-Mercaptobenzothiazole
Obesity and overweight
Opium
Pesticides (including Carbaryl, Diazinon, Lindane, Malathion, Pendimethalin, Permethrin)
Phenyl and octyl tin compounds
<i>ortho</i> -Phenylenediamine dihydrochloride
Physical inactivity and sedentary work
Red and processed meats
Shiftwork
Styrene
Tetrabromobisphenol A (TBBPA)
Tungsten
Welding and welding fumes

---

In addition, the Advisory Group endorsed the current system of expert reviews with strict management of conflict of interests; encouraged the Secretariat to explore the use of systematic review tools to further increase transparency and efficiency; supported recent recommendations of a separate Advisory Group on Quantitative Risk Characterization that the Monographs could progressively include exposure–response relationships, particularly from epidemiological studies, as a basis for estimates of global cancer burden by

IARC; recognized the need for systematic identification of mechanistic data, with transparent selection of publications and inclusion of high-throughput and high-content data streams, to focus on clear elucidation of mechanistic processes; and recommended exploration of additional opportunities to address cancer risk in low- and middle-income countries, including enhanced retrieval of relevant exposure data for Monographs and increased dissemination of pertinent evaluations (Straif et al., 2014).

VOLUME 110: PERFLUORO-OCTANOIC ACID, TETRAFLUOROETHYLENE, DICHLOROMETHANE, 1,2-DICHLOROPROPANE, AND 1,3-PROPANE SULFONE (3–10 JUNE 2014)

In June 2014, a Working Group assessed the carcinogenicity of perfluoro-octanoic acid (PFOA), tetrafluoroethylene (TFE), dichloromethane (DCM), 1,2-dichloropropane (1,2-DCP), and 1,3-propane sulfone (1,3-PS). 1,2-DCP was classified as *carcinogenic to humans* (Group 1), based on *sufficient evidence* that exposure causes cancer of the biliary tract. The most important human evidence came from studies of workers in a small offset printing plant in Osaka, Japan, with a very high risk of cholangiocarcinoma. The Working Group classified DCM as *probably carcinogenic to humans* (Group 2A), based on *limited evidence* in humans for biliary tract cancer and non-Hodgkin lymphoma and *sufficient evidence* in experimental animals. TFE was upgraded from *possibly carcinogenic to humans* (Group 2B) to *probably carcinogenic to humans* (Group 2A), based on *inadequate evidence* in humans and *sufficient evidence* in experimental animals with unusual results (neoplasms at multiple sites and with very high incidence observed in exposed rodents of both sexes, including liver haemangiosarcoma, hepatocellular carcinoma, and histiocytic sarcoma in mice, and renal cell adenoma or carcinoma [combined], hepatocellular carcinoma, mononuclear cell leukaemia, and the rare liver haemangiosarcoma in female rats). 1,3-PS was classified as *probably carcinogenic to humans* (Group 2A), based on *inadequate evidence* in humans and *sufficient evidence* in experimental animals with a mechanistic upgrade supported by strong evidence for genotoxicity. PFOA was classified as *possibly carcinogenic to humans* (Group 2B), based on *limited evidence* in humans for testicular and kidney cancer and *limited evidence* in experimental animals (Benbrahim-Tallaa et al., 2014).

VOLUME 111: FLUORO-EDENITE, SILICON CARBIDE FIBRES AND WHISKERS, AND CARBON NANOTUBES (30 SEPTEMBER–7 OCTOBER 2014)

In October 2014, a Working Group reviewed the carcinogenicity of fluoro-

edenite, silicon carbide (SiC) fibres and whiskers, and carbon nanotubes (CNTs), including single-walled and multi-walled types (SWCNTs and MWCNTs). Fluoro-edenite fibrous amphibole was classified as *carcinogenic to humans* (Group 1), based on *sufficient evidence* in humans that it causes mesothelioma and *sufficient evidence* in experimental animals. SiC fibres are by-products of the manufacture of SiC particles by the Acheson process; SiC whiskers are produced by other processes. Occupational exposures associated with the Acheson process were classified as *carcinogenic to humans* (Group 1), based on *sufficient evidence* in humans that they cause lung cancer. Fibrous SiC was classified as *possibly carcinogenic to humans* (Group 2B), based on *limited evidence* in humans that it causes lung cancer and *inadequate evidence* in experimental animals. SiC whiskers were upgraded from *possibly carcinogenic to humans* (Group 2B) to *probably carcinogenic to humans* (Group 2A), based on *inadequate evidence* in humans, *sufficient evidence* in experimental animals, and consideration of their physical properties.

There was no epidemiological study on CNTs. Regarding carcinogenicity in experimental animals, there was *sufficient evidence* for MWCNT-7, *limited evidence* for two types of MWCNTs with dimensions similar to MWCNT-7, and *inadequate evidence* for SWCNTs. MWCNT-7 was classified as *possibly carcinogenic to humans* (Group 2B), and SWCNTs and MWCNTs excluding MWCNT-7 were categorized as *not classifiable as to their carcinogenicity to humans* (Group 3) (Grosse et al., 2014).

HANDBOOK VOLUME 15: BREAST CANCER SCREENING (11–18 NOVEMBER 2014)

Breast cancer is the leading cancer in women worldwide, and the potential role of primary prevention is limited because most risk factors are directly linked with endogenous hormone levels and reproductive factors. Therefore, secondary prevention is a priority. In addition to breast cancer screening by mammography, clinical examination, and self-examination, which were already evaluated in 2002, the Working Group for this Handbook extended its review to

non-mammographic imaging techniques such as magnetic resonance imaging (MRI), digital breast tomosynthesis (or 3D mammography), breast-specific positron emission tomography, ultrasound as an adjunct to mammography for women with dense breasts, and computer-assisted diagnosis in combination with digital mammography; also, the effectiveness of screening high-risk women was evaluated.

Based on available data, there is sufficient evidence for the effectiveness of mammography screening in women aged 50–74 years. While the evidence for overdiagnosis is also sufficient, overall the Working Group concluded that there is a net benefit in screening women aged 50–69 years. Data on breast self-examination remain unconvincing. In contrast, clinical breast examination showed sufficient evidence for shifting the stage distribution of tumours detected towards a lower stage. Of all the new technologies considered, sufficient evidence was reached only for an increased detection rate, mostly of invasive tumours, with adjunct tomosynthesis compared with mammography alone. MRI as an adjunct to mammography in high-risk women with a *BRCA1* or *BRCA2* mutation provided an increased sensitivity but decreased specificity (Lauby-Secretan et al., 2015a).

VOLUME 112: TETRACHLORVINPHOS, PARATHION, MALATHION, DIAZINON, AND GLYPHOSATE (3–10 MARCH 2015)

In March 2015, a Working Group of 17 experts from 11 countries reviewed the carcinogenicity of five organophosphate pesticides. Four insecticides (tetrachlorvinphos, parathion, malathion, and diazinon) and glyphosate, the most widely used herbicide worldwide, were evaluated. The insecticides tetrachlorvinphos and parathion were classified as *possibly carcinogenic to humans* (Group 2B), based on *sufficient evidence* in experimental animals. The insecticides malathion and diazinon and the herbicide glyphosate were classified as *probably carcinogenic to humans* (Group 2A). For malathion and glyphosate, the evidence in experimental animals was *sufficient* and the evidence in humans was *limited*. For diazinon, *limited evidence* was found in both experimental animals and humans. The

*limited* evidence in humans supporting these three Group 2A classifications comprised reports of increased cancer risks from occupational cohort and case–control studies in Canada, Sweden, and the USA. The large Agricultural Health Study reported positive associations for malathion (prostate cancer) and diazinon (non-Hodgkin lymphoma subtypes, leukaemia, and lung cancer). An increased risk of non-Hodgkin lymphoma with glyphosate use was reported in multiple case–control studies but was not seen in the Agricultural Health Study. Strong mechanistic evidence, particularly for genotoxicity and oxidative stress, was found for malathion, diazinon, and glyphosate. Together with the *limited evidence* of human carcinogenicity for diazinon, this strong mechanistic evidence formed the basis for the Group 2A classification. The mechanistic evidence independently supported the Group 2A classifications of malathion and glyphosate (Guyton et al., 2015).

#### VOLUME 113: DDT, LINDANE, AND 2,4-D (2–9 JUNE 2015)

In June 2015, a Working Group of 26 experts from 13 countries evaluated the carcinogenicity of the insecticides dichlorodiphenyltrichloroethane (DDT) and lindane and the herbicide 2,4-dichlorophenoxyacetic acid (2,4-D). DDT was heavily used for insect control in agriculture and public health, but current use is largely restricted to malaria control. DDT was classified as *probably carcinogenic to humans* (Group 2A), based on *limited evidence* in humans and *sufficient evidence* in experimental animals.

Epidemiological studies found positive associations between exposure to DDT and non-Hodgkin lymphoma, testicular cancer, and liver cancer. Lindane was formerly used for insect control, but its use is now largely banned. Lindane was classified as *carcinogenic to humans* (Group 1), based on *sufficient evidence* in both humans and experimental animals. Epidemiological studies of agricultural workers exposed to lindane showed a 60% increased risk of non-Hodgkin lymphoma. 2,4-D is a high production volume chemical that has been used since the 1940s to control weeds in agriculture, forestry, and urban settings. 2,4-D was classified as *possibly carcinogenic to humans* (Group 2B), based on *inadequate evidence* in humans and *limited evidence* in experimental animals. Experimental studies provided strong evidence that 2,4-D induces oxidative stress and moderate evidence that 2,4-D causes immunosuppression. However, epidemiological studies did not find strong or consistent increases in cancer risk in relation to 2,4-D exposure (Loomis et al., 2015).

#### VOLUME 114: CONSUMPTION OF RED MEAT AND PROCESSED MEAT (6–13 OCTOBER 2015)

In October 2015, a Working Group assessed the carcinogenicity of the consumption of red meat and processed meat. Red meat refers to unprocessed mammalian muscle meat (e.g. beef, veal, pork, and lamb), including that which may be minced or frozen. Processed meat refers to meat that has been transformed through salting, curing, fermentation,

smoking, or other processes to enhance flavour or improve preservation. Meat curing and smoking can result in the formation of carcinogenic chemicals, including *N*-nitroso compounds (NOCs) and polycyclic aromatic hydrocarbons (PAHs). High-temperature cooking by pan-frying, grilling, or barbecuing produces high amounts of carcinogens, including heterocyclic aromatic amines (HAAs) and PAHs.


The Working Group assessed more than 800 epidemiological studies, including large cohorts in many countries on several continents and in populations with diverse ethnicities and diets. A meta-analysis of colorectal cancer in 10 cohort studies reported a statistically significant dose–response relationship with a 17% increased risk (95% confidence interval [CI], 1.05–1.31) per 100 g/day of red meat and an 18% increased risk (95% CI, 1.10–1.28) per 50 g/day of processed meat. The Working Group classified consumption of processed meat as *carcinogenic to humans* (Group 1), based on *sufficient evidence* for colorectal cancer. A positive association was found between consumption of processed meat and stomach cancer. Consumption of red meat was classified as *probably carcinogenic to humans* (Group 2A), based on substantial epidemiological data showing high *limited evidence* for colorectal cancer and on strong mechanistic evidence. Consumption of red meat was also positively associated with pancreatic cancer and with prostate cancer.

#### Financial support from the following bodies is gratefully acknowledged:

American Cancer Society, Atlanta, USA  
Centers for Disease Control and Prevention, Atlanta, USA  
European Commission, Brussels, Belgium  
Institut national du Cancer (INCa), Paris, France  
National Cancer Institute, National Institutes of Health, USA  
National Institute of Environmental Health Sciences, National Institutes of Health, USA  
University of Kent, United Kingdom







# SECTION OF MECHANISMS OF CARCINOGENESIS (MCA)

**Section head**  
Dr Zdenko Herceg

THE SECTION OF MECHANISMS OF CARCINOGENESIS (MCA) CONDUCTS STUDIES AIMED AT ELUCIDATING MOLECULAR MECHANISMS BY WHICH ENVIRONMENTAL EXPOSURES INDUCE GENETIC AND EPIGENETIC ALTERATIONS AND DEREGULATE MOLECULAR PATHWAYS CRITICAL FOR CANCER DEVELOPMENT AND PROGRESSION, THUS ENHANCING THE EVIDENCE BASE DIRECTLY RELEVANT TO STUDIES OF CANCER CAUSATION AND PREVENTION. EMPHASIS IS PLACED ON EVENTS THAT PRECEDE OR DRIVE TUMOUR INITIATION AND PROGRESSION. KEY MCA STRATEGIES INCLUDE INNOVATIVE RESEARCH AND THE DEVELOPMENT OF GENOMIC/EPIGENOMIC AND SCREENING METHODOLOGIES AND BIOINFORMATICS RESOURCES THAT ARE APPLICABLE TO EXPERIMENTAL MODELS AND BIOBANKS ASSOCIATED WITH POPULATION-BASED AND EPIDEMIOLOGICAL STUDIES. MCA ALSO CONTRIBUTES TO TRANSLATIONAL STUDIES, THROUGH THE DISCOVERY OF MECHANISM-BASED BIOMARKERS OF EXPOSURE, EARLY DETECTION, AND RISK STRATIFICATION. MCA STUDIES ARE INTERDISCIPLINARY IN NATURE, AND THE SYNERGISTIC COLLABORATIONS WITH OTHER IARC LABORATORY-BASED SCIENTISTS AND EPIDEMIOLOGISTS AS WELL AS EXTERNAL GROUPS ADVANCE MAJOR IARC PROGRAMMES. THE SECTION COMPRISES TWO GROUPS, THE EPIGENETICS GROUP (EGE) AND THE MOLECULAR MECHANISMS AND BIOMARKERS GROUP (MMB), WHICH WORK IN CLOSE COLLABORATION TO CREATE SYNERGIES AND BETTER EXPLOIT AND FURTHER EXPAND UNIQUE RESEARCH TOOLS AND EXPERTISE.



# EPIGENETICS GROUP (EGE)

## **Group head**

Dr Zdenko Herceg

## **Scientist**

Dr Hector Hernandez-Vargas

## **Secretariat**

Ms Asiedua Asante  
(until February 2014)  
Ms Elizabeth Page

## **Visiting scientists**

Dr Fabienne Lesueur  
(until January 2014)  
Dr Terence Dwyer  
(until June 2014)  
Dr Zsuzsa Rakosy  
(until July 2015)  
Dr Hae Dong Woo

## **Postdoctoral fellows**

Dr Srikant Ambatipudi  
Dr Davide Degli Esposti  
Dr Nora Fernandez-Jimenez  
Dr Akram Ghantous  
Dr Reetta Holmila  
(until February 2014)  
Dr Nawapol Kunkeaw  
(until November 2015)  
Dr Ho Sun Lee  
(until September 2014)  
Dr Vibha Patil  
Dr Ruethairat Sriraksa  
(until August 2014)  
Dr Fazlur Talukdar

## **Students**

Mr Pierre-Benoît Ancy  
(until December 2015)  
Ms Marine Benaissa  
(until November 2014)  
Mr Clément Guillot  
(until February 2014)  
Ms Andrea Hallaburkova  
(until July 2015)  
Ms Marija Klasic  
(until May 2015)  
Mr Quentin Mandier  
(until March 2015)  
Ms Athena Sklias  
Mr Diego Uribe  
(until November 2014)

## **Laboratory technicians**

Ms Marie-Pierre Cros  
Mr Cyrille Cuenin

## **Bioinformatics assistant**

Mr Vincent Cahais

## **Trainees**


Ms Cansu Cirzi  
(until September 2014)  
Mr Antonin Jay  
(until May 2015)

The Epigenetics Group (EGE) conducts studies aimed at providing critical insights into epigenetic mechanisms of carcinogenesis through the identification of epigenome alterations and molecular pathways deregulated by environmental exposures. Another focus of EGE is identifying epigenetic biomarkers of exposure and cancer risk and contributing to the characterization of key components of the exposome. This is achieved through mechanistic studies of functionally important epigenetic “driver” genes and molecular pathways altered by specific cancer risk agents and by the application of cutting-edge epigenomics in conjunction with unique biospecimens from population-based cohorts (Figure 1). EGE also develops epigenomic methodologies, profiling strategies, and bioinformatics tools, applicable to population-based cohorts and molecular epidemiology studies coordinated by IARC researchers and external collaborators.

EXPOSURE TO AFLATOXIN B<sub>1</sub> IN UTERO IS ASSOCIATED WITH DNA METHYLATION CHANGES IN WHITE BLOOD CELLS OF INFANTS IN THE GAMBIA

Exposure to environmental toxins during embryonic development may lead to epigenetic changes that influence disease risk in childhood and later life. EGE investigated the consequences of early-life exposure to aflatoxin at the epigenome (DNA methylation [DNAm]) level. Aflatoxin exposure in women from a rural region in The Gambia was assessed in plasma taken at 1–16 weeks of pregnancy, and global DNAm of white blood cells from their infants was measured using the Illumina Infinium HumanMethylation450 BeadChip. Aflatoxin exposure in the mothers was found to be significantly correlated with DNAm in their infants for a subset of CpG sites. Aflatoxin-associated differential methylation was observed in growth factor genes, immune-related genes, and a gene involved in aflatoxin detoxification (Figure 2) (Hernandez-Vargas et al., 2015). In addition, EGE identified that the effect of maternal nutrition on DNAm at specific genomic loci exhibits the hallmarks of “metabolic imprinting”, including a critical window of sensitivity (in the pre-implantation embryo) and a dose–response relationship between

Figure 1. Research themes, collaborators, technological platforms, and resources of the Epigenetics Group (EGE). EGE conducts studies aiming to characterize epigenetic alterations and molecular pathways deregulated by specific cancer risk factors and to identify epigenetic biomarkers of exposure, early detection, and risk stratification. It also develops epigenomic and profiling strategies and bioinformatics tools applicable to in vitro models and population-based studies. EGE capitalizes on recent conceptual and technological advances that have resulted in exciting opportunities for cancer epigenetics in understanding the causes of common cancers. EGE’s programme is carried out in close collaboration with IARC scientists and epidemiologists as well as external collaborators, many of whom are part of international networks established to share technological platforms and biological resources. © IARC.




exposure and outcome (Silver et al., 2015). These studies show that maternal exposure and diet during the early stages of pregnancy is associated with changes in epigenome patterns of infants. This reinforces the need for interventions, especially during critical periods of fetal and infant development.

TARGETED DEEP DNA METHYLATION ANALYSIS OF CIRCULATING CELL-FREE DNA IN PLASMA USING MASSIVELY PARALLEL SEMICONDUCTOR SEQUENCING

Circulating cell-free DNA (cfDNA) isolated from the plasma of individuals with cancer has been shown to harbour cancer-associated changes in DNAm, and thus represents an attractive target for biomarker discovery. However, the reliable detection of DNAm changes in body fluids has proven to be technically

challenging. EGE has developed a novel method that enables sensitive and targeted deep DNAm analysis in minute amounts of DNA present in body fluids using massively parallel semiconductor sequencing (the Ion Torrent PGM sequencer). This approach was applied to assess in plasma cfDNA the methylation of a panel of genes, including *FBLN1*, *HINT2*, *LAMC1*, *LTBP1*, *LTBP2*, *PSMA2*, *PSMA7*, *PXD*, *TGFB1*, *UBE2L3*, *VIM*, and *YWHAZ*, and to evaluate the potential of these genes as novel biomarkers for hepatocellular carcinoma in two different case–control studies, one in France and one in Thailand. Methylation in cfDNA was detected for specific genes (*FBLN1*, *PSMA7*, *PXD*, and *VIM*), with substantial differences in methylation patterns between cases and controls (Figure 3) (Vaca-Paniagua et al., 2015a, and unpublished data from

Figure 2. Differential methylation associated with early-life exposure to aflatoxin. (A) Distribution of aflatoxin exposure during pregnancy in all mothers. (B) Quantile–quantile plot of the *P*-values after the association between DNA methylation and aflatoxin exposure (as a continuous variable). (C) Manhattan plot to illustrate the distribution of *P*-values across somatic chromosomes. (D) Heat map of the 71 CpGs associated with in utero aflatoxin B<sub>1</sub> (AFB<sub>1</sub>) exposure. Annotations in the lower panel illustrate the corresponding aflatoxin exposure and sex. Reprinted with permission from Hernandez-Vargas et al. (2015), by permission of Oxford University Press.








EGE). These results provide evidence that changes in methylation levels of *VIM* and *FBLN1* in cfDNA are associated with hepatocellular carcinoma and may represent useful plasma-based biomarkers for improved diagnostic accuracy and patient surveillance (Vaca-Paniagua et al., 2015a, and unpublished data from EGE). This study represents a proof of principle demonstrating the applicability of massively parallel semiconductor sequencing as a non-invasive, cost-effective, and time-efficient approach to identify, develop, and validate epigenetic biomarkers that are potentially translatable into epidemiological and clinical settings.

#### DEVELOPMENT OF EPIGENOMIC METHODOLOGIES AND BIOINFORMATIC TOOLS APPLICABLE TO POPULATION-BASED COHORTS AND MOLECULAR EPIDEMIOLOGY

EGE has exploited improvements in the throughput and cost of methylation, histone modifications, and microRNA sequencing brought about by the recent establishment of a new-generation array platform (Illumina Infinium) for methylome and transcriptome profiling, and next-generation sequencing (NGS)-based platforms (Illumina MiSeq, Illumina Genome Analyzer, and Ion Torrent) at IARC and external collaborators

(Figure 1). These methodologies have enabled EGE to move from focused approaches to comprehensive epigenome-wide approaches and to develop several new and original topics in cancer epigenetics (Ghantous et al., 2014; Hernandez-Vargas et al., 2015; Kuasne et al., 2015; Lambert et al., 2015; Martin et al., 2014; Silver et al., 2015; Vaca-Paniagua et al., 2015a). These developments have also motivated the building of bioinformatics capacity within EGE, with a first generation of data-mining tools specifically designed for epigenomic analyses.

Figure 3. DNA methylation analysis of plasma circulating cell-free DNA (cfDNA) by targeted deep sequencing to evaluate potential epigenetic biomarkers of cancer. (A) General outline of the study and methodology development. (B–E) The DNA isolated from plasma of cases and controls was subjected to targeted deep DNA methylation analysis using massively parallel semiconductor sequencing. *VIM* methylation in circulating DNA in cases from France (B) and from Thailand (C), in tissue (D), and in The Cancer Genome Atlas (TCGA) data (E); the grey area represents the area analysed by massively parallel sequencing in this study. CLD, chronic liver diseases; CTR, controls; HCC, hepatocellular carcinoma. The error bars represent the standard error of the mean. Compiled from Vaca-Paniagua et al. (2015a).



**EGE is grateful to the following for their collaboration:**

Gabriella Tikellis, Victoria, Australia; Christoph Bock, Vienna, Austria; François Fuks, André Nogueira da Costa, Brussels, Belgium; Sheila Lima, Natalia Motta de Araujo, Felipe Pinto, Rio de Janeiro, Silvia Rogatto, São Paulo, Brazil; Anastas Gospodinov, Sofia, Bulgaria; Chantal Matar, Ottawa, Canada; Gordana Lauc, Nino Sincic, Zagreb, Croatia; Saadi Khochbin, Claire Vourc'h, Grenoble, Patrick Mehlen, Philippe Merle, Peter Mulligan, Isabelle Chemin, Jean-Yves Blay, Julien Marie, Alain Puissieux, Lyon, Ellen Obberghen-Schilling, Nice, Jacqueline Clavel, Paris, Thierry Frebourg, Rouen, France; Rudolf Kaaks, Christoph Plass, Heidelberg, Zhao-Qi Wang, Jena, Germany; Soterios Kyrtopoulos, Athens, Greece; Margit Balazs, Debrecen, Hungary; Bernardo Bonanni, Milan, Italy; Felipe Vaca Paniagua, Mexico City, Mexico; Anne-Lise Børresen-Dale, Vessela N. Kristensen, Siri Haberg, Oslo, Norway; Manel Esteller, Barcelona, Jose Ramon Bilbao, Bilbao, Spain; Nicole Probst, Basel, Switzerland; Temduang Limpaboon, Khon Kaen, Thailand; Yun Yun Gong, Belfast, Michael Routledge, Leeds, Branwen Hennig, Andrew Pretince, Elio Riboli, Paolo Vineis, London, Terry Dwyer, Oxford, United Kingdom; Robert A. Waterland, Houston, Steve Horvath, Joseph Wiemels, Los Angeles, Jia Chen, New York, Stephanie London, Research Triangle Park, Bing Ren, San Diego, Martyn Smith, San Francisco, USA.

**Financial support from the following bodies is gratefully acknowledged:**

Association pour la recherche sur le Cancer (ARC), France  
Agence nationale de recherches sur le sida et les hépatites virales (ANRS), France  
Bill & Melinda Gates Foundation, USA  
Canadian Institutes of Health Research, Canada  
European Commission, Brussels, Belgium  
Institut national du Cancer (INCa), Paris, France  
INSERM, Paris, France  
La Ligue contre le Cancer, Comité du Rhône, France  
National Cancer Institute, National Institutes of Health, USA





# MOLECULAR MECHANISMS AND BIOMARKERS GROUP (MMB)

**Group head**

Dr Jiri Zavadil

**Scientists**

Dr Michael Korenjak  
Dr Elisabetta Kuhn  
(until September 2014)  
Dr Magali Olivier

**Research assistant**

Dr Stéphanie Villar

**Secretariat**

Ms Sylvie Nouveau

**Visiting scientists**

Dr Monica Hollstein  
Dr Zuzana Vojtechova  
(until July 2015)

**Postdoctoral fellows**

Dr Xavier Castells Domingo  
(until February 2015)  
Dr Gihan Hosny  
Dr Sengkwawoh Lueong Smiths  
Dr Manuraj Pandey  
Dr Yan Song  
(until October 2014)

**Students**

Ms Maude Ardin  
Ms Sarah Barrin  
(until September 2014)  
Ms Hana Huskova  
Ms Claire Tissot  
(until November 2014)  
Ms Maria Zhivagui

The overarching objective of the Molecular Mechanisms and Biomarkers Group (MMB) is to establish an evidence base for cancer prevention, by identifying molecular mechanisms and biomarkers of carcinogenesis associated with specific environmental and lifestyle risk factors. MMB characterizes new biomarkers of exposure and tumorigenesis by mutational signature screens in experimental *in vitro* models, as well as in tumour tissues and plasma circulating cell-free DNA (cfDNA), taking advantage of existing epidemiological studies and also supporting new ones. MMB develops and validates screening methods and bioinformatics tools applicable to population-based and mechanistic studies. Collectively, MMB aims to advance the understanding of mechanisms of carcinogenesis and to facilitate evidence-based cancer prevention strategies.

#### IDENTIFICATION OF CANCER MUTATIONAL SIGNATURES AND DRIVER MUTATIONS *IN VITRO*


Oncogenic stress in primary cells can result in a bypass of their finite lifespan, followed by clonal expansion due to the accumulation of mutations that support cellular immortalization. MMB exploits this property by combining carcinogen exposure of primary cells with barrier bypass–clonal expansion (BBCE) assays. Deep DNA sequencing of immortalized cell clones from carcinogen-exposed murine embryonic fibroblasts yielded genome-wide mutational signatures matching those found in human cancers (Olivier et al., 2014). It has also resulted in the identification of recurrent selected mutations in known cancer driver genes (Figure 1). MMB currently characterizes the mutational signatures of new candidate carcinogens and studies the roles of selected driver mutations in cell immortalization. In sum, the BBCE assays provide a powerful strategy for the identification of mutation spectra introduced by environmental chemicals and of driver mutations critical for cellular transformation.

#### MUTATIONAL SIGNATURE OF CARCINOGENIC ARISTOLOCHIC ACID IN UROLOGICAL TUMOURS


Exposure to aristolochic acid (AA) leads to severe nephropathies and urothelial cancers. MMB devised a customized low-coverage exome sequencing approach to identify the signature of AA exposure in formalin-fixed, paraffin-embedded upper tract urothelial carcinoma (UTUC) and renal cell carcinoma (RCC) tumours from the residents of endemic nephropathy regions in Croatia and

Bosnia with a history of consumption of bread made from wheat contaminated by AA-containing seeds of *Aristolochia clematitis*. A mutational signature consistent with exposure to AA was observed in 5 RCC and 15 UTUC tumours (Figure 2) (Jelaković et al., 2015). In addition, MMB contributed to a study identifying AA signature-containing RCC tumours in Romanian patients (Scelo et al., 2014). The identification of multiple tumour types associated with AA exposure presents new epidemiological and public health implications for

**Figure 1. Recurrent mutations in known cancer driver genes modelled in an *in vitro* clonal selection system. Concentric tracks represent 25 immortalized clones arising from murine embryonic fibroblast cultures harbouring a transgene expressing activation-induced cytidine deaminase (AID) or exposed to various mutagenic insults: AA, aristolochic acid; AFB1, aflatoxin B.; B[a]P, benzo[a]pyrene; MNNG, N-methyl-N'-nitro-N-nitrosoguanidine; Spont, spontaneously immortalized (untreated); UVC, ultraviolet light class C. Dots represent enriched single base substitutions (mutations) located in particular chromosomal positions (chromosomes shown in the centre). The observed mutations were mostly exposure-specific (orange dots) and also non-specific (grey dots). On the perimeter, 86 recurrently mutated cancer genes are shown (red, oncogenes; blue, tumour suppressor genes; green, chromatin-associated factors; black, other cancer genes), with the observed number of mutations shown in parentheses. © IARC.**



**Figure 2. Mutational signatures in urological tumours of endemic nephropathy (EN) patients. (A) Signature (Sig) 22 corresponding to the mutagenic effects of aristolochic acid (AA) was observed in renal cell carcinoma (RCC) and upper tract urothelial carcinoma (UTUC) tumours of Croatian and Bosnian patients with EN. The bar graphs on the left show the individual signatures found in the urological tumours studied and the AA single base substitutions (SBSs) are represented by colours and labelled on top of each graph, and the frequencies of each of the possible combinations of an SBS in a particular trinucleotide context (listed under each graph) are shown; the predominant T > A in the C\_G context is the typical feature of the AA signature. The UTUC samples also harboured the signature for increased APOBEC enzyme activity. The bar graphs on the right show the relative percentage contribution of each signature to the mutation load in individual tumour samples. (B) Concurrent UTUC tumours found in distinct anatomical sites (the renal pelvis and upper ureter) of one EN patient harbour a high number of overlapping AA-specific mutations, suggesting a possible mechanism of tumour spread by tumour cell seeding along the urinary tract. © IARC.**



the incidence and prevention of AA-associated cancers worldwide. The screen developed by MMB can address the role of AA in cancers observed in high-risk populations exposed to the compound through the widespread use of alternative herbal remedies.

#### ASSESSING THE PERFORMANCE OF DEEP SEQUENCING FOR THE IDENTIFICATION OF CLINICALLY RELEVANT SOMATIC TUMOUR MUTATIONS IN CIRCULATING cfDNA IN LUNG CANCER

Circulating cfDNA extracted from the plasma of cancer patients may contain a significant fraction of tumour DNA. Somatic mutation analysis is part of the standard management of metastatic lung cancer to select gene-targeted therapies. Biopsy samples are often the only material available to access the tumour DNA, but they provide

limited amounts of DNA and may not be representative of the entire tumour mass. To investigate whether cfDNA could be used as a surrogate tissue for detecting clinically relevant mutations in lung cancer from non-smokers, MMB used deep sequencing that enables highly sensitive mutation detection (Couraud et al., 2014). The results demonstrate that this method is suitable for the detection of tumour mutations in cfDNA with good sensitivity and specificity. Thus, cfDNA may be a promising resource for diagnosis and follow-up of lung cancer.

#### BIOINFORMATICS TOOLS FOR MOLECULAR CANCER RESEARCH

The recent interest in genome-wide mutational signatures observed in human cancers uncovered a need for user-friendly tools that would enable streamlined data analyses accessible

to scientists with limited expertise in bioinformatics. To fill this gap, MMB developed MutSpec, an open-source software package embedded in the popular, user-friendly bioinformatics platform Galaxy. MutSpec includes tools performing variant annotation and advanced statistics for identifying mutational signatures present in cancer genomes and comparing the signatures obtained with those in the COSMIC database and other sources. MutSpec can analyse data from whole-exome, whole-genome, or targeted sequencing performed in human or mouse samples. The results are organized in tabular and rich graphical summaries. MutSpec facilitates systematic analyses of mutation spectra by a wider range of scientists with basic bioinformatics skills, to promote new studies on cancer etiology.


**MMB is grateful to the following for their collaboration:**

Richard Cotton, Melbourne, Heather Thorne, Victoria, Australia; Shahrokh F. Shariat, Vienna, Austria; Joëlle Nortier, Sandrine Rorive, Thierry Roumeguère, Brussels, Belgium; David Malkin, Toronto, Canada; Min Dai, Jian Huang, Guohui Li, Yamei Niu, Yan Song, Weimin Tong, Beijing, China; Damir Dittrich, Krešimir Karlović, Maja Mišić, Karla Tomić, Slavonski Brod, Fran Borovecki, Bojan Jelaković, Sandra Karanović, Neda Slade, Zagreb, Croatia; Tomas Stopka, Ruth Tachezy, Zuzana Vojtechova, Prague, Czech Republic; Gerard Zalzman, Caen, Jean-Paul Binguier, Barbara Charbotel, Isabelle Chemin, Sebastien Couraud, Mojgan Devouassoux-Shisheboran, Charles Dumontet, Béatrice Fervers, Claire Tissot, Lyon, Géraldine Cancel-Tassin, Olivier Cussenot, Yann Neuzillet, Francois Radvanyi, Evanguelos Xylinas, Paris, France; Thangarajan Rajkumar, Rajaraman Swaminathan, Chennai, Ganesh Bakshi, Rajesh Dikshit, Mumbai, India; Mardhiah Mohammad, Arifin Bin Kaderi Mohd, Kuantan Pahang, Malaysia; Rosa María Álvarez Gómez, Hector Aquiles Maldonado, Enrique Bargalló, David Cantú de León, Veronica Fragoso Ontiveros, Luis Alonso Herrera Montalvo, Alejandro Mohar Betancourt, Carlos Perez Plasencia, Felipe Vaca Paniagua, Mexico City, Mexico; Peter E.M. Taschner, Leiden, The Netherlands; Anne-Lise Borrensen-Dale, Anita Langerod, Oslo, Norway; Steve Rozen, Patrick Tan, Bin Tean Teh, Singapore; Philipp Bucher, Lausanne, Shana J. Sturla, Zurich, Switzerland; Mark LaBarge, Martha Stampfer, Berkeley, Adriana Heguy, New York, Ronald A. Herbert, Arun Pandiri, Research Triangle Park, Kathleen G. Dickman, Arthur P. Grollman, Thomas Rosenquist, Viktoria S. Sidorenko, Stony Brook, USA.

**Financial support from the following bodies is gratefully acknowledged:**

European Commission, Brussels, Belgium  
Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, France  
National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH),  
Research Triangle Park (NC), USA  
INSERM/Institut national du Cancer (INCa), Paris, France





## SECTION OF MOLECULAR PATHOLOGY (MPA)

### Section head

Dr Hiroko Ohgaki

### Secretariat

Ms Anne-Sophie Hameau

### Project assistant

Ms Asiedua Asante

### IT assistants

Mr Alberto Machado

Ms Delphine Nicolas

### Research assistants

Ms Christine Carreira

Ms Aurelie Salle

### Visiting scientists and fellows

Dr Shintaro Fukushima

(until March 2015)

Dr Xiang Jiao

(until July 2014)

Dr Cong Li

(until August 2015)

Dr Ji Eun Oh

Dr Takashi Ohta

(until April 2014)

Dr Kaishi Satomi

Dr Kei Seno

(until August 2015)

Dr Koichiro Sumi

THE SECTION OF MOLECULAR PATHOLOGY (MPA) CONDUCTS ORIGINAL RESEARCH TO ELUCIDATE THE MOLECULAR BASIS AND GENETIC PATHWAYS OF HUMAN NEOPLASMS. MPA'S SPECIFIC AIMS ARE TO PROVIDE GENETIC INFORMATION THAT WILL BE USED AS THE BASIS FOR FUTURE MOLECULAR DIAGNOSIS AND CLASSIFICATION OF BRAIN TUMOURS, TO IDENTIFY GENETIC MARKERS FOR PROGNOSIS AND NOVEL TREATMENT STRATEGIES, AND TO USE GENETIC DATA TO IDENTIFY NEW CLUES TO UNDERSTAND THE ETIOLOGY OF HUMAN TUMOURS (KIM ET AL., 2014A; LOUIS ET AL., 2014; OHGAKI ET AL., 2014). GENETIC STUDIES ARE CARRIED OUT, USING TUMOUR SAMPLES FROM PATIENTS WITH EXCELLENT CLINICAL DATA THAT HAVE BEEN COLLECTED AT A POPULATION LEVEL OR INTERNATIONALLY, TO PROVIDE UNIQUE DATA COMBINING THE PATHOLOGY, GENETICS, CLINICAL FEATURES, AND EPIDEMIOLOGY OF TUMOURS. MPA'S RESEARCH PROGRAMME IS A KEY ELEMENT OF IARC'S GOALS OF ELUCIDATING THE MECHANISMS OF CARCINOGENESIS AND UNDERSTANDING THE ETIOLOGY OF CANCER.

MPA is also responsible for the World Health Organization (WHO) Classification of Tumours series (WHO Blue Books). MPA works with internationally recognized pathologists from around the world to reach consensus regarding tumour classification. Most human tumours have been diagnosed and classified based on histological features; more recently, molecular markers are increasingly being used to



define disease entities, taking advantage of rapid progress in the understanding of the genetics of human neoplasms.

Several of the main projects of MPA over the 2014–2015 biennium are detailed below.


**ALTERATIONS OF THE *RRAS* AND *ERCC1* GENES AT 19Q13 IN GEMISTOCYTIC ASTROCYTOMAS**

Gemistocytic astrocytoma (WHO grade II) is a rare variant of diffuse astrocytoma, characterized by the presence of neoplastic gemistocytes and a consistent tendency to progress to secondary glioblastoma (WHO grade IV) and have a poor prognosis. Other than frequent *TP53* mutations (> 80%), little has been known about the molecular profile of gemistocytic astrocytomas. Exome sequencing was carried out in gemistocytic astrocytomas, and homozygous deletion of genes was identified at 19q13, i.e. *RRAS* and *ERCC1*. Further screening showed *RRAS* homozygous deletion in 7 of 42 (17%) gemistocytic astrocytomas and in 3 of 24 (13%) secondary glioblastomas. Patients with gemistocytic astrocytoma and secondary glioblastoma with *RRAS* deletion tended to have shorter survival times than those without deletion. Also, *ERCC1* homozygous deletion or promoter methylation was found in 10 of 42 (24%) gemistocytic astrocytomas and in 8 of 24 (33%) secondary glioblastomas. Homozygous deletions of *RRAS* and *ERCC1* were absent in other low-grade diffuse gliomas and in primary (de novo) glioblastomas (Ohta et al., 2014).

**LOSS OF *FUBP1* EXPRESSION IN GLIOMAS PREDICTS *FUBP1* MUTATION AND IS ASSOCIATED WITH OLIGODENDROGLIAL DIFFERENTIATION, *IDH1* MUTATION, AND 1p/19q LOSS**

Far upstream element-binding protein 1 (*FUBP1*) regulates several target genes, such as *MYC* and *p21*. *FUBP1* is upregulated in a variety of tumours and acts as an oncoprotein by stimulating proliferation and inhibiting apoptosis. *FUBP1* expression profiles in gliomas were examined by immunohistochemistry and immunofluorescence. *FUBP1* expression was higher in all glioma subtypes compared with normal

**Figure 1. Genetic pathways to primary and secondary glioblastomas. Note that secondary glioblastomas share a common origin of cells with oligodendrogliomas. © IARC.**



brain tissue, and was associated with increased cell proliferation. Loss of *FUBP1* expression predicted *FUBP1* mutation with a sensitivity of 100% and a specificity of 90%, and was associated with oligodendroglial differentiation, *IDH1* mutation, and 1p/19q loss, suggesting that *FUBP1* immunohistochemistry is useful for glioma diagnosis (Baumgarten et al., 2014).

**THE *OLIG2* LABELLING INDEX IS CORRELATED WITH HISTOLOGICAL AND MOLECULAR CLASSIFICATIONS IN LOW-GRADE DIFFUSE GLIOMAS**

Diagnosis of low-grade diffuse gliomas based on histology is highly subjective, with significant inter-observer variability. *Olig2* expression was assessed by immunohistochemistry in WHO grade II diffuse astrocytomas, oligoastrocytomas, and oligodendrogliomas. The mean *Olig2* labelling index was 44% in diffuse astrocytomas, 59% in oligoastrocytomas, and 76% in oligodendrogliomas. The *Olig2* labelling index was significantly higher in gliomas with 1p/19q loss with or without *IDH1/2* mutation than in those carrying *TP53* mutation with or without *IDH1/2* mutation or in those with *IDH1/2* mutation only (Suzuki et al., 2014).

***TP53*, *MSH4*, AND *LATS1* GERMLINE MUTATIONS IN A FAMILY WITH CLUSTERING OF NERVOUS SYSTEM TUMOURS**

Exome DNA sequencing of blood samples from a Li–Fraumeni family with a *TP53* germline mutation and multiple nervous system tumours revealed additional germline mutations. Missense mutations in the *MSH4* DNA repair gene (c.2480T > A; p.1827N) were detected in three patients with gliomas. Two family members without a *TP53* germline mutation who developed peripheral schwannomas also carried the *MSH4* germline mutation and, in addition, a germline mutation of the *LATS1* gene (c.286C > T; p.R96W). *LATS1* is a downstream mediator of NF2 but has not previously been found to be related to schwannomas. Therefore, the entire coding sequence of the *LATS1* gene in sporadic schwannomas was screened, and a single base deletion at codon 827 was found in a spinal schwannoma. Mutational loss of *LATS1* function may thus play a role in some inherited schwannomas, but only exceptionally in sporadic schwannomas. This is the first study reporting a germline *MSH4* mutation. Since it was present in all patients, it may have contributed to the subsequent acquisition of *TP53* and *LATS1* germline mutations (Kim et al., 2014a).

## ALTERATIONS IN THE NF2/LATS1/LATS2/YAP PATHWAY IN SCHWANNOMAS

Schwannoma is a benign nerve sheath tumour composed of well-differentiated Schwann cells. Other than frequent *NF2* mutations (50–60%), the molecular basis of schwannomas is not fully understood. *LATS1* and *LATS2* are downstream molecules of *NF2* and negative regulators of the *YAP* oncogene in the Hippo signalling pathway. MPA assessed mutations of the *NF2*, *LATS1*, and *LATS2* genes, promoter methylation of *LATS1* and *LATS2*, and expression of *YAP* and phosphorylated *YAP* (p*YAP*) in 82 sporadic schwannomas. Targeted sequencing using the Ion Torrent Proton instrument revealed *NF2* mutations in 45 (55%) schwannomas, *LATS1* mutations in 2 (2%) schwannomas, and *LATS2* mutations in 1 (1%) schwannoma. Methylation-specific polymerase chain reaction (PCR) showed promoter methylation of *LATS1* and *LATS2* in 14 (17%) and 25 (30%) cases, respectively. Overall, 62 (76%) cases had at least one alteration in the *NF2*, *LATS1*, and/or *LATS2* genes. Immunohistochemistry revealed nuclear *YAP* expression in 18 of 42 (43%) and reduced cytoplasmic p*YAP* expression in 15 of 49 (31%) schwannomas analysed, all of which had at least one alteration in the *NF2*, *LATS1*, and/or *LATS2* genes. These results suggest that an abnormal Hippo signalling pathway is involved in the pathogenesis of the majority of sporadic schwannomas (Oh et al., 2015).

## ROLE OF MICRORNAS IN THE PATHOGENESIS AND PROGRESSION OF MEDULLOBLASTOMAS

Medulloblastoma is the most frequent malignant central nervous system tumour in children. MicroRNAs (miRs) are small, non-coding RNAs that target protein-coding and non-coding RNAs and play roles in a variety of cellular processes through regulation of multiple targets.

MPA assessed miR-22 expression and its effect on cell proliferation and apoptosis in medulloblastomas. Quantitative reverse transcription PCR (RT-PCR) revealed significantly lower expression of miR-22 in 19 of 27 (70%) medulloblastomas and three

medulloblastoma cell lines, compared with normal cerebellum. Forced expression of miR-22 by lentiviral vector transfection reduced cell proliferation and induced apoptosis, while knockdown of miR-22 increased proliferative activity in DAOY and ONS-76 medulloblastoma cells. Microarray analysis in DAOY cells with forced miR-22 expression showed significant changes in expression profiles; *PAPST1* was the most significantly (10-fold) downregulated gene. Quantitative RT-PCR revealed *PAPST1* mRNA upregulation in 18 of 27 (67%) medulloblastomas. In addition, a luciferase reporter assay suggested that miR-22 directly targets the *PAPST1* gene, and lentivirus-mediated knockdown of *PAPST1* suppressed proliferation of medulloblastoma cells. These results suggest that frequently downregulated miR-22 expression is associated with cell proliferation in medulloblastomas, and this may be at least in part via *PAPST1*, which is a novel target of miR-22 (Xu et al., 2014).

miR-9, a key regulator of neuronal development, is aberrantly expressed in brain malignancies. MPA showed that miR-9 expression is frequently downregulated in medulloblastomas, and that this is at least in part due to promoter methylation. Low miR-9 expression correlated significantly with the diagnosis of unfavourable histopathological variants and with poor clinical outcome. Furthermore, *HES1* was identified as a direct target of miR-9 in medulloblastoma. Restoration of miR-9 was shown to trigger cell cycle arrest, inhibit clonal growth, and promote cell differentiation. Re-expression of miR-9 may constitute a novel epigenetic regulation strategy against medulloblastomas (Fiaschetti et al., 2014).

## WHO CLASSIFICATION OF TUMOURS SERIES (WHO BLUE BOOKS)

The objective of this project is to establish a histopathological and molecular classification and grading of human tumours that is accepted and used worldwide. Without clearly defined clinical and histopathological diagnostic criteria and, more recently, genetic and expression profiles, epidemiological studies and clinical trials are difficult to conduct. Therefore, this project is of

great importance not only for pathology communities but also for cancer registration, epidemiological studies, clinical trials, and cancer research in general.

IARC has been responsible for this project since the third edition (2000–2005; 10 volumes). The current (fourth) edition of the WHO Classification of Tumours series was initiated in 2006 with four new series editors (Dr Fred Bosman, University of Lausanne, Switzerland; Dr Elaine Jaffe, National Institutes of Health, Bethesda, USA; Dr Sunil Lakhani, University of Queensland, Brisbane, Australia; and Dr Hiroko Ohgaki, IARC). So far, seven volumes have been published, and for each volume, 20 000–50 000 copies were printed and distributed worldwide.

In 2014–2015, the sixth volume (Tumours of Female Reproductive Organs) and seventh volume (Tumours of the Lung, Pleura, Thymus and Heart) have been published, and preparation of the eighth volume (Tumours of the Urinary System and Male Genital Organs), the ninth volume (Head and Neck Tumours), and the tenth volume (Tumours of Endocrine Organs) is under way. In addition, updates to the first and second volumes of the fourth edition, Tumours of the Central Nervous System and Tumours of Haematopoietic and Lymphoid Tissues, are in progress.

Figure 2. Cover of *WHO Classification of Tumours of Female Reproductive Organs*, fourth edition.



**Figure 3. Working Group members at the consensus and editorial meeting of *WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart*. The meeting was held at IARC on 24–26 April 2014. © IARC/Roland Dray.**



The sixth volume, *Tumours of Female Reproductive Organs*, was published in April 2014. It was edited by four volume editors (Dr Robert J. Kurman, Johns Hopkins University, Baltimore, USA; Dr Maria Luisa Carcangiu, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy; Dr C. Simon Herrington, Centre for Oncology and Molecular Medicine, Ninewells Hospital and Medical School, Dundee, United Kingdom; and Dr Robert H. Young, Massachusetts General Hospital, Harvard Medical School, Boston, USA) and prepared by 92 authors from 18 countries.

The seventh volume, *Tumours of the Lung, Pleura, Thymus and Heart*, was published in March 2015. It was edited by five volume editors (Dr William D. Travis, Memorial Sloan Kettering Cancer Center, New York, USA; Dr Elisabeth Brambilla, Centre Hospitalier Universitaire de Grenoble, France; Dr


Allen P. Burke, University of Maryland, Baltimore, USA; Dr Alexander Marx, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany; and Dr Andrew G. Nicholson, Royal Brompton Hospital, London, United Kingdom) and prepared by 157 authors from 29 countries.

The eighth volume, *Tumours of the Urinary System and Male Genital Organs*, is being edited by four volume editors (Dr Holger Moch, University Hospital Zurich, Zurich, Switzerland; Dr Peter A. Humphrey, Yale University School of Medicine, New Haven, USA; Dr Thomas M. Ulbright, IU Health Pathology Laboratory, Indiana University School of Medicine, Indianapolis, USA; and Dr Victor E. Reuter, Memorial Sloan Kettering Cancer Center, New York, USA) and prepared by 103 authors from 19 countries. The consensus and editorial meeting was held in collaboration with

the University of Zurich on 11–13 March 2015, and the book is scheduled to be published in early 2016.

The ninth volume, *Head and Neck Tumours*, is being prepared by five volume editors (Dr Adel K. El-Naggar, MD Anderson Cancer Center, Houston, USA; Dr John K.C. Chan, Queen Elizabeth Hospital, Hong Kong Special Administrative Region, China; Dr Jennifer R. Grandis, Clinical and Translational Science Institute, UCSF School of Medicine, San Francisco, USA; Dr Takashi Takata, Hiroshima University, Hiroshima, Japan; and Dr Pieter J. Slootweg, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands). The consensus and editorial meeting is scheduled for January 2016.

**Figure 4. Cover of *WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart*, fourth edition.**




**MPA is grateful to the following for their collaboration:**

S.R. Lakhani, Brisbane, K. McDonald, Sydney, Australia; S.Q. Lv, Chongqing, J.K.C. Chan, Hong Kong Special Administrative Region, China; A. Vital, Bordeaux, E. Brambilla, Grenoble, J. Lachuer, Lyon, D. Figarella-Branger, Marseille, France; H. Stein, Berlin, Jürgen Thiele, Cologne, G. Reifenberger, Düsseldorf, U. Sure, Essen, M. Mittelbronn, Frankfurt, A. von Deimling, O.D. Wiestler, Heidelberg, R. Siebert, Kiel, A. Marx, Mannheim, G. Kloppel, Munich, W. Paulus, Münster, Germany; S.A. Pileri, Bologna, F. Giangaspero, Rome, Italy; Y. Nakazato, Gunma, T. Takata, Hiroshima, H. Yokoo, Maebashi, Japan; P.J. Slootweg, Nijmegen, The Netherlands; E. Campo, Barcelona, Spain; F. Bosman, Lausanne, M.A. Grotzer, P. Kleihues, H. Moch, T. Shalaby, M. Weller, Zurich, Switzerland; S. Herrington, Dundee, A. Nicholson, London, United Kingdom; A. Burke, R. Kurman, Baltimore, E.S. Jaffe, Bethesda, R.P. Hasserjian, N.L. Harris, D.N. Louis, R. Young, Boston, M.M. Le Beau, Chicago, A.K. El-Naggar, Houston, T.M. Ulbright, Indianapolis, D.W. Ellison, Memphis, P.A. Humphrey, New Haven, A. Orazi, V.E. Reuter, W.D. Travis, New York, J.R. Grandis, S.H. Swerdlow, Pittsburgh, W.K. Cavenee, San Diego, A. Perry, San Francisco, D.A. Arber, Stanford, USA.

**Financial support from the following bodies is gratefully acknowledged:**

Charles Rodolphe Brupbacher Foundation, Switzerland  
Krebsliga Zürich, Switzerland  
MEDIC Foundation, Switzerland



## SECTION OF INFECTIONS (INF)

**Section head**  
Dr Massimo Tommasino

THE SECTION OF INFECTIONS (INF) CONSISTS OF TWO GROUPS: THE INFECTIONS AND CANCER BIOLOGY GROUP (ICB) AND THE INFECTIONS AND CANCER EPIDEMIOLOGY GROUP (ICE). THE GROUPS HAVE SIMILAR GOALS IN EVALUATING THE ROLE OF INFECTIOUS AGENTS IN HUMAN CARCINOGENESIS USING COMPLEMENTARY STRATEGIES. ICB IS MAINLY FOCUSED ON THE CHARACTERIZATION OF THE BIOLOGICAL PROPERTIES OF WELL-ESTABLISHED AND NOVEL POTENTIAL ONCOGENIC VIRUSES. IN ADDITION, ICB OFFERS MANY LABORATORY ASSAYS THAT ARE WIDELY USED IN EPIDEMIOLOGICAL RESEARCH. THE WORK IN ICE FOCUSES ON THE ELUCIDATION OF THE SPECTRUM OF CANCERS ASSOCIATED WITH INFECTIONS AND THE IMPACT OF PREVENTION STRATEGIES.

In the 2014–2015 biennium, ICB has performed several functional studies on well-known and potential oncogenic viruses, such as Epstein–Barr virus (EBV) and members of the human papillomavirus (HPV) family. In particular, research by ICB highlighted the fact that oncogenic viruses share the ability to deregulate the same cellular pathways, although via different mechanisms. Thus, functional studies can be used as a tool to predict the role of novel viruses in human carcinogenesis.

Recent research efforts in ICE include the estimation of the global burden of cancer attributable to hepatitis B virus and hepatitis C virus infection, and that due to HIV after the introduction of antiretroviral treatment. Special efforts have been made to establish multiyear studies on the effectiveness of HPV

vaccination and HPV-based screening in Bhutan and Rwanda, the first two low-income countries to successfully adopt HPV vaccination practices. Much energy has also gone into the improvement of statistical and other quantitative methods to estimate infection-associated cancers.

In addition, ICB and ICE have performed several collaborative studies that led to the characterization of the relationship between natural variations of mucosal high-risk HPV types, geographical distribution, and the severity of cervical disease. The two Groups have also intensively collaborated to better understand the natural history of HPV infection in the oral cavity and to further define the role of the viral infection in the etiology of cancer of the head and neck in Europe and Asia.



# INFECTIONS AND CANCER BIOLOGY GROUP (ICB)

## **Group head**

Dr Massimo Tommasino

## **Scientists**

Dr Rosita Accardi-Gheit

Dr Tarik Gheit

## **Technical assistants**

Ms Sandrine McKay-Chopin

Ms Cécilia Sirand

## **Secretariat**

Ms Isabelle Rondy

(until June 2015)

Ms Nicole Sutty

## **Visiting scientists**

Dr Andres Castillo

(until June 2014)

Dr Sébastien Chevalier

(until June 2015)

Dr Alba Lucia Combita

(until October 2014)

Dr Ramona Gabriela Ursu

(until July 2015)

Dr Noel Whitaker

(until December 2014)

## **Postdoctoral fellows**

Dr Sankhadeep Dutta

Dr Lisa Kitasato

(until August 2014)

Dr Mariafrancesca Scalise

(until April 2015)

Dr Maha Siouda

(until June 2014)

Dr Vitaly Smelov

(until June 2015)

Dr Montserrat Torres Hortal

(until June 2014)

## **Students**

Ms Maiken Angell Hansen

(until June 2015)

Mr Gennaro Altamura

(until February 2015)

Ms Claudia Aveni

(until September 2015)

Ms Johanna Ira Blase

Ms Dounia Benamar

(until July 2014)

Ms Serena Fasiello

(until October 2014)

Mr Roberto Gallus

(until May 2015)

Ms Alison Grant

(until July 2014)

Ms Irene Masini

(until January 2015)

Ms Lucia Minoni

Ms Laura Pacini

Ms Ingunn Tjelde Fauskrud

(until June 2015)

Ms Gessica Torre

Ms Katharina Wiedorfer

(until December 2014)



The main goal of the Infections and Cancer Biology Group (ICB) is to elucidate molecular mechanisms of both well-established and potential oncogenic viruses in deregulating pathways related to cellular proliferation and transformation as well as to the immune response. ICB's findings showed that several oncogenic viruses have the ability to induce epigenetic changes and deregulate cellular gene expression. As a consequence, these viruses promote cellular transformation and inactivate pathways involved in the innate immune response (Figure 1). In the 2014–2015 biennium, ICB has characterized new biological properties of some of these viruses (Bazot et al., 2014; Leitz et al.,


2014; Shterzer et al., 2014; Siouda et al., 2014; Frecha et al., 2015; Pacini et al., 2015).

In addition to functional studies, ICB has performed several collaborative epidemiological studies using laboratory assays established by the Group, aiming to characterize the natural history of several viruses at different anatomical regions (Hampras et al., 2014; Donà et al., 2015; Franceschi et al., 2015; Hampras et al., 2015; Torres et al., 2015) and their contribution to cancer development (Anantharaman et al., 2014a; Bussu et al., 2014; Corbex et al., 2014; Gheit et al., 2014; Iannacone et al., 2014; Joshi et al., 2014; Toll et al., 2014).

ROLE OF HUMAN PAPILLOMAVIRUS INFECTION AND OTHER CO-FACTORS IN THE ETIOLOGY OF HEAD AND NECK CANCER IN EUROPE AND INDIA (HPV-AHEAD)

For four years (2010–2015), ICB has coordinated the HPV-AHEAD consortium, which included a multi-disciplinary team in Europe and India, to evaluate the role of human papillomavirus (HPV) infection and other cofactors in the development of head and neck cancer (HNC) in Europe and India. The consortium collected and analysed plasma/serum samples ( $n = 4000$ ) from many European centres and HNC tissues ( $n = 8000$ ) from 42 centres in

Figure 1. Viral oncoproteins alter cellular gene expression, deregulating key pathways involved in cellular transformation and immune response. Many viral oncoproteins, such as LMP1 from Epstein–Barr virus (EBV) or E7 from several human papillomavirus (HPV) types, have the ability to induce the formation or alter the composition of transcriptional regulatory complexes, resulting in the deregulation of cellular gene expression. The figure shows, as an example, a mechanism characterized in ICB studies of E7 oncoprotein from beta HPV type 38 (reviewed in Tommasino, 2014). This virus belongs to genus beta of the HPV phylogenetic tree, which is suspected to be involved, together with ultraviolet (UV) radiation, in the development of non-melanoma skin cancer. Beta HPV 38 E7 oncoprotein has the ability to increase the level of a p53 antagonist,  $\Delta Np73\alpha$ , leading to the formation of a transcriptional regulatory complex containing  $\Delta Np73\alpha$ , IKK $\beta$ , and two epigenetic enzymes, DNA methyltransferase 1 (DNMT1) and enhancer of zeste homologue 2 (EZH2). This complex binds many promoters, inducing epigenetic changes (e.g. histone 3 K27 trimethylation and/or DNA methylation) and repressing the expression of genes encoding innate immunity sensors (e.g. Toll-like receptor 9) and pro-apoptotic genes (e.g. *Pig3*). © IARC.



16 European countries as well as from 6 centres in India. HNC tissues were analysed by several laboratory assays, including detection of viral DNA and RNA, to precisely determine the fraction of HNCs attributable to mucosal high-risk HPV types in many geographical regions in Europe and India. Analyses of the results are under way.

#### EPIDERMODYSPLASIA VERRUCIFORMIS-ASSOCIATED GENES *EVER1* AND *EVER2* AS POTENTIAL NOVEL DNA SENSORS OF THE INNATE IMMUNITY TARGETED BY EBV

A recent study has shown that the products of two human genes, *EVER1* and *EVER2*, which appear to be associated with virus-induced carcinogenesis, may act as exogenous DNA sensors of the innate immunity (Frecha et al., 2015). Both genes were initially identified because they are mutated in patients with the rare genetic disorder epidermodysplasia verruciformis (EV). Patients with EV have an increased susceptibility to infection with cutaneous HPV types and development of squamous cell carcinoma. It has also been shown that specific single-nucleotide polymorphisms in *EVER1* and *EVER2* are associated with an increased risk of persistent infection with mucosal high-risk HPV types and consequent development of premalignant and malignant cervical lesions. ICB's recent findings showed

that the expression of both genes was strongly upregulated immediately after infection with EBV or herpes simplex virus 1 in primary or immortalized human cells, suggesting that the activation of *EVER* expression could be part of the innate immune response to exogenous DNA. Importantly, *EVER1* and *EVER2* transcription were strongly repressed at a later stage of EBV infection. Finally, EBV infection was hampered in cells expressing ectopic levels of *EVER1* or *EVER2*. Together, these findings indicate a link between *EVER* proteins and oncogenic virus infections; the proteins most likely serve as DNA sensors as part of the innate immune response.

#### NATURAL HISTORY OF BETA HPV TYPES AND THEIR ROLE IN HUMAN CARCINOGENESIS

Due to the development by ICB of a Luminex-based diagnostic platform that enables the detection of more than 140 double-stranded DNA viruses, ICB has established a large number of collaborative epidemiological studies. One of the focuses of the Group's research is to evaluate the role of cutaneous HPV types in the development of non-melanoma skin cancer. The best candidates are the cutaneous HPV types that belong to the genus beta of the viral phylogenetic tree, which is subdivided into five species (beta 1–5). They were initially isolated in skin cancer of cancer-

prone patients with the rare autosomal recessive genetic disorder EV (reviewed in Tommasino, 2014). Patients with EV are highly susceptible to infection with beta HPV types and ultraviolet (UV) radiation-induced skin cancers. It is now clear that beta HPV types are also abundantly present in the skin of healthy individuals. In a recent study, using anti-HPV antibodies and viral DNA as a marker of infection, ICB provided evidence that non-EV individuals with a history of skin cancer show a higher positivity for beta HPV infections compared with control subjects (Iannacone et al., 2014).

In agreement with other independent studies, ICB showed that the beta HPV types, in addition to the skin, can colonize different sites of the anogenital tract (Hampras et al., 2014; Donà et al., 2015; Torres et al., 2015), suggesting that their tropism is not strictly limited to the skin. Determination of the prevalence of beta HPV types in the anal canal of HIV-positive and HIV-negative men who have sex with men showed that HPV types belonging to the beta 1 and beta 3 species are increased in immunocompromised individuals. In contrast, the beta 2 species was equally distributed in the two groups (Torres et al., 2015). The fact that impairment of the host's immune surveillance affects beta HPV infections differently indicates that beta species have different biological properties.

#### ICB is grateful to the following for their collaboration:

Marc Arbyn, John-Paul Bogers, Antwerp, Belgium; Luisa Lina Villa, São Paulo, Brazil; Francisco Aguayo, Santiago, Chile; François Aubin, Besançon, Uzma A. Hasan, Lyon, Christine Clavel, Reims, France; Devasena Anantharaman, Paul Brennan, David Forman, Zdenko Herceg, Maimuna Mendy, Rengaswamy Sankaranarayanan (IARC collaborators), Lyon, France; Gerhard Dyckhoff, Lutz Gissmann, Christel Herold-Mende, Dana Holzinger, Michael Pawlita, Rüdiger Ridder, Daniele Viariso, Heidelberg, Heiner Boeing, Potsdam, Germany; George Mosialos, Thessaloniki, Greece; Radhakrishnan Pillai, Thiruvananthapuram, India; David Hughes, Dublin, Ireland; Diego Serraino, Aviano, Vito de Pinto, Catania, Cesare Indiveri, Cosenza, Fausto Chiesa, Susanna Chiocca, Fausto Maffini, Marta Tagliabue, Milan, Giovanna Romeo, Rome, Lawrence Banks, Manola Comar, Trieste, Italy; Xavier Bosch, Xavier Castellsagué, Laia Alemany, Silvia de Sanjosé, Belén Lloveras Rubio, Barcelona, Spain; Christine Pierce-Campbell, Anna R. Giuliano, Dana E. Rollison, Tampa, USA.

#### Financial support from the following bodies is gratefully acknowledged:

Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA)  
Comité du Rhône de la Ligue Nationale contre le Cancer (LNCC)  
European Commission fund HPV-AHEAD



# INFECTIONS AND CANCER EPIDEMIOLOGY GROUP (ICE)

**Group head and special advisor**

Dr Silvia Franceschi

**Scientists**

Dr Iacopo Baussano  
Dr Gary Clifford  
Dr Jean-Damien Combes  
Dr Catherine de Martel  
Dr Martyn Plummer  
Dr Salvatore Vaccarella

**Visiting scientists**

Dr Delphine Maucort-Boulch  
Dr Robert Newton  
Dr Christian Partensky  
Dr Jonathan Wakefield  
(until January 2014)

**Data managers**

Ms Vanessa Tenet  
Mr Jérôme Vignat

**Secretariat**

Ms Dominique Bouchard  
(until February 2014)  
Ms Véronique Chabanis  
Ms Susan Gamon

**Postdoctoral fellows**

Dr Alyce A. Chen  
(until September 2014)  
Dr Jean-Claude Dusingize  
(until June 2014)  
Dr Chunqing Lin  
Dr Stephen Tully

**Students**

Mr Henri Crozel  
(until July 2014)  
Mr Fulvio Lazzarato  
Mr Tharcisse Mpunga

In 2014–2015, the Infections and Cancer Epidemiology Group (ICE) has contributed to progress in the understanding and prevention of cancer associated with infections by means of three main types of studies.

**IMPLEMENTATION AND MONITORING OF HPV VACCINATION AND HPV-BASED SCREENING IN LOW-INCOME COUNTRIES**

Bhutan and Rwanda, in which human papillomavirus (HPV) vaccination started in 2010 and 2011, respectively, are two model countries chosen by ICE to provide the first evaluations of the effectiveness and sustainability of an entirely HPV-based cervical cancer prevention strategy in low-income countries. Figure 1 shows the fairly high pre-vaccination prevalence of HPV in Bhutan (Baussano et al., 2014b; Tshomo et al., 2014).


Screening of HIV-positive women is a special challenge. In Kenya, ICE showed a relatively high efficacy of cryotherapy in treating cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) (77%; 95% CI, 66–86%) but very frequent persistence of HPV infection (78%) (de Vuyst et al., 2014). ICE also reported for the first time that in women co-infected with HIV and HPV, triage with a tri-marker methylation test was not inferior to cytology in predicting CIN2 or worse and was superior to visual inspection with acetic acid (VIA) (de Vuyst et al., 2015).

ICE also took advantage of the historical IARC cell repository (from 27 different countries) to study variants that may affect the transformation potential of high-risk HPV types. The distribution of HPV 33 variants, for instance, varies by region, and the A1 sublineage was strongly over-represented in cervical cancer cases compared with controls in Africa and Europe (Chen et al., 2014a, 2014b).

**SPECTRUM, NATURAL HISTORY, AND PREVENTION OF INFECTION-ASSOCIATED CANCERS OTHER THAN CERVICAL CANCER**

The contribution of HPV infection to head and neck cancer (HNC) is still ill defined and varies substantially by cancer site and world region. ICE carried out a meta-analysis of studies in which the


**Figure 1. Age-specific prevalence of human papillomavirus (HPV) DNA and of cytological abnormalities among 2505 women in Bhutan in 2011–2012. Reprinted with permission from Tshomo et al. (2014). © 2014 Tshomo et al.; licensee BioMed Central Ltd.**



prevalence of molecular and serological HPV markers was compared across different HNC and cancer-free controls (Combes and Franceschi, 2014). Data on markers of HPV-driven carcinogenesis, i.e. in situ hybridization or HPV E6/E7 mRNA, showed that HPV-attributable HNC is frequent in oropharyngeal cancer (OPC) (~50%) but rare in cancers of the oral cavity (~3%), larynx (~7%), and hypopharynx (~0%). ICE also showed

that HPV prevalence differs by sex and country, possibly as a consequence of the vast international variation in smoking habits in men and women (Combes et al., 2014a). Nevertheless, HPV-positive OPC may systematically cause more OPC in men than in women, for reasons that are unclear but may include higher prevalence of HPV or lifestyle risk factors in men (Figure 2).

**Figure 2. Age-standardized (world) incidence rates of oropharyngeal cancer (OPC) per 100 000 people stratified by country, sex, and estimates of human papillomavirus (HPV) status. Corresponding male (M) to female (F) ratios are also shown in the table. Reprinted from Combes et al. (2014a), by permission from the American Association for Cancer Research.**



ICE regularly updates the fraction of cancer attributable to infections worldwide by region and individual carcinogenic infectious agent; see Plummer et al. (2015) for *Helicobacter pylori*. Recently, such a fraction was quantified in a particularly vulnerable population: HIV-positive people in the USA (Figure 3). The infection-attributable

fraction was 40%, i.e. 10 times that seen in the general population (de Martel et al., 2015). The attributable fraction in HIV-positive people was also higher than that in the general population of any other world region, including sub-Saharan Africa, where 33% of cancers are attributable to infection.


ICE published several model-based reports on the natural history of HPV infections and on the performance and costs of different strategies of

vaccination and screening, using high-quality data sets for IARC and European consortia (Franceschi and Baussano, 2014). ICE also reviewed the main principles of transmission dynamics, the basic structure of infection transmission models, and their use in combination with empirical data. The review also summarized models of carcinogenesis and their possible integration with models of the natural history of infections (Baussano et al., 2014a).

To disentangle the impacts of temporal changes in lifestyle, screening, and diagnostic practices on cancer trends, ICE produced ad hoc modifications of the age–period–cohort (APC) model in which non-identifiability was partly circumvented by making assumptions based on a consistent relationship between age and individual cancer incidence. For instance, it was shown that in the absence of cervical screening, incidence rates of cervical cancer for 2006–2010 in the Nordic countries would have been 3–5 times those observed (Vaccarella et al., 2014). Diagnostic changes (mainly the spread of neck ultrasonography and other imaging techniques) may account for more than 50% of differentiated thyroid carcinomas currently diagnosed in women younger than 80 years in many high-income countries, notably the Republic of Korea (> 80%), France, Italy, the USA, and Australia (Franceschi and Vaccarella, 2015; Vaccarella et al., 2015).

Finally, ICE staff participated in the development and dissemination of the R package for statistical computing.

Figure 3. Cancer attributable to infection in the general population and HIV-positive people in the USA in 2008. AF, attributable fraction; EBV, Epstein–Barr virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HPV, human papillomavirus; *H. pylori*, *Helicobacter pylori*; KSHV, Kaposi sarcoma-associated herpesvirus. Reprinted with permission from de Martel et al. (2015).



**ICE is grateful to the following for their collaboration:**

Alex Vorsters, Antwerp, Belgium; Tshokey, Ugyen Tshomo, Thimphu, Bhutan; Marc Brisson, Montreal, Canada; You-Lin Qiao, Fang-hui Zhao, Beijing, China; Matti Lehtinen, Tampere, Finland; Isabelle Heard, Jean Lacau St Guily, Paris, Christine Clavel, Véronique Dalstein, Reims, France; Luigino Dal Maso, Diego Serraino, Aviano, Francesca Carozzi, Florence, Carlo La Vecchia, Milan, Franco Merletti, Guglielmo Ronco, Turin, Italy; Chris Meijer, Peter J.F. Snijders, Amsterdam, The Netherlands; Maurice Gatera, Fidele Ngabo, Marie-Chantal Umulisa, Kigali, Rwanda; Xavier Castellsagué, Silvia de Sanjosé, Barcelona, Spain; Joakim Dillner, Stockholm, Sweden; Julian Peto, London, Valérie Beral, Oxford, United Kingdom; Eric Engels, Mark Schiffman, Meredith Shiels, Bethesda, USA.

**Financial support from the following bodies is gratefully acknowledged:**

Agence Nationale de Recherche sur le Sida et les Hépatites (ANRS), Paris, France  
Bill & Melinda Gates Foundation, Seattle, USA  
Comité du Rhône de la Ligue Nationale contre le Cancer, Lyon, France  
European Commission, Brussels, Belgium  
Fondation de France, Paris, France  
Institut national du Cancer (INCa), Paris, France







MGP  
INSTRUMENTS

RATE



CONTAMINATION

● CPS

CAP OFF

DOSE RATE

$\mu\text{Sv/h}$  ●

CAP ON

ON/OFF

LIGHT



**RAM GENE-1**

MARK II

## SECTION OF ENVIRONMENT AND RADIATION (ENV)

### Section head

Dr Joachim Schüz

### Deputy section head

Dr Ausrele Kesminiene

### Scientists

Dr Isabelle Deltour  
Dr Carolina Espina Garcia  
Dr Maria Leon-Roux  
Dr Valerie McCormack  
Dr Fiona McKenzie  
Dr Ann Olsson  
Dr Evgenia Ostroumova  
Dr Sara Schonfeld  
Dr Isabelle Thierry-Chef

### Staff

Ms Christine Bassier  
Ms Catherine Chassin  
Mr Gilles Ferro  
Ms Tracy Lignini  
Ms Véronique Luzon  
Ms Monika Moissonnier

### Visiting scientists

Dr Isabel Dos Santos Silva  
Dr Tracy Lightfoot  
Dr George Luta  
Dr Karl-Christian Nordby

### Postdoctoral fellows

Dr Helen Bailey  
(until January 2015)  
Dr Rémi Béranger  
(until April 2015)  
Dr Anya Burton  
Dr Rachel Denholm  
(until April 2014)  
Dr Caroline Dickens  
(until September 2014)  
Dr Sonia El-Zaemey  
Dr Friederike Erdmann  
Dr Eleonora Feletto  
Dr Ghassan Hamra  
(until June 2014)  
Dr Rachel Hanisch  
(until March 2015)  
Dr Tomoko Inamasu  
Dr Lucian Krille  
Dr Charlotte Le Cornet  
Dr Leah Schinasi  
(until August 2014)  
Dr Kayo Togawa

### Students

Mr Simon Ducarroz  
(until September 2015)  
Ms Olivia Febvey  
(until March 2014)

THE SECTION OF ENVIRONMENT AND RADIATION (ENV) IS CHARGED WITH INVESTIGATING ENVIRONMENTAL, LIFESTYLE, OCCUPATIONAL, AND RADIATION-RELATED CAUSES OF CANCER IN HUMAN POPULATIONS. THESE EXOGENOUS FACTORS ARE EXPLORED WITH THE GOAL OF CONTRIBUTING TO CANCER PREVENTION AND INCREASING THE UNDERSTANDING OF BIOLOGICAL MECHANISMS OF CARCINOGENESIS. ENV ACHIEVES THESE OBJECTIVES THROUGH COLLABORATIVE INTERNATIONAL EPIDEMIOLOGICAL STUDIES USING A MULTIDISCIPLINARY APPROACH, WHEN POSSIBLE, OR THROUGH THE INITIATION OF INDIVIDUAL ANALYTICAL EPIDEMIOLOGICAL STUDIES. ANOTHER APPROACH USED IS THE COORDINATION OF INTERNATIONAL CONSORTIA OF EPIDEMIOLOGICAL STUDIES.

Central to ENV is the investigation of external environmental exposures, such as pollutants and occupational exposures, and lifestyle factors. Major areas of interest are pesticides, asbestos, other occupational risk factors for lung cancer, and uranium. Potential interactions between environmental and other factors for the risk of and survival from cancer are investigated in studies in sub-Saharan African countries, with a focus on breast and oesophageal cancers. ENV is also involved in many projects related to ionizing radiation from medical diagnostic examinations, occupational activities, and environmental exposures from fallout from nuclear accidents, nuclear weapons testing, and nuclear waste disposal. With regard to non-

ionizing radiation, research activities include investigations of mobile phone use and studies on extremely low-frequency magnetic fields and childhood cancer.

Translating research into prevention policy is particularly important for environmental risk factors, many of which are modifiable. ENV has played a large role in IARC's update of the European Code Against Cancer, which makes recommendations about what actions to take to improve general health and reduce the risk of cancer.

#### ENVIRONMENTAL AND OCCUPATIONAL EXPOSURES

##### PESTICIDES

Parental exposure to pesticides has been suggested to increase the risk of cancer in their offspring. Data from case-control studies participating in the Childhood Leukemia International Consortium were pooled, totalling more than 8000 cases of acute lymphoblastic leukaemia (ALL), more than 1300 cases of acute myeloid leukaemia (AML), and more than 14 000 controls. A 20% increased risk of ALL was observed for paternal occupational exposure before conception and a 90% increased risk of AML for maternal occupational exposure during pregnancy (Bailey et al., 2014a). Home pesticide use before conception, during pregnancy, and after birth also showed positive associations with the risk of ALL (a 30–50% increased risk) as well as AML (a similarly increased risk, except for after birth, where there was no association) (Bailey et al., 2015a). In contrast, a register-based nested case-control approach in the Nordic populations, totalling almost 10 000 cases and more than 30 000 controls, showed no association between paternal or maternal exposure to pesticides and the risk of testicular cancer in their sons (Le Cornet et al., 2015). Risks of haematological malignancies in agricultural workers are currently being investigated by pooling large cohort studies from France, Norway, and the USA; a systematic review suggested a positive association between exposures to some pesticides and the risk of non-Hodgkin lymphoma (Schinasi and Leon, 2014).

#### OCCUPATIONAL RISK FACTORS FOR LUNG CANCER

A study pooling data from 16 case-control studies on lung cancer from Europe and Canada with information on occupational history and lifetime smoking history (the SYNERGY project), comprising almost 20 000 cases and more than 23 000 controls, showed some positive associations between occupations and lung cancer after adjustment for smoking. Risk increases were about 30–50% for bricklayers (Consonni et al., 2015), painters, miners (Taeger et al., 2015), and welders. Increased risks of lung cancer seen in cooks (Bigert et al., 2015) and hairdressers are most likely attributable to their smoking behaviour. No increased risk was seen in bakers. The results are summarized in Figure 1. Further findings indicate that after accounting for co-occurring respiratory diseases, chronic bronchitis and emphysema have a positive association with lung cancer risk (Denholm et al., 2014). Using a modelling approach, analyses are under way to investigate the effect of known lung carcinogens such as respirable crystalline silica, nickel, chromium, polycyclic aromatic hydrocarbons, and asbestos, including the effects accounting for smoking and simultaneous exposures to several of these carcinogens. Cancer risks in workers exposed to asbestos in a large open-pit mine in the Southern Urals,

Russian Federation, are also being explored, including the quantification of known associations such as with mesothelioma or lung cancer, but asbestos may also be related to other cancers for which the scientific evidence has not been established so far, for instance stomach or colorectal cancer. Although the use of asbestos has been banned in many countries, the peak burden of mesothelioma is still to occur, as illustrated using mortality data for Germany (Schonfeld et al., 2014a).

#### RADIATION

##### IONIZING RADIATION AND RISK OF DEATH FROM CANCER IN NUCLEAR WORKERS

Quantification of the risks associated with very low doses of ionizing radiation is a challenging task because the expected effects are small and difficult to detect. Nevertheless, even small effects become non-negligible when considering millions of people exposed occupationally or millions of patients undergoing diagnostic procedures involving ionizing radiation. A landmark international study coordinated by IARC, the International Nuclear Workers Study (INWORKS) of more than 300 000 nuclear workers in France, the United Kingdom, and the USA, examined causes of death in the workers and has provided the strongest evidence yet that long-term exposure to low-dose radiation increases the risk of subsequent death

Figure 1. Occupations showing (left) increased lung cancer risk after adjustment for smoking, (centre) no increased risk after adjustment for smoking, and (right) no increased risk; data from the SYNERGY project (pool of 16 case-control studies from Europe and Canada). © IARC/ Joachim Schüz.



**Table 1. Comparison between risks derived from analyses of the Life Span Study population exposed to higher radiation doses and dose rates, and risks observed in the INWORKS study**

Cause of death	INWORKS		Life Span Study	
	Number of deaths	Excess relative risk	Number of deaths	Excess relative risk
Leukaemia, excluding chronic lymphocytic leukaemia	531	2.96 (90% CI, 1.17–5.21) <sup>a</sup>	94	2.63 (90% CI, 1.50–4.27) <sup>b</sup>
Solid cancer	17 957	0.47 (90% CI, 0.18–0.79) <sup>c</sup>	3475	0.32 (95% CI, 0.01–0.50) <sup>d</sup>

CI, confidence interval.

<sup>a</sup> Leuraud et al. (2015).

<sup>b</sup> Metz-Flamant C, Laurent O, Samson E, Caër-Lorho S, Acker A, Hubert D, et al. (2013). Mortality associated with chronic external radiation exposure in the French combined cohort of nuclear workers. *Occup Environ Med.* 70(9):630–8. <http://dx.doi.org/10.1136/oemed-2012-101149> PMID:23716722

<sup>c</sup> Richardson et al. (2015).

<sup>d</sup> Cardis E, Vrijheid M, Blettner M, Gilbert E, Hakama M, Hill C, et al. (2005). Risk of cancer after low doses of ionising radiation: retrospective cohort study in 15 countries. *BMJ.* 331(7508):77. <http://dx.doi.org/10.1136/bmj.38499.599861.E0> PMID:15987704

caused by leukaemia (excluding chronic lymphocytic leukaemia) (Leuraud et al., 2015) and solid cancer (Richardson et al., 2015). The workers received average doses of just 1.1 mSv per year above background radiation, which is about 2–3 mSv per year from sources such as cosmic rays and radon (Thierry-Chef et al., 2015). Although based on a substantially lower dose distribution, the estimated excess relative risk of leukaemia mortality excluding chronic lymphocytic leukaemia (2.96 per Gy; 90% CI, 1.17–5.21) was consistent with risks derived from analyses of other populations exposed to higher radiation doses and dose rates (Table 1). The rate of mortality from all cancers was estimated to increase with cumulative dose by 51% per Gy (90% CI, 23–82%), lagged 10 years (Richardson et al., 2015). A similar association was estimated for all solid cancers (an increase of 47% per Gy; 90% CI, 18–79%), and further excluding lung cancer deaths from the analysis led to a minimal change in the magnitude of the estimated association, suggesting that positive bias due to confounding by smoking was unlikely. These findings show the importance of adherence to the basic principles of radiation protection: to optimize protection to reduce exposures as much as is reasonably achievable and – in the case of patient exposure – to justify that the exposure does more good than harm.

### CANCER RISK RELATED TO COMPUTED TOMOGRAPHY EXAMINATIONS DURING CHILDHOOD

The growing use of computed tomography (CT) technology raises concerns about radiological protection, especially for children and adolescents. The EPI-CT multinational collaborative study, which aims to estimate individual radiation organ doses (and associated uncertainties) from CTs in young people and assess subsequent cancer risk, was specifically designed to address factors that can affect the interpretation of results from CT studies, including reverse causation, confounding by predisposing factors and other causes, and possible effect modification (Bosch


de Basea et al., 2015). To date, the study includes 1 163 571 patients from nine European countries (Belgium, Denmark, France, Germany, the Netherlands, Norway, Spain, Sweden, and the United Kingdom). Data on 2 166 479 CT examinations (53.33% of them head CT scans) have been retrieved from participating radiology departments. An in vitro assessment of the  $\gamma$ -H2AX-foci assay as a cellular biomarker of age-dependent radiosensitivity demonstrated that it is feasible to apply the assay in a multicentre prospective study in paediatric CT imaging (Vandevorde et al., 2015). EPI-CT, the first large-scale international collaborative study, will contribute to estimating effects of low-level radiation in children and providing a basis for the optimization of paediatric CT protocols and patient protection, and also has the potential to consolidate a European paediatric cohort for long-term follow-up.

### LIFESTYLE AND BEHAVIOUR

#### BREAST CANCER

In a study of more than 12 000 women with histologically confirmed breast cancer in South Africa and Namibia, it was found that estrogen receptor-positive cancer dominated in all races but that Black women had a modest excess of aggressive subtypes (Figure 2; Dickens et al., 2014a). In more than 1000 breast cancer patients from the largest hospital in Southern Africa,

**Figure 2. Cumulative age-specific percentages of breast cancer subtypes in patients from South Africa and Namibia, by race. Numbers within bars indicate subtype percentages. Reprinted from Dickens et al. (2014a) by permission from the American Association for Cancer Research.**



the risk of late-stage breast cancer increased with increasing distance from a patient's residence to the hospital, highlighting the prevention potential in this population (Dickens et al., 2014b). To study factors influencing breast cancer survival in sub-Saharan Africa, ENV has recently launched a large-scale survival study including South Africa, Namibia, Uganda, and Nigeria, the African Breast Cancer - Disparities in Outcomes (ABC-DO) study.

### ESOPHAGEAL CANCER

Oesophageal cancer has a peculiar spatial distribution worldwide, including a high-incidence easterly corridor in Africa, which stretches north-south from Ethiopia and Kenya to South Africa (Figure 3). ENV has established a consortium (the ESCCAPE project) with ongoing case-control studies in Kenya and the United Republic of Tanzania and pilot work in Ethiopia, Malawi, and South Africa. Consumption of hot

beverages and food is a candidate risk factor, and a tea temperature survey in the United Republic of Tanzania showed that participants started drinking tea at a mean temperature of 70.6 °C (Munishi et al., 2015). In Ethiopia, another candidate risk factor is khat chewing, which is also a suspected risk factor for malignant oral disorders (El-Zaemey et al., 2015).

### CHILDHOOD CANCERS

Childhood cancer, especially ALL, shows great international variation, although the disease may be underdiagnosed in low- and middle-income countries (Erdmann et al., 2015a). ENV therefore aims to involve more such countries in the research and has established the Global Acute Leukaemia network (GALnet). Recent research from high-income countries suggests roles, although modest, of parental pesticide exposure (see above) and parental home paint exposure (Bailey et al., 2015b), and a protective effect of maternal

supplementation with folic acid (Metayer et al., 2014).

### CANCER PREVENTION

The European Code Against Cancer is a preventive tool aimed at reducing the cancer burden by informing people about how to avoid or reduce carcinogenic exposures, adopt behaviours to reduce their cancer risk, or participate in organized intervention programmes. The fourth edition of the Code was launched in October 2014. This update, led by ENV together with the Quality Assurance Group, also includes recommendations on occupational and environmental exposures as well as ionizing radiation and ultraviolet radiation; the Code is shown in Figure 4. It is estimated that the cancer burden could be reduced by up to one half if scientific knowledge on the causes of cancer could be translated into successful prevention.

Figure 3. Incidence of oesophageal cancer (EC) in men and women in African countries, showing high rates in countries along the Great Rift Valley. Reprinted from Schaafsma et al. (2015). © 2015 Schaafsma et al.




Figure 4. The fourth edition of the European Code Against Cancer, launched in October 2014: 12 recommendations to reduce your cancer risk (<http://cancer-code-europe.iarc.fr>). © IARC.

# European Code Against Cancer

## 12 ways to reduce your cancer risk

- 1 Do not smoke. Do not use any form of tobacco.
- 2 Make your home smoke free. Support smoke-free policies in your workplace.
- 3 Take action to be a healthy body weight.
- 4 Be physically active in everyday life. Limit the time you spend sitting.
- 5 Have a healthy diet:
  - Eat plenty of whole grains, pulses, vegetables and fruits.
  - Limit high-calorie foods (foods high in sugar or fat) and avoid sugary drinks.
  - Avoid processed meat; limit red meat and foods high in salt.
- 6 If you drink alcohol of any type, limit your intake. Not drinking alcohol is better for cancer prevention.
- 7 Avoid too much sun, especially for children. Use sun protection. Do not use sunbeds.
- 8 In the workplace, protect yourself against cancer-causing substances by following health and safety instructions.
- 9 Find out if you are exposed to radiation from naturally high radon levels in your home. Take action to reduce high radon levels.
- 10 For women:
  - Breastfeeding reduces the mother's cancer risk. If you can, breastfeed your baby.
  - Hormone replacement therapy (HRT) increases the risk of certain cancers. Limit use of HRT.
- 11 Ensure your children take part in vaccination programmes for:
  - Hepatitis B (for newborns)
  - Human papillomavirus (HPV) (for girls).
- 12 Take part in organized cancer screening programmes for:
  - Bowel cancer (men and women)
  - Breast cancer (women)
  - Cervical cancer (women).

The European Code Against Cancer focuses on actions that individual citizens can take to help prevent cancer. Successful cancer prevention requires these individual actions to be supported by governmental policies and actions.

Find out more about the European Code Against Cancer at: <http://cancer-code-europe.iarc.fr>

International Agency for Research on Cancer



These recommendations are the result of a project coordinated by the International Agency for Research on Cancer and co-financed by the



## ENV is grateful to the following for their collaboration:

Messaouda Oudjehih, Algeria; Bruce Armstrong, Graham Giles, John Hopper, Ewan MacFarlane, Elizabeth Milne, Susan Peters, Malcom Sim, Freddy Sitas, Jennifer Stone, Australia; Irina Malakhova, Vladimir Masyakin, Belarus; Sarah Baatout, Jérémie Dabin, Hilde Hengels, Lara Struelens, Belgium; Luis Felipe Ribeiro Pinto, Maria Pombo-de-Oliveira, Brazil; Norman Boyd, Rayjean Hung, Claire Infant-Rivard, Daniel Krewski, Jack Siemiatycki, Canada; Maria Luisa Garmendia, Anita Pinto Pereira, Chile; Tse Lap Ah, Ava Kong, Xiadong Shi, China; Ana Maria Mora, Costa Rica; Eva Kralikova, Czech Republic; Ioannis Basinas, Susanne Oksbjerg Dalton, Jeannette Falck Winther, Christoffer Johansen, Johnni Hansen, Aslak Harbo Poulsen, Per Kragh Andersen, Mads Melbye, Jørgen Olsen, Kjeld Schmiegelow, Torben Sigsgaard, Denmark; Sameera Ezzat, Dorria Salem, Egypt; Abebe Alemayehu, Abraham Aseffa, Mathewos Assefa, Abate Bani, Nigatu Endalafar, Samson Eshete, Tufa Gemechu, Endale Kassa, Ethiopia; Anssi Auvinen, Esa Läära, Carita Lindholm, Sisko Salomaa, Eero Pukkala, Antti Tossavainen, Finland; Isabelle Baldi, Marie-Odile Bernier, Bruno Combourieu, Jacqueline Clavel, Béatrice Fervers, Aude Flechon, Joelle Fevotte, Marcel Goldberg, Janet Hall, Martine Hours, Dominique Laurier, Pierre Lebailly, Nicole Le Moual, Amélie Massardier-Pilonchery, Klervi Leuraud, Carlo Maccia, Jean-Luc Rehel, Anne-Sophie Villegier, Joe Wiart, Marie Zins, France; Maria Blettner, Thomas Behrens, Thomas Brüning, Maria Gomolka, Bernd Grosche, Karl-Heinz Jöckel, Peter Kaatsch, Benjamin Kendzia, Stefan Pfister, Claudia Rössig, Brigitte Schlehofer, Martin Stanulla, Dirk Taeger, Hajo Zeeb, Gunde Ziegelberger, Germany; Cathy Segbafia, Ghana; Sameer Bakshi, Desh Deepak, Rajaraman Swaminathan, India; Mehri Sirous, Reza Sirous, Islamic Republic of Iran; Anath Flugelma, Siegal Sadetzki, Israel; Paola Armaroli, Dario Consonni, Silvano Gallus, Susanna Lagorio, Franco Merletti, Silvia Minozzi, Dario Mirabelli, Nereo Segnan, Italy; Masaharu Hoshi, Hiroaki Katayama, Chisato Nagata, Toru Takebayashi, Naohito Yamaguchi, Shunichi Yamashita, Hidenori Yonehara, Shinji Yoshinaga, Japan; Faris Madanat, Jordan; Kazbek Apsalikov, Tatyana Belikhina, Gulmara Kenzhina, Sergey Lukashenko, Anastassiya Mechsheryakova, Lyudmila Pivina, Kazakhstan; Nicholas Kigen, Diana Menya, Rose Ndumia, Margaret Oduor, Stephen Ogendo, Walter Otieno, Sudhir Vinayak, Kenya; Jong Won Lee, Jisun Kim, Sue K. Park, Hee Young Shin, Keun-Young Yoo, Republic of Korea; Andreas Jahnen, Johannes Hermen, Luxembourg; Kondwani Chalulu, Charles Dzamalala, Malawi; Shivaani Mariapun, Nadia Rajaram, Teo Soo-Hwang, Malaysia; Martin Lajous, Ruy López-Ridaura, Mexico; Reinette Koegelenberg, Annelie Zietsman, Namibia; Maartje Brouwer, Carla van Gils, Michael Hauptmann, Hans Kromhout, Roel Vermeulen, Johanna Wanders, The Netherlands; John Dockerty, Jeroen Douwes, Alistair Woodward, New Zealand; Godson Ana, Charles Adeyinka Adisa, Jonathan Biobebe Brown, Nigeria; Alicja Javorska, Eva Godske Friberg, Kristina Kjærheim, Hilde Langseth, Astrid Liland, Karl-Christian Nordby, Hilde Olerud, Tore Tynes, Giske Ursin, Tamara Zhunussova, Norway; Beata Peplonska, Poland; Faleh Mohamed Hussain Ali, Qatar; Alexander Akleyev, Tamara Azizova, Igor Bukhtiyarov, Sergei Kashanskiy, Alexander Karachunskiy, Evgeny Kovalevskiy, Lyudmila Krestinina, Sergei Romanov, Mikhail Sokolnikov, Nikolaj Startsev, Yulia Tsareva, Russian Federation; Kee-Seng Chia, Mikael Hartman, Miao Hui, Charmaine Lee Pei Ling, Singapore; Caroline Dickens, Herbert Cubasch, Raquel Duarte, Maureen Joffe, Noelene Kotschan, Angela Mathee, Elvira Singh, Frank Winde, South Africa; Magda Bosch de Basea, Elisabeth Cardis, Beatriz Perez-Gomez, Manolis Kogevinas, Marina Pollan, Isidro Sanchez-Garcia, Spain; Nagla Gasmelseed, Sudan; Anders Ahlbom, Carolina Bigert, Maria Feychting, Per Gustavsson, Lena Hillert, Magnus Kaijser, Beatrice Melin, Arvid Nordenskjöld, Nils Plato, Sweden; Niels Kuster, Mary Mahy, Anne-Marie Perucic, Armando Perugia, Martin Röösl, Edouard Tursan d'Espaignet, Switzerland; Gibson Kibiki, Amos Mwasamwaja, United Republic of Tanzania; Selin Aytac, Vahit Ozman, Turkey; Moses Galukande, Robert Newton, Uganda; Paul Elliott, John Harrison, Richard Haylock, John Hipwell, Elima Jedy-Agba, Sally Kinsey, Patricia McKinney, Ann McNeill, Jackie O'Hagan, Mark Pearce, Julian Peto, Eve Roman, Anthony J. Swerdlow, Mireille Toledano, Jane Wardle, Michael Watts, Martin Wiseman, United Kingdom; Christopher Abnet, Laura Beane-Freeman, Amy Berrington de Gonzales, Kim Bertrand, Wesley Bolch, Louise Brinton, Celia Byrne, Robert D. Daniels, Sanford Dawsey, Jane Hoppin, Ahmedin Jemal, Matthew Keifer, Martha Linet, Huiyan Ma, Catherine Metayer, Choonsik Lee, Gertraud Maskarinec, Megan Rice, David Richardson, Marc Schenker, Mary Schubauer-Berigan, Steven Simon, Logan Spector, Rulla Tamimi, Christopher Scott, Celine Vachon, Stephen Waring, USA; Groesbeck Parham, Zambia.

**Financial support from the following bodies is gratefully acknowledged:**

Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), France  
American Cancer Society, USA  
Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA), France  
Children with Cancer, United Kingdom  
Danish Cancer Society, Denmark  
European Commission  
Institut national du Cancer (INCa), France  
Ministry for the Environment, Nature Conservation, Building and Nuclear Safety, Germany  
National Institutes of Health (NIH), USA  
Scientific Research Institute of Occupational Health of the Russian Academy of Medical Sciences, Russian Federation  
Supreme Council of Health, Qatar  
Susan G. Komen for the Cure, USA  
Union for International Cancer Control (UICC), Switzerland





## SECTION OF NUTRITION AND METABOLISM (NME)

**Section head**  
**Dr Isabelle Romieu**

DIET, NUTRITION, METABOLIC/HORMONAL IMBALANCES, EXCESS ENERGY CONSUMPTION, OBESITY, AND PHYSICAL INACTIVITY ARE THOUGHT TO BE IMPORTANT CONTRIBUTORS TO INCREASING CANCER INCIDENCE RATES WORLDWIDE. HOWEVER, THE MECHANISMS OF ACTION OF THESE FACTORS REMAIN POORLY UNDERSTOOD. IN ADDITION, THE CONTRIBUTING INFLUENCES OF DIETARY TRANSITIONS FROM TRADITIONAL DIETS TO DIETS TYPICAL OF INDUSTRIALIZED COUNTRIES, WHICH IS TAKING PLACE IN LOW- AND MIDDLE-INCOME COUNTRIES (E.G. IN LATIN AMERICA), AND OF EXPOSURES IN FETAL LIFE OR EARLY INFANCY ARE NOT WELL STUDIED. THUS, THE MAIN OBJECTIVE OF THE SECTION OF NUTRITION AND METABOLISM (NME) IS TO ADDRESS THESE ISSUES BY EVALUATING THE ASSOCIATION OF DIET, DIETARY PATTERNS, NUTRITION, PHYSICAL ACTIVITY, AND ENERGY IMBALANCE WITH CANCER RISK IN HIGH-INCOME AND MEDIUM-TO-LOW-INCOME COUNTRIES USING COHORT AND CASE–CONTROL DESIGNS OR HUMAN INTERVENTION STUDIES. THE EMPHASIS IS ON IMPROVING THE ASSESSMENT OF DIETARY EXPOSURES THROUGH STANDARDIZED DIETARY METHODOLOGIES RELEVANT TO INTERNATIONAL STUDY SETTINGS; APPLYING BIOMARKERS AND METABOLOMICS TO STUDY CELLULAR, BIOCHEMICAL, AND PHYSIOLOGICAL CHANGES; AND CONSIDERATION OF GENE–ENVIRONMENT INTERACTIONS. THE TRANSLATION OF FINDINGS INTO PUBLIC HEALTH RECOMMENDATIONS FOR CANCER PREVENTION IS OF MAJOR IMPORTANCE TO THE SECTION.



# BIOMARKERS GROUP (BMA)

## **Group head**

Dr Augustin Scalbert

## **Scientists**

Dr Dinesh Barupal Kumar  
(until August 2015)

Dr Sabina Rinaldi

## **Database manager**

Ms Vanessa Neveu

## **Laboratory technicians**

Mr David Achaintre

Ms Audrey Gicquiau

Ms Anne-Sophie Navionis

Ms Béatrice Vozar

Mr Jean-Christophe Yorke  
(until June 2015)

Ms Nivonirina Robinot

## **Secretariat**

Ms Dominique Bouchard

Ms Karine Racinoux

## **Postdoctoral fellows**

Dr Marion Carayol

(until March 2015)

Dr William Cheung

Dr William Edmands

(until April 2014)

Dr Pekka Keski-Rahkonen

Dr Parinya Panuwet

Dr Joseph Rothwell

Dr Raul Zamora-Ros

(until September 2015)

## **Students**

Mr Dorian Appelgren  
(until August 2014)

Ms Rastani Harastani  
(until June 2015)

Ms Eloïse Rouaix

(until August 2014)

Mr Roland Wedekind

(until May 2015)

Ms Eline van Roekel

(until October 2015)


The activities of the Biomarkers Group (BMA) have shown a significant development over the 2014–2015 biennium, with the recruitment of three new technicians and three postdoctoral researchers, the relocation of the BMA laboratory and offices to the tower building with a larger space, and the acquisition of two new mass spectrometers and a robot for sample handling.

Several methods based on mass spectrometry have been developed to analyse the metabolome in blood and urine samples (polyphenols, sex steroids, and intermediate metabolism). Methodological studies on the application of these methods to epidemiological studies have been performed (Carayol et al., 2015). The methods were applied to a prospective study on the etiology of hepatocellular carcinoma, in collaboration with the Nutritional Epidemiology Group (NEP), and studies on breast cancer are in progress.

Standard operating procedures were developed to analyse the metabolome on a broader scale (> 3000 metabolites detected) in urine and plasma samples by high-resolution mass spectrometry (Edmands et al., 2014, 2015). These methods were used to characterize the food metabolome (Scalbert et al., 2014) and to identify novel dietary biomarkers (coffee, tea, red wine, citrus fruits, and apples) in a cross-sectional study in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (Figure 1) (Edmands et al., 2015). A new database is being developed called Exposome-Explorer, which includes detailed information on all known dietary biomarkers.

A new food composition table for all known polyphenols was built within the EPIC study, in collaboration with the Dietary Exposure Assessment Group (DEX), and was used to calculate the intake of more than 400 polyphenols in the EPIC cohort (Figure 2). In parallel, a new analytical method was developed to measure the levels of 34 polyphenol biomarkers in urine. The method was applied to 24-hour urine samples collected from 475 subjects in the EPIC cohort. High correlations were observed between polyphenol biomarkers and

**Figure 1.** Heat map showing clusters of signals detected by high-resolution mass spectrometry and associated with the consumption of six specific foods, in 475 urine samples collected in the European Prospective Investigation into Cancer and Nutrition (EPIC) cross-sectional study. Numbers indicate metabolites identified as best predictors of intake. Reprinted with permission from Edmands et al. (2015).




intake measurements, showing the high quality of the new food composition table. Studies on reproductive and menstrual factors, as well as on energy and macronutrient intake and the risk of differentiated thyroid cancer, have been undertaken within the EPIC cohort (Zamora-Ros et al., 2015a), and circulating inflammatory factors and sex steroids are currently being analysed in the same studies. Associations between growth factors, adipokines, and body size in young Mexican women have been inves-

tigated in the Mexican Teachers' Cohort, in collaboration with NEP (Rinaldi et al., 2014a, 2015) to assess whether different adipose tissues are associated with different metabolic alterations.

A method based on gas chromatography has been validated to determine in plasma/serum 60 fatty acids from dietary sources and endogenous metabolism. It is currently being applied to large epidemiological studies, in collaboration with NEP.

**Figure 2.** Polyphenol intake in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study. Intake (in mg/day) is shown for the two main classes of polyphenols (flavonoids, blue bars; phenolic acids, red bars) in the 10 countries of the cohort. Compiled from Zamora-Ros R, Knaze V, Rothwell JA, Hémon B, Moskal A, Overvad K, et al. (2015). Dietary polyphenol intake in Europe: the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Eur J Nutr.* <http://dx.doi.org/10.1007/s00394-015-0950-x> PMID:26081647.



**BMA is grateful to the following for their collaboration:**

Andrea Gsur, Vienna, Austria; Barbara Vanaelst, Belgium; Liang Li, David Wishart, Edmonton, Canada; Maria Luisa Garmendia, Santiago, Chile; Gloria Sanchez, Medellín, Colombia; Ana Cecilia Rodriguez, San Jose, Costa Rica; Anne Tjønneland, Copenhagen, Kim Overvad, Aarhus, Denmark; Kati Hanhineva, Kuopio, Finland; Henry Déchaud, Michel Pugeat, Bron, Cren Cecile, Béatrice Fervers, Lyon, Laure Dossus, Marina Kvaskoff, Françoise Clavel-Chapelon, Marie-Christine Boutron-Ruault, Fabienne Lesueur, Paris, Claudine Manach, INRA, France; Rudolf Kaaks, Annetkatrin Lukanova, Cornelia Ulrich, Heidelberg, Heiner Boeing, Potsdam, Germany; Antonia Trichopoulou, Athens, Greece; Lorraine Brennan, David Hugues, Dublin, Ireland; Vittorio Krogh, Sabina Sieri, Bernardo Bonanni, Milan, Domenico Palli, Florence, Salvatore Panico, Naples, Rosario Tumino, Ragusa, Italy; Gabriela Torres, Ruy Lopez, Martin Lajous, Cuernavaca, Mexico; Eiliv Lund, Elisabete Weiderpass, Tromsø, Norway; Shane Norris, Herbert Cubash, Eunice van den Berg, Raquel Duarte, Maureen Joffe, Johannesburg, Este Vorster, Christina Venter, Potchefstroom, South Africa; Carlos Gonzales, Barcelona, Maria José Sánchez, Granada, Carmen Navarro, Murcia, Aurelio Barricarte, Pamplona, Miren Dorronsoro, San Sebastian, Spain; Jonas Manjer, Malmö, Joakim Hennings, Maria Sandström, Umeå, Sweden; Roel Vermeulen, Petra H.M. Peeters, Utrecht, Ellen Kampman, Wageningen, Bas Bueno de Mesquita, Bilthoven, The Netherlands; Hector Keun, London, Kay-Tee Khaw, Cambridge, Travis Ruth, Tsilidis Kostantinos, Tim Key, Oxford, Paolo Vineis, Marc Gunter, London, United Kingdom; Anne Zeleniuch-Jacquotte, New York, Rashmi Sinha, Cari Kitahara, Bethesda, Peggy Porter, Seattle, Megan Rice, Boston, Steve Rappaport, Berkeley, USA.

**Financial support from the following bodies is gratefully acknowledged:**

Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA), Lyon, France  
European Commission, Brussels, Belgium  
Institut national du Cancer (INCa), Paris, France  
World Cancer Research Fund, London, United Kingdom



# DIETARY EXPOSURE ASSESSMENT GROUP (DEX)

## **Group head**

Dr Nadia Slimani

## **Scientists**

Dr Heinz Freisling  
Dr Inge Huybrechts

## **Database managers**

Ms Corinne Casagrande  
Dr Aurélie Moskal

## **Technical assistants**

Ms Viktoria Knaze  
Ms Geneviève Nicolas

## **Secretariat**

Ms Dominique Bouchard  
(until January 2015)  
Ms Dominique Meunier  
Ms Karine Racinoux  
(until August 2014)

## **Postdoctoral students**

Dr Elom Aglago  
Dr Silvia Bel-Serrat  
Dr Anne-Kathrin Illner  
(until November 2014)  
Dr Edwige Landais  
(until January 2015)  
Dr Tobias Mayer  
Dr Amy Mullee  
Dr Hwayoung Noh  
Dr Min Kyung Park

## **Doctoral student**

Ms Cristina Julian Almarcegui  
(until August 2014)

## **Master's students**

Ms Evelien Dieleman  
(until June 2015)  
Ms Chiara Romano  
(until February 2015)  
Ms Vickà Rita I. Versele  
(until June 2014)

## **Bachelor's students**

Ms Marlène De Backer  
(until May 2014)  
Ms Lore Decrop  
(until May 2015)  
Ms Mona Delagrangue  
(until May 2015)  
Ms Aoibheann Dunne  
Mr Joren Maes  
(until June 2015)  
Ms Heleen Van Puyvelde  
(until May 2015)

## **Trainee**

Ms Josefina De Ridder  
(until May 2014)



International nutrition surveillance systems to monitor trends and better understand the nutrition transition and its association with the global burden of noncommunicable diseases (NCDs) are currently lacking. To address this gap, the Dietary Exposure Assessment Group (DEX) launched the IARC-WHO Global Nutrition Surveillance initiative in 2014–2015, with the aim of collecting standardized dietary data worldwide, using DEX methodologies, to support dietary surveillance, research, and prevention of cancer and other NCDs, and ultimately to promote more concerted prevention and research action plans. The GloboDiet-Europe consortium, involving seven countries using the DEX methodology in their national surveys (Austria, Belgium, France, Germany, Malta, the Netherlands, and Switzerland), has been developed as a proof of concept of the global initiative, and the legal consortium framework to support it is being explored. In parallel, pilot initiatives have been pursued in other regions worldwide (Latin America,


Asia, and Africa). Korean (Park et al., 2015), Mexican, and Brazilian versions of GloboDiet have been completed, and road maps for their local validation and implementation are advanced. In Africa, an inventory, conducted as a prerequisite of any implementation, highlighted a lack of comparable dietary assessment methods and support infrastructure for research across the 18 countries represented, and elucidated specific needs and obstacles for implementation.

DEX, as part of its advanced methodological research on improving dietary assessment (Freisling and Slimani, 2015; Leclercq et al., 2015; Julián-Almárcegui et al., 2015; Slimani et al., 2015) and its contribution to the transfer of knowledge and training (Figure 1), and through partnerships and grant projects (e.g. Determinants, Intake, Status, Health [EuroDISH]; Biobanking and Biomolecular Resources Research Infrastructure – Large Prospective Cohorts [BBMRI-LPC]; Determinants of Diet and Physical Activity [DEDIPAC]; and Pilot Study for the Assessment of Nutrient Intake and Food Consumption Among Kids in Europe [PANCAKE]),

has led the development of a strong virtual research environment/research infrastructure (GloboDiet-VRE/RI) concept. GloboDiet-VRE/RI aims to support the GloboDiet initiative, as well as new international targeted tools (e.g. tools targeted to children validated in the PANCAKE project) (Freisling et al., 2015; Ocké et al., 2015) and validation against biomarkers of WHO health indicators obtained with GloboDiet (e.g. sodium intakes) (De Keyzer et al., 2015a). This GloboDiet-VRE will feed into the European Strategy Forum on Research Infrastructures (ESFRI) road map of implementation of a pan-European Union interfaced food and nutrient intake RI.

New approaches to analyse nutrient patterns in international study settings have been initiated by DEX in collaboration with the Nutritional Epidemiology Group (NEP), starting with a first European-wide nutrient patterns analysis (Moskal et al., 2014). These patterns were shown to be associated with moderate but significant long-term differences in weight gain in adults.

Figure 1. Towards an integrated approach to measure diet in international epidemiological studies. Reprinted from Illner AK, Freisling H, Boeing H, Huybrechts I, Crispim SP, Slimani N (2012). Review and evaluation of innovative technologies for measuring diet in nutritional epidemiology. *Int J Epidemiol.* 41(4):1187–203. <http://dx.doi.org/10.1093/ije/dys105> PMID:22933652, by permission of Oxford University Press.



**DEX is grateful to the following for their collaboration:**

Madjid Atek, Algiers, Algeria; Peter M. Abuja, Jan-Eric Litton, Kurt Zatloukal, Graz, Mario Döller, Kufstein, Jürgen König, Petra Rust, Vienna, Austria; Koenraad Cuypers, Jean Tafforeau, Herman Van Oyen, Brussels, Belgium; Waliou Hounkpatin Amoussa, Cotonou, Benin; Claudia Choma Bettiga Almeida, Sandra Crispim, Curitiba, Cristiane Cominetti, Maria do Rosario Gondim Peixoto, Goiânia, Severina Carla Lima, Clelia De Oliveira Lyra, Natal, Rosangela Pereira, Rosely Sichier, Rio de Janeiro, Regina Fisberg, Dirce Maria Lobo Marchioni, São Paulo, Brazil; Brice U. Saha Foudjo, Yaoundé, Cameroon; Christine M. Friedenreich, Nonsikelelo Mathe, Edmonton, Hélène Delisle, Isabel Fortier, Montreal, Canada; Catterina Ferreccio, Santiago, Chile; João Breda, Jo Jewell, Copenhagen, Anja Pia Bilttoft-Jensen, Tue Christensen, Ellen Trolle, Søborg, Denmark; Ayoub Al Jawaldeh, Sahar Saad Zaghloul, Cairo, Egypt; Liisa Korkalo, Helsinki, Finland; Carine Dubuisson, Céline Ménard, Jean-Luc Volatier, Maisons-Alfort, Edwige Landais, Claire Mouquet, Yves Martin-Prével, Montpellier, Sandrine Lioret, Villejuif, Lionel Brunie, Villeurbanne, France; Wolfgang Ahrens, Bremen, Thorsten Heuer, Carolin Krems, Karlsruhe, Veit Grote, Munich, Germany; Paul Amuna, Francis Zotor, Accra, Ledo James, Tema, Ghana; Antonia Trichopolou, Athens, Greece; Cecily Kelleher, Celine Murrin, Dublin, Ireland; Anna Lartey, Warren Lee, Catherine Leclercq, Rome, Italy; Norie Sawada, Tokyo, Junko Ishihara, Kanagawa, Japan; Catherine Mutie, Nairobi, Kenya; Jeongseon Kim, Republic of Korea; Alexander Kalimbira, Lilongwe, Malawi; Daniel Cauchi, Charmaine Gauci, Msida, Malta; Gabriela Garcia, Juan Ángel Rivera Dommarco, Tania Sanchez Pimienta, Cuernavaca, Mexico; Karima El Rhazi, Fez, Asmae El Hamdouchi, Rabat-Kenitra, Morocco; Hilde Liisa Nashandi, Windhoek, Namibia; Marga C. Ocké, Caroline van Rossum, Bilthoven, Edvard Beem, Jolien Wenink, Jildau Bouwman, The Hague, Jeanne de Vries, Pieter van't Veer, Wageningen, The Netherlands; Oluseye Olusegun Onabanjo, Abeokuta, Kingsley Ikechukwu Ubaaji, Awka, Olaide Ruth Aderibigbe, Ibadan, Nigeria; Lene Frost Andersen, Arnhild Bergljot Haga Rimestad, Oslo, Norway; Maria Antonia Calhau, Lisbon, Portugal; Mojca Gabrijelcic, Ljubljana, Slovenia; Mieke Faber, Cape Town, Shane A. Norris, Johannesburg, Johann Jerling, Annamarie Kruger, Covic Namukolo, Este Vorster, Potchefstroom, South Africa; Teresa Robledo, Madrid, Spain; Esther Camenzind-Frey, Christine Zuberbuehler, Bern, Timothy Armstrong, Francesco Branca, Oleg Chestnov, Riccardo Lampariello, Julie Torode, Geneva, Karl Presser, Zurich, Switzerland; Igor Spiroski, Skopje, The former Yugoslav Republic of Macedonia; Hajer Aounallah-Skhiri, Jalila El Ati, Tunis, Tunisia; Alex Mokori, Kampala, Uganda; Omar Dary, Cambridge, Mitrou Giota, London, Paul Finglas, Norwich, Barrie Margetts, Southampton, United Kingdom; Alanna J. Moshfegh, Beltsville, James Hebert, Nitin Shivappa, Columbia, Zo Rambeloston, Research Triangle Park, Cheryl A.M. Anderson, San Diego, Chessa Lutter, Washington DC, USA; Chakare Benhura, Jephath Chifamba, Tatenda Machiweni, Carol Mahachi, Harare, Zimbabwe.

**Financial support from the following bodies is gratefully acknowledged:**

European Commission  
Federal Office of Public Health, Switzerland  
Institut national du Cancer (INCa), France  
Max Rubner Institute, Germany  
Ministry for Health, Health Promotion and Disease Prevention Directorate, Malta  
Scientific Institute of Public Health, Belgium  
The State of the Netherlands, Minister of Public Health, Welfare and Sport, The Netherlands  
University of Vienna, Austria  
World Cancer Research Fund



# NUTRITIONAL EPIDEMIOLOGY GROUP (NEP)

## **Group head**

Dr Isabelle Romieu

## **Scientists**

Dr Véronique Chajès

Dr Pietro Ferrari

Dr Mazda Jenab

## **Senior visiting scientists**

Dr Michael Leitzmann

(until August 2015)

Dr Duncan Thomas

## **Visiting scientists**

Dr Laure Dossus

Dr Maria Luisa Garmendia

(until May 2014)

Dr Gihan Hosny

(until August 2015)

Dr Hortensia Moreno Macias

(until July 2014)

Dr Grégory Ninot

Dr Cristian Ricci

## **Database managers**

Ms Carine Biessy

Mr Bertrand Hemon

Mr Abraham Tewa

## **Laboratory technician**

Ms Anne-Sophie Navionis

(until May 2015)

## **Secretariat**

Ms Nadia Akel

Ms Cécile Le Duc

Ms Elizabeth Page

(until June 2014)

## **Postdoctoral fellows**

Dr Amina Amadou-Yacouba

(until March 2015)

Dr Jordi de Batlle

(until November 2014)

Dr Marion Carayol

Dr Talita Duarte-Salles

(until April 2015)

Dr So Yeon Kong

(until September 2014)

Dr Cecilie Kyrø

(until March 2015)

Dr Kuanrong Li

Dr Ildir Licaj

(until March 2014)

Dr Marco Matejcic

Dr Fiona McKenzie

(until March 2014)

Dr Faidra Stavropoulou

(until June 2015)

Dr Magdalena Stepien

Dr Christine Taljaard

(until September 2015)

## **Doctoral students**

Ms Nada Assi

Ms Flavie Perrier

## **Master's student**

Ms Sahar Yammine

(until June 2015)

## EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION (EPIC)

The Nutritional Epidemiology Group (NEP) ensures the coordination of the European Prospective Investigation into Cancer and Nutrition (EPIC) by centralizing up-to-date cancer end-point/vital status data (Table 1), centralizing multiple end-points and updated exposure information, delivering project-specific databases to the EPIC network, and tracking biological sample retrieval/use.

### NUTRITIONAL AND LIFESTYLE CANCER PREDICTORS

#### OBESITY

Maintaining a healthy weight is important for cancer prevention. NEP's analysis, in collaboration with the Dietary Exposure Assessment Group (DEX) and the Biomarkers Group (BMA), of circulating industrial trans fatty acids (biomarkers of highly processed foods) shows a positive association with weight gain over time (Chajès et al., 2015) and has been extended to countries in Latin America, the Middle East, and Africa.

## ALCOHOL CONSUMPTION AND CANCER

Higher lifetime alcohol consumption was identified as a major determinant of mortality (Ferrari et al., 2014). However, an inverse association was noted for papillary and follicular thyroid carcinomas (Sen et al., 2015). A consortium of worldwide cohorts was created to evaluate alcohol–cancer associations at less-studied anatomical sites.

### EARLY ENVIRONMENTAL EXPOSURE, METABOLIC DISORDERS, AND CANCER

NEP's study of fetal and childhood exposures and the incidence of intermediate cancer outcomes shows an influence of supplementation with docosahexaenoic acid (DHA) on methylation at *IGF2/H19* imprinted genes (Lee et al., 2014a) and an important role of breastfeeding on lowered adiposity and total cholesterol levels in childhood (Ramirez-Silva et al., 2015).

#### BREAST CANCER

NEP's work on dietary and lifestyle patterns has shown reduced breast

cancer risk in women with nutrient patterns high in micronutrients originating from vegetables, fruits, and cereals, or women who score highly on a healthy lifestyle index (McKenzie et al., 2015). Further analysis showed a link between higher alcohol consumption and breast cancer of all receptor-based phenotypes, particularly among women consuming alcohol before their first full-term pregnancy (Figure 1) (Romieu et al., 2015).

Two nutrients of interest are dietary folate and fatty acids. Higher intake of dietary folate was associated with lower risk of estrogen receptor (ER)-negative breast cancers in premenopausal women (de Batlle et al., 2015). Preliminary biomarker-based results suggest different breast cancer risks for specific fatty acid subgroups (Pouchieu et al., 2014).


### STUDIES ON BREAST CANCER IN LOW- AND MIDDLE-INCOME COUNTRIES

NEP collaborated with national institutions in Mexico in the large prospective Mexican Teachers' Cohort to explore

**Table 1. Description of the European Prospective Investigation into Cancer and Nutrition (EPIC) study**

Sex	Country	Number of participants	Person-years	Number of incident cancers	Number of incident deaths
Women	France	74 523	1 420 115	9015	5723
	Italy	32 577	498 612	3561	1551
	Spain	25 808	479 249	2288	1528
	United Kingdom	60 967	1 007 559	7325	7669
	Netherlands	29 751	484 984	3579	3042
	Greece	16 614	181 903	770	1213
	Germany	30 255	411 560	2354	1453
	Sweden	30 328	552 306	4620	4668
	Denmark	29 875	490 930	5778	4110
	Norway	37 200	514 326	3802	1452
	Total	367 898	6 041 544	43 092	32 409
Men	France	—	—	—	—
	Italy	15 168	237 627	1829	1133
	Spain	15 629	284 030	2466	2155
	United Kingdom	26 917	424 843	4445	6396
	Netherlands	10 260	166 222	869	885
	Greece	11 947	121 475	740	1537
	Germany	22 833	311 217	2597	2590
	Sweden	23 494	413 112	4764	5455
	Denmark	27 178	428 296	6206	5886
	Norway	—	—	—	—
	Total	153 426	2 386 821	23 916	26 037

**Figure 1. Dose–response curve of breast cancer (BC) risk with alcohol intake at recruitment. The dose–response curve is displayed up to 35 g/day, corresponding to the 99th percentile of the alcohol intake distribution. Reprinted with permission from Romieu et al. (2015).**



predictors of mammographic density (Rinaldi et al., 2014a; Rice et al., 2015). Results from a multicentre case–control study conducted in Mexico show increased breast cancer risks with increasing body shape silhouette over the life course (Amadou et al., 2014a), high carbohydrate intake (Amadou et al., 2015), and lower scores on a healthy lifestyle index (Fanidi et al., 2015).

NEP leads a World Cancer Research Fund (WCRF)-funded study of dietary/lifestyle determinants of breast cancer in the understudied population of Soweto, South Africa, with structured collection of individual, clinical, and pathological information, biological specimens, and detailed anthropometry (DEXA/ultrasound). This study will provide relevant information on tumour subtype frequencies and specific risk factors for breast cancer incidence and survival.

#### MOLECULAR SUBTYPES OF PREMENOPAUSAL BREAST CANCER IN LATIN AMERICAN WOMEN (PRECAMA): A MULTICENTRE POPULATION-BASED CASE–CONTROL STUDY

NEP coordinates the PRECAMA project to explore risk factors for premenopausal breast cancer among Hispanic women in four Latin American countries (Chile,

Colombia, Costa Rica, and Mexico). The standardized protocols (refined phenotyping, identification of endogenous or exogenous risk factors) and structured collection of individual, clinical, and pathological information and biological specimens were successful in the feasibility study (<http://precama.iarc.fr>). The main study is now under way, with Brazil also joining.

#### COLORECTAL CANCER

Inverse associations with risk of colorectal cancer were observed with higher circulating selenoprotein P levels (a selenium status indicator) (Hughes et al., 2015), higher plasma alkylresorcinols (biomarkers of whole-grain intake), for the distal colon cancer only (Kyrø et al., 2014a), and lower endogenous energy excess, for rectal cancer only. Post-diagnosis survival of colorectal cancer patients was improved with lower pre-diagnostic general/abdominal adiposity (Fedirko et al., 2014a) or concordance with the WCRF/American Institute of Cancer Research (WCRF/AICR) cancer prevention guidelines (Romaguera et al., 2015).

#### HEPATOCELLULAR CARCINOMA

Associations with decreased risk of hepatocellular carcinoma were observed

with higher consumption of monounsaturated fats (Duarte-Salles et al., 2015), vegetables (Bamia et al., 2015a), or coffee/tea (Bamia et al., 2015b) and with lower consumption of sugary drinks and of milk/cheeses (Duarte-Salles et al., 2014). Multiplatform metabolomic analyses identified distinct profiles between cases and matched controls (Fages et al., 2015), particularly with respect to levels of some amino acids.

#### METHODOLOGICAL RESEARCH

NEP has developed statistical techniques to correct for measurement errors in episodically consumed foods (Agogo et al., 2014) and to evaluate individual-level and aggregate-level evidence of diet–disease associations using multilevel modelling (Sera and Ferrari, 2015). Analytical frameworks were conceptualized to explore major sources of variability in large-dimensional data (e.g. metabolomics; Fages et al., 2014) and to model the “meeting-in-the-middle” principle linking dietary/lifestyle exposures and cancer risks through metabolomics (Assi et al., 2015). The treelet transform was identified as an informative technique to investigate dietary patterns in breast cancer etiology.

**NEP is grateful to the following for their collaboration:**

Marisa Breitenbach, Liz Almeida, Brazil; Robert W. Bruce, Ahmed El-Soheemy, Gail McKeown-Eyssen, Parminder Raina, Canada; Eva Bustamante, Eva Ana María Carrasco, Camila Corvalan, Maria Luisa Garmendia, Ricardo Uayi, Chile; Carolina Echeverri, Miguel Roldan, Gloria Sanchez, Colombia; Diego Guillén, Ana Cecilia Rodriguez, Costa Rica; Kim Overvad, Anne Tjønneland, Denmark; Pierre-Yves Bello, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon, Benedicte Elena-Hermann, Béatrice Fervers, Martine Laville, Fabienne Lesueur, France; Heiner Boeing, Rudolf Kaaks, Tobias Pischon, Germany; Antonia Trichopoulou, Dimitrios Trichopoulos, Greece; David Hughes, Ireland; Franco Berrino, Vittorio Krogh, Domenico Palli, Salvatore Panico, Rosario Tumino, Paolo Vineis, Italy; Hideyuki Hyogo, Japan; Isabel Alvarado Cabrera, Albino Barraza-Villareal, Martin Lajous, Alejandro Mohar, Ruy Lopez Ridaura, Juan Rivera, Gabriela Torres-Mejia, Eduardo Lazcano, Mexico; Bas Bueno de Mesquita, Petra Peeters, The Netherlands; Eiliv Lund, Guri Skeie, Elisabete Wiedepass, Norway; Herbert Cubasch, Maureen Joffe, Shane Norris, Este Vorster, Johann Jerling, South Africa; Aurelio Barricarte, Carlos A. González, Miren Dorronsoro, Carmen Navarro, José Ramon Quirós, María José Sánchez Pérez, Spain; Göran Hallmans, Jonas Manjer, Sweden; Amanda Cross, Marc Gunter, John E. Hesketh, Timothy J. Key, Kay-Tee Khaw, Teresa Norat, Elio Riboli, Afshan Siddiq, United Kingdom; Laura Beretta, Elizabeth Donato, Veronika Fedirko, Andrew T. Gewirtz, Viktor Kipnis, Peggy Porter, Usha Ramakrishnan, Megan Rice, USA.

**Financial support from the following bodies is gratefully acknowledged:**

American Institute for Cancer Research, Washington DC, USA  
Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA)  
European Commission, Brussels, Belgium  
Institut national du Cancer (INCa), Paris, France  
La Fondation de France, France  
La Ligue nationale contre le Cancer, France  
Le Comité du Rhône de la Ligue nationale contre le Cancer  
World Cancer Research Fund, London, United Kingdom







## SECTION OF GENETICS (GEN)

**Section head**  
Dr Paul Brennan

THE SECTION OF GENETICS (GEN) COMPRISES THE GENETIC EPIDEMIOLOGY GROUP (GEP), THE GENETIC CANCER SUSCEPTIBILITY GROUP (GCS), AND THE BIOSTATISTICS GROUP (BST). THE WORK OF THE SECTION COMBINES LARGE POPULATION-BASED STUDIES WITH LABORATORY AND BIOINFORMATICS EXPERTISE TO IDENTIFY SPECIFIC GENES AND GENETIC PROFILES THAT CONTRIBUTE TO THE DEVELOPMENT OF CANCER AND ELUCIDATE HOW THEY EXERT THEIR EFFECT ALONG WITH ENVIRONMENTAL FACTORS. THE SECTION ALSO TRIES TO IDENTIFY INDIVIDUALS WHO ARE AT HIGH ENOUGH RISK THAT THEY ARE LIKELY TO BENEFIT FROM EXISTING RISK REDUCTION STRATEGIES.

GEN's projects usually involve extensive fieldwork in collaboration with external investigators in order to develop large-scale epidemiological studies with appropriate clinical and exposure data, as well as biosample collection. This typically occurs within GEP, which has a primary interest in the analysis and identification of common genetic susceptibility variants and their interaction with non-genetic risk factors. Genetic analysis comprises either candidate gene or genome-wide genotyping studies, as well as sequencing work. GEP studies also assess non-genetic exposures, partly in recognition of the importance of non-genetic factors in driving cancer incidence, and also to facilitate accurate assessment of gene-environment interactions. In contrast, GCS places more focus on identification of uncommon or rare genetic variants that

may have a larger effect than common single-nucleotide polymorphisms but that are not sufficiently frequent to be captured by current genome-wide association genotyping arrays. GCS's approach has been to use genomic and bioinformatic techniques to complement more traditional approaches for the study of rare genetic variants. GCS also uses genomics to explore how the variants may be conferring genetic susceptibility to cancer. Thus, the research programme of GCS complements that of GEP, and also provides a facility for high-throughput genomic techniques and the related bioinformatics to support GEN's large-scale molecular epidemiology projects and other IARC genomics projects. BST interacts at all stages to provide overall statistical support within GEN and more widely across research Sections of the Agency.



# BIostatISTICS GROUP (BST)

## Group head

Dr Graham Byrnes

## Secretariat

Ms Isabelle Rondy

Ms Nicole Suty (until June 2015)

## Assistant (biostatistics)

Mr Liacine Bouaoun

The Biostatistics Group (BST) continued to collaborate with several Sections at IARC. In some cases this involved the development of novel techniques, in others the identification of appropriate standard approaches, and in all cases with the goal of ensuring the reliability of scientific findings at the Agency.

Methodological highlights included the modelling contribution to the estimation of global cancer burden due to overweight and obesity (Arnold et al., 2015a), the identification of somatic mutation patterns suggesting that aristolochic acid may be an important factor in hepatocellular carcinoma in Romania

(Scelo et al., 2014), the development of an approach to epigenetic analysis of childhood cancer risk (Ghantous et al., 2015), and the exploration of the “meeting-in-the-middle” approach to multi-omics analysis (Assi et al., 2015).

Other contributions included refining the use of multiple data types to identify germline genetic factors associated with risk of aerodigestive tract cancers (Delahaye-Sourdeix et al., 2015a, 2015b).

Routine statistical oversight also contributed to some articles on risk factors for thyroid cancer (e.g. Zamora-Ros et al., 2015a).

## **BST is grateful to the following for their collaboration:**

John Mathews, James Dowty, John Burgess, Melbourne, Australia; Francesca Damiola, Pierre Hainaut, Lyon, France; Elisabeth Cardis, Barcelona, Spain; Sarah Darby, Oxford, United Kingdom.



# GENETIC CANCER SUSCEPTIBILITY GROUP (GCS)

## **Group head**

Dr James McKay

## **Scientists**

Dr Behnoush Abedi-Ardekani  
Dr Lynnette Fernandez-Cuesta  
Dr Matthieu Foll  
Dr Florence Le Calvez-Kelm

## **Visiting scientist**

Dr Behnoush Abedi-Ardekani  
(until December 2014)

## **Laboratory technicians**

Ms Amélie Chabrier  
Mr Geoffroy Durand  
Ms Nathalie Forey  
Ms Nivonirina Robinot  
(until October 2015)

## **Bioinformaticians**

Dr Maxime Vallée  
(until November 2014)  
Ms Catherine Voegelé

## **Secretariat**

Ms Isabelle Rondy  
Ms Nicole Suty  
(until June 2015)

## **Postdoctoral fellows**

Dr Patrice Avogbe  
Dr Mohd Arifin Bin Kaderi  
(until April 2014)  
Dr Lynnette Fernandez-Cuesta  
(until December 2014)  
Dr Maroulio Pertesi  
(until April 2015)

## **Students**

Mr Georgios Antonopoulos  
(until March 2014)  
Mr Thomas Boyer  
(until September 2015)  
Ms Manon Delahaye  
(until November 2014)  
Ms Tiffany Delhomme  
Ms Violeta Facciolla  
(until March 2014)  
Ms Yellana Ikdoumi  
(until July 2014)  
Ms Noemie Leblay  
Ms Marion Perez  
(until September 2014)

The Genetic Cancer Susceptibility Group (GCS) has two equally weighted roles within IARC. First, GCS acts as a laboratory, bioinformatics, and pathology resource for genomic research at the Agency. Second, in close collaboration with its Section partners the Genetic Epidemiology Group (GEP) and the Biostatistics Group (BST), GCS undertakes genetic and genomics research to identify cancer-related genes and explore their mechanisms of action. Through this knowledge, GCS aims to provide insights into cancer etiology, early detection, and prevention.

During the 2014–2015 biennium, GCS has welcomed three scientists into the Group: Dr Matthieu Foll, Dr Lynnette Fernandez-Cuesta, and Dr Behnoush Abedi-Ardekani. Their joining the Group has strongly reinforced its scientific profile in bioinformatics, somatic mutations, and genomic-related pathology, respectively.

#### GENOME-WIDE ASSOCIATION STUDIES

One of GCS's key scientific findings during the biennium was through a very large imputation-based genome-wide association study (GWAS) of lung cancer. This was undertaken through a collaboration between IARC, the Institute of Cancer Research (United Kingdom), Dartmouth College (USA), and the United States National Cancer Institute (US NCI) (Wang et al., 2014a). It included 21 594 cancer cases and 54 156 controls, making it one of the largest genetic studies of lung cancer carried out to date. This analysis identified three novel

variants: one small-effect, common allele (rs13314271, located near *TP63*) and two large-effect, rare alleles (rs17879961, a missense variant [I157T] in *CHEK2*, and rs11571833, a truncating variant that results in the loss of the final 93 amino acids of *BRCA2*). Also, rs11571833 was observed to be similarly strongly associated with upper aerodigestive tract cancer (Delahaye-Sourdeix et al., 2015a). The association noted with the *CHEK2* variant validated GCS's previous observation of an inverse association with lung cancer and contrasts with the well-described increase in risk described for this variant in other cancers. In the case of *BRCA2*, susceptibility to lung and upper aerodigestive tract cancer had not been previously linked to genetic variation in this well-studied gene. Both findings suggest that alternative susceptibility mechanisms are at work and highlight how unexpected findings from agnostic genetic studies inform cancer etiology.

GCS also coordinated a meta-analysis-based GWAS of Hodgkin lymphoma that identified a susceptibility locus near *TCF3*, a gene critical to B-cell development (Cozen et al., 2014), and GCS was involved in the validation of rare variants linked with breast cancer in *RINT1* (Park et al., 2014a) and the MRE11A-RAD50-nibrin (MRN) complex (Damiola et al., 2014a). GEN has completed recruitment of a multicentre case–control study of 2535 nasopharyngeal cancer (NPC) cases and 2652 controls from centres in Malaysia (Sarawak), Thailand, Singapore, and Indonesia. Linkage analysis of 17

NPC cases from an extended pedigree recruited from Malaysia identified 6p22.1 as an area of interest. This region contains the *HLA-A* gene, previously implicated in NPC. In collaboration with the US NCI, GCS identified that allele HLA-A\*24:07 segregates with NPC in this pedigree. The HLA-A\*24:07 allele is relatively common to Sarawak and very rare elsewhere. Work is in progress to determine whether this allele is associated with NPC in the case–control study.

#### GENETIC SERVICES PLATFORM

The Genetic Services Platform has overseen the installation of an additional liquid-handling robot to assist in GCS's laboratory protocols and the management of the almost 100 000 DNA samples, originating from about 75 studies, that are housed within GCS. In addition, an Ion Torrent Proton next-generation sequencer has been installed, and collaborative links have been maintained with local service providers to access additional genomic techniques, such as Illumina (HiSeq/HiScan technology). In bioinformatics, GCS has overseen two technical updates of IARC's high-performance computer cluster and data management systems, and has placed particular emphasis on the development of algorithms able to detect low-allele-frequency variants in the context of targeted next-generation sequencing-based resequencing. GCS has played a key role in the development of the Bioinformatics Steering Committee, a group that monitors bioinformatics across the Agency.

#### GCS is grateful to the following for their collaboration:

Professor Gilles Thomas and his team at Synergy Lyon Cancer (Lyon, France) for high-performance computing support. Professor Thomas was an inspiration to GCS and is deeply missed. Other collaborators include: Melissa C. Southey, Melbourne, Australia; Henrik Hjalgrim, Copenhagen, Denmark; Francesca Damiola, Charles Dumontet, Uzma Hasan, Joel Lachuer, Lyon, France; Fabienne Lesueur, Paris, France; Jajah Fachiroh, Dewajani Purnomosari, Yogyakarta, Indonesia; Beena Devi, Kuching, Malaysia; Anke van den Berg, Groningen, The Netherlands; Tam Ha, Singapore; Suleeporn Sangrajrang, Bangkok, Thailand; Ruth Jarrett, Glasgow, United Kingdom; Chris Amos, Hanover, USA; Wendy Cozen, Los Angeles, USA; David E. Goldgar, Sean V. Tavtigian, Salt Lake City, USA; Allan Hildesheim, Bethesda, USA.

**Financial support from the following bodies is gratefully acknowledged:**

Association Aide à la recherche en biologie moléculaire, France  
Fondation ARC pour la recherche contre le Cancer, France  
Institut national du Cancer (INCa), France  
La Ligue contre le Cancer Rhône-Alpes, France  
National Cancer Institute, National Institutes of Health, USA





# GENETIC EPIDEMIOLOGY GROUP (GEP)

**Group head**

Dr Paul Brennan

**Scientists**

Dr Devasena Anantharaman  
Dr Estelle Chanudet-van den Brink  
Dr Mattias Johansson  
Dr Ghislaine Scélo

**Technical assistants**

Ms Valérie Gaborieau  
Ms Hélène Renard

**Laboratory technician**

Ms Priscilia Chopard

**Project assistants**

Ms Laurène Bouvard  
Ms Carole Goutorbe  
(until April 2014)

**Secretariat**

Ms Charlotte Volatier

**Visiting scientists**

Dr Behnoush Abedi-Ardekani  
(until January 2015)  
Dr Risa Chaisuparat  
(until December 2014)  
Dr Hooman Khademi Kohnehshahri  
Dr Peng Li

**Postdoctoral fellows**

Dr Robert Carreras Torres  
Dr Corina Lesseur Perez  
Dr David Muller  
(until September 2015)  
Dr Sandra Perdomo Velasquez  
(until November 2015)  
Dr Carolina Santamaria Ulloa  
Dr Chanida Vinayanuwattikun  
Dr Cheng Wang  
(until March 2014)  
Dr Magdalena Wozniak  
(until October 2014)

**Students**


Mr Anouar Fanidi  
(until October 2015)  
Ms Lise Jacqueroux  
(until August 2015)

The overall goal for the Genetic Epidemiology Group (GEP) is to identify genetic susceptibility variants of various cancer sites and study their interaction with environmental factors. An additional goal is to develop accurate risk prediction models that take both demographic information (e.g. age and sex) and biomarkers (genetic and non-genetic) into account. GEP focuses specifically on cancers related to tobacco use and alcohol consumption (lung and aerodigestive tract cancers) and cancers with moderate incidence rates (such as kidney and pancreatic cancers). GEP devotes substantial resources to extensive fieldwork, with the goal of recruiting large series of cases and controls, comprising extensive questionnaire information and biological samples. Genetic analyses usually comprise a genome-wide approach initially, with subsequent large-scale coordinated replication studies in diverse populations. This latter aspect is aided by the development of international consortia in which GEP takes a leading role. Confirmed susceptibility loci are investigated in more detail with a variety of techniques, including in silico, expression, and sequencing studies, which are often conducted in collaboration with other IARC Groups. In addition to studies of genetic factors, GEP is conducting a wide range of studies involving non-genetic factors, including evaluations of circulating biomarkers such as human papillomavirus (HPV) antibodies for head and neck cancers, cotinine for lung cancer, and dietary biomarkers for multiple cancers. GEP also performs extensive evaluations of questionnaire data, particularly of data that have been collected during fieldwork. Some prominent examples of the Section's work over the 2014–2015 biennium are described here.

#### GENETICS OF KIDNEY CANCER

The first phase of the CAGEKID study (part of the International Cancer Genome Consortium) has been completed, with complete whole-genome sequencing of 100 tumour–germline DNA pairs collected through the IARC central European study and in the United Kingdom. Initial important findings included the observation of a large majority of patients from Romania who

**Figure 1. Mutation patterns from whole-genome sequencing of 94 conventional renal cell carcinomas from four different countries, showing a notable excess in the proportion of A:T > T:A mutations in cases from Romania.** Reprinted with permission from Brennan P, Wild C (2015). *Genomics of cancer and a new era for cancer prevention*. PLoS Genet. <http://dx.doi.org/10.1371/journal.pgen.1005522>.




had an unexpectedly high frequency of A:T > T:A transversions, consistent with exposure to aristolochic acid (Scelo et al., 2014). These results show that the processes underlying clear-cell renal cell carcinoma (ccRCC) tumorigenesis may vary in different populations and suggest that aristolochic acid may be an important ccRCC carcinogen in Romania, a finding with major public health implications (Figure 1). In parallel, the genome-wide analysis of renal cancer susceptibility has been completed, in a large study comprising germline genetic data on more than 10 000 renal cancer cases and 20 000 controls. This work is being undertaken in collaboration with the United States National Cancer Institute, and initial analyses point to several new genetic loci for this cancer.

#### GENOME-WIDE ANALYSIS OF TOBACCO-RELATED CANCERS

GEP has coordinated a large OncoArray analysis of more than 7000 cancers of the oral cavity or oropharynx, along with a similar number of controls. A prominent finding from this study is the important role of the HLA region for oropharyngeal cancer, suggesting an important interaction with HPV (Figure 2). GEP has identified specific HLA loci that are associated with multiple forms of HPV antibody expression (Chen et al., 2015). In addition, GEP is contributing a large series of cases to the genome-wide study of lung cancer that is due to report its findings at the end of 2015.

**Figure 2. Manhattan plot of oropharyngeal OncoArray genome-wide association studies (GWASs).** The vertical axis shows  $-\log_{10}(P\text{-values})$  for 7.5 million single-nucleotide polymorphisms (SNPs), 432 220 genotyped sites (OncoArray platform), and 7 099 472 imputed sites. The red horizontal line represents  $P = 5 \times 10^{-8}$ , and the blue horizontal line represents  $P = 5 \times 10^{-7}$ . Noticeably, there is a strong genome-wide significant signal at 6p21.32 in the MHC region (leading SNP, rs3828805;  $P = 2.03 \times 10^{-12}$ ). Also noticeable is rs1229984 at 4q23 ( $P = 8.53 \times 10^{-9}$ ), a previously known locus, and there is a suggestive signal for rs1961637 at 2q36.1 ( $P = 3.03 \times 10^{-7}$ ).  $P$ -values are the result of a fixed-effect meta-analysis of three GWASs by region (Europe, North America, and South America), comprising 2666 cases and 6585 controls; all analyses are adjusted by age, sex, and eigenvectors. © IARC.



**GEP is grateful to the following for their collaboration:**

Marcelo Fernando Figari, Marta Vilensky, Buenos Aires, Argentina; Allison Hodge, Melbourne, Gianluca Severi, Victoria, Australia; Jan-Eric Litton, Kurt Zatloukal, Graz, Austria; Gyl Ramos, Curitiba, José Carlos de Oliveira, Goiânia, Marisa Breitenbach, Sergio Koifman, Rio de Janeiro, Marcelo Benedito Menezes, Luis Paulo Kowalski, José Eduardo Levi, Victor Wünsch-Filho, São Paulo, José Roberto Vasconcelos de Podestà, Vitoria, Brazil; Isabelle Fortier, Mark Lathrop, Montreal, Tom Hudson, Rayjean Hung, Mark Minden, Liran Shlush, Toronto, Canada; Paula Rodriguez, Bogotá, Colombia; Ozren Polasek, Split, Croatia; Lenka Foretova, Brno, Vladimir Janout, Olomouc, Vladimir Bencko, Ivana Holcatova, Prague, Czech Republic; Mads Melbye, Copenhagen, Denmark; Andres Metspalu, Tartu, Estonia; Seppo Koskinen, Kari Kuulasmaa, Markus Perola, Veikko Salomaa, Erkki Vartiainen, Helsinki, Finland; Maria Paula Curado, Markus Pasterk, Lyon, Olivier Cussenot, Jean-François Deleuze, Marc-Henri Stern, Paris, Emmanuelle Rial-Sebbag, Toulouse, Marcel Goldberg, Marie Zins, Villejuif, France; Wolfgang Ahrens, Bremen, Michael Pawlita, Tim Waterboer, Heidelberg, Klaus Kuhn, Erich Wichmann, Munich, Jerzy Adamski, Melanie Waldenberger, Neuherberg, Germany; Pagona Lagiou, Athens, Greece; Bela Melegh, Pécs, Hungary; Frosti Jonsson, Unnur Thorsteinsdottir, Reykjavik, Iceland; Rajesh Dikshit, Mumbai, India; Reza Malekzadeh, Tehran, Islamic Republic of Iran; Claire Healy, Dublin, Ireland; Jerry Polesel, Aviano, Lorenzo Simonato, Padua, Stefania Boccia, Rome, Franco Merletti, Turin, Italy; Janis Klovins, Riga, Latvia; Beena Devi, Kuching, Malaysia; Jasper Bovenberg, Aerdenhout, Evert-Ben van Veen, The Hague, Ronald Stolk, Groningen, Gert-Jan van Ommen, Leiden, Piet A. van den Brandt, Maastricht, C.M. van Duijn, Rotterdam, The Netherlands; Gry Kvalheim, Øivind Middtun, Per Magne Ueland, Bergen, Kristian Hveem, Steinar Krokstad, Arnulf Langhammer, Levanger, Kristina Kjaerheim, Per Magnus, Thomas Nilsen, Oslo, Norway; Beata Swiatkowska, Łódź, Jolanta Lissowska, Warsaw, Łukasz Kozera, Wrocław, Poland; Ciprian Bolca, Dana Mates, Jinga Viorel, Bucharest, Romania; Alexander Boroda, Anush Mukeriya, Egor Prokhortchouk, David Zaridze, Moscow, Russian Federation; Miodrag Ognjanovic, Simona Ognjanovic, Belgrade, Serbia; Tam Ha, Singapore; Eleonora Fabianova, Banska Bystrica, Slovakia; Ivo Gut, Barcelona, Spain; Jonas Manjer, Malmö, Lars Egevad, Nancy Pedersen, Alicja Wolk, Stockholm, Kjell Grankvist, Göran Hallmans, Mikael Johansson, Börje Ljungberg, Margaretha Tagewall, Umeå, Ulf Landegren, Lars Lind, Johan Sundström, Uppsala, Sweden; Sulee Sangrajrang, Bangkok, Thailand; Tatiana Macfarlane, Aberdeen, Hisham Mehanna, Birmingham, George Davey-Smith, Richard Martin, Andrew Ness, Bristol, Michael Taussig, Cambridge, Philip Haycock, Clifton, David Conway, Glasgow, Alvis Brazma, Aarno Palotie, Hinxton, Rosamonde Banks, Leeds, Paul Burton, Leicester, John Field, Liverpool, Clare Berry, Alissa Goodman, Elio Riboli, Paolo Vineis, London, Caroline Relton, Max Robinson, Newcastle, Rory Collins, Oxford, Angus Roberts, Sheffield, United Kingdom; Mauricio Cuello, Montevideo, Uruguay; Susan Gapstur, Marji McCullough, Victoria Stevens, Atlanta, Gypsyamber D'Souza, Judith Hoffman-Bolton, Kala Visvanathan, Baltimore, Demetrius Albanes, Neil Caporaso, Stephen Chanock, Aimee Kreimer, Lee Moore, Mark Purdue, Nathaniel Rothman, Stephanie Weinstein, Bethesda, Jiali Han, Aditi Hazra, Jing Ma, Howard Sesso, Meir Stampfer, Boston, Neil Hayes, Chapel Hill, Chris Amos, Hanover, Loïc Le Marchand, Honolulu, Samir Hanash, Houston, Qiuyin Cai, Xiao-Ou Shu, Wei Zheng, Nashville, Alan Arslan, Gloria Ho, Anne Jacquotte, New York, Lesley Butler, Jian Min Yuan, Pittsburgh, Christian Abnet, Chu Chen, Ross Prentice, Jon Wakefield, Seattle, USA.

**Financial support from the following bodies is gratefully acknowledged:**

European Commission, Brussels, Belgium  
French Ministry of Social Affairs and Health – Directorate-General of Health/Direction générale de la Santé (DGS)  
National Institutes of Health, USA  
World Cancer Research Fund, London, United Kingdom



## SECTION OF EARLY DETECTION AND PREVENTION (EDP)

### Section head

Dr Rolando Herrero  
Dr Rengaswamy Sankaranarayanan  
(until June 2015)

PREVENTION AND EARLY DETECTION, INCLUDING INTERVENTIONS TO REDUCE EXPOSURE, SCREENING, AND EARLY DIAGNOSIS, CAN DECREASE CANCER INCIDENCE AND MORTALITY AND IMPROVE QUALITY OF LIFE. UNTIL MARCH 2015, THE SECTION OF EARLY DETECTION AND PREVENTION (EDP) WAS COMPOSED OF THREE GROUPS: THE PREVENTION AND IMPLEMENTATION GROUP (PRI), THE QUALITY ASSURANCE GROUP (QAS), AND THE SCREENING GROUP (SCR). THE SECTION WAS SUBSEQUENTLY RESTRUCTURED AND NOW CONSISTS OF ONLY TWO GROUPS: PRI AND SCR. THE ACTIVITIES OF QAS DURING THE 2014–2015 BIENNIUM ARE REPORTED HERE UNDER SCR.

EDP carries out research on resource-appropriate public health policies and feasible, quality-assured, and cost-effective prevention and early detection strategies for the control of common cancers such as breast, cervical, colorectal, oral, oesophageal, and stomach cancer globally, with an emphasis on low- and middle-income countries (LMICs). Prevention offers the most cost-effective long-term strategy for cancer control. The Section's main focus areas in primary prevention are the development and implementation of safe, effective, and affordable vaccination schemes for human papillomavirus (HPV)-related cancers and the evaluation of the impact of *Helicobacter pylori* eradication on stomach cancer. The major focuses of EDP's early detection research are assessing new technologies and alternative screening approaches, as well as the impact of improved awareness and access to health services for the early detection of major cancers such as breast, cervical, oral, and colorectal cancer.

The Section designs and conducts research studies in collaboration with investigators in national cancer organizations, health services, universities, and other key groups within and outside the Agency. EDP works closely with other international organizations to develop, implement, and promote effective strategies for preventing and controlling cancer in the context of national cancer control programmes. In the Section's studies, there is a continuing emphasis on developing training resources, augmenting capacity for cancer prevention and early detection initiatives, and scaling up of prevention and early detection services within local health systems. The establishment of cancer research networks in LMICs to exchange experiences and enhance the local capacity is among EDP's priorities. The Section continues to expand its activities to implementation research, to support the efforts of national health systems to translate scientific findings into the well-being of the population.



# PREVENTION AND IMPLEMENTATION GROUP (PRI)

**Group head**

Dr Rolando Herrero

**Scientists**

Dr Maribel Almonte  
Dr Hugo De Vuyst  
Dr Paula González  
(until July 2014)  
Dr Raúl Murillo  
Dr Jin Young Park

**Secretariat**

Ms Karima Abdedayem

**Project assistant**

Ms Maria de la Luz Hernandez

**Postdoctoral fellow**

Dr Claudia Robles

**Doctoral student**

Dr Robin Ohannessian



The Prevention and Implementation Group (PRI) investigates cancer epidemiology and prevention with a focus on human papillomavirus (HPV) vaccines, *Helicobacter pylori* eradication for gastric cancer prevention, triage methods for HPV-positive women, and the promotion and evaluation of cervical cancer control programmes. Recently, PRI began to include implementation research objectives in ongoing projects and national implementation activities.

#### CERVICAL CANCER STUDIES IN GUANACASTE, COSTA RICA

The Costa Rica Vaccine Trial (CVT) recruited approximately 7500 women aged 18–25 years into a randomized trial of bivalent HPV vaccine (HPV 16/18). The final results confirmed efficacy of the vaccine against HPV 16/18-related lesions and those related to other HPV types. Follow-up is continuing, and after cross-over vaccination, a new unvaccinated control group was recruited for long-term assessment of vaccine efficacy and safety (Gonzalez et al., 2015; Panagiotou et al., 2015). A combined analysis confirmed protective efficacy regardless of the number of doses (Kreimer et al., 2015a). Plans are under way for a randomized trial of one versus two doses of the bivalent and nonavalent vaccines. The efficacy of the vaccine to prevent vulvar HPV 16/18 infections was also evaluated (Lang Kuhs et al., 2014a).

#### MULTICENTRE STUDY OF HPV SCREENING AND TRIAGE (ESTAMPA)

The ESTAMPA study investigates emerging cervical cancer screening and triage techniques in Latin America. About 50 000 women aged 30–64 years will be screened with HPV testing; all HPV-positive women will be referred for colposcopy, biopsy, and treatment as needed, and recalled for a second screening after 18 months. The main outcome is advanced cancer precursors. The performance of visual, cytological, and molecular methods to identify HPV-positive women at higher risk of disease will be evaluated, contributing towards the establishment of organized screening in the region. The study began in Colombia, Paraguay, Honduras, and Uruguay (recruitment, ~8000) and will

Figure 1. ESTAMPA study: participants in the cervical pathology training course held in Cuernavaca, Morelos, Mexico, on 11–13 February 2015. © IARC/Roland Dray.



soon start in Costa Rica, Argentina, Peru, Mexico, and Bolivia (Figure 1).

#### EPIDEMIOLOGY AND PREVENTION OF *H. PYLORI* INFECTION AND GASTRIC CANCER

The ENIGMA study investigates the worldwide epidemiology of *H. pylori* infection and gastric cancer. The prevalence of infection, precancer, and cofactors are investigated in population samples from high- and low-risk areas. A multilevel analysis (ecological, cross-sectional, and analytical) will assess age-specific infection prevalence to predict cancer trends, as well as bacterial (including microbiome), host, and environmental factors explaining geographical patterns. ENIGMA has been completed in low- and high-risk areas in Chile (700 people each), and there are plans to expand the study to all continents.

In collaboration with the National Cancer Center of the Republic of Korea, PRI is conducting a randomized controlled clinical trial of *H. pylori* eradication for gastric cancer prevention (the HELPER study), which aims to recruit 11 000 subjects aged 40–65 years who are attending endoscopy within the National Cancer Screening Program. *H. pylori*-positive subjects are randomized to quadruple eradication therapy or placebo. All participants (current recruitment, ~1200) will be routinely screened within the National Cancer Screening Program every 2 years for 10 years.

PRI has also initiated a randomized trial with the University of Latvia to determine whether combined *H. pylori* and pepsinogen screening followed by eradication therapy in *H. pylori*-positive subjects and endoscopic follow-up of those with atrophic gastritis reduces gastric cancer mortality compared with standard care. The study aims to recruit 30 000 subjects aged 40–64 years in Latvia, Belarus, and the Russian Federation (current pilot recruitment, ~3000).

In December 2013, PRI convened a Working Group of experts to review the evidence regarding *H. pylori* eradication strategies for gastric cancer prevention. The experts recommended consideration of programmes in high-risk areas in the context of scientific assessment of the value of such interventions (Herrero et al., 2014a) (Figure 2).

#### CERVICAL CANCER PREVENTION IN AFRICA

PRI is collaborating with the World Health Organization (WHO) Department of Reproductive Health and Research (RHR) and the United Republic of Tanzania in a study with more than 2000 women to build HPV testing capacity and to assess the reproducibility, feasibility, and acceptability of rapid HPV testing at different levels of the health care system (the AISHA study). Also with RHR, PRI is planning a large trial of three screen-and-treat algorithms currently recommended by WHO (the CESTA study).

Figure 2. *Helicobacter pylori* eradication as a strategy for preventing gastric cancer. The Working Group met at IARC in Lyon on 4–6 December 2013. © IARC/Roland Dray.



#### SUPPORT OF HPV VACCINATION AND SCREENING PROGRAMMES IN LATIN AMERICA

In the context of the National Cervical Screening Programme of Argentina, which is implementing HPV-based screening, extensive political and educational meetings have been held

and the development of guidelines and educational materials and the setting up of laboratories have been completed for the first province to implement the programme, Jujuy Province (Arrossi et al., 2015a). A cluster randomized trial within this programme demonstrated a 4-fold increase in screening participation when community health workers invited

women to self-collect their HPV tests compared with an invitation to attend a clinic (Arrossi et al., 2015b). Expansion to other provinces in Argentina is well under way. The materials developed and the experience gained should be useful for other programmes in the region, most of which also collaborate with PRI.

#### PRI is grateful to the following for their collaboration:

Silvina Arrossi, Rosa Laudi, Laura Thuyaret, Instituto Nacional de Cáncer, Buenos Aires, Laura Fleider, Silvio Tatti, Hospital de Clínicas “José de San Martín”, Buenos Aires, Juan Mural, Hospital Posadas, Buenos Aires, Alejandra Picconi, Instituto Malbran, Buenos Aires, Argentina; Carolina Terán, Universidad San Francisco Xavier de Chuquisaca, Sucre, Bolivia; Paulo Naud, Hospital de Clínicas, Porto Alegre, Brazil; Johanna Acevedo, Paz Cook, Catterina Ferreccio, Marcela Lagos, Javiera Leniz, Vanessa van de Wyngard, Pontificia Universidad Católica, Santiago, Carla Molina, Universidad Nacional de Chile, Santiago, Lorena Báez, Ministerio de Salud de Chile, Chile; Armando Baena, Astrid Bedoya, Gloria Sánchez, Universidad de Antioquia, Medellín, Oscar Gamboa, Mauricio Gonzalez, Mónica Molano, Carolina Wiesner, Instituto Nacional de Cancerología, Bogotá, Carlos Pérez, Jairo Bonilla, Hospital San Jose, Bogotá, Colombia; Alejandro Calderón, Luis Bernardo Sáenz, Caja Costarricense de Seguro Social, San Jose, Silvia Jimenez, Paula González, Carolina Porras, Ana Cecilia Rodriguez, Proyecto Epidemiológico Guanacaste, Costa Rica; Mauricio Maza, Basic Health International, San Salvador, El Salvador; Francis Mégraud, INSERM, CHU Pellegrin, Bordeaux, France; Anabelle Ferrera, Universidad Nacional Autónoma de Honduras, Tegucigalpa, Jackeline Figueroa, Secretaria de Salud, Tegucigalpa, Honduras; Il Ju Choi, Young-Il Kim, Byung Ho Nam, National Cancer Center, Goyang-si Gyeonggi-do, Republic of Korea; Sergejs Isajevs, Petra Krike, Marcis Leja, University of Latvia, Latvia; Aurelio Cruz, Pilar Hernandez, Eduardo Lazcano, Jorge Salmerón, Instituto Nacional de Salud Pública, Mexico City, Mexico; Maria Liz Bobadilla, Nelly Maldonado, Veronica Villagra, Laboratorio Central Nacional, Asunción, Elena Kasamatsu, Laura Mendoza, María Isabel Rodríguez, Instituto de Investigaciones en

Ciencias de la Salud, Asunción, Ana Soilan, COLPODIG, Asunción, Paraguay; Manuel Álvarez, Carlos Santos, Gustavo Sarria, Instituto Nacional de Enfermedades Neoplásicas, Lima, Jorge Andrés Ferrandiz, Programa Esperanza, Ministerio de Salud de Perú, Gino Venegas, Liga Nacional de Lucha contra el Cáncer, Lima, Peru; Xavier Bosch, Xavier Castellsagué, Eduardo Franco, Silvia de Sanjosé Llongueras, Institut Català d'Oncologia, Barcelona, Spain; Nathalie Broutet, WHO, Geneva, Pierre Vassilakos, Hôpitaux Universitaires de Genève, Switzerland; Mabula Kasubi, Muhimbili National Hospital, Dar es Salaam, Yuma Safina, Ministry of Health and Social Welfare, Dar es Salaam, John Theopista, WHO Country Office, United Republic of Tanzania; Wim Quint, Linda Struijk, Leen-Jan van Doorn, DDL Diagnostic Laboratory, Rijswijk, The Netherlands; Guillermo Rodríguez, Comisión Honoraria de Lucha contra el Cáncer, Montevideo, Uruguay; Maria Constanza Camargo, Michael Cook, Allan Hildesheim, Hormuzd A Katki, Aimée R. Kreimer, Douglas R. Lowy, Charles Rabkin, Mark Schiffman, John T. Schiller, Diane Solomon, Sholom Wacholder, National Cancer Institute, Bethesda, Michael Chung, University of Washington, Seattle, Teresa Darragh, University of California, San Francisco, Jose Jerónimo, PATH, Seattle, Silvana Luciani, Pan American Health Organization (PAHO), Washington DC, USA.

**Financial support from the following bodies is gratefully acknowledged:**

Center for Global Health, National Cancer Institute (NCI), Bethesda, Maryland, USA  
Pan American Health Organization (PAHO), Noncommunicable Diseases and Mental Health Department,  
Washington DC, USA  
WHO Department of Reproductive Health and Research, Geneva, Switzerland  
Union for International Cancer Control (UICC), Geneva, Switzerland

## SCREENING GROUP (SCR)

### Group head

Dr Rengaswamy Sankaranarayanan

### Scientists

Dr Partha Basu  
Dr Catherine Sauvaget  
Dr Kirstin Grosse Frie  
(until September 2014)  
Dr Richard Muwonge  
Dr Patricia Villain

### Informatics officer

Mr Eric Lucas

### Programme assistants

Ms Evelyn Bayle  
(until November 2015)  
Ms Maria Teresita Fernan

### Technical assistant

Ms Krittika Guinot

### Secretariat

Ms Sandrine Montigny

### Senior visiting scientists

Dr Groesbeck Parham  
(until July 2014)  
Dr Sujha Subramanian  
Dr Walter Prendiville  
(until July 2015)  
Dr Fang-Hui Zhao

### ICRETT fellows

Dr Partha Basu  
(until October 2014)  
Ms Kalyani Mantravadi Subramaniam  
(until July 2015)  
Dr Smita Joshi  
(until July 2015)

### Postdoctoral fellows

Dr Diama Bhadra Andrade Peixoto  
do Vale  
Dr Farida Selmouni  
Dr Vitaly Smelov  
(until September 2015)

## QUALITY ASSURANCE GROUP (QAS)

UNTIL MARCH 2015

### Group head

Dr Lawrence von Karsa

### Scientist

Dr Patricia Villain

### Secretariat

Ms Nadia Akel  
(until June 2014)  
Ms Maria Teresita Fernan  
Ms Tracy Lignini  
(until August 2014)

### Visiting scientists

Dr Peter Dean  
Dr Nereo Segnan  
Dr Eero Suonio

The Screening Group (SCR) conducts studies of the early detection of common cancers, predominantly in low- and middle-income countries (LMICs), evaluating the accuracy, acceptability, feasibility, safety, and cost-effectiveness of early detection methods for breast, cervical, colorectal, and oral cancers and addressing how the evidence generated can influence early detection policies in LMICs (Khuhaprema et al., 2014; Krishnan et al., 2015; Parham et al., 2015; Rajaraman et al., 2015). The Group contributes scientific evidence to support the development of resource-appropriate policies to deliver effective early detection services (Sankaranarayanan et al., 2014a). SCR evaluates selected primary prevention

initiatives and explores pragmatic ways of integrating both primary and secondary prevention strategies into cervical cancer control (Sankaranarayanan et al., 2015). SCR engages substantially in developing training resources and educational programmes.


#### CERVICAL CANCER CONTROL

The effectiveness of one and two doses of human papillomavirus (HPV) vaccine was compared with that of three doses among girls aged 10–18 years in preventing cervical neoplasia in a multicentre study involving 17 729 women in India. Results after 4 years of follow-up indicate that the immunogenicity of two doses was non-inferior to that of


three doses. Although the single dose evoked lower antibody levels, they are much higher than natural infection and are as avid as three-dose antibodies (Figures 1 and 2). One dose provided similar protection against incident and persistent HPV 16/18/6/11 infections as two and three doses.

The long-term impact of screening with HPV testing, cytology, or visual inspection with acetic acid (VIA) on cervical cancer is being addressed by following up about 230 000 women in India. SCR evaluated the triaging options for HPV- and VIA-positive women (Muwonge et al., 2014; Basu et al., 2015). Cytology or VIA triage of HPV-positive women substantially reduced colposcopy

**Figure 1.** Mean fluorescence intensity (MFI) values for HPV 16, 18, 6, and 11 L1 antibodies at different time points among girls who completed vaccination per protocol (vaccination at days 1, 60, and 180 for the 3-dose group or at days 1 and 180 for the 2-dose group) and those who did not have their complete vaccine schedules (vaccination at days 1 and 60, or a single dose). Reprinted from Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, et al., for the Indian HPV vaccine study group (2015). Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicenter prospective cohort study. *Lancet Oncol.* [http://dx.doi.org/10.1016/S1470-2045\(15\)00414-3](http://dx.doi.org/10.1016/S1470-2045(15)00414-3).



**Figure 2. Geometric mean fluorescence intensity (MFI) avidity index of HPV 16, 18, 6, and 11 L1 antibodies at 18 months after the first dose among girls who completed vaccination per protocol and those who did not have their complete vaccine schedules. Reprinted from Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, et al., for the Indian HPV vaccine study group (2015). Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicenter prospective cohort study. *Lancet Oncol.* [http://dx.doi.org/10.1016/S1470-2045\(15\)00414-3](http://dx.doi.org/10.1016/S1470-2045(15)00414-3).**



referral, although 16–18% of cases of cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) were missed. HPV testing could triage VIA-positive women very efficiently, with an insignificant drop in sensitivity (Basu et al., 2015). The validity of colposcopy by nurses was addressed in a follow-up study (Thulaseedharan et al., 2015a). A study among 1109 HIV-positive women in India observed 41.0% high-risk HPV positivity (Joshi et al., 2014). Meta-analysis of the efficacy of cold coagulation demonstrated a 95% cure rate for CIN2/3, comparable to that of cryotherapy or excision (Dolman et al., 2014). Scaling up of the VIA screen-and-treat programme in Zambia was evaluated (Parham et al., 2015). HPV viral load was observed to have a key role in colposcopy.

A pilot study involving 6000 women to implement HPV screening and triage by liquid-based cytology and HPV genotyping in Thailand has been completed. A study involving 592 midwives in Government Health Services in Côte d'Ivoire indicated that despite sufficient knowledge about cervical cancer prevention, the attitudes and practices of midwives need improvement by capacity-building activities (Tchounga et al., 2014).

#### BREAST CANCER SCREENING

In a randomized trial involving 130 000 women in Trivandrum, India, the second

round of screening by clinical breast examination (CBE) has been completed and the third round is in progress. The role of breast awareness in improving early detection and survival of breast cancer patients is being investigated at other sites in India.

#### ORAL CANCER SCREENING

The natural history of oral precancerous lesions is being addressed in the randomized trial of oral visual screening in Kerala, India. The cohort has substantially contributed to addressing mortality related to cardiovascular disease, tobacco, and obesity in South Asia (Zheng et al., 2014). The inputs and impact of “social marketing” to increase awareness for early detection are being evaluated in Sri Lanka.

#### COLORECTAL CANCER SCREENING

A pilot study in Thailand involving 130 000 people indicated that colorectal cancer screening with immunochemical faecal occult blood testing (iFOBT), triage colonoscopy, and treatment of adenomas and early cancers by endoscopic resection can be implemented successfully in government health services (Khuhaprema et al., 2014). SCR is currently providing technical support in scaling up colorectal cancer screening in five provinces in Thailand.

#### TECHNICAL SUPPORT TO NATIONAL CANCER CONTROL PROGRAMMES

SCR provided technical support to national cancer control programmes in Albania, Algeria, Bosnia and Herzegovina, Cambodia, China, Fiji, Georgia, Lebanon, Madagascar, Mauritania, Morocco, Myanmar, Papua New Guinea, Sri Lanka, Thailand, Timor-Leste, Tunisia, and Uzbekistan in collaboration with national governments, World Health Organization (WHO) headquarters and regional offices, the International Atomic Energy Agency (IAEA), and the United Nations Population Fund (UNFPA).

#### CONTINUED ACTIVITIES OF THE QUALITY ASSURANCE GROUP (QAS)

SCR is contributing to the preparation of the European Screening Report, which will describe the current coverage and status of breast, cervical, and colorectal cancer screening programmes in 28 European countries. The supplements to the second edition of the European Guidelines for Quality Assurance in Cervical Cancer Screening have been published (Anttila et al., 2015; von Karsa et al., 2015). The European Code Against Cancer, a collection of key recommendations to promote primary and secondary prevention of cancer, was launched in October 2014.

## **SCR is grateful to the following for their collaboration:**

### *Africa*

Miraldina da Ganda Manuel, Maternidade Lucrecia Paim, Luanda, Angola; Jean-Marie Dangou, WHO Regional Office for Africa, Division of Prevention and Control of Noncommunicable Diseases, Brazzaville, Congo; Charles Gombe Mbalawa, Judith Malanda-Mfinga, Université Marien Ngouabi, Brazzaville, Congo; Ala Alwan, Ibtihal Fadhil, WHO Regional Office for the Eastern Mediterranean (WHO-EMRO), Cairo, Egypt; Namory Keita, Dr Koulibaly, CHU Donka, Conakry, Guinea; Siné Bayo, Amadou Dolo, Ibrahima Teguede, Hôpital G. Touré, Bamako, Mali; Shyam Sundar Manraj, National Cancer Control Programme, Port Louis, Mauritius; Rachid Bekkali, Maria Bennani, Youssef Chami, The Lalla Salma Association Against Cancer, Rabat, Morocco; Chakib Nejjari, Faculty of Medicine of Fez, Morocco; Hassan Nouhou, Faculté des Sciences de la Santé, Université de Niamey, Niamey, Niger; Lynette Denny, Department of Obstetrics and Gynaecology, Faculty of Health Sciences, Cape Town, South Africa; Greta Dreyer, University Hospital, Pretoria, South Africa; Twalib A. Ngoma, Ocean Road Cancer Institute (ORCI), Dar es Salaam, United Republic of Tanzania; Mike Chiranje, Professor of Obstetrics and Gynaecology, University of Zimbabwe, Harare, Zimbabwe.

### *Asia*

Ashrafun Nessa, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh; Jiang-Guo Chen, Qidong Liver Cancer Institute, Qidong, China; Youlin Qiao, Cancer Institute of the Chinese Academy of Medical Sciences, Beijing, China; Li Qing, University Hospital, Cheng Du, China; An-Ping Wang, Ping Wang, Shaanxi Province Cancer Hospital/Institute, Xian, China; B.V. Bhat, Krishnanandha Pai, Malabar Cancer Care Society, Kannur, India; Neerja Bhatla, Shachi Vashist, All India Institute of Medical Sciences, New Delhi, India; Shila Thomas, Pulikatil Okkaru Esmay, Anil Kumar, Christian Fellowship Community Health Centre, Ambilikai, India; Rajendra Badwe, Surendra Shastri, Kedhar Deodhar, Rohini Kelkar, Sharmila Pimple, Gauravi Mishra, N. Jambhekar, B. Rekhi, R. Mulherkar, Tata Memorial Centre, Mumbai, India; Smita Joshi, Uma Divate, Jehangir Clinical Development Centre (JCDC) Pvt. Ltd Jehangir Hospital Premises, Pune, India; Tanvir Kaur, India Council of Medical Research, New Delhi, India; Ravi Mehrotra, Director, Institute of Cytology & Preventive Oncology, New Delhi, India; Bhagwan M. Nene, Kasturi Jayant, M.K. Chauhan, Sanjay Hingmire, Ruta Deshpande, A. Chiwate, S.G. Malvi, Nargis Dutt Memorial Cancer Hospital, Barshi, India; M. Radhakrishna Pillai, Rajan Panicker, Janki Mohan Babu, Priya Prabhu, Rajiv Gandhi Centre for Biotechnology, Trivandrum, India; Paul Sebastian, Kunnambathu Ramadas, Ramani Wesley, Thara Somanathan, Beela Sara Mathew, Regional Cancer Centre, Trivandrum, India; S. Ramalingam, PSG Institute of Medical Sciences & Research, Coimbatore, India; P. Usha Rani Reddy, T. Mandapal, B. Nagarjuna Reddy, MNJ Cancer Institute, Hyderabad, India; V. Shanta, R. Swaminathan, K. Malliga, Cancer Institute (WIA), Chennai, India; Gerard Selvam, Tamil Nadu Health Systems Project Cervical Screening Programme, Chennai, India; Kalpana S. Dave, Parimal J. Jivarajani, Rohini Patel, Gujarat Cancer & Research Institute, M.P. Shah Cancer Hospital, Ahmedabad, India; Maqsood Siddiqi, Sutapa Biswas, Soma Roychowdhury, Cancer Foundation of India, Kolkata, India; Yogesh Verma, STNM Hospital, Gangtok, Sikkim, India; Eric Zomawia, Civil Hospital, Aizawl, Mizoram, India; Nada Alwan, Professor of Pathology, Baghdad University Medical College, Baghdad, Iraq; Alongkone Phengsavanh, Phouthone Sithideth, Faculty of Medical Sciences, Vientiane, Lao People's Democratic Republic; M. Man Shrestha, B. Singh Karki, BP Koirala Memorial Cancer Hospital, Bharatpur, Nepal; Surendra Shrestha, Nepal Network of Cancer Treatment & Research, Banepa, Nepal; A.V. Laudico, Philippine Cancer Society, Manila, Philippines; Hai Rim Shin, Regional Adviser, NCD, WHO-WIPRO, Manila, Philippines; Kee-Seng Chia, National University of Singapore, Singapore; Swee Chong Quek, KK Women's & Children's Hospital, Singapore; Kanishka Karunaratne, Director, National Cancer Institute, Sri Lanka; Eshani Fernando, Suraj Perera, National Cancer Control Programme, Sri Lanka; Weerawut Imsamran, Suleeporn Sangrajrang, National Cancer Institute, Thailand; Surathat Pongnikorn, Lampang Cancer Centre, Lampang, Thailand; Hutchia Sriplung, University of Songkhla, Songkhla, Thailand; Murat Tuncer, Murat Gültekin, National Cancer Control Programme, Turkey; Gokhan Tulunay, Serdar Yalvac, A. Nejat Ozgul, SB Ankara Etlik Maternity and Women's Health Teaching Research Hospital, Ankara, Turkey.

### *Australia*

Newell Johnson, Griffith University, Queensland, Australia.

### *Europe*

Nelly Enwerem-Bromson, IAEA, Vienna, Austria; Marc Arbyn, Scientific Institute of Public Health, Brussels, Belgium; Ian Magrath, International Network for Cancer Treatment and Research, Brussels, Belgium; Christine Bergeron, Laboratoire Cerba, Cergy-Pontoise, France; Xavier Carcopino, Hôpital Nord, Service de Gynécologie, Marseille, France; Lutz Gissmann, Division of Genome Modifications and Carcinogenesis, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany; Michael Pawlita, DKFZ, Heidelberg, Germany; Peter Sasieni, Biostatistics and Cancer Epidemiology Group, Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Cancer Research UK Clinical Centre at Barts and The London School of Medicine and Dentistry, Wolfson Institute of Preventive Medicine, United Kingdom; Margaret Stanley, University of Cambridge, United Kingdom; Stephen W. Duffy, Cancer Research UK Centre for Epidemiology,

Mathematics and Statistics, Wolfson Institute of Preventive Medicine, London, United Kingdom; Etienne Krug, Andreas Ulrich, Nathalie Broutet, WHO, Geneva, Switzerland.

#### *North America*

Prabhat Jha, Cindy Gauvreau, Centre for Global Health Research, Canada; Susan E. Horton, Department of Economics, University of Waterloo, Canada; Hellen Gelband, Center for Disease Dynamics, Washington DC, USA; Paul Blumenthal, Lynne Gaffikin, San Francisco, USA; André Ilbawi, MD Anderson Cancer Center, Houston, USA; Silvana Luciani, Pan American Health Organization, Washington DC, USA; Vivien Tsu, J. Jerónimo, PATH, Seattle, USA; Ted Trimble, Lisa Stevens, National Cancer Institute, Bethesda, USA; Ben Anderson, Professor of Surgery, University of Seattle, Seattle, USA.

#### *South America*

Silvina Arrossi, Programme Manager, National Cervical Screening Programme, Buenos Aires, Argentina; Silvio Tatti, Faculty of Medicine, Buenos Aires, Argentina; Paulo Naud, Jean Matos, Instituto de Prevencao do Cancer de Colo do Utero, Porte Alegre, Brazil; Leticia Fernandez Garrote, Yaima Galan Alvarez, National Institute of Oncology and Radiobiology, Havana, Cuba; Antonio L. Cubilla, Instituto de Patología e Investigación, Universidad Nacional de Asunción, Paraguay; C.L. Santos, C.V. Sologuren, Instituto Especializado de Enfermedades Neoplásicas, Lima, Peru.

#### **QAS is grateful to the following for their collaboration:**

Egor Zaitsev, Minsk, Belarus; Guido Van Hal, Antwerp, Marc Arbyn, Antonis Lanaras, Josef Novotny, Emma Woodford, Wendy Yared, Brussels, Eric Van Cutsem, Jurgen Jacobs, Leuven, Belgium; Dusan Vojvodic, Bosnia and Herzegovina; Yulia Panayotova, Sofia, Bulgaria; Linda Rabeneck, Robert Riddell, Toronto, Canada; Melita Jelavic, Dunja Skoko-Poljak, Zagreb, Croatia; Pavlos Pavlou, Efronsini Iacovou, Nicosia, Cyprus; Ondrej Majek, Brno, Jan Danes, Eva Kralikova, Julius Špičák, Stepan Suchánek, Prague, Czech Republic; Gunta Lazdane, Gauden Galea, Elsebeth Lynge, Frederiek Mantingh, Jørgen Olsen, Copenhagen, Denmark; Piret Veerus, Tallinn, Estonia; Ahti Anttila, Paivi Heikkila, Stefan Lönnberg, Nea Malilla, Pekka Nieminen, Pekka Puska, Harri Vainio, Helsinki, Anssi Auvinen, Matti Lehtinen, Tampere, Peter Dean, Turku, Finland; Christine Berling, Boulogne-Billancourt, Guy Launoy, Caen, Christine Bergeron, Cergy Pontoise, Jean Faivre, Dijon, Patrice Heid, Rosemarie Ancelle-Park, Daniel Levy-Bruhl, Paris, Jean-François Rey, St Laurent du Var, Agnès Rogel, Frank Assogba, Saint-Maurice, Gilbert Lenoir, Villejuif, France; Levan Jugeli, Tbilisi, Georgia; Michael Vieth, Bayreuth, Lutz Altenhofen, Berlin, Christian Pox, Bochum, Karen Bundewig, Bonn, Vanessa Kääb-Sanyal, Daniela Malek, Berlin, Werner Boecker, Münster, Germany; Maria Tsantidou, Athens, Greece; András Budai, Janina Kulka, Szilvia Má dai, Budapest, Hungary; P. Fitzpatrick, Thérèse Mooney, Dublin, Ireland; Gad Rennert, Haifa, Israel; Maria Pia Foschini, Bologna, Eugenio Paci, Marco Zappa, Florence, Luigi Bisanti, Milan, Giorgio Minoli, Montorfano, Paolo Giorgi-Rossi, Pasqualino Rossi, Rome, Paola Armaroli, Rita Banzi, Cristina Bellisario, Ettore Bidoli, Marta Dotti, Alfonso Frigerio, Livia Giordano, Silvia Minozzi, Antonio Ponti, Mauro Risio, Guglielmo Ronco, Giuseppe Salamina, Anna Sapino, Nereo Segnan, Carlo Senore, Mariano Tomatis, Turin, Italy; Chisato Hamashima, Hiroshi Saito, Tokyo, Japan; Mohammed Tarawneh, Jordan; Won Chul Lee, Seoul, Republic of Korea; Marcis Leja, Inta Liepniece-Karele, Daiga Santare, Riga, Latvia; Rugile Ivanauskiene, Kaunas, Viaceslavas Zaksas, Vaida Momkuviene, Vilnius, Lithuania; Guy Dargent, Isabell Ladiges, Astrid Scharpantgen, Luxembourg, Luxembourg; Miriam Dalmas, Nadine Delicata, Joseph Psaila, Valletta, Malta; Nebojsa Crnogorac, Rajko Strahinja, Montenegro; Loubna Abousselham, Rabat, Morocco; Chris Meijer, Peter Snijders, Flora van Leeuwen, Jelle Wesseling, Marlou Bijlsma, Delft, Mireille Broeders, Roland Holland, Hans Lelivelt, Martin Thijssen, Ruben Van Engen, Nijmegen, Iris Lansdorp-Vogelaar, Harry de Koning, Esther de Vries, Jacques Fracheboud, Ernst Kuipers, Ellen Paap, Rotterdam, Johannes van Delden, Paul Van Diest, Utrecht, The Netherlands; Lars Aabakken, Michael Bretthauer, Geir Hoff, Solveig Hofvind, Oslo, Norway; Arkadiusz Chil, Kielce, Michal Kaminski, Jaroslaw Regula, Witold Zatonski, Jolanta Kotowska, Wrocław, Poland; Vitor José Lopes Rodrigues, Manuela Lacerda, António Morais, Coimbra, Vitor Rodrigues, Lisbon, Isabel Amendoeira, Porto, Portugal; Luciana Neamtii, Florian Nicula, Cluj-Napoca, Romania; Aleksandra Jaric, Snežana Žujković, Belgrade, Tatiana Pavlovic, Serbia; Alenka Repse-Fokter, Celje, Snježana Frković-Grazio, Jožica Maučec Zakotnik, Maja Primic-Žakelj, Ljubljana, Slovenia; Xavier Bosch, Josep Espinàs Piñol, Melitta Jakab, Manolis Kogevinas, Barcelona, Isabel Portillo Villares, G. Nieves Ascunce, Ana Molina Barceló, Rosana Peiro-Pérez, Elena Pérez Sanz, Dolores Salas Trejo, Jose Martin-Moreno, Valencia, Spain; Tibor Tot, Falun, Joakim Dillner, Lena Dillner, Miriam Elfström, Sven Törnberg, Stockholm, Sweden; Franco Cavalli, Bellinzona, Chris De Wolf, Bern, Douglas Bettcher, Bettina Borisch, Andreas Ullrich, Geneva, Switzerland; Müjdegül Zayıfoğlu Karaca, Ankara, Turkey; Bakhar Charyevna Agaeva, Mive Berdymyradova, Bahtygul Karriyeva, Jahan Nurmuhamedova, Bazargeldy Rehimgulyev, Ashgabat, Turkmenistan; Philippa Pearmain, Birmingham, Annie Anderson, Robert Steele, Dundee, Stephen Halloran, Kenneth Young, Guildford, Phil Quirke, Leeds, Roland Valori, Leicester, Roger Leicester, Clare Monk, Wendy Atkin, Jack Cuzick, Stephen Duffy,



Andrew Hall, Rebecca Howell-Jones, Nathalie Massat, Anne McNeill, Sue Moss, Teresa Norat, Nick Perry, Julian Peto, Janet Rimmer, Jane Wardle, Clive Wells, Kelly Winstanley, Martin Wiseman, London, Paul Hewitson, Oxford, Julietta Patnick, Sheffield, United Kingdom; Mona Saraiya, Robert Smith, Atlanta, Berta Geller, Burlington, Michael Pignone, David Ransohoff, Chapel Hill, Sidney Winawer, New York, David Lieberman, Portland, USA.

**Financial support from the following bodies is gratefully acknowledged (SCR and QAS):**

Bill & Melinda Gates Foundation, Seattle, USA  
Centers for Disease Control and Prevention, Atlanta, USA  
European Commission (EAHC), Brussels, Belgium  
Ministry of Health, Government of Thailand  
National Cancer Institute, Bangkok, Thailand  
National Cancer Control Programme, Ministry of Health and Indigenous Medicine, Colombo, Sri Lanka  
National Institutes of Health, National Cancer Institute, Bethesda, USA  
Union for International Cancer Control (UICC), Geneva, Switzerland



EPSON

### PRACTICAL INFORMATION

- Connection to the wireless network (WIFI)  
SSID: TARC\_Visitors  
Password:
- Should you need an adapter for French electric plugs, please ask the Reception. Please make sure you give it back! Thank you.
- To use the headset for translation:  
English: press 1    French: press 2    Russian: press 3



## OFFICE OF THE DIRECTOR

### Director

Dr Christopher P. Wild

### Director's Office team

#### Scientific officer

Dr Eduardo Seleiro

#### Personal assistant to the Director

Ms Margot Geesink

#### Administrative assistant

Ms Susan Haver-Legros  
(until September 2014)

#### Secretary

Ms Laurence Marnat

#### Senior visiting scientists

Dr David Forman  
Dr John Gropman  
(until September 2014)  
Sir Andrew J. Hall  
(until May 2014)

#### Special advisor (Noncommunicable Diseases)

Dr Silvia Franceschi

#### Special advisor (Cancer Control)

Dr Rengaswamy Sankaranarayanan

THE OFFICE OF THE DIRECTOR COMPRISES A SMALL TEAM THAT SUPPORTS THE DIRECTOR IN THE IMPLEMENTATION OF IARC'S STRATEGY AND PROGRAMME, AS WELL AS THREE GROUPS WHOSE ACTIVITIES SPAN ACROSS THE AGENCY – THE COMMUNICATIONS GROUP (COM), THE EDUCATION AND TRAINING GROUP (ETR), AND THE LABORATORY SERVICES AND BIOBANK GROUP (LSB) – TOGETHER WITH THE GAMBIA HEPATITIS INTERVENTION STUDY (GHIS), A LONG-TERM SCIENTIFIC PROJECT OF IARC, WHICH IS MANAGED BY THE DIRECTOR. THE ACTIVITIES OF THESE FOUR GROUPS ARE DESCRIBED IN THE FOLLOWING SECTIONS.

The team in the Office of the Director is responsible for assisting in the coordination of specific scientific initiatives, particularly cross-cutting projects involving multiple research Sections; for supporting the establishment and development of strategic partnerships with IARC's network of scientific, governmental, and nongovernmental institutional collaborators; and for assisting in exchanges with the Scientific and Governing Councils and with current and potential Participating States. The Director's Office also supports the activities of several advisory groups and committees, notably the Senior Leadership Team and the IARC Ethics Committee.

Several high-level partnership agreements were signed during the 2014–2015 biennium to formalize and promote institutional collaborations in cancer research and in cancer prevention and control, including with the Lalla Salma Foundation for Cancer Prevention and Treatment in Morocco, with the Health Ministers' Council for the Gulf Cooperation Council States and the Gulf Centre for Cancer Control and Prevention, and with the United States National Cancer Institute's Center for Global Health (NCI-CGH).

In addition, the Director's Office, together with a small working group comprising Dr Silvia Franceschi, Special Advisor on Noncommunicable Diseases (NCDs), and Dr Rengaswamy Sankaranarayanan, Special Advisor on Cancer Control, supports and advises the Director in the coordination of collaborations with a number of key partners in global policy development for cancer prevention and control, including the World Health Organization (WHO) headquarters and regional offices, the International Atomic Energy Agency's Programme of Action for Cancer Therapy (IAEA-PACT), the NCI-CGH, and the Union for International Cancer Control (UICC).

An important focus is the ongoing collaboration with WHO and other partners supporting the planning and implementation of the Global Monitoring Framework for the Prevention and Control of NCDs. Agency staff members participated in numerous planning meetings in the context of the various WHO initiatives in this area, and contributed to the updates of the Global Status Report on NCDs 2014 and of the Global Action Plan for the Prevention and Control of

NCDs. More broadly, IARC continues to work alongside other United Nations (UN) agencies in the UN Interagency Task Force on the Prevention and Control of NCDs, supporting the development and implementation of the global response to NCDs. IARC contributes in particular to the areas of improved surveillance of cancer, through the Global Initiative for Cancer Registry Development (GICR), and of cervical cancer control, including through collaborative research with the WHO Human Reproduction Programme.

A major undertaking for the Director's Office over the biennium was supporting the development of the IARC Medium-Term Strategy for 2016–2020. The process for the development of the Medium-Term Strategy involved broad internal consultation and reflection at all levels of the Agency's personnel, as well as external consultation with the Agency's stakeholders, structured in two stages, the first aimed at key opinion leaders in cancer research, public health, and international cooperation, and the

second aimed at the broader community of IARC's collaborators. Another novel component in the development of the Medium-Term Strategy was the creation of the IARC Project Tree, a framework linking the contribution of each individual project, presented in the Programme and Budget, with the strategic priorities of IARC articulated through the Medium-Term Strategy.

# COMMUNICATIONS GROUP (COM)

**Group head**

Dr Nicolas Gaudin

**Secretary**

Ms Bernadette Geoffre

**Knowledge manager**

Ms Teresa Lee

**English editor**

Dr Karen Müller

**Technical editor**

Ms Jessica Cox

**Press officer**

Ms Véronique Terrasse

**Institutional webmaster**

Ms Maria de la Trinidad Valdivieso  
Gonzalez

**Web architect**

Mr Kees Kleihues-van Tol

**Technical assistants**

Mr Ussama Anas  
Ms Natacha Blavoyer  
Ms Latifa Bouanzi  
Mr Roland Dray  
Ms Sylvia Lesage  
Mr Othman Yaqoubi

**Consultant**

Ms Mary Roark  
(until June 2014)

The objective of the Communications Group (COM), as an integral part of the Director's Office, is to present a clear and coherent image of IARC and its work to the scientific community, the media, and the general public. COM also provides information- and publication-related services to the research Sections.

#### KNOWLEDGE MANAGEMENT SERVICES

The Knowledge Management Centre comprises the IARC Library and the IARC Publications Programme. After the restructuring of COM in 2013, knowledge management activities during the 2014–2015 biennium focused on establishing the workflows, policies, frameworks, and technical infrastructure needed to forward IARC's digital publishing and dissemination strategy.

#### AGREEMENT WITH WHO PRESS

The commercial agreement with the distributor of IARC publications, WHO Press, was renegotiated in 2014, dividing responsibilities for sales into two parts, print and electronic. WHO Press retained rights to sell IARC titles in print, while IARC became responsible for distribution of titles in electronic formats.

#### DIGITAL DISTRIBUTION CHANNELS

As part of the transition to electronic formats, COM increased its channels of online dissemination, by establishing its own license and workflows to service academic and research institutions directly, and by entering into contracts with major electronic book aggregators that service those markets.

In addition to focusing on diversifying business models, the Knowledge Management Centre sought reputable channels through which to disseminate publications freely. IARC became a participating publisher in HINARI, a programme created by WHO together with major commercial publishers to enable institutions in low- and middle-income countries to access one of the world's largest collections of biomedical and health literature. IARC also entered into an agreement with the United States National Library of Medicine to deposit full-text content in PubMed Bookshelf, a free digital repository of life sciences books.

COM continued its support of PubCan, an integrated online database that brings together IARC publications content in a dynamic and cross-searchable format. May 2014 saw the launch of ICD-O-3 Online, one of the three main components of PubCan, and in April 2015 the PubCan web architect took up a temporary post to continue development of the platform under COM supervision.

#### DIGITAL STRATEGY

COM continued to develop its strategic vision, engaging a consultant from November 2013 to June 2014 to review IARC's publications activities in the light of current global media trends and practices, and to articulate actionable steps for IARC publishing. Key recommendations from the consultancy were: improved marketing by better aligning IARC publishing activities with external scientific events and through strategic alliances; the streamlining and standardization of publishing workflows in concert with careful technology selection; a strategy for the increased output and digital dissemination of the WHO Classification of Tumours series; raising of awareness within the Agency about publishing trends and business models; and investment in producing and outputting flexible electronic content.

#### OPEN ACCESS

IARC's Open Access Policy was launched in January 2015. As approved by the Governing Council in May 2015, the IARC Open Access Fund was established, whereby a maximum of €50 000 per annum for 3 years can be spent in support of open access publishing.

During the 2014–2015 biennium, IARC published several key reference publications:

#### WHO CLASSIFICATION OF TUMOURS

[WHO Classification of Tumours of Female Reproductive Organs, 4th edition](#) (print)  
[WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th edition](#) (print)

#### IARC MONOGRAPHS

[Volume 104, Malaria and Some Polyomaviruses \(SV40, BK, JC, and Merkel Cell Viruses\)](#) (print)  
[Volume 105, Diesel and Gasoline Engine Exhausts and Some Nitroarenes](#) (print)  
[Volume 106, Trichloroethylene, Tetrachloroethylene and Some Other Chlorinated Agents](#) (print)  
[Volume 107, Polychlorinated Biphenyls and Polybrominated Biphenyls](#) (PDF)  
[Volume 108, Some Drugs and Herbal Products](#) (PDF)  
[Volume 112, Some Organophosphate Insecticides and Herbicides: Diazinon, Glyphosate, Malathion, Parathion, and Tetrachlorvinphos](#) (Monograph on Glyphosate, PDF)

#### IARC WORKING GROUP REPORTS

[Primary end-points for prophylactic HPV vaccine trials, IARC Working Group Report No. 7](#) (PDF)  
[Helicobacter pylori eradication as a strategy for preventing gastric cancer, IARC Working Group Report No. 8](#) (PDF)  
[Mycotoxin control in low- and middle-income countries, IARC Working Group Report No. 9](#) (print, PDF, and EPUB)  
[Lutte contre les mycotoxines dans les pays à revenu faible et intermédiaire, Rapports des Groupes de travail du CIRC N° 9](#) (print, PDF, and EPUB)  
[Control de las micotoxinas en los países de ingresos bajos y medios, IARC. Informes de grupos de trabajo N° 9](#) (print, PDF, and EPUB)

#### IARC SCIENTIFIC PUBLICATIONS

[Cancer Incidence in Five Continents, Vol. X, IARC Scientific Publication No. 164](#) (print and PDF)  
[Air Pollution and Cancer, IARC Scientific Publication No. 161](#) (PDF)

#### IARC TECHNICAL PUBLICATIONS

[Planning and developing population-based cancer registration in low- and middle-income settings, IARC Technical Publication No. 43](#) (print, PDF, and EPUB)  
[Planification et développement des registres du cancer basés sur la population dans les pays à revenu faible ou intermédiaire, Publications techniques du CIRC N° 43](#) (PDF)

[Planificación y desarrollo de registros de cáncer de base poblacional en los países de ingresos bajos y medios, IARC. Publicaciones técnicas N° 43 \(PDF\)](#)  
[The Origin of the International Agency for Research on Cancer, IARC Technical Report No. 6 \(PDF\)](#)

#### NON-SERIAL PUBLICATIONS

[World Cancer Report 2014 \(print and EPUB\)](#)  
[The Cancer Atlas, 2nd edition \(print; joint publication with the American Cancer Society\)](#)  
[International Agency for Research on Cancer: The First 50 Years, 1965–2015 \(print, PDF, and EPUB\)](#)

#### ELECTRONIC RESOURCES

[International Classification of Diseases for Oncology: ICD-O-3 Online \(<http://codes.iarc.fr/>\)](#)  
[Cancer Incidence in Five Continents, CI5plus. IARC CancerBase No. 9 \(<http://ci5.iarc.fr/CI5plus/Default.aspx>\)](#)  
[Cancer Incidence in Five Continents, Vol. I–X \(<http://ci5.iarc.fr/CI5I-X/Default.aspx>\)](#)  
[European Code Against Cancer, 4th edition \(<http://cancer-code-europe.iarc.fr/>\)](#)

#### EDITING, LANGUAGE, AND TRANSLATION SERVICES

COM provides English editing services to all IARC Groups, for manuscripts of book chapters, of peer-reviewed journals, or for publication in one of the established IARC Publications series, and administers external translation services for longer documents. COM also organizes successful language courses for the Agency's personnel in both working languages plus Spanish.

#### MEDIA SERVICES

Media services play a pivotal role in communicating IARC's mission and work clearly and coherently to the world at large. During the 2014–2015 biennium, the Agency's visibility in the media was reinforced and played a key role in promoting the work of IARC to the general public, the scientific community, and a wider range of stakeholders, including policy-makers. Interaction with strategic media outlets was increased, and a database of more than 4500 contacts was developed and updated. A wide range of communication tools and activities were also developed to

ensure that IARC research was featured regularly in mainstream and scientific media.

During the biennium, 17 IARC press releases were issued, more than 140 IARC news items were published, and two international press conferences were organized by IARC: in February 2014 (on World Cancer Day) in London, to launch *World Cancer Report 2014*, and in October 2014, to launch the fourth edition of the European Code Against Cancer, with the collaboration of the European Commission. Several Monograph evaluations were the focus of media outreach, such as the Monographs on Glyphosate and on Consumption of Red Meat and Processed Meat. Other communication materials produced included Q&As, a video on IARC's research in Latin America to improve cervical cancer screening in the region, and several web interviews of participants in the IARC Summer School. Continual contact with key media outlets was maintained, and regular interviews were set up with IARC experts throughout the biennium. Media training was provided to IARC scientific spokespeople on an ad hoc basis.





## WEB SERVICES

The Web services team ensures that all IARC websites and subsites present a unified look and feel and a consistent information architecture. During the 2014–2015 biennium, the Web services team successfully developed and launched the following websites:

### PUBLIC WEBSITES

Education and Training Programme (<http://training.iarc.fr/>)

ABC-DO: The African Breast Cancer – Disparities in Outcomes study (<http://abc-do.iarc.fr/>)

ICD-O-3 Online: International Classification of Diseases for Oncology (<http://codes.iarc.fr/>)

PRECAMA study: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (<http://precama.iarc.fr/>)

EPIC: European Prospective Investigation into Cancer and Nutrition (new release) (<http://epic.iarc.fr/>)

IARC Handbooks of Cancer Prevention (<http://handbooks.iarc.fr/index.php>)

BCNet: Low- and Middle-Income Countries Biobank and Cohort Building Network (<http://bcnet.iarc.fr/>)

European Code Against Cancer, 4th edition (<http://cancer-code-europe.iarc.fr/index.php/en/>)

GICR: Global Initiative for Cancer Registry Development (<http://gicr.iarc.fr/>)

CO-CHER: Cooperation on Chernobyl Health Research (<http://co-cher.iarc.fr/>)

BBMRI-LPC: Second Scientific Call for Access (<http://bbmri-lpc.iarc.fr/>)

EPICentre: The lifestyle and cancer blog (<http://blogs.iarc.fr/epicentre/>)

ESCAPE: The Oesophageal Squamous Cell Carcinoma African Prevention Effort (<http://esccape.iarc.fr/>)

### MEETING WEBSITES

Emerging Issues in Oncogenic Virus Research (<http://www.iarc.fr/oncogenicviruses2016/>)

Global Cancer: Occurrence, Causes, and Avenues to Prevention (<http://www.iarc.fr/conference2016>)

# EDUCATION AND TRAINING GROUP (ETR)

**Group head**

Ms Anouk Berger

**Senior visiting scientist**

Dr Rodolfo Saracci

**Assistant, courses programme**

Ms Susan Anthony

**Responsible officer, fellowship programme**

Dr Zdenko Herceg

**Assistant, fellowship programme**

Ms Eve El Akroud  
(until January 2015)  
Ms Isabelle Battaglia

**Secretary**

Ms Mira Delea

As a core statutory function of the Agency, IARC's education and training programme has made a substantial contribution to the development of human resources for cancer research in many countries and has also helped to shape the Agency's research strategy and widen its network of collaborators.

Key achievements of IARC's education and training programme during 2014–2015 are presented here. Whereas the Education and Training Group (ETR) coordinates the Agency's activities in these areas, many initiatives are led by the research Groups.

#### POSTDOCTORAL FELLOWSHIPS

During 2014–2015, new IARC Postdoctoral Fellowships were awarded to 23 postdoctoral fellows from 17 different countries (Figure 1). Research Return Grants were awarded to six fellows from low- and middle-income countries (LMICs) to establish their research activity in their own country. Most fellowships were co-funded by the European Union under the Marie Skłodowska-Curie Actions–People–COFUND Programme.

Under the bilateral agreement with Cancer Council Australia, one new IARC-Australia Postdoctoral Fellowship

**Table 1. Senior Visiting Scientist Awards, 2014 and 2015**

2014	
Professor Michael Leitzmann	University of Regensburg, Regensburg, Germany
Professor Walter Prendiville	University of Pittsburgh Medical Center, Pittsburgh, USA, and Beacon Hospital, Dublin, Ireland
Professor Kyle Steenland	Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, USA
2015	
Professor Fanghui Zhao	Department of Cancer Epidemiology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

was awarded and two were extended for an additional year. Under the bilateral agreement with the Irish Cancer Society, the first IARC-Ireland Postdoctoral Fellowship was awarded in 2014.

#### SENIOR VISITING SCIENTIST AWARD AND EXPERTISE TRANSFER FELLOWSHIP


Four Senior Visiting Scientist Awards were conferred in 2014–2015 (Table 1). Beyond the development of collaborative research projects, the Senior Visiting Scientist Award often leads to the expansion of important research initiatives or the joint production of key resources for capacity-building.

Activities carried out in 2014 by Dr Esther de Vries (The Netherlands), who was awarded an Expertise Transfer Fellowship in 2013, enabled the evaluation and improvement of cancer registry data in Colombia as well as the running of training activities.

#### SHORT-TERM FELLOWSHIPS

In collaboration with the Union for International Cancer Control (UICC), the UICC-IARC Development Fellowship enables one participant of the IARC Summer School to return to IARC for a period of 3 months for further training and collaborative work. In 2014, this fellowship was awarded to a researcher

**Figure 1. IARC Postdoctoral Fellowships awarded in 2014 and 2015, by country of origin. © IARC.**



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data source: IARC  
Map production: IARC  
World Health Organization

from Sri Lanka. In 2015, this initiative was expanded thanks to the increased contribution of UICC, which allowed the support of three researchers, from Ethiopia, Ukraine, and Serbia.

#### HOSTING ENVIRONMENT

The Agency also hosts a number of trainees, students, postdocs, and visiting scientists supported by project funds from the research Groups. A total of 270 Early Career and Visiting Scientists worked at IARC during the biennium.

The Agency continued to support the Early Career Scientists Association (ECSA), which was created in 2013. Among other activities, ECSA successfully held its first Scientific Day in April 2014, followed by a Scientific and Career Day in April 2015. Within the framework of the IARC Postdoctoral Fellowship Charter, which allows a more structured approach to postdoctoral training at IARC, and in collaboration with ECSA, ETR continued to develop the programme of generic courses for Early Career Scientists (Table 2).

Relationships with universities have been strengthened or developed. At the local level, links with two doctoral schools

**Table 2. Generic courses for Early Career Scientists, 2014 and 2015**

#### Research skill development

Epidemiology for non-epidemiologists: a short introduction

Biostatistics: generalized linear models using Stata

BioConductor for integrative genomic analyses

#### Responsible conduct of research

Biomedical research ethics

#### Communication skills

Presentation skills

Effective scientific posters

#### Leadership and management

Project management (twice)

Grant writing (three times)

Financial management (twice)


Task management (twice)

of the University of Lyon have been reinforced. At the international level, a collaboration with the University of Warwick (United Kingdom) has been set up for the hosting of doctoral students.

#### IARC SUMMER SCHOOL IN CANCER EPIDEMIOLOGY

The IARC Summer School in Cancer Epidemiology was held in Lyon in June–

**Figure 2. IARC Summer School 2015, Module 2: Introduction to Cancer Epidemiology. © IARC/Roland Dray.**



July in 2014 and 2015, with the goal of improving the methodological and practical skills of cancer researchers and health professionals. Modules on cancer registration (Cancer Registration: Principles and Methods in 2014 and Cancer Survival Methods for Cancer Registries in 2015) and cancer epidemiology (Introduction to Cancer Epidemiology) were organized each year (Figure 2).

During the biennium, the Summer Schools enabled the training of a total of 133 researchers and health professionals from 63 countries, 112 of them (84%) from 50 different LMICs. The Summer School modules were very well received by the participants.

Additional financial support for the Summer School came from the United States National Cancer Institute (NCI) as well as from the Nordic Cancer Union (NCU) and the Klinik und Poliklinik für Gynäkologie, Martin Luther University, Halle, Germany.

#### SPECIALIZED AND ADVANCED COURSES

Specialized or advanced courses are organized by IARC's scientific Groups, sometimes with the support of ETR. The majority of these courses are associated with collaborative research projects, where IARC is transferring skills needed to conduct the projects and to enable the subsequent implementation of

the research findings in the countries concerned. In some instances, specialized courses are co-organized with external partners and held at diverse locations throughout the world (Table 3). During the biennium, these courses enabled the training of a total of about 1100 scientists and health professionals.

#### E-LEARNING

Complementing its redesigned website (<http://training.iarc.fr/>), ETR launched an IARC Education and Training Newsletter in 2014, aimed at former Early Career and Visiting Scientists at IARC as well as course participants.

IARC is seeking to expand the production of e-Learning resources. A system to record and disseminate presentations, training courses, workshops, and other materials online was set up by the Agency in 2014. The system was used to capture some sessions of the Summer School and of the first Russian-language cancer registration course, held in Kazakhstan. The materials are available from the websites of ETR and the Global Initiative for Cancer Registry Development (GICR).

Partnership initiatives have been pursued to develop e-Learning materials and courses. Collaborations have been established with the Institut Català d'Oncologia (ICO), Spain, leading to the launch of a joint

Figure 3. Flyer for the joint IARC-ICO online course in cancer epidemiology.



online course in cancer epidemiology aimed at Latin American countries (<http://www.e-oncologia.org/cursos/postgrado-fundamentos-metodologicos-investigacion/#.VjO5lNKrTIU>; Figure 3), and with the London School of Hygiene & Tropical Medicine (United Kingdom), involving IARC's contribution to the contents of an e-Learning module, Introduction to Cancer Epidemiology ([http://dl.ishtm.ac.uk/download/open-access/gn09/EPM307\\_GN09\\_010\\_010.html](http://dl.ishtm.ac.uk/download/open-access/gn09/EPM307_GN09_010_010.html)).

**Table 3. Specialized and advanced courses, 2014 and 2015**

Course title	Location	Number of participants	External collaborations
<b>2014</b>			
Cervical cancer screening and treatment with cold coagulation	Fez, Morocco	11	Fondation Lalla Salma – Prévention et Traitement des Cancers
Course on visual inspection with acetic acid (VIA), colposcopy, and treatment of cervical neoplasia	Barshi, India	15	Tata Memorial Centre Rural Cancer Project, India; National Cancer Control Programme, Sri Lanka; Bill & Melinda Gates Foundation through the Alliance for Cervical Cancer Prevention (ACCP)
Training course on screening and treatment of cervical neoplasia	Kigali, Rwanda	14	National Cancer Institute Rwanda; UICC
Training course on colposcopy and LEEP procedures in the management of abnormal cytology	Bangkok, Thailand	57	National Cancer Institute Thailand; Thai Society for Colposcopy and Cervical Pathology
Master Trainers course on cervical cancer screening and treatment of precancerous lesions	Barshi, India	17	Tata Memorial Centre Rural Cancer Project, India
GoToWebinar training on EPIC-Soft GloboDiet	Online courses (4)	45	
Cancer survival methods for cancer registries	Chennai, India	29	UICC; GICR
Building blocks for cancer system performance measurement and evaluation (Spanish)	Ottawa, Canada	18	GICR; IARC Regional Hub for Latin America
Basic training in cancer registration	Mozambique	5	AFCRN (IARC Regional Hub for Sub-Saharan Africa)
Cancer registration (for Francophone countries)	Abidjan, Côte d'Ivoire	11	AFCRN (IARC Regional Hub for Sub-Saharan Africa)
Cancer registration	Cairo, Egypt	25	WHO EMRO
Cancer registration	Yangon, Myanmar	80	IARC Regional Hub for Southern, Eastern and South-East Asia; NCI Bangkok
Cancer registration workshop	Shanghai, China	80	United States National Cancer Institute; GICR
IARC cancer registration course (for Russian-speaking registries)	Astana, Kazakhstan	28	IARC Regional Hub for Northern Africa, Central and Western Asia; National Institute for Postgraduate Medical Education, Kazakhstan; Central Asian Cancer Institute, Kazakhstan
Principles of cancer registration and CanReg	San Salvador, El Salvador	52	IARC Regional Hub for Latin America
Uses of cancer registry data in cancer control research	Ankara, Turkey	25	IARC Regional Hub for Northern Africa, Central and Western Asia; GICR; MECC; NCIC; UC Irvine
<b>2015</b>			
Cancer registration	Russian Federation	34	IARC Regional Hub for Northern Africa, Central and Western Asia; GICR; WHO EURO; European Network of Cancer Registries (ENCR); Petrov Research Institute of Oncology, Saint Petersburg, Russian Federation
Second training course on cervical pathology – ESTAMPA study	Cuernavaca, Mexico	20	Instituto de Salud Publica de Mexico (INSP); WHO Department of Reproductive Health and Research; UICC; Pan American Health Organization (PAHO)
Reunión de Consenso de Colposcopia – Estudio multicéntrico de tamizaje y triaje de cáncer de cuello uterino usando pruebas del virus del papiloma humano (ESTAMPA)	Bogotá, Colombia	26	San José Hospital, Bogotá, Colombia
Colposcopy and LEEP procedures in the management of abnormal cytology	Myanmar	34	National Cancer Institute Thailand; TSCCP, Thailand; University of Medicine, Magway, Myanmar; AOGIN
Training course on early detection of breast, cervical, colorectal, and oral cancer	Sri Lanka	110	National Cancer Institute Sri Lanka; WHO Country Office; UICC

**Table 3. Specialized and advanced courses, 2014 and 2015 (continued)**

Course title	Location	Number of participants	External collaborations
Cervical cancer screening and management of preinvasive lesions	Thailand	20	National Cancer Institute Thailand; TSCCP, Thailand
Workshop on colposcopy	Morocco	30	African Organisation for Research and Training in Cancer (AORTIC)
GloboDiet reference manager application training: Malta	Online course	5	EU-MENU
GloboDiet train-the-trainers course: Malta	Online course	7	EU-MENU
GloboDiet train-the-trainers course: Malta	Lyon, France, and online course	7	EU-MENU
GloboDiet introduction training – organization of the work: Ireland and Africa	Lyon, France, and online course	3	EU-MENU
GloboDiet training for Latin America (Brazil and Mexico): specific procedures to develop GloboDiet-related files	Online courses (continuous)	7	EU-MENU
Evaluation of GloboDiet in the African context	Online courses	37	EU-MENU
CanReg5 course	The Gambia	5	MRC Gambia; AFCRN (IARC Regional Hub for Sub-Saharan Africa)
CanReg5 training	Mexico	4	IARC Regional Hub for Latin America; INCAN Mexico
Cancer registry workshop	Islamic Republic of Iran	20	Iran University of Medical Sciences; Ministry of Health, Islamic Republic of Iran; IARC Regional Hub for Southern, Eastern and South-East Asia
Cancer registry, basic data analysis	Thailand	35	National Cancer Institute Thailand; IARC Regional Hub for Southern, Eastern and South-East Asia; GICR; IACR
Population-based cancer registry workshop	Indonesia	70	United States National Cancer Institute; Jakarta Cancer Registry; IARC Regional Hub for Southern, Eastern and South-East Asia
CanReg5 course, Pre-meeting Workshop, 37th IACR Meeting	India	20	IACR; Tata Memorial Centre; CDC
Examining solutions for cancer registration in low- and middle-income countries, Pre-meeting Workshop, 37th IACR Meeting	India	30	IACR; Tata Memorial Centre; CDC
Population-based cancer registry workshop	Panama	22	PAHO/INC
Cancer registration in the Gulf countries: principles and updates	Kuwait	19	GICR; Gulf Centre for Cancer Control & Prevention (GCCP); Kuwait Ministry of Health
BCNet training	Lyon, France	25	LMICs Biobank and Cohort Building Network (BCNet)

# LABORATORY SERVICES AND BIOBANK GROUP (LSB)

**Group head**

Dr Maimuna Mendy

**Secretary**

Ms Sally Moldan

**Data management assistant**

Mr Ny Haingo Andrianarisoa

**Biobank process management assistant**

Dr Elodie Caboux

**Laboratory services management assistant**

Ms Brigitte Chapot

**Biobank technicians**

Mr Thomas Cler  
(until January 2015)

Ms Elodie Colney

Mr José Garcia

Ms Sophie Guillot

Mr Christophe Lallemand

Ms Gertrude Tchoua

**Laboratory aides**

Ms Marcelle Essertel  
(until April 2014)

Ms Nicole Farina

Ms Maria Maranhao  
(until November 2014)

**Students**

Mr Edwin Bouchet  
(until March 2014)

Ms Ninon Guichard  
(until March 2015)

Mr Tadinho Spencer



The Laboratory Services and Biobank Group (LSB) was formed in 2010 to manage the IARC Biobank facility and the common laboratory platforms. The Group was reorganized in 2014 to address the growing complexity of its workload, which has changed because of the increasing services provided to IARC scientific Groups as well as external collaborators and the growing support that LSB provides to low- and middle-income countries (LMICs). The Group required a stronger process management role and data management capacity.

To ensure that biospecimens are kept under optimal conditions, LSB liaises closely with the Administrative Services Office (ASO), and the two Groups were reorganized simultaneously to address overlapping and complementary responsibilities. LSB now has 10.5 positions (reduced from 13); one post was moved to ASO, two posts were eliminated, and a data management assistant position was created.

#### LABORATORY SERVICES

##### COMMON LABORATORY PLATFORMS

Laboratory Services has continued, in conjunction with the Laboratory Steering Committee, to oversee the common laboratory platforms and the maintenance of equipment. Efforts to reinforce interactions between laboratory-based and epidemiological research include the upgrading, updating, and acquisition of state-of-the-art scientific instruments. During the biennium, the shared platforms acquired new equipment, including a benchtop next-generation sequencer of medium capacity, a nucleic acid small-volume extractor, upgraded liquid-handling instruments to provide high-throughput facilities, an enzyme-linked immunosorbent assay (ELISA) plate reader, a vacuum concentrator, a modular high-throughput thermal cycler and real-time detection system, and a digital droplet polymerase chain reaction (PCR) system.

#### HEALTH AND SAFETY

Health and safety issues are managed in collaboration with the Occupational Health and Safety Committee. Improve-

ments include the installation of an emergency button to stop the liquid nitrogen supply from the main tank in case of an emergency and the installation of cameras for surveillance when personnel are working alone in the cryogenic rooms. During the biennium, advice was provided to several Groups on the relocation of their offices and laboratories.

The 5-year authorization for handling radioisotopes was renewed, and permission to use genetically modified organisms (GMOs) was also granted for another 5 years.

#### IARC BIOBANK

The IARC Biobank maintains biological sample collections from international collaborative studies and operates a service platform for sample retrieval, DNA extraction, and shipment of biological material worldwide. IARC's facilities also serve as a custodian for collections from LMICs.

Sample location records for 5 million of the more than 7 million biological specimens in the Biobank have been uploaded into the IARC sample management system (SAMI) database. Data about the European Prospective Investigation into Cancer and Nutrition (EPIC) study's collection, which were managed by a commercial program (Tetraed), were also migrated into SAMI.

New samples arrive at IARC with a set of minimum data, which are managed centrally and recorded in SAMI using newly developed standard operating procedures and working instructions. Standard practices are implemented across the Agency for the efficient management of the reception, shipment, and storage of biological samples under optimal conditions to provide reliable material.

A revision of the [Common Minimum Technical Standards and Protocols for Biological Resource Centres](#), first published in 2007, was started in 2015.

#### BIOBANK SERVICES

The Biobank continues to provide pre-analytical services and operates on

a cost-recovery basis, with a major contribution from the central IARC Regular Budget for infrastructure and salaries. During the biennium, a total of 16 projects were conducted relating to 24 requests from international institutions. This resulted in more than 12 540 sample retrievals from liquid nitrogen, 9280 DNA extractions, 22 000 DNA aliquots, and the shipment of 122 parcels to 21 countries worldwide. In addition to the implementation of stringent quality control measures, the Biobank participated in international proficiency schemes and scored very highly in the DNA extraction and DNA quantification programmes.


#### BCNET

Activities to establish the LMICs Biobank and Cohort Building Network (BCNet) continued, and the network is developing into a focal point for LMIC biobanking. A report of the situational analysis, conducted in 2013, was published during the biennium (Mendy et al., 2014). Four additional organizations have joined BCNet (Breast Care International, Ghana; the Centre for Infectious Disease Research in Zambia; Gadjah Mada University, Indonesia; and Institut Pasteur, Tunisia), bringing the membership to 29 institutions from 18 countries. The network's website (<http://bcnet.iarc.fr/>) was launched in September 2014.

#### TRAINING

With funding and support from the United States National Cancer Institute's Center for Global Health (NCI-CGH) and other partners, the first BCNet Training Workshop was held at IARC in November 2015, covering ethical, legal, and social issues (ELSI); quality; and information technology.

LSB continues to provide on-site training for colleagues from LMICs. During the biennium, LSB hosted students from Ghana, Indonesia, Lithuania, and The Gambia. Training is organized in collaboration with Centre Léon Bérard to include training in the handling and processing of fresh tissue.



#### COLLABORATIONS

In collaboration with the McCabe Centre for Law and Cancer and Melbourne Law School (Australia), IARC is contributing to the training of future professionals in the field of cancer research with a project to examine ELSIs associated with cancer biobanking in LMICs. A master's student spent 8 weeks at IARC to research issues including informed consent and access to data and samples; conduct an analysis of international, regional, and national laws and policies; and assist in writing and editing generic templates (consent forms, access policies, and access agreements). The report will be published soon.

In 2014, IARC joined the pan-European Biobanking and BioMolecular resources Research Infrastructure–European Research Infrastructure Consortium ([BBMRI-ERIC](#)) as an observer. IARC will share its expertise in international networking and interoperability issues to ensure that compatible structures developed within Europe will be accessible to the wider international community.

LSB continues to support the African Organisation for Research and Training in Cancer (AORTIC), linking the organization with BBMRI and BCNet and other biobanking organizations in Europe.

#### GRANTS

Two grant awards were received, within the European Union's Horizon 2020 programme: (i) ADOPT BBMRI-ERIC, which aims to expand BBMRI beyond Europe (October 2015–September 2018), and (ii) B3Africa (Bridging Biobanking and Biomedical Research across Europe and Africa), for which IARC is leading the Training and Dissemination work packages (July 2015–June 2018).



# THE GAMBIA HEPATITIS INTERVENTION STUDY (GHIS)

**Group head**

Dr Ramatoulie Njie

**Acting head of cancer registry**

Mr Lamin Bojang

**Trainee hepatologist**

Dr Sheikh Omar Bittaye

**Tumour registration officers**

Mr Yusupha Bah

Mr Ebrima Bojang

Mr Modou Musa Sisawo

Mr Lamin Sanneh

**Data entry clerk**

Ms Mariatou Rahman

**PA/administrator**

Ms Mama Cham

The Gambia Hepatitis Intervention Study (GHIS), now in its third decade, is a collaborative project undertaken by IARC, the government of the Republic of The Gambia, and the Medical Research Council (MRC), United Kingdom. GHIS was initiated in 1986 to evaluate the effectiveness of hepatitis B virus vaccination in childhood for the prevention of infection, chronic liver disease, and hepatocellular carcinoma in adulthood in a high-risk population. Led by the Director's Office, GHIS is a high-profile project of the Agency. At the beginning of GHIS, a population-based National Cancer Registry (NCR) was established. Cancer cases are identified through public health facilities and private clinics.

Dr Ramatoulie Njie, the hepatologist managing the project, together with a team of tumour registration officers, carries out enhanced surveillance of chronic liver disease and cancer in hospitals and health centres around the country. She is assisted by a junior

doctor from the local Edward Francis Small Teaching Hospital (EFSTH), who has been seconded to the MRC liver clinic and is trained in ultrasonography and liver biopsy techniques. Suspected cases of liver cancer are assessed by ultrasonography, by quantitative  $\alpha$ -fetoprotein assays, and, in many cases, by histological confirmation from liver biopsy samples. Histopathology reporting is carried out by two independent pathologists: in The Gambia by Professor O. Khalil at EFSTH and in Lyon by Dr Behnoush Abedi-Ardekani at IARC. All confirmed cases of liver cancer are recorded in the NCR, and cases of chronic liver disease are recorded in a linked database.

Dr Freddie Bray, head of the Section of Cancer Surveillance (CSU) at IARC, together with Mr Morten Ervik, IT development manager in CSU, made a comprehensive site visit to The Gambia on 10–13 March 2015. All major health facilities and sources of data capture were visited. An on-site training

programme was held for the tumour registration officers, and a number of recommendations were made about measures to improve the quality of the NCR to the highest possible standard. These measures are currently being implemented and are expected to improve the identification of liver cancer cases and enable record linkage to the vaccine trial database.

The statistical analysis plan for GHIS was discussed at a special one-day meeting held at IARC in Lyon on 13 April 2015. The meeting was attended by Professor Hazel Inskip of the MRC Statistical Epidemiology Unit at the University of Southampton (United Kingdom) and Sir Andrew Hall, formerly of the London School of Hygiene & Tropical Medicine (United Kingdom), both of whom were instrumental in setting up the project three decades ago. A series of action points were detailed, and these are also being implemented.

# SECTION OF SUPPORT TO RESEARCH (SSR)

## OFFICE OF DIRECTOR OF ADMINISTRATION AND FINANCE

### Director of administration and finance

Mr David Allen

### Administrative officer

Ms Virginie Vocanson

### Assistant (Documents)

Ms Agnès Meneghel

### Secretary

Ms Anne-Magali Maillol

## ADMINISTRATIVE SERVICES OFFICE

### Administrative services officer

Ms Elisabeth Françon

### Administrative assistant

Ms Sophie Servat

### Assistants (Procurement)

Ms Fabienne Lelong

Mr Didier Louis

Ms Sandrine Macé

### Assistant (Registry)

Mr François Deloche

### Assistant (Security and building management)

Mr Jean-Alain Pedil

### Secretary

Ms Valérie Rut

### Support staff

Mr José Cardia Lima (Technician) (until October 2014)

Mr Thomas Cler (Laboratory maintenance)

Mr José Garcia (Laboratory and administration)

Mr William Goudard (Space maintenance)

Mr Antoine Hernandez (Driver)

Mr Michel Javin (Reprography)

Mr Hafed Lamouchi (Electronic maintenance)

Mr Ludovic Ripert (Storekeeper) (until October 2014)

Ms Séverine Sarboni (Reception)

## GRANTS, BUDGET, AND FINANCE OFFICE

### Administration and finance officer

Ms Angkana Santhiprechachit

### Resource mobilization and grant officer

Dr Olaf Kelm

### Budget officer

Ms Editta Odame

### Finance officers

Ms Julie Goux

Mr Rommel Nidea

### Assistants (Budget)

Mr Thomas Odin

Ms Madeleine Ongaro

Mr Franck Rousset

### Assistants (Accounts)

Mr Pascal Binet

Ms Laurence Piau

Ms Adèle Séguret

Ms Christine Abou-Rizk (Temporary)

### Assistants (Resource mobilization)

Ms Nathalie Lamandé

Ms Claire Salignat

### Secretary

Ms Lobna Boulegroun

### Support staff

Ms Belinda Annibaldi (Finance)

(Temporary) (until December 2014)

## HUMAN RESOURCES OFFICE

### Human resources officer

Ms Dina D'Amico

### Assistants (Human resources)

Ms Catherine Bassompierre

Ms Isabelle Battaglia

(until December 2014)

Ms Maud Bessenay

Ms Julianna Soos (Training) (Temporary)

### Secretary

Ms Sophie Sibert

### Central Secretarial Services (CSS)

Ms Dominique Bouchard

Ms Nandini Deleu

Ms Marieke Dusenberg

Ms Carole Lastricani (until August 2014)

### Staff physician

Dr Michel Baduraux (until April 2014)

Dr Pierre-Olivier Dondoglio

### Secretary to IARC Staff Association Committee and Staff physician

Ms Isabelle Poncet

### Relocation assistant

Ms Christine Astier

### Consultant

Mr Rommel Arca (Training)

(until February 2015)

## INFORMATION TECHNOLOGY SERVICES

### System analyst

Mr Philippe Damiecki

### IT officers

Mr Philippe Boutarin

Mr Christopher Jack

### Assistants (Informatics)

Ms Lucile Alteyrac

Mr Nicolas Tardy

### Support staff

Mr Sébastien Agathe (Informatics technician)

Mr Rémi Valette (SharePoint and .Net developer) (Temporary)

The role of the Section of Support to Research (SSR) is to support the achievement of IARC's scientific objectives through efficient and effective management of the Agency's resources and provision of administrative services, ensuring accountable risk mitigation and implementing strategies to strengthen IARC's capacity.

The Section is made up of specialized administrative units that manage and provide services intrinsic to the successful implementation of IARC's scientific programme in the areas of: Resource Mobilization, Budget, and Finance; Human Resources; Procurement, Conference, Office Administration, and Buildings; and Information and Communications Technology. SSR ensures that the Agency's activities uphold the highest standards of management, efficiency, and accountability in the use of the funding made available by its Participating States and donors.

In addition to the regular provision of services, during 2014–2015 the SSR team's achievements in five areas have contributed substantively to the continued efforts to maintain IARC's

status as a leader in the ever-changing international research environment.

During the biennium, SSR spearheaded the introduction of a new IARC intranet, with the aim of providing more complete and accessible information on the workings of the Agency. As part of this major project, a review of IARC's key administrative processes was carried out, resulting in the issuance of updated and new policies and procedures organized in a modern electronic interface for ease of use. In the continued effort towards streamlining, the re-engineered processes are being automated to increase efficiency and reduce workload across the Agency.

Notable progress was made with our host country's agreement to build a new IARC building and the commitment for the corresponding funding. During the biennium, IARC was fully engaged in the preparation of complete detailed specifications setting forth the anticipated requirements over the next 25 years, with highly appreciated support from Scientific Council members with recent experience in similar projects. Alongside looking at the future "Nouveau Centre", SSR

continued to ensure that IARC's scientific activities were not interrupted by the continued technical failings experienced in the current premises. In view of several incidents with various degrees of severity, a formal IARC Business Continuity Plan is now in place to ensure a smooth response to anticipated and unexpected events. In addition, in view of the escalating international terrorist threat and specifically events in France during 2014–2015, enhanced understandings were reached with local authorities and several investments were made towards heightening IARC's security measures.

In parallel with the preparation of the IARC Medium-Term Strategy for 2016–2020, major efforts were made towards ensuring full funding of the ambitious goals set forth in the document. Most importantly for current and potential donors, SSR continues to ensure effective management of resources entrusted to IARC, as consistently recognized by the WHO external auditors. To better communicate how the ongoing activities at the Agency contribute to the overall strategic goals, the IARC Project Tree was introduced as a framework for the 2016–2017 budget



approved by the Governing Council, and several investments were made to enhance support to project management and reporting to improve the visibility of the efficiency and effectiveness of our projects. The enhancement of the IARC enterprise resource planning (ERP) system to render it compatible with the International Public Sector Accounting Standards (IPSAS) will further support transparency, effective oversight, and financial reporting.

Several made-to-measure and sustainable programmes aimed at enhancing staff development, motivation, and productivity were put in place. Principal among these is the IARC Learning and Development Framework, which sets forth an innovative means to ensure that IARC staff members are equipped

with the right competencies to meet the current and future needs of the Agency within the limited resources available. Efforts continue towards supporting IARC supervisors in carrying out their staff management functions through discussion sessions and targeted training, and an electronic platform to manage the yearly performance management and development process was implemented. In addition, the restructuring of several Groups within the Agency was supported in efforts to ensure alignment within the context of continuously evolving scientific and operational expectations.

The new IARC intranet was the first project implemented at IARC on the Microsoft SharePoint platform, introduced with the purpose of more

effectively managing and sharing knowledge across the Agency and with collaborators. Subsequent projects have introduced templates to capture and facilitate different types of collaborations within the Agency and with external collaborators. This is an exciting new area, which will continue in the next biennium with the implementation of modern document retention and management tools across IARC.

SSR strives to continually improve the Agency's processes and support services by collecting feedback through a yearly services survey. SSR also holds biannual town hall meetings to communicate the Section's objectives and planned activities, and holds information sessions when required to explain new policies and procedures.





# COMMITTEES

## LABORATORY STEERING COMMITTEE (LSC)

Laboratory research directly involves seven Groups or Sections at IARC (BMA, EGE, GCS, ICB, LSB, MMB, and MPA). The IARC Laboratory Steering Committee (LSC) oversees the IARC core laboratory facilities and advises the Director on their most efficient use. Significant tasks of the LSC over the biennium have concerned the reallocation

of laboratory space and the move of the Biomarkers Group (BMA) to the 6th and 13th floors of the tower building, as well as the purchase of new laboratory equipment, including four robots for handling liquid biospecimens, two mass spectrometers, a pyrosequencer, and a next-generation sequencer of medium capacity. An inventory of current needs

for equipment maintenance and a plan for replacement of old items of equipment were prepared. The LSC also played an active role in the reclassification of laboratory technician posts, the definition of space requirements for laboratory activities in the “Nouveau Centre”, and the organization of Laboratory Technical Watch seminars.

## BIOBANK STEERING COMMITTEE (BSC)

The IARC Biobank Steering Committee (BSC) continues to support biobanking activities at the Agency and advises the Director regarding the strategic development of the Biobank both internally and with external collaborators and projects, including the growing involvement in international biobanking capacity-building in low- and middle-income countries.

Following the establishment of a sample Access Policy for the Agency

during the 2012–2013 biennium, the BSC has supported the Biobank in the development of standard operating procedures and working instructions to ensure that samples are received and shipped from the Agency in optimal condition and according to strict international regulations.

The BSC also approved the proposal for a revision of the Common Minimum Technical Standards and Protocols for Biological Resource Centres, first

published in 2007, which was started in 2015.

The BSC also participated in discussions about plans for the Biobank of the new IARC building, according to the future needs of the Agency, and proposed the development of contingency plans for different types of events that could threaten the integrity of the current biospecimen collections.

The biennium witnessed the formation of the new Bioinformatics Steering Committee (BISC), which is tasked with overseeing matters related to bioinformatics in support of the Agency's own and collaborative projects. The BISC, led by chair Dr James McKay (GCS) and vice-chair Dr Jiri Zavadil (MMB), consists of 14 members representing all Groups with bioinformatics needs. The BISC oversees two working groups.

The Bioinformatics Working Group, led by Dr Magali Olivier (MMB), is responsible for facilitating interaction in bioinformatics within the Agency and with collaborative partners. This group holds biweekly sessions attended by about 30 participants from IARC and local bioinformatics groups. With the Education and Training Group (ETR), the Bioinformatics Working Group has also developed courses in bioinformatics for

IARC staff members. The Informatics Working Group, led by Mr Christopher Jack (ITS), is responsible for the information technology aspects of the Agency's scientific activities and has overseen two major technical expansions of IARC's high-performance computing capacity, ensuring that the computing environment matches the Agency's current demand.

## ETHICS COMMITTEE (IEC)

The IARC Ethics Committee (IEC) ensures that research conducted or supported by IARC conforms to international ethical standards for research involving humans, and that measures are in place to safeguard the rights and welfare of participants. The IEC ethical review is complementary to local/national ethical approval. The committee is composed of

15 senior members of diverse nationalities with complementary expertise in epidemiology, genetics, oncology, law, and bioethics. Dr Jean-Pierre Boissel (chair, 2010–2013) terminated his mandate in 2014, and Dr Béatrice Fervers was appointed to the role of chair, supported by Dr Paolo Vineis as vice-chair. During the period 2014–2015 (up to September

2015), the IEC evaluated 74 new projects and 13 resubmissions of projects previously reviewed by the IEC. In addition, the IEC regularly considers specific ethical issues on a broader level to advise the Agency. An example is the discussion document on the ethical issues raised by incidental findings in genomic studies, prepared in 2014.

## OCCUPATIONAL HEALTH AND SAFETY COMMITTEE (OHSC)

The mission of the IARC Occupational Health and Safety Committee (OHSC) is to ensure, in close collaboration with the Staff Physician and the IARC administration, that excellent working conditions are provided to all IARC personnel. In support of the process of the conception of the new IARC building, the OHSC produced a report in 2014 outlining recommendations on office spaces and optimal physical

working conditions, including social space and dedicated recreational areas. The report also took into consideration the expectations of IARC personnel who were interviewed through a questionnaire developed by the OHSC and the Staff Association. The activities of the OHSC also included (i) the revision of the procedures to be followed in case of an accident with biological samples and in the event of a colleague feeling

faint or dizzy, (ii) regular and specific safety trainings, and (iii) implementation of measures and controls to improve laboratory safety. In collaboration with the Laboratory Services and Biobank Group (LSB), the OHSC has started to work on management of exposure to chemicals and biological hazards in the Agency and is currently exploring the options for developing a risk assessment methodology.

# GOVERNING AND SCIENTIFIC COUNCILS

THE INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (IARC) WAS ESTABLISHED IN MAY 1965, THROUGH A RESOLUTION OF THE EIGHTEENTH WORLD HEALTH ASSEMBLY, AS AN EXTENSION OF THE WORLD HEALTH ORGANIZATION, AFTER A FRENCH INITIATIVE. IT IS GOVERNED BY ITS OWN GOVERNING BODIES: THE IARC GOVERNING COUNCIL AND THE IARC SCIENTIFIC COUNCIL.

## GOVERNING COUNCIL

IARC's general policy is directed by a Governing Council, composed of the representatives of Participating States and of the Director-General of the World Health Organization. It meets every year in ordinary session in Lyon, usually the week before the World Health Assembly. The Governing Council elects IARC's Director for a five-year term. The Council re-elected Dr Christopher P. Wild in May 2013 to serve for a second five-year term as from 1 January 2014. The chairperson of the Governing Council prepares the meetings together with the Secretariat and advises the Director throughout the year. In May 2015, Morocco was admitted as the first IARC Participating State from the African continent, bringing the total number of IARC Participating States to 25.



## SCIENTIFIC COUNCIL

The Scientific Council consists of highly qualified scientists selected on the basis of their technical competence in cancer research and allied fields. Members of the Scientific Council are appointed as experts and not as representatives of Participating States. When a vacancy arises on the Scientific Council, the Participating State that nominated the departing member may nominate up to two experts to replace that member. Scientific Council members are appointed for four-year terms by the Governing Council. The Scientific Council reviews the scientific activities of the Agency and makes recommendations on its

programme of permanent activities and priorities. The Scientific Council meets every year in ordinary session in late January/early February.

## BUDGET

IARC activities are partially funded by the regular budget contributions paid by its Participating States. In addition, substantial funding comes from extrabudgetary sources, mainly grant awards, both national and international. The regular budget for the 2014–2015 biennium was approved in May 2013 at a level of €40 424 491.

## PARTICIPATING STATES AND REPRESENTATIVES AT IARC GOVERNING COUNCIL'S FIFTY-SIXTH SESSION, 15–16 MAY 2014

### UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND

Dr Mark Palmer, Chairperson  
Director, International Strategy  
Medical Research Council  
London

Dr Nathan Richardson  
Head, Molecular and Cellular Medicine  
Medical Research Council  
London

### FRANCE

Professor Agnès Buzyn,  
Vice-Chairperson  
Présidente, Institut national du Cancer  
(INCa)  
Boulogne-Billancourt

Mr Armel T'Kint De Roodenbeke  
Ministère des Affaires étrangères  
Paris

### SWITZERLAND

Dr Diane Steber Büchli, Rapporteur  
Collaboratrice scientifique, Division  
internationale, Office fédéral de la  
Santé publique  
Bern

### AUSTRALIA

Professor Chris Baggoley  
Chief Medical Officer  
Department of Health  
Canberra

### AUSTRIA

Dr Hemma Bauer  
Austrian Federal Ministry of Science,  
Research and Economy  
Vienna

### BELGIUM

Mr Lieven De Raedt  
Attaché Relations Internationales  
SPF Santé publique, Sécurité de la  
Chaîne Alimentaire et Environnement  
Brussels

### BRAZIL

Dr Luiz Antonio Santini (unable to  
attend)  
Director General, Brazilian National  
Cancer Institute (INCA)  
Rio de Janeiro

Dr Marisa Dreyer Breitenbach  
Research Coordinator, Brazilian  
National Cancer Institute (INCA)  
Rio de Janeiro

### CANADA

Dr Stephen M. Robbins  
Scientific Director, Institute of Cancer  
Research  
Canadian Institutes of Health Research,  
University of Calgary  
Calgary, Alberta

Ms Lucero Hernandez  
Senior Policy Advisor, Multilateral  
Relations Division  
Office of International Affairs for the  
Health Portfolio  
Ottawa, Ontario

### DENMARK

Professor Herman Autrup  
University of Aarhus School of Public  
Health  
Aarhus

### FINLAND

Professor Juhani Eskola  
Director-General, National Institute for  
Health and Welfare (THL)  
Helsinki

Professor Harri Vainio  
Director-General, Finnish Institute of  
Occupational Health  
Helsinki

### GERMANY

Dr Chariklia Balas  
Advisor, Division of Global Health  
Federal Ministry of Health  
Bonn

### INDIA

Professor G.K. Rath (unable to attend)  
Chief, Dr B.R. Ambedkar Institute  
Rotary Cancer Hospital (DBAIRCH)  
All India Institute of Medical Sciences  
(AIIMS)  
New Delhi

### IRELAND

Mr Keith Comiskey  
Department of Health  
Dublin

### ITALY

No Representative

### JAPAN

Dr Yousuke Takasaki  
Deputy Director, Division of International  
Affairs  
Ministry of Health, Labour and Welfare  
Tokyo

Mr Kenji Okada  
Ministry of Health, Labour and Welfare  
Tokyo



#### NETHERLANDS

Dr Jack Hutten  
Acting Head, Division of Public Health  
Care  
Ministry of Health, Welfare and Sport  
The Hague

Mr Jeroen Hulleman  
Senior Policy Advisor, Public Health  
Directorate  
Ministry of Health, Welfare and Sport  
The Hague

#### NORWAY

Dr Edgar Rivedal  
Scientific Coordinator, Norwegian  
Scientific Committee for Food Safety  
Oslo

Dr Karianne Solaas  
Senior Adviser, The Research Council  
of Norway  
Oslo

#### QATAR

Dr Faleh Mohamed Hussain Ali  
Assistant Secretary General for Policy  
Affairs, The Supreme Council of Health  
Doha

#### REPUBLIC OF KOREA

Dr Duk-Hyoung Lee  
Director, National Cancer Control  
Institute  
National Cancer Center  
Gyeonggi-do

#### RUSSIAN FEDERATION

Dr Svetlana Axelrod  
Deputy Director, Department of  
International Cooperation and Public  
Relations  
Ministry of Health  
Moscow

Ms Lidia Gabuniya  
Main Expert, Department of  
International Cooperation and Public  
Relations  
Ministry of Health  
Moscow

Professor Boris Alexeev  
Deputy Director, P.A. Gertsen Moscow  
Research Institute of Oncology  
Moscow

#### SPAIN

Dr Rafael de Andrés Medina  
Chief, Documents and Technical Studies  
Department  
Instituto de Salud Carlos III  
Madrid

#### SWEDEN

Professor Mats Ulfendahl  
Secretary-General, Swedish Research  
Council – Medicine  
Stockholm

#### TURKEY

Professor Murat Tuncer (unable to  
attend)  
Rector, Hacettepe University  
Ankara

#### UNITED STATES OF AMERICA

Dr Lisa Stevens  
Deputy Director for Planning and  
Operations  
Center for Global Health, National  
Cancer Institute  
Department of Health and Human  
Services  
Rockville, Maryland

Dr Charlie Darr  
International Health Analyst, Multilateral  
Office  
Office of Global Affairs  
Department of Health and Human  
Services

Dr Pamela Protzel-Berman  
Deputy Director, Division of Cancer  
Prevention and Control  
Centers for Disease Control and  
Prevention  
Department of Health and Human  
Services

#### WORLD HEALTH ORGANIZATION

Dr Oleg Chestnov  
Assistant Director-General,  
Noncommunicable Diseases and Mental  
Health (NMH)  
WHO headquarters, Geneva

Ms Joanne McKeough  
Office of the Legal Counsel  
WHO headquarters, Geneva

Dr Andreas Ullrich  
Medical Officer, Prevention of  
Noncommunicable Diseases (PND)  
WHO headquarters, Geneva

#### OBSERVERS

#### SCIENTIFIC COUNCIL

Professor Mads Melbye (unable to  
attend)  
Outgoing chairperson

Professor Cornelia (Neli) Ulrich  
Incoming chairperson

#### UNION FOR INTERNATIONAL CANCER CONTROL (UICC)

Mr Juerg Boller  
Chief Operating Officer, Union for  
International Cancer Control (UICC)  
Geneva

#### SOUTH AFRICA

Ms Sandhya Singh  
Director – Noncommunicable Diseases  
National Department of Health

#### EXTERNAL AUDIT

Mr Lito Q. Martin (unable to attend)  
Director, International Audit and  
Relations Office, Commission on Audit  
Quezon City, Philippines

## PARTICIPATING STATES AND REPRESENTATIVES AT IARC GOVERNING COUNCIL'S FIFTY-SEVENTH SESSION, 13–14 MAY 2015

### UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND

Dr Mark Palmer, Chairperson  
Director, International Strategy  
Medical Research Council  
London

Dr Adam Babbs  
Programme Manager – Cancer  
Medical Research Council  
London

### FRANCE

Professor Agnès Buzyn,  
Vice-Chairperson  
Présidente, Institut national du Cancer  
(INCa)  
Boulogne-Billancourt

Mr Jean-Baptiste Rouffet  
Chargé de mission Europe  
Direction générale de la Santé  
Paris

### CANADA

Ms Lucero Hernandez, Rapporteur  
Senior Policy Advisor, Multilateral  
Relations Division  
Office of International Affairs for the  
Health Portfolio  
Ottawa, Ontario

Dr Stephen M. Robbins  
Scientific Director, Institute of Cancer  
Research  
Canadian Institutes of Health Research,  
University of Calgary  
Calgary, Alberta

### AUSTRALIA

Professor Chris Baggoley  
Chief Medical Officer  
Department of Health  
Canberra

### AUSTRIA

Dr Britta Kunert  
Austrian Federal Ministry of Science,  
Research and Economy  
Vienna



### BELGIUM

Mr Lieven De Raedt  
Attaché Relations Internationales  
SPF Santé publique, Sécurité de la  
Chaîne Alimentaire et Environnement  
Brussels

### BRAZIL

Dr Luiz Antonio Santini (unable to  
attend)  
Director General, Brazilian National  
Cancer Institute (INCA)  
Rio de Janeiro

### DENMARK

Professor Mads Melbye  
Director, Statens Serum Institut  
Copenhagen

### FINLAND

Professor Juhani Eskola  
Director-General, National Institute for  
Health and Welfare (THL)  
Helsinki

Professor Eero Pukkala  
Finnish Cancer Registry  
Cancer Society of Finland  
Helsinki

### GERMANY

Dr Chariklia Balas (unable to attend)  
Advisor, Division of Global Health  
Federal Ministry of Health  
Bonn

### INDIA

Dr Jagdish Prasad  
Director General of Health Services  
Ministry of Health and Family Welfare  
New Delhi

### IRELAND

Mr Keith Comiskey  
Department of Health  
Dublin

### ITALY

Professor Walter Ricciardi (unable to  
attend)  
Commissioner  
Istituto Superiore di Sanità  
Rome

Dr Filippo Belardelli  
Director, Department of Haematology,  
Oncology and Molecular Medicine  
Istituto Superiore di Sanità  
Rome

### JAPAN

Dr Eiji Hinoshita  
Director, Office of International  
Cooperation  
Ministry of Health, Labour and Welfare  
Tokyo

### MOROCCO

Dr Rachid Bekkali  
Directeur général, Fondation Lalla  
Salma  
Rabat

Dr Latifa Belakhel  
Chef de Service de la Prévention et de  
Contrôle du Cancer  
Ministère de la Santé  
Rabat

#### NETHERLANDS

Dr Marianne Donker  
Director, Public Health Department  
Ministry of Health, Welfare and Sport  
The Hague

Mr Marc Fakkel  
Policy Advisor, Public Health  
Department  
Ministry of Health, Welfare and Sport  
The Hague

#### NORWAY

Dr Edgar Rivedal  
Senior Adviser, Norwegian Scientific  
Committee for Food Safety  
Oslo

Dr Karianne Solaas  
Senior Adviser, The Research Council  
of Norway  
Oslo

#### QATAR

Dr Faleh Mohamed Hussain Ali  
Assistant Secretary General for Policy  
Affairs, The Supreme Council of Health  
Doha

#### REPUBLIC OF KOREA

Dr Eui-Jun Park  
Deputy Director, Division of Disease  
Control Policy  
Ministry of Health and Welfare  
Seoul

Dr Duk-Hyoung Lee  
Director, National Cancer Control  
Institute  
National Cancer Center  
Gyeonggi-do

#### RUSSIAN FEDERATION

Dr Svetlana Axelrod  
Deputy Director, Department of  
International Cooperation and Public  
Relations  
Ministry of Health  
Moscow

Ms Lidia Gabuniya  
Consultant, Department of International  
Cooperation and Public Relations  
Ministry of Health  
Moscow

Dr Olga Kovaleva  
Deputy Head, Financial and Economic  
Department  
Ministry of Health  
Moscow

Dr Andrey Kaprin  
Director, P.A. Gertsen Moscow  
Research Institute of Oncology  
Moscow

#### SPAIN

Dr Rafael de Andrés Medina  
Head, EU and Internationalization  
Division  
Instituto de Salud Carlos III  
Madrid

#### SWEDEN

Professor Mats Ulfendahl  
Secretary-General, Swedish Research  
Council – Medicine  
Stockholm

Dr Karin Schmekel  
Deputy Director, Ministry of Education  
and Research  
Stockholm

#### SWITZERLAND

Dr Diane Steber Büchli  
Collaboratrice scientifique, Division  
internationale, Office fédéral de la Santé  
publique  
Bern

#### TURKEY

Professor Murat Tuncer  
Rector, Hacettepe University  
Ankara

#### UNITED STATES OF AMERICA

Dr Lisa Stevens  
Deputy Director for Planning and  
Operations  
Center for Global Health, National  
Cancer Institute  
Department of Health and Human  
Services  
Rockville, Maryland

Ms Mary Blanca Rios  
Senior Advisor, Department of State  
Bureau of International Organization  
Affairs  
Washington, DC

Dr Mona Saraiya  
Associate Director, Office of  
International Cancer Control  
Centers for Disease Control and  
Prevention  
Atlanta, Georgia

#### WORLD HEALTH ORGANIZATION

Dr Oleg Chestnov  
Assistant Director-General,  
Noncommunicable Diseases and Mental  
Health (NMH)  
WHO headquarters, Geneva

Ms Joanne McKeough  
Office of the Legal Counsel  
WHO headquarters, Geneva

Dr Andreas Ullrich  
Senior Advisor to ADG/NMH & IARC  
Liaison Officer  
WHO headquarters, Geneva

#### OBSERVERS

#### SCIENTIFIC COUNCIL

Professor Cornelia (Neli) Ulrich  
Outgoing chairperson

Professor James F. Bishop  
Incoming chairperson

#### IARC ETHICS COMMITTEE

Professor Béatrice Fervers  
Chair, IARC Ethics Committee

#### UNION FOR INTERNATIONAL CANCER CONTROL (UICC)

Mr Cary Adams  
Chief Executive Officer, Union for  
International Cancer Control (UICC)  
Geneva

#### MEXICO

Dr Alejandro Mohar Betancourt (unable  
to attend)  
Epidemiology Unit, National Cancer  
Institute of Mexico  
Mexico City

#### EXTERNAL AUDIT

Mr Lito Q. Martin (unable to attend)  
Director, International Audit and  
Relations Office, Commission on Audit  
Quezon City, Philippines



## SCIENTIFIC COUNCIL MEMBERS (2014)

Professor Mads Melbye, Chairperson  
Executive Vice President, Statens  
Serum Institut  
Copenhagen, Denmark

Professor Cornelia (Neli) Ulrich,  
Vice-Chairperson  
National Center for Tumor Diseases  
(NCT) Heidelberg  
Division of Preventive Oncology  
German Cancer Research Center  
Heidelberg, Germany

Professor Paul W. Dickman, Rapporteur  
Department of Medical Epidemiology  
and Biostatistics (MEB)  
Karolinska Institutet  
Stockholm, Sweden

Dr Al-Hareth M. Al-Khater  
Acting Medical Director, National Center  
for Cancer Care & Research  
Hamad Medical Corporation Office  
Doha, Qatar

Dr Ahti Anttila  
Mass Screening Registry  
Finnish Cancer Registry  
Helsinki, Finland

Dr Nuria Aragonés  
Environmental and Cancer  
Epidemiology  
National Center of Epidemiology  
Instituto de Salud Carlos III  
Madrid, Spain

Professor James F. Bishop  
Executive Director, Victorian  
Comprehensive Cancer Centre  
Royal Melbourne Hospital  
Melbourne, Victoria, Australia

Professor Bettina Borisch  
Institute of Social and Preventive  
Medicine  
University of Geneva Medical School  
Geneva, Switzerland

Professor Françoise Clavel-Chapelon  
Director, Nutrition, Hormones and  
Women's Health  
INSERM U1018  
Villejuif, France

Dr Luca Gianni  
Director, Department of Medical  
Oncology  
Fondazione Centro San Raffaele del  
Monte Tabor  
Milan, Italy

Dr Inger Torhild Gram  
Institute for Community Medicine  
University of Tromsø  
Tromsø, Norway

Dr Murat Gültekin  
Cancer Control Department  
Ministry of Health of Turkey  
Ankara, Turkey

Professor Lukas A. Huber  
Director, Biocenter and Cell Biology  
Division  
Medical University of Innsbruck  
Innsbruck, Austria

Professor Nicholas C. Jones  
Paterson Institute for Cancer Research  
Christie Hospital NHS Trust  
Manchester, United Kingdom

Dr In-Hoo Kim  
Director, Research Institute  
National Cancer Center  
Goyang, Republic of Korea

Dr Deirdre Murray  
National Cancer Control Programme  
Office  
Department of Public Health, HSE  
South (Cork & Kerry)  
Cork, Ireland

Dr Luis Felipe Ribeiro Pinto  
Head, Molecular Carcinogenesis  
Program  
Head of Education, Brazilian National  
Cancer Institute (INCA)  
Rio de Janeiro, Brazil

Professor Thangarajan Rajkumar  
Department of Molecular Oncology  
Cancer Institute (WIA)  
Chennai, India

Professor Martyn Smith  
Division of Environmental Health  
Sciences, School of Public Health  
University of California  
Berkeley, California, USA

Professor Christos Sotiriou  
Jules Bordet Institute  
Brussels, Belgium

Professor John J. Spinelli  
Head, Cancer Control Research  
British Columbia Cancer Agency  
Vancouver, British Columbia, Canada

Dr Sergei Tjulandin  
Cancer Research Center (CRC)  
Moscow, Russian Federation

Professor Piet A. van den Brandt  
Department of Epidemiology  
Maastricht University  
Maastricht, The Netherlands

Dr Teruhiko Yoshida  
Chief, Division of Genetics  
National Cancer Center Research  
Institute (NCCRI)  
Tokyo, Japan



## SCIENTIFIC COUNCIL MEMBERS (2015)

Professor Cornelia (Neli) Ulrich,  
Chairperson  
Jon M. & Karen Huntsman Presidential  
Professor  
Senior Director, Population Sciences  
Huntsman Cancer Institute  
Salt Lake City, Utah, USA

Professor James F. Bishop,  
Vice-Chairperson  
Executive Director, Victorian  
Comprehensive Cancer Centre  
Melbourne, Victoria, Australia

Dr Deirdre Murray, Rapporteur  
National Cancer Control Programme  
Office  
Department of Public Health, HSE  
South (Cork & Kerry)  
Cork, Ireland

Dr Al-Hareth M. Al-Khater  
Acting Medical Director, National Center  
for Cancer Care & Research  
Hamad Medical Corporation Office  
Doha, Qatar

Dr Nuria Aragonés (unable to attend)  
Environmental and Cancer  
Epidemiology  
National Center of Epidemiology  
Instituto de Salud Carlos III  
Madrid, Spain

Professor Stephen J. Chanock  
Director, Division of Cancer  
Epidemiology and Genetics  
National Cancer Institute  
Bethesda, Maryland, USA

Professor Françoise Clavel-Chapelon  
Director, Nutrition, Hormones and  
Women's Health  
INSERM U1018  
Villejuif, France

Professor Paul W. Dickman  
Department of Medical Epidemiology  
and Biostatistics (MEB)  
Karolinska Institutet  
Stockholm, Sweden



Dr Luca Gianni  
Director, Department of Medical  
Oncology  
Fondazione Centro San Raffaele del  
Monte Tabor  
Milan, Italy

Dr Inger Torhild Gram  
Institute for Community Medicine  
University of Tromsø  
Tromsø, Norway

Dr Murat Gültekin  
Cancer Control Department  
Ministry of Health of Turkey  
Ankara, Turkey

Professor Lukas A. Huber (unable to  
attend)  
Director, Biocenter and Cell Biology  
Division  
Medical University of Innsbruck  
Innsbruck, Austria

Professor Nicholas C. Jones  
Paterson Institute for Cancer Research  
Christie Hospital NHS Trust  
Manchester, United Kingdom

Professor Ellen Kampman  
Wageningen University  
Division of Human Nutrition  
Wageningen, The Netherlands

Dr In-Hoo Kim  
Director, Research Institute  
National Cancer Center  
Goyang, Republic of Korea

Dr Luis Felipe Ribeiro Pinto  
Head, Molecular Carcinogenesis  
Program  
Head of Education, Brazilian National  
Cancer Institute (INCA)  
Rio de Janeiro, Brazil

Professor Ole Raaschou-Nielsen  
Danish Cancer Society  
Department of Work, Environment and  
Cancer  
Copenhagen, Denmark

Professor Thangarajan Rajkumar  
Department of Molecular Oncology  
Cancer Institute (WIA)  
Chennai, India

Professor Martin Rössli  
Swiss Tropical and Public Health  
Institute  
Basel, Switzerland

Professor Christos Sotiriou (unable to  
attend)  
Jules Bordet Institute  
Brussels, Belgium

Professor John J. Spinelli  
Head, Cancer Control Research  
British Columbia Cancer Agency  
Vancouver, British Columbia, Canada

Dr Sergei Tjulandin  
Cancer Research Center (CRC)  
Moscow, Russian Federation

Professor Elisabete Weiderpass Vainio  
Group Leader, Program on Genetic  
Research  
Folkhälsan Research Center,  
Biomedicum 1  
Helsinki, Finland

Dr Teruhiko Yoshida  
Chief, Division of Genetics  
National Cancer Center Research  
Institute (NCCRI)  
Tokyo, Japan



# IARC STAFF PUBLICATIONS 2014–2015

- Abbas S, Linseisen J, Rohrmann S, Beulens JW, Buijsse B, Amiano P, et al. (2014). Dietary vitamin D intake and risk of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition: the EPIC-InterAct study. *Eur J Clin Nutr.* 68(2):196–202. <http://dx.doi.org/10.1038/ejcn.2013.235> PMID: 24253760
- Accardi R, Gheit T (2014). Cutaneous HPV and skin cancer. *Presse Med.* 43(12P2):e435–43. <http://dx.doi.org/10.1016/j.lpm.2014.08.008> PMID: 25451638
- Accardi R, Gruffat H, Sirand C, Fusil F, Gheit T, Hernandez-Vargas H, et al. (2015). The mycotoxin aflatoxin B1 stimulates Epstein-Barr virus-induced B-cell transformation in in vitro and in vivo experimental models. *Carcinogenesis.* 36(11):1440–51. <http://dx.doi.org/10.1093/carcin/bgv142> PMID:26424750
- Adel Fahmideh M, Lavebratt C, Schüz J, Rööslä M, Tynes T, Grotzer MA, et al. (2015). *CCDC26*, *CDKN2BAS*, *RTEL1* and *TERT* polymorphisms in pediatric brain tumor susceptibility. *Carcinogenesis.* 36(8):876–82. <http://dx.doi.org/10.1093/carcin/bgv074> PMID:26014354
- Adewole I, Martin DN, Williams MJ, Adebamowo C, Bhatia K, Berling C, et al. (2014). Building capacity for sustainable research programmes for cancer in Africa. *Nat Rev Clin Oncol.* 11(5):251–9. <http://dx.doi.org/10.1038/nrclinonc.2014.37> PMID: 24614139
- Agarwal D, Pineda S, Michailidou K, Herranz J, Pita G, Moreno LT, et al.; kConFab Investigators; Australian Ovarian Cancer Study Group; GENICA Network; TNBCC (2014). FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. *Br J Cancer.* 110(4):1088–100. <http://dx.doi.org/10.1038/bjc.2013.769> PMID:24548884
- Agogo GO, van der Voet H, van't Veer P, Ferrari P, Leenders M, Muller DC, et al. (2014). Use of two-part regression calibration model to correct for measurement error in episodically consumed foods in a single-replicate study design: EPIC case study. *PLoS ONE.* 9(11):e113160. <http://dx.doi.org/10.1371/journal.pone.0113160> PMID:25402487
- Ahlbom A, Feychting M, Holmberg L, Johansson LA, Mathiesen T, Pettersson D, et al. (2015). Comments on Hardell and Carlberg Increasing Rates of Brain Tumors in the Swedish National Inpatient Register and the Causes of Death Register. *Int. J. Environ. Res. Public Health* 2015, 12, 3793–3813. *Int J Environ Res Public Health.* 12(9):11662–4 <http://dx.doi.org/10.3390/ijerph120911662> PMID: 26393624
- Ahrens W, Pohlabeled H, Foraita R, Nelis M, Lagiou P, Lagiou A, et al. (2014). Oral health, dental care and mouthwash associated with upper aerodigestive tract cancer risk in Europe: the ARCAGE study. *Oral Oncol.* 50(6):616–25. <http://dx.doi.org/10.1016/j.oraloncology.2014.03.001> PMID:24680035
- Aleksandrova K, Bamia C, Drogan D, Lagiou P, Trichopoulou A, Jenab M, et al. (2015). The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition. *Am J Clin Nutr.* 102(6):1498–508. <http://dx.doi.org/10.3945/ajcn.115.116095> PMID:26561631
- Aleksandrova K, Boeing H, Nöthlings U, Jenab M, Fedirko V, Kaaks R, et al. (2014a). Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. *Hepatology.* 60(3):858–71. <http://dx.doi.org/10.1002/hep.27016> PMID:24443059
- Aleksandrova K, Chuang SC, Boeing H, Zuo H, Tell GS, Pischon T, et al. (2015). A prospective study of the immune system activation biomarker neopterin and colorectal cancer risk. *J Natl Cancer Inst.* 107(4):d3v010. <http://dx.doi.org/10.1093/jnci/d3v010> PMID:25713165
- Aleksandrova K, Drogan D, Boeing H, Jenab M, Bas Bueno-de-Mesquita H, Jansen E, et al. (2014b). Adiposity, mediating biomarkers and risk of colon cancer in the European Prospective Investigation into Cancer and Nutrition study. *Int J Cancer.* 134(3):612–21. <http://dx.doi.org/10.1002/ijc.28368> PMID:23824948
- Aleksandrova K, Jenab M, Bueno-de-Mesquita HB, Fedirko V, Kaaks R, Lukanova A, et al. (2014c). Biomarker patterns of inflammatory and metabolic pathways are associated with risk of colorectal cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). *Eur J Epidemiol.* 29(4):261–75. <http://dx.doi.org/10.1007/s10654-014-9901-8> PMID:24791703

- Aleksandrova K, Pischon T, Jenab M, Bueno-de-Mesquita HB, Fedirko V, Norat T, et al. (2014). Combined impact of healthy lifestyle factors on colorectal cancer: a large European cohort study. *BMC Med.* 12(1):168. <http://dx.doi.org/10.1186/s12916-014-0168-4> PMID:25319089
- Allum WH, Bonavina L, Cassivi SD, Cuesta MA, Dong ZM, Felix VN, et al. (2014). Surgical treatments for esophageal cancers. *Ann N Y Acad Sci.* 1325(1):242–68. <http://dx.doi.org/10.1111/nyas.12533> PMID:25266029
- Almonte M, Ferreccio C, Luciani S, Gonzales M, Delgado JM, Santos C, et al. (2015). Visual inspection after acetic acid (VIA) is highly heterogeneous in primary cervical screening in Amazonian Peru. *PLoS ONE.* 10(1):e0115355. <http://dx.doi.org/10.1371/journal.pone.0115355> PMID:25635965
- Amadou A, Degoul J, Hainaut P, Chajes V, Biessy C, Torres Mejia G, et al. (2015). Dietary carbohydrate, glycemic index, glycemic load, and breast cancer risk among Mexican women. *Epidemiology.* 26(6): 917–24. <http://dx.doi.org/10.1097/EDE.0000000000000374> PMID:26340313
- Amadou A, Torres Mejia G, Fagherazzi G, Ortega C, Angeles-Llerenas A, Chajes V, et al. (2014a). Anthropometry, silhouette trajectory, and risk of breast cancer in Mexican women. *Am J Prev Med.* 46(3 Suppl 1):S52–64. <http://dx.doi.org/10.1016/j.amepre.2013.10.024> PMID:24512931
- Amadou A, Torres-Mejía G, Hainaut P, Romieu I (2014b). Breast cancer in Latin America: global burden, patterns, and risk factors. *Salud Publica Mex.* 56(5):547–54. PMID:25604300
- Amorim CE, Daub JT, Salzano FM, Foll M, Excoffier L (2015). Detection of convergent genome-wide signals of adaptation to tropical forests in humans. *PLoS ONE.* 10(4):e0121557. <http://dx.doi.org/10.1371/journal.pone.0121557> PMID:25849546
- Anantharaman D, Chabrier A, Gaborieau V, Franceschi S, Herrero R, Rajkumar T, et al. (2014b). Genetic variants in nicotine addiction and alcohol metabolism genes, oral cancer risk and the propensity to smoke and drink alcohol: a replication study in India. *PLoS ONE.* 9(2):e88240. <http://dx.doi.org/10.1371/journal.pone.0088240> PMID:24505444
- Anantharaman D, Gheit T, Waterboer T, Halec G, Carreira C, Abedi-Ardekani B, et al. (2014a). No causal association identified for human papillomavirus infections in lung cancer. *Cancer Res.* 74(13):3525–34. <http://dx.doi.org/10.1158/0008-5472.CAN-13-3548> PMID:24760422
- Andreotti G, Birmann BM, Cozen W, De Roos AJ, Chiu BC, Costas L, et al. (2015). A pooled analysis of cigarette smoking and risk of multiple myeloma from the International Multiple Myeloma Consortium. *Cancer Epidemiol Biomarkers Prev.* 24(3):631–4. <http://dx.doi.org/10.1158/1055-9965.EPI-14-1145> PMID:25538226
- Antilla A, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, et al. (2015). European guidelines for quality assurance in cervical cancer screening, 2nd edition. Supplements. Luxembourg: Publications Office of the European Union.
- Antoni S, Soerjomataram I, Moore S, Ferlay J, Sitas F, Smith DP, et al. (2014). The ban on phenacetin is associated with changes in the incidence trends of upper-urinary tract cancers in Australia. *Aust N Z J Public Health.* 38(5):455–8. <http://dx.doi.org/10.1111/1753-6405.12252> PMID:25169832
- Antilla A, Lönnberg S, Ponti A, Suonio E, Villain P, Coebergh JW, et al. (2015). Towards better implementation of cancer screening in Europe through improved monitoring and evaluation and greater engagement of cancer registries. *Eur J Cancer.* 51(2):241–51. <http://dx.doi.org/10.1016/j.ejca.2014.10.022> PMID:25483785
- Arbyn M, Tommasino M, Depuydt C, Dillner J (2014a). Are 20 human papillomavirus types causing cervical cancer? *J Pathol.* 234(4):431–5. <http://dx.doi.org/10.1002/path.4424> PMID:25124771
- Arbyn M, Verdoort F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, et al. (2014b). Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. *Lancet Oncol.* 15(2):172–83. [http://dx.doi.org/10.1016/S1470-2045\(13\)70570-9](http://dx.doi.org/10.1016/S1470-2045(13)70570-9) PMID:24433684
- Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, et al. (2015b). Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. *Eur J Cancer.* 51(9):1164–87. <http://dx.doi.org/10.1016/j.ejca.2013.09.002> PMID:24120180
- Arnold M, Liu L, Kenter GG, Creutzberg CL, Coebergh JW, Soerjomataram I (2014a). Second primary cancers in survivors of cervical cancer in the Netherlands: implications for prevention and surveillance. *Radiother Oncol.* 111(3):374–81. <http://dx.doi.org/10.1016/j.radonc.2014.04.011> PMID:24833558
- Arnold M, Moore SP, Hassler S, Ellison-Loschmann L, Forman D, Bray F (2014b). The burden of stomach cancer in indigenous populations: a systematic review and global assessment. *Gut.* 63(1):64–71. <http://dx.doi.org/10.1136/gutjnl-2013-305033> PMID:24153248
- Arnold M, Pandeya N, Byrnes G, Renehan AG, Stevens GA, Ezzati M, et al. (2015a). Global burden of cancer attributable to high body-mass index in 2012: a population-based study. *Lancet Oncol.* 16(1):36–46. [http://dx.doi.org/10.1016/S1470-2045\(14\)71123-4](http://dx.doi.org/10.1016/S1470-2045(14)71123-4) PMID:25467404
- Arnold M, Soerjomataram I, Ferlay J, Forman D (2015c). Global incidence of oesophageal cancer by histological subtype in 2012. *Gut.* 64(3):381–7. <http://dx.doi.org/10.1136/gutjnl-2014-308124> PMID:25320104
- Arrossi S, Thouyaret L, Herrero R, Campanera A, Magdaleno A, Cuberli M, et al.; EMA Study team (2015b). Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): a population-based cluster-randomised trial. *Lancet Glob Health.* 3(2):e85–94. [http://dx.doi.org/10.1016/S2214-109X\(14\)70354-7](http://dx.doi.org/10.1016/S2214-109X(14)70354-7) PMID:25617202
- Arrossi S, Thouyaret L, Laudi R, Marín O, Ramírez J, Paolino M, et al. (2015a). Implementation of HPV-testing for cervical cancer screening in programmatic contexts: the Jujuy demonstration project in Argentina. *Int J Cancer.* 137(7):1709–18. <http://dx.doi.org/10.1002/ijc.29530> PMID:25807897
- Arroyo-Quiroz C, Kurth T, Cantu-Brito C, Lopez-Ridaura R, Romieu I, Lajous M (2014). Lifetime prevalence and underdiagnosis of migraine in a population sample of Mexican women. *Cephalalgia.* 34(13):1088–92. <http://dx.doi.org/10.1177/0333102414529196> PMID:24711606
- Asiki G, Seeley J, Srey C, Baisley K, Lightfoot T, Archileo K, et al. (2014). A pilot study to evaluate aflatoxin exposure in a rural Ugandan population. *Trop Med Int Health.* 19(5):592–9. <http://dx.doi.org/10.1111/tmi.12283> PMID:24612197
- Assi N, Fages A, Vineis P, Chadeau-Hyam M, Stepien M, Duarte-Salles T, et al. (2015). A statistical framework to model the meeting-in-the-middle principle using metabolomic data: application to hepatocellular carcinoma in the EPIC study. *Mutagenesis.* 30(6):743–53. <http://dx.doi.org/10.1093/mutage/gev045> PMID:26130468

- Asztalos M, Huybrechts I, Temme E, Van Oyen H, Vandevijvere S (2014). Association of physical activity, waist circumference and body mass index with subjective health among Belgian adults. *Eur J Public Health*. 24(2):205–9. <http://dx.doi.org/10.1093/eurpub/ckt069> PMID:23756647
- Atun R, Jaffray DA, Barton MB, Bray F, Baumann M, Vikram B, et al. (2015). Expanding global access to radiotherapy. *Lancet Oncol*. 16(10):1153–86. [http://dx.doi.org/10.1016/S1470-2045\(15\)00222-3](http://dx.doi.org/10.1016/S1470-2045(15)00222-3) PMID:26419354
- Auvinen A, Seppä K, Pasanen K, Kurttio P, Patama T, Pukkala E, et al. (2014). Chernobyl fallout and cancer incidence in Finland. *Int J Cancer*. 134(9):2253–63. <http://dx.doi.org/10.1002/ijc.28554> PMID:24135935
- Babron MC, Kazma R, Gaborieau V, McKay J, Brennan P, Sarasin A, et al. (2014). Genetic variants in DNA repair pathways and risk of upper aerodigestive tract cancers: combined analysis of data from two genome-wide association studies in European populations. *Carcinogenesis*. 35(7):1523–7. <http://dx.doi.org/10.1093/carcin/bgu075> PMID:24658182
- Badwe RA, Dikshit R, Laversanne M, Bray F (2014). Cancer incidence trends in India. *Jpn J Clin Oncol*. 44(5):401–7. <http://dx.doi.org/10.1093/jjco/hyu040> PMID:24755545
- Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, et al. (2015). Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. *Br J Cancer*. 112(3):580–93. <http://dx.doi.org/10.1038/bjc.2014.579> PMID:25422909
- Bailey HD, Fritschi L, Infante-Rivard C, Glass DC, Miligi L, Dockerty JD, et al. (2014a). Parental occupational pesticide exposure and the risk of childhood leukemia in the offspring: findings from the Childhood Leukemia International Consortium. *Int J Cancer*. 135(9):2157–72. <http://dx.doi.org/10.1002/ijc.28854> PMID:24700406
- Bailey HD, Fritschi L, Metayer C, Infante-Rivard C, Magnani C, Petridou E, et al. (2014b). Parental occupational paint exposure and risk of childhood leukemia in the offspring: findings from the Childhood Leukemia International Consortium. *Cancer Causes Control*. 25(10):1351–67. <http://dx.doi.org/10.1007/s10552-014-0441-z> PMID:25088805
- Bailey HD, Infante-Rivard C, Metayer C, Clavel J, Lightfoot T, Kaatsch P, et al. (2015a). Home pesticide exposures and risk of childhood leukemia: findings from the Childhood Leukemia International Consortium. *Int J Cancer*. 137(11):2644–63. <http://dx.doi.org/10.1002/ijc.29631> PMID:26061779
- Bailey HD, Metayer C, Milne E, Petridou ET, Infante-Rivard C, Spector LG, et al. (2015b). Home paint exposures and risk of childhood acute lymphoblastic leukemia: findings from the Childhood Leukemia International Consortium. *Cancer Causes Control*. 26(9):1257–70. <http://dx.doi.org/10.1007/s10552-015-0618-0> PMID:26134047
- Bailey HD, Miller M, Greenop KR, Bower C, Attia J, Marshall GM, et al. (2014c). Paternal intake of folate and vitamins B6 and B12 before conception and risk of childhood acute lymphoblastic leukemia. *Cancer Causes Control*. 25(12):1615–25. <http://dx.doi.org/10.1007/s10552-014-0466-3> PMID:25281326
- Balcells E, Gimeno-Santos E, de Batlle J, Ramon MA, Rodríguez E, Benet M, et al.; PAC-COPD Study Group (2015). Characterisation and prognosis of undiagnosed chronic obstructive pulmonary disease patients at their first hospitalisation. *BMC Pulm Med*. 15(1):4. <http://dx.doi.org/10.1186/1471-2466-15-4> PMID:25595204
- Bamia C, Lagiou P, Jenab M, Aleksandrova K, Fedirko V, Trichopoulos D, et al. (2015a). Fruit and vegetable consumption in relation to hepatocellular carcinoma in a multi-centre, European cohort study. *Br J Cancer*. 112(7):1273–82. <http://dx.doi.org/10.1038/bjc.2014.654> PMID:25742480
- Bamia C, Lagiou P, Jenab M, Trichopoulos A, Fedirko V, Aleksandrova K, et al. (2015b). Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. *Int J Cancer*. 136(8):1899–908. <http://dx.doi.org/10.1002/ijc.29214> PMID:25219573
- Bandera EV, Maskarinec G, Romieu I, John EM (2015). Racial and ethnic disparities in the impact of obesity on breast cancer risk and survival: a global perspective. *Adv Nutr*. 6(6):803–19. <http://dx.doi.org/10.3945/an.115.009647> PMID:26567202
- Barraza-Villarreal A, Escamilla-Núñez MC, Schilman A, Hernandez-Cadena L, Li Z, Romanoff L, et al. (2014). Lung function, airway inflammation, and polycyclic aromatic hydrocarbons exposure in Mexican schoolchildren: a pilot study. *J Occup Environ Med*. 56(4):415–9. <http://dx.doi.org/10.1097/JOM.000000000000111> PMID:24500378
- Bassig BA, Cerhan JR, Au WY, Kim HN, Sangrajrang S, Hu W, et al. (2015). Genetic susceptibility to diffuse large B-cell lymphoma in a pooled study of three Eastern Asian populations. *Eur J Haematol*. 95(5):442–8. <http://dx.doi.org/10.1111/ejh.12513> PMID:25611436
- Basu P, Mittal S, Banerjee D, Singh P, Panda C, Dutta S, et al. (2015). Diagnostic accuracy of VIA and HPV detection as primary and sequential screening tests in a cervical cancer screening demonstration project in India. *Int J Cancer*. 137(4):859–67. <http://dx.doi.org/10.1002/ijc.29458> PMID:25631198
- Baumgarten P, Harter PN, Tönjes M, Capper D, Blank AE, Sahm F, et al. (2014). Loss of FUBP1 expression in gliomas predicts *FUBP1* mutation and is associated with oligodendroglial differentiation, *IDH1* mutation and 1p19q loss of heterozygosity. *Neuropathol Appl Neurobiol*. 40(2):205–16. <http://dx.doi.org/10.1111/nan.12088> PMID:24117486
- Baussano I (2015). Effectiveness and impact of different HPV vaccination and screening strategies. *HPV Today*. 32–33:14.
- Baussano I, Dillner J, Lazzarato F, Ronco G, Franceschi S (2014c). Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. *Infect Agent Cancer*. 9(1):4. <http://dx.doi.org/10.1186/1750-9378-9-4> PMID:24438317
- Baussano I, Franceschi S, Plummer M (2014a). Infection transmission and chronic disease models in the study of infection-associated cancers. *Br J Cancer*. 110(1):7–11. <http://dx.doi.org/10.1038/bjc.2013.740> PMID:24300979
- Baussano I, Tshomo U, Clifford GM, Tenet V, Tshokey T, Franceschi S (2014b). Cervical cancer screening program in Thimphu, Bhutan: population coverage and characteristics associated with screening attendance. *BMC Womens Health*. 14(1):147. <http://dx.doi.org/10.1186/s12905-014-0147-0> PMID:25433538
- Bazot Q, Deschamps T, Tafforeau L, Siouda M, Leblanc P, Harth-Hertle ML, et al. (2014). Epstein-Barr virus nuclear antigen 3A protein regulates *CDKN2B* transcription via interaction with MIZ-1. *Nucleic Acids Res*. 42(15):9700–16. <http://dx.doi.org/10.1093/nar/gku697> PMID:25092922
- Bedoya AM, Tate DJ, Baena A, Córdoba CM, Borrero M, Pareja R, et al. (2014). Immunosuppression in cervical cancer with special reference to arginase activity. *Gynecol Oncol*. 135(1):74–80. <http://dx.doi.org/10.1016/j.ygyno.2014.07.096> PMID:25084511
- Béghin L, Dauchet L, De Vriendt T, Cuenca-García M, Manios Y, Toti E, et al.; HELENA Study Group (2014). Influence of parental socio-economic status on diet quality of European adolescents: results from the HELENA study. *Br J Nutr*. 111(7):1303–12. <http://dx.doi.org/10.1017/S0007114513003796> PMID:24330831

- Bel-Serrat S, Mouratidou T, Huybrechts I, Cuenca-García M, Manios Y, Gómez-Martínez S, et al. (2014a). The role of dietary fat on the association between dietary amino acids and serum lipid profile in European adolescents participating in the HELENA study. *Eur J Clin Nutr.* 68(4):464–73. <http://dx.doi.org/10.1038/ejcn.2013.284> PMID:24495993
- Bel-Serrat S, Mouratidou T, Huybrechts I, Labayen I, Cuenca-García M, Palacios G, et al.; HELENA Study Group (2014b). Associations between macronutrient intake and serum lipid profile depend on body fat in European adolescents: the Healthy Lifestyle in Europe by Nutrition in Adolescence (HELENA) study. *Br J Nutr.* 112(12):2049–59. <http://dx.doi.org/10.1017/S0007114514003183> PMID:25366323
- Bel-Serrat S, Mouratidou T, Jiménez-Pavón D, Huybrechts I, Cuenca-García M, Mistura L, et al.; HELENA Study Group (2014c). Is dairy consumption associated with low cardiovascular disease risk in European adolescents? Results from the HELENA study. *Pediatr Obes.* 9(5):401–10. <http://dx.doi.org/10.1111/j.2047-6310.2013.00187.x> PMID:23852857
- Bellaminutti S, Seraceni S, De Seta F, Gheit T, Tommasino M, Comar M (2014). HPV and *Chlamydia trachomatis* co-detection in young asymptomatic women from high incidence area for cervical cancer. *J Med Virol.* 86(11):1920–5. <http://dx.doi.org/10.1002/jmv.24041> PMID:25132162
- Bellaud G, Gheit T, Pugin A, Prétet JL, Tommasino M, Mougin C, et al. (2014). Prevalence of human papillomavirus DNA in eyebrow hairs plucked from patients with psoriasis treated with TNF inhibitors. *J Eur Acad Dermatol Venereol.* 28(12):1816–20. <http://dx.doi.org/10.1111/jdv.12308> PMID:24206262
- Bellaud G, Gheit T, Pugin A, Prétet JL, Tommasino M, Mougin C, et al. (2015). Prevalence of human polyomavirus DNA in eyebrow hairs plucked from patients with psoriasis treated with TNF inhibitors. *J Eur Acad Dermatol Venereol.* 29(5):1019–21. <http://dx.doi.org/10.1111/jdv.12439> PMID:24597770
- Benbrahim-Tallaa L, Lauby-Secretan B, Loomis D, Guyton KZ, Grosse Y, El Ghissassi F, et al.; International Agency for Research on Cancer Monograph Working Group (2014). Carcinogenicity of perfluorooctanoic acid, tetrafluoroethylene, dichloromethane, 1,2-dichloropropane, and 1,3-propane sultone. *Lancet Oncol.* 15(9):924–5. [http://dx.doi.org/10.1016/S1470-2045\(14\)70316-X](http://dx.doi.org/10.1016/S1470-2045(14)70316-X) PMID:25225686
- Benson VS, Pirie K, Schüz J, Reeves GK, Beral V, Green J (2014). Authors' response to: The case of acoustic neuroma: comment on mobile phone use and risk of brain neoplasms and other cancers. *Int J Epidemiol.* 43(1):275. <http://dx.doi.org/10.1093/ije/dyt186> PMID:24078152
- Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R; Collaborative Group on Epidemiological Studies of Ovarian Cancer (2015). Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. *Lancet.* 385(9980):1835–42. [http://dx.doi.org/10.1016/S0140-6736\(14\)61687-1](http://dx.doi.org/10.1016/S0140-6736(14)61687-1) PMID:25684585
- Béranger R, Blain J, Baudinet C, Faure E, Fléchon A, Boyle H, et al. (2014a). Testicular germ cell tumours and early exposures to pesticides: the TESTEPERA pilot study [in French]. *Bull Cancer.* 101(3):225–35. PMID:24691186
- Béranger R, Pérol O, Bujan L, Faure E, Blain J, Le Cornet C, et al. (2014b). Studying the impact of early life exposures to pesticides on the risk of testicular germ cell tumors during adulthood (TESTIS project): study protocol. *BMC Cancer.* 14(1):563. <http://dx.doi.org/10.1186/1471-2407-14-563> PMID:25095793
- Berwick M, MacArthur J, Orlov I, Kanetsky P, Begg CB, Luo L, et al.; GEM Study Group (2014). *MITF* E318K's effect on melanoma risk independent of, but modified by, other risk factors. *Pigment Cell Melanoma Res.* 27(3):485–8. <http://dx.doi.org/10.1111/pcmr.12215> PMID:24406078
- Bešević J, Gunter MJ, Fortner RT, Tsilidis KK, Weiderpass E, Charlotte Onland-Moret N, et al. (2015). Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study. *Br J Cancer.* 113(11):1622–31. <http://dx.doi.org/10.1038/bjc.2015.377> PMID:26554655
- Bigert C, Gustavsson P, Straif K, Pesch B, Brüning T, Kendzia B, et al. (2015). Lung cancer risk among cooks when accounting for tobacco smoking: a pooled analysis of case-control studies from Europe, Canada, New Zealand, and China. *J Occup Environ Med.* 57(2):202–9. <http://dx.doi.org/10.1097/JOM.0000000000000337> PMID:25654522
- Bijlsma M, Rendering A, Chin-On N, Debska A, von Karsa L, Knöpnadel J, et al. (2014). Quality criteria for health checks: development of a European consensus agreement. *Prev Med.* 67:238–41. <http://dx.doi.org/10.1016/j.ypmed.2014.08.005> PMID:25117528
- Blanco-Becerra LC, Miranda-Soberanis V, Barraza-Villarreal A, Junger W, Hurtado-Díaz M, Romieu I (2014a). Effect of socioeconomic status on the association between air pollution and mortality in Bogota, Colombia. *Salud Publica Mex.* 56(4):371–8. PMID:25604177
- Blanco-Becerra LC, Miranda-Soberanis V, Hernández-Cadena L, Barraza-Villarreal A, Junger W, Hurtado-Díaz M, et al. (2014b). Effect of particulate matter less than 10µm (PM<sub>10</sub>) on mortality in Bogota, Colombia: a time-series analysis, 1998–2006. *Salud Publica Mex.* 56(4):363–70. PMID:25604176
- Bolchi A, Canali E, Santoni A, Spagnoli G, Viariso D, Accardi R, et al. (2015). Thioredoxin-displayed multi-peptide immunogens. *Methods Mol Biol.* 1348:137–51. [http://dx.doi.org/10.1007/978-1-4939-2999-3\\_14](http://dx.doi.org/10.1007/978-1-4939-2999-3_14) PMID:26424270
- Bonora E, Rizzato C, Diquigiovanni C, Oudot-Mellakh T, Campa D, Vargiolu M, et al.; NMTC Consortium (2014). The *FOXE1* locus is a major genetic determinant for familial nonmedullary thyroid carcinoma. *Int J Cancer.* 134(9):2098–107. <http://dx.doi.org/10.1002/ijc.28543> PMID:24127282
- Boraska V, Franklin CS, Floyd JA, Thornton LM, Huckins LM, Southam L, et al.; Wellcome Trust Case Control Consortium 3 (2014). A genome-wide association study of anorexia nervosa. *Mol Psychiatry.* 19(10):1085–94. <http://dx.doi.org/10.1038/mp.2013.187> PMID:24514567
- Börnhorst C, Bel-Serrat S, Pigeot I, Huybrechts I, Ottavaere C, Sioen I, et al.; IDEFICS consortium (2014a). Validity of 24-h recalls in (pre-)school aged children: comparison of proxy-reported energy intakes with measured energy expenditure. *Clin Nutr.* 33(1):79–84. <http://dx.doi.org/10.1016/j.clnu.2013.03.018> PMID:23622780
- Börnhorst C, Huybrechts I, Hebestreit A, Krogh V, De Decker A, Barba G, et al.; IDEFICS and the I.Family consortia (2014b). Usual energy and macronutrient intakes in 2–9-year-old European children. *Int J Obes.* 38 Suppl 2:S115–23. <http://dx.doi.org/10.1038/ijo.2014.142> PMID:25376213
- Borraccino A, Migliore E, Piccioni P, Baussano I, Carosio A, Bugiani M (2014). Yield of tuberculosis contact investigation in a low-incidence country. *J Infect.* 68(5):448–54. <http://dx.doi.org/10.1016/j.jinf.2013.12.005> PMID:24418415

- Bosch de Basea M, Pearce MS, Kesminiene A, Bernier MO, Dabin J, Engels H, et al. (2015). EPI-CT: design, challenges and epidemiological methods of an international study on cancer risk after paediatric and young adult CT. *J Radiol Prot.* 35(3):611–28. <http://dx.doi.org/10.1088/0952-4746/35/3/611> PMID:26226081
- Bosetti C, Rosato V, Li D, Silverman D, Petersen GM, Bracci PM, et al. (2014). Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium. *Ann Oncol.* 25(10):2065–72. <http://dx.doi.org/10.1093/annonc/mdu276> PMID:25057164
- Boto-Ordóñez M, Rothwell JA, Andres-Lacueva C, Manach C, Scalbert A, Urpi-Sarda M (2014). Prediction of the wine polyphenol metabolic space: an application of the Phenol-Explorer database. *Mol Nutr Food Res.* 58(3):466–77. <http://dx.doi.org/10.1002/mnfr.201300411> PMID:24123832
- Braganza MZ, de González AB, Schonfeld SJ, Wentzensen N, Brenner AV, Kitahara CM (2014). Benign breast and gynecologic conditions, reproductive and hormonal factors, and risk of thyroid cancer. *Cancer Prev Res (Phila).* 7(4):418–25. <http://dx.doi.org/10.1158/1940-6207.CAPR-13-0367> PMID:24449056
- Brand JS, Onland-Moret NC, Eijkemans MJ, Tjønneland A, Roswall N, Overvad K, et al. (2015a). Diabetes and onset of natural menopause: results from the European Prospective Investigation into Cancer and Nutrition. *Hum Reprod.* 30(6):1491–8. <http://dx.doi.org/10.1093/humrep/dev054> PMID:25779698
- Brand JS, Onland-Moret NC, Eijkemans MJC, Tjønneland A, Roswall N, Overvad K, et al. (2015b). Diabetes and onset of natural menopause: results from the European Prospective Investigation into Cancer and Nutrition EDITORIAL COMMENT. *Obstet Gynecol Surv.* 70(8):507–8. <http://dx.doi.org/10.1097/OGX.0000000000000235>
- Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, Kohler B, et al. (2015a). Cancer Incidence in Five Continents: inclusion criteria, highlights from Volume X and the global status of cancer registration. *Int J Cancer.* 137(9):2060–71. <http://dx.doi.org/10.1002/ijc.29670> PMID:26135522
- Bray F, Jemal A, Torre LA, Forman D, Vineis P (2015b). Long-term realism and cost-effectiveness: primary prevention in combatting cancer and associated inequalities worldwide. *J Natl Cancer Inst.* 107(12):djv273. <http://dx.doi.org/10.1093/jnci/djv273> PMID:26424777
- Bray F, Soerjomataram I (2015). Chapter 2: The changing global burden of cancer: transitions in human development and implications for cancer prevention and control. In: Gelband H, Jha P, Sankaranarayanan R, Horton R, editors. *Disease control priorities, 3rd edition (DCP3), Volume 3: Cancer.* Washington (DC), USA: The World Bank.
- Bray F, Soerjomataram I, Mery L, Ferlay J (2015c). Improving the quality and coverage of cancer registries globally. *Lancet.* 386(9998):1035–6. [http://dx.doi.org/10.1016/S0140-6736\(15\)00135-X](http://dx.doi.org/10.1016/S0140-6736(15)00135-X) PMID:26382988
- Brennan P, Wild CP (2015). Genomics of cancer and a new era for cancer prevention. *PLoS Genet.* 11(11):e1005522. <http://dx.doi.org/10.1371/journal.pgen.1005522> PMID:26540230
- Brenner DR, Amos CI, Brhane Y, Timofeeva MN, Caporaso N, Wang Y, et al.; EPIC Investigators (2015). Identification of lung cancer histology-specific variants applying Bayesian framework variant prioritization approaches within the TRICL and ILCCO consortia. *Carcinogenesis.* 36(11):1314–26. <http://dx.doi.org/10.1093/carcin/bgv128> PMID:26363033
- Brenner DR, Wozniak MB, Feyt C, Holcatova I, Janout V, Foretova L, et al. (2014). Physical activity and risk of pancreatic cancer in a central European multicenter case-control study. *Cancer Causes Control.* 25(6):669–81. <http://dx.doi.org/10.1007/s10552-014-0370-x> PMID:24695987
- Brinton LA, Cook MB, McCormack V, Johnson KC, Olsson H, Casagrande JT, et al.; European Rare Cancer Study Group (2014). Anthropometric and hormonal risk factors for male breast cancer: Male Breast Cancer Pooling Project results. *J Natl Cancer Inst.* 106(3):dj465. <http://dx.doi.org/10.1093/jnci/dj465> PMID:24552677
- Bruce N, Dherani M, Liu R, Hosgood HD 3rd, Sapkota A, Smith KR, et al. (2015). Does household use of biomass fuel cause lung cancer? A systematic review and evaluation of the evidence for the GBD 2010 study. *Thorax.* 70(5):433–41. <http://dx.doi.org/10.1136/thoraxjnl-2014-206625> PMID:25758120
- Buckland G, Ros MM, Roswall N, Bueno-de-Mesquita HB, Travier N, Tjønneland A, et al. (2014). Adherence to the Mediterranean diet and risk of bladder cancer in the EPIC cohort study. *Int J Cancer.* 134(10):2504–11. <http://dx.doi.org/10.1002/ijc.28573> PMID:24226755
- Buckland G, Travier N, Huerta JM, Bueno-de-Mesquita HB, Siersema PD, Skeie G, et al. (2015). Healthy lifestyle index and risk of gastric adenocarcinoma in the EPIC cohort study. *Int J Cancer.* 137(3):598–606. <http://dx.doi.org/10.1002/ijc.29411> PMID:25557932
- Buijsse B, Boeing H, Drogan D, Schulze MB, Feskens EJ, Amiano P, et al.; InterAct Consortium (2015). Consumption of fatty foods and incident type 2 diabetes in populations from eight European countries. *Eur J Clin Nutr.* 69(4):455–61. <http://dx.doi.org/10.1038/ejcn.2014.249> PMID:25424603
- Bunyavanich S, Schadt EE, Himes BE, Lasky-Su J, Qiu W, Lazarus R, et al. (2014). Integrated genome-wide association, coexpression network, and expression single nucleotide polymorphism analysis identifies novel pathway in allergic rhinitis. *BMC Med Genomics.* 7(1):48. <http://dx.doi.org/10.1186/1755-8794-7-48> PMID:25085501
- Bussu F, Sali M, Gallus R, Petrone G, Zannoni GF, Autorino R, et al. (2014). Human papillomavirus (HPV) infection in squamous cell carcinomas arising from the oropharynx: detection of HPV DNA and p16 immunohistochemistry as diagnostic and prognostic indicators – a pilot study. *Int J Radiat Oncol Biol Phys.* 89(5):1115–20. <http://dx.doi.org/10.1016/j.ijrobp.2014.04.044> PMID:25035216
- Camargo MJ, Russomano FB, Tristão MA, Huf G, Prendiville W (2015). Large loop versus straight-wire excision of the transformation zone for treatment of cervical intraepithelial neoplasia: a randomised controlled trial of electrosurgical techniques. *BJOG.* 122(4):552–7. <http://dx.doi.org/10.1111/1471-0528.13200> PMID:25516462
- Campa D, Mergarten B, De Vivo I, Boutron-Ruault MC, Racine A, Severi G, et al. (2014). Leukocyte telomere length in relation to pancreatic cancer risk: a prospective study. *Cancer Epidemiol Biomarkers Prev.* 23(11):2447–54. <http://dx.doi.org/10.1158/1055-9965.EPI-14-0247> PMID:25103821
- Campmans-Kuijpers MJ, Sluijs I, Nöthlings U, Freisling H, Overvad K, Weiderpass E, et al. (2015). Isocaloric substitution of carbohydrates with protein: the association with weight change and mortality among patients with type 2 diabetes. *Cardiovasc Diabetol.* 14(1):39. <http://dx.doi.org/10.1186/s12933-015-0202-7> PMID:25896172
- Campos NG, Burger EA, Sy S, Sharma M, Schiffman M, Rodriguez AC, et al. (2014). An updated natural history model of cervical cancer: derivation of model parameters. *Am J Epidemiol.* 180(5):545–55. <http://dx.doi.org/10.1093/aje/kwu159> PMID:25081182



- Cao Y, Lindström S, Schumacher F, Stevens VL, Albanes D, Berndt S, et al. (2014). Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival. *J Natl Cancer Inst.* 106(6):dju085. <http://dx.doi.org/10.1093/jnci/dju085> PMID:24824313
- Carayol M, Licaj I, Achaintre D, Sacerdote C, Vineis P, Key TJ, et al. (2015). Reliability of serum metabolites over a two-year period: a targeted metabolomic approach in fasting and non-fasting samples from EPIC. *PLoS ONE.* 10(8):e0135437. <http://dx.doi.org/10.1371/journal.pone.0135437> PMID:26274920
- Carbone A, Vaccher E, Gloghini A, Pantanowitz L, Abayomi A, de Paoli P, et al. (2014). Diagnosis and management of lymphomas and other cancers in HIV-infected patients. *Nat Rev Clin Oncol.* 11(4):223–38. <http://dx.doi.org/10.1038/nrclinonc.2014.31> PMID:24614140
- Castelino JM, Dominguez-Salas P, Routledge MN, Prentice AM, Moore SE, Hennig BJ, et al. (2014). Seasonal and gestation stage associated differences in aflatoxin exposure in pregnant Gambian women. *Trop Med Int Health.* 19(3):348–54. <http://dx.doi.org/10.1111/tmi.12250> PMID:24372685
- Castelino JM, Routledge MN, Wilson S, Dunne DW, Mwachia JK, Gachuhi K, et al. (2015). Aflatoxin exposure is inversely associated with IGF1 and IGFBP3 levels in vitro and in Kenyan schoolchildren. *Mol Nutr Food Res.* 59(3):574–81. <http://dx.doi.org/10.1002/mnfr.201300619> PMID:24668606
- Castellsagué X, Pawlita M, Roura E, Margall N, Waterboer T, Bosch FX, et al. (2014). Prospective seroepidemiologic study on the role of human papillomavirus and other infections in cervical carcinogenesis: evidence from the EPIC cohort. *Int J Cancer.* 135(2):440–52. <http://dx.doi.org/10.1002/ijc.28665> PMID:24338606
- Castro FA, Dominguez A, Puschel K, Van De Wyngard V, Snijders PJ, Franceschi S, et al. (2014). Serological prevalence and persistence of high-risk human papillomavirus infection among women in Santiago, Chile. *BMC Infect Dis.* 14(1):361. <http://dx.doi.org/10.1186/1471-2334-14-361> PMID:24990706
- Caygill CP, Gatenby PA, Herceg Z, Lima SC, Pinto LF, Watson A, et al. (2014). Comparative genomic analysis of esophageal cancers. *Ann N Y Acad Sci.* 1325(1):69–76. <http://dx.doi.org/10.1111/nyas.12524> PMID:25266016
- Cerhan JR, Berndt SI, Vijai J, Ghesquières H, McKay J, Wang SS, et al. (2014). Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. *Nat Genet.* 46(11):1233–8. <http://dx.doi.org/10.1038/ng.3105> PMID:25261932
- Cettier J, Bayle ML, Béranger R, Billoir E, Nuckols JR, Combourieu B, et al. (2015). Efficiency of wipe sampling on hard surfaces for pesticides and PCB residues in dust. *Sci Total Environ.* 505:11–21. <http://dx.doi.org/10.1016/j.scitotenv.2014.09.086> PMID:25306091
- Chajès V, Biessy C, Ferrari P, Romieu I, Freisling H, Huybrechts I, et al. (2015). Plasma elaidic acid level as biomarker of industrial *trans* fatty acids and risk of weight change: report from the EPIC study. *PLoS ONE.* 10(2):e0118206. <http://dx.doi.org/10.1371/journal.pone.0118206> PMID:25675445
- Chajès V, Romieu I (2014). Nutrition and breast cancer. *Maturitas.* 77(1):7–11. <http://dx.doi.org/10.1016/j.maturitas.2013.10.004> PMID:24215727
- Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A (2014). International variations in bladder cancer incidence and mortality. *Eur Urol.* 66(1):59–73. <http://dx.doi.org/10.1016/j.eururo.2013.10.001> PMID:24451595
- Chen AA, Gheit T, Franceschi S, Tommasino M, Clifford GM (2015). Human papillomavirus 18 genetic variation and cervical cancer risk worldwide. *J Virol.* 89(20):10680–7. <http://dx.doi.org/10.1128/JVI.01747-15> PMID:26269181
- Chen AA, Heideman DA, Boon D, Chen Z, Burk RD, De Vuyst H, et al. (2014a). Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer. *Virology.* 448:356–62. <http://dx.doi.org/10.1016/j.virol.2013.10.033> PMID:24314666
- Chen AA, Heideman DA, Boon D, Gheit T, Snijders PJ, Tommasino M, et al.; IARC HPV Variant Study Group (2014b). Human papillomavirus 45 genetic variation and cervical cancer risk worldwide. *J Virol.* 88(8):4514–21. <http://dx.doi.org/10.1128/JVI.03534-13> PMID:24501412
- Chen D, Gaborieau V, Zhao Y, Chabrier A, Wang H, Waterboer T, et al. (2015). A systematic investigation of the contribution of genetic variation within the MHC region to HPV seropositivity. *Hum Mol Genet.* 24(9):2681–8. <http://dx.doi.org/10.1093/hmg/ddv015> PMID:25616963
- Cheng TH, Gorman M, Martin L, Barclay E, Casey G, Saunders B, et al.; CGEMS (2015). Common colorectal cancer risk alleles contribute to the multiple colorectal adenoma phenotype, but do not influence colonic polyposis in FAP. *Eur J Hum Genet.* 23(2):260–3. <http://dx.doi.org/10.1038/ejhg.2014.74> PMID:24801760
- Childs EJ, Mocchi E, Campa D, Bracci PM, Gallinger S, Goggins M, et al. (2015). Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. *Nat Genet.* 47(8):911–6. <http://dx.doi.org/10.1038/ng.3341> PMID:26098869
- Chuang SC, Fanidi A, Ueland PM, Relton C, Middtun O, Vollset SE, et al. (2014). Circulating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk. *Cancer Epidemiol Biomarkers Prev.* 23(3):461–8. <http://dx.doi.org/10.1158/1055-9965.EPI-13-0770> PMID:24357106
- Chuang SC, Lee YC, Wu GJ, Straif K, Hashibe M (2015). Alcohol consumption and liver cancer risk: a meta-analysis. *Cancer Causes Control.* 26(9):1205–31. <http://dx.doi.org/10.1007/s10552-015-0615-3> PMID:26134046
- Clarys P, Deliens T, Huybrechts I, Deriemaeker P, Vanaelst B, De Keyser W, et al. (2014). Comparison of nutritional quality of the vegan, vegetarian, semi-vegetarian, pesco-vegetarian and omnivorous diet. *Nutrients.* 6(3):1318–32. <http://dx.doi.org/10.3390/nu6031318> PMID:24667136
- Coll G, Combes JD, Isfan F, Rochette E, Chazal J, Lemaire JJ, et al. (2015). Incidence and survival of childhood central nervous system tumors: a report of the regional registry of childhood cancers in Auvergne-Limousin. *Neurochirurgie.* 61(4):237–43. <http://dx.doi.org/10.1016/j.neuchi.2015.01.005> PMID:26123613
- Colquhoun A, Arnold M, Ferlay J, Goodman KJ, Forman D, Soerjomataram I (2015). Global patterns of cardia and non-cardia gastric cancer incidence in 2012. *Gut.* 64(12):1881–8. <http://dx.doi.org/10.1136/gutjnl-2014-308915> PMID:25748648
- Combes JD, Chen AA, Franceschi S (2014a). Prevalence of human papillomavirus in cancer of the oropharynx by gender. *Cancer Epidemiol Biomarkers Prev.* 23(12):2954–8. <http://dx.doi.org/10.1158/1055-9965.EPI-14-0580> PMID:25205515

- Combes JD, Franceschi S (2014). Role of human papillomavirus in non-oropharyngeal head and neck cancers. *Oral Oncol.* 50(5):370–9. <http://dx.doi.org/10.1016/j.oraloncology.2013.11.004> PMID:24331868
- Combes JD, Guan P, Franceschi S, Clifford GM (2015). Judging the carcinogenicity of rare human papillomavirus types. *Int J Cancer.* 136(3):740–2. PMID:24917192
- Combes JD, Pawlita M, Waterboer T, Hammouda D, Rajkumar T, Vanhems P, et al. (2014b). Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer. *Int J Cancer.* 135(10):2453–61. <http://dx.doi.org/10.1002/ijc.28888> PMID:24729277
- Companiononi O, Bonet C, Muñoz X, Weiderpass E, Panico S, Tumino R, et al. (2014). Polymorphisms of *Helicobacter pylori* signaling pathway genes and gastric cancer risk in the European Prospective Investigation into Cancer-Eurgast cohort. *Int J Cancer.* 134(1):92–101. <http://dx.doi.org/10.1002/ijc.28357> PMID:23824692
- Consonni D, De Matteis S, Pesatori AC, Bertazzi PA, Olsson AC, Kromhout H, et al. (2015). Lung cancer risk among bricklayers in a pooled analysis of case-control studies. *Int J Cancer.* 136(2):360–71. <http://dx.doi.org/10.1002/ijc.28986> PMID:24861979
- Conti S, Minelli G, Ascoli V, Marinaccio A, Bonafede M, Manno V, et al. (2015). Peritoneal mesothelioma in Italy: trends and geography of mortality and incidence. *Am J Ind Med.* 58(10):1050–8. <http://dx.doi.org/10.1002/ajim.22491> PMID:26351019
- Conway DI, Brenner DR, McMahon AD, Macpherson LM, Agudo A, Ahrens W, et al. (2015). Estimating and explaining the effect of education and income on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case-control studies from 27 countries. *Int J Cancer.* 136(5):1125–39. <http://dx.doi.org/10.1002/ijc.29063> PMID:24996155
- Cook MB, Guénel P, Gapstur SM, van den Brandt PA, Michels KB, Casagrande JT, et al. (2015). Tobacco and alcohol in relation to male breast cancer: an analysis of the Male Breast Cancer Pooling Project consortium. *Cancer Epidemiol Biomarkers Prev.* 24(3):520–31. <http://dx.doi.org/10.1158/1055-9965.EPI-14-1009> PMID:25515550
- Corbex M, Bouzbid S, Traverse-Glehen A, Aouras H, McKay-Chopin S, Carreira C, et al. (2014). Prevalence of papillomaviruses, polyomaviruses, and herpesviruses in triple-negative and inflammatory breast tumors from Algeria compared with other types of breast cancer tumors. *PLoS ONE.* 9(12):e114559. <http://dx.doi.org/10.1371/journal.pone.0114559> PMID:25478862
- Cortot AB, Younes M, Martel-Planche G, Guibert B, Isaac S, Souquet PJ, et al. (2014). Mutation of *TP53* and alteration of p14<sup>arf</sup> expression in *EGFR*- and *KRAS*-mutated lung adenocarcinomas. *Clin Lung Cancer.* 15(2):124–30. <http://dx.doi.org/10.1016/j.clc.2013.08.003> PMID:24169260
- Costas L, Infante-Rivard C, Zock JP, Van Tongeren M, Boffetta P, Cusson A, et al. (2015). Occupational exposure to endocrine disruptors and lymphoma risk in a multi-centric European study. *Br J Cancer.* 112(7):1251–6. <http://dx.doi.org/10.1038/bjc.2015.83> PMID:25742473
- Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanché H, et al.; BioCAST/IFCT-1002 investigators (2014). Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. *Clin Cancer Res.* 20(17):4613–24. <http://dx.doi.org/10.1158/1078-0432.CCR-13-3063> PMID:25013125
- Cozen W, Timofeeva MN, Li D, Diepstra A, Hazelett D, Delahaye-Sourdeix M, et al. (2014). A meta-analysis of Hodgkin lymphoma reveals 19p13.3 *TCF3* as a novel susceptibility locus. *Nat Commun.* 5:3856. <http://dx.doi.org/10.1038/ncomms4856> PMID:24920014
- Crispin SP, Nicolas G, Casagrande C, Knaze V, Illner AK, Huybrechts I, et al. (2014). Quality assurance of the international computerised 24 h dietary recall method (EPIC-Soft). *Br J Nutr.* 111(3):506–15. <http://dx.doi.org/10.1017/S0007114513002766> PMID:24001201
- Croagh D, Frede J, Jones PH, Kaur P, Partensky C, Phillips WA (2014). Esophageal stem cells and genetics/epigenetics in esophageal cancer. *Ann N Y Acad Sci.* 1325(1):8–14. <http://dx.doi.org/10.1111/nyas.12521> PMID:25266010
- Crowe FL, Appleby PN, Travis RC, Barnett M, Brasky TM, Bueno-de-Mesquita HB, et al.; Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group (2014). Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies. *J Natl Cancer Inst.* 106(9):dju240. <http://dx.doi.org/10.1093/jnci/dju240> PMID:25210201
- Cuenca-García M, Ortega FB, Ruiz JR, Labayen I, Moreno LA, Patterson E, et al.; HELENA Study Group (2014). More physically active and leaner adolescents have higher energy intake. *J Pediatr.* 164(1):159–166.e2. <http://dx.doi.org/10.1016/j.jpeds.2013.08.034> PMID:24094763
- Currier JM, Ishida MC, González-Horta C, Sánchez-Ramírez B, Ballinas-Casarrubias L, Gutiérrez-Torres DS, et al. (2014). Associations between arsenic species in exfoliated urothelial cells and prevalence of diabetes among residents of Chihuahua, Mexico. *Environ Health Perspect.* 122(10):1088–94. PMID:25000461
- da Costa AN, Plymoth A, Santos-Silva D, Ortiz-Cuaran S, Camey S, Guilloreaux P, et al. (2015). Osteopontin and latent-TGF  $\beta$  binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. *Int J Cancer.* 136(1):172–81. <http://dx.doi.org/10.1002/ijc.28953> PMID:24803312
- Dadvand P, Nieuwenhuijsen MJ, Agustí À, de Batlle J, Benet M, Beelen R, et al. (2014). Air pollution and biomarkers of systemic inflammation and tissue repair in COPD patients. *Eur Respir J.* 44(3):603–13. <http://dx.doi.org/10.1183/09031936.00168813> PMID:24558180
- Dahlin AM, Hollegaard MV, Wibom C, Andersson U, Hougaard DM, Deltour I, et al. (2015). *CCND2*, *CTNBN1*, *DDX3X*, *GLI2*, *SMARCA4*, *MYC*, *MYCN*, *PTCH1*, *TP53*, and *MLL2* gene variants and risk of childhood medulloblastoma. *J Neurooncol.* 125(1):75–8. <http://dx.doi.org/10.1007/s11060-015-1891-1> PMID:26290144
- Dai Y, Cros MP, Pontoizeau C, Elena-Hermann B, Bonn GK, Hainaut P (2014). Downregulation of transcription factor E4F1 in hepatocarcinoma cells: HBV-dependent effects on autophagy, proliferation and metabolism. *Carcinogenesis.* 35(3):635–50. <http://dx.doi.org/10.1093/carcin/bgt353> PMID:24163401

- Dal Maso LD, Suligoi B, Franceschi S, Braga C, Buzzoni C, Polesel J, et al.; Cancer and AIDS Registries Linkage Study (2014). Survival after cancer in Italian persons with AIDS, 1986–2005: a population-based estimation. *J Acquir Immune Defic Syndr*. 66(4):428–35. <http://dx.doi.org/10.1097/QAI.000000000000184> PMID:24798769
- Dallat MA, Soerjomataram I, Hunter RF, Tully MA, Cairns KJ, Kee F (2014). Urban greenways have the potential to increase physical activity levels cost-effectively. *Eur J Public Health*. 24(2):190–5. <http://dx.doi.org/10.1093/eurpub/ckt035> PMID:23531527
- Dalton SO, Steding-Jessen M, Jakobsen E, Mellemegaard A, Østerlind K, Schüz J, et al. (2015). Socioeconomic position and survival after lung cancer: influence of stage, treatment and comorbidity among Danish patients with lung cancer diagnosed in 2004–2010. *Acta Oncol*. 54(5):797–804. <http://dx.doi.org/10.3109/0284186X.2014.1001037> PMID:25761702
- Damiola F, Byrnes G, Moissonnier M, Pertesi M, Deltour I, Fillon A, et al. (2014b). Contribution of *ATM* and *FOXE1* (*TTF2*) to risk of papillary thyroid carcinoma in Belarusian children exposed to radiation. *Int J Cancer*. 134(7):1659–68. <http://dx.doi.org/10.1002/ijc.28483> PMID:24105688
- Damiola F, Pertesi M, Oliver J, Le Calvez-Kelm F, Voegele C, Young EL, et al. (2014a). Rare key functional domain missense substitutions in *MRE11A*, *RAD50*, and *NBN* contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. *Breast Cancer Res*. 16(3):R58. <http://dx.doi.org/10.1186/bcr3669> PMID:24894818
- Darabi H, McCue K, Beesley J, Michailidou K, Nord S, Kar S, et al.; German Consortium of Hereditary Breast and Ovarian Cancer; kConFab/AOCS Investigators (2015). Polymorphisms in a putative enhancer at the 10q21.2 breast cancer risk locus regulate *NRBF2* expression. *Am J Hum Genet*. 97(1):22–34. <http://dx.doi.org/10.1016/j.ajhg.2015.05.002> PMID:26073781
- de Battle J, Ferrari P, Chajes V, Park JY, Slimani N, McKenzie F, et al. (2015). Dietary folate intake and breast cancer risk: European Prospective Investigation into Cancer and Nutrition. *J Natl Cancer Inst*. 107(1):367. <http://dx.doi.org/10.1093/jnci/dju367> PMID:25505228
- De Keyzer W, Bracke T, McNaughton SA, Parnell W, Moshfegh AJ, Pereira RA, et al. (2015b). Cross-continental comparison of national food consumption survey methods – a narrative review. *Nutrients*. 7(5):3587–620. <http://dx.doi.org/10.3390/nu7053587> PMID:25984745
- De Keyzer W, Dofková M, Lillegaard IT, De Maeyer M, Andersen LF, Ruprich J, et al. (2015a). Reporting accuracy of population dietary sodium intake using duplicate 24 h dietary recalls and a salt questionnaire. *Br J Nutr*. 113(3):488–97. <http://dx.doi.org/10.1017/S0007114514003791> PMID:25582315
- de Martel C, Maucourt-Boulch D, Plummer M, Franceschi S (2015). World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. *Hepatology*. 62(4):1190–200. <http://dx.doi.org/10.1002/hep.27969> PMID:26146815
- de Martel C, Plummer M, Franceschi S (2014). Infections causing cancers: world burden and potential for prevention. *Public Health Forum*. 22(3):12.e1–4. <http://dx.doi.org/10.1016/j.phf.2014.07.003>
- de Moraes AC, Bel-Serrat S, Manios Y, Molnar D, Kafatos A, Cuenca-García M, et al. (2015). Dietary protein and amino acids intake and its relationship with blood pressure in adolescents: the HELENA study. *Eur J Public Health*. 25(3):450–6. <http://dx.doi.org/10.1093/eurpub/cku233> PMID:25619683
- De Ruyc K, De Boevre M, Huybrechts I, De Saeger S (2015). Dietary mycotoxins, co-exposure, and carcinogenesis in humans: short review. *Mutat Res Rev Mutat Res*. 766:32–41. <http://dx.doi.org/10.1016/j.mrrev.2015.07.003> PMID:26596546
- de Vries E, Arroyave I, Pardo C, Wiesner C, Murillo R, Forman D, et al. (2015a). Trends in inequalities in premature cancer mortality by educational level in Colombia, 1998–2007. *J Epidemiol Community Health*. 69(5):408–15. <http://dx.doi.org/10.1136/jech-2014-204650> PMID:25492898
- de Vries E, Uribe C, Pardo C, Lemmens V, Van de Poel E, Forman D (2015b). Gastric cancer survival and affiliation to health insurance in a middle-income setting. *Cancer Epidemiol*. 39(1):91–6. <http://dx.doi.org/10.1016/j.canep.2014.10.012> PMID:25652310
- de Vuyst H, Franceschi S, Plummer M, Mugo NR, Sakr SR, Meijer CJ, et al. (2015). Methylation levels of *CADM1*, *MAL*, and *MIR124-2* in cervical scrapes for triage of HIV-infected, high-risk HPV-positive women in Kenya. *J Acquir Immune Defic Syndr*. 70(3):311–8. <http://dx.doi.org/10.1097/QAI.0000000000000744> PMID:26473640
- de Vuyst H, Mugo NR, Franceschi S, McKenzie K, Tenet V, Njoroge J, et al. (2014). Residual disease and HPV persistence after cryotherapy for cervical intraepithelial neoplasia grade 2/3 in HIV-positive women in Kenya. *PLoS ONE*. 9(10):e111037. <http://dx.doi.org/10.1371/journal.pone.0111037> PMID:25343563
- Dejardin O, Jones AP, Racht B, Morris E, Bouvier V, Jooste V, et al. (2014). The influence of geographical access to health care and material deprivation on colorectal cancer survival: evidence from France and England. *Health Place*. 30:36–44. <http://dx.doi.org/10.1016/j.healthplace.2014.08.002> PMID:25194994
- Delahaye-Sourdeix M, Anantharaman D, Timofeeva MN, Gaborieau V, Chabrier A, Vallée MP, et al. (2015a). A rare truncating *BRCA2* variant and genetic susceptibility to upper aerodigestive tract cancer. *J Natl Cancer Inst*. 107(5):djv037. <http://dx.doi.org/10.1093/jnci/djv037> PMID:25838448
- Delahaye-Sourdeix M, Oliver J, Timofeeva MN, Gaborieau V, Johansson M, Chabrier A, et al. (2015b). The 12p13.33/*RAD52* locus and genetic susceptibility to squamous cell cancers of upper aerodigestive tract. *PLoS ONE*. 10(3):e0117639. <http://dx.doi.org/10.1371/journal.pone.0117639> PMID:25793373
- Deltour I, Tretyakov F, Tsareva Y, Azizova TV, Schüz J (2015). Mortality of populations potentially exposed to ionising radiation, 1953–2010, in the closed city of Ozyorsk, Southern Urals: a descriptive study. *Environ Health*. 14(1):91. <http://dx.doi.org/10.1186/s12940-015-0078-8> PMID:26613590
- Denholm R, Schüz J, Straif K, Stücker I, Jöckel KH, Brenner DR, et al. (2014). Is previous respiratory disease a risk factor for lung cancer? *Am J Respir Crit Care Med*. 190(5):549–59. <http://dx.doi.org/10.1164/rccm.201402-0338OC> PMID:25054566
- Denny L, Prendiville W (2015). Cancer of the cervix: early detection and cost-effective solutions. *Int J Gynaecol Obstet*. 131 Suppl 1:S28–32. <http://dx.doi.org/10.1016/j.ijgo.2015.02.009> PMID:26433500
- DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A (2015). International variation in female breast cancer incidence and mortality rates. *Cancer Epidemiol Biomarkers Prev*. 24(10):1495–506. <http://dx.doi.org/10.1158/1055-9965.EPI-15-0535> PMID:26359465
- Dickens C, Duarte R, Zietsman A, Cubasch H, Kellett P, Schüz J, et al. (2014a). Racial comparison of receptor-defined breast cancer in Southern African women: subtype prevalence and age-incidence analysis of nationwide cancer registry data. *Cancer Epidemiol Biomarkers Prev*. 23(11):2311–21. <http://dx.doi.org/10.1158/1055-9965.EPI-14-0603> PMID:25143359

- Dickens C, Joffe M, Jacobson J, Venter F, Schüz J, Cubasch H, et al. (2014b). Stage at breast cancer diagnosis and distance from diagnostic hospital in a periurban setting: a South African public hospital case series of over 1,000 women. *Int J Cancer*. 135(9):2173–82. <http://dx.doi.org/10.1002/ijc.28861> PMID:24658866
- Dik VK, Bueno-de-Mesquita HB, Van Oijen MG, Siersema PD, Uiterwaal CS, Van Gils CH, et al. (2014a). Coffee and tea consumption, genotype-based *CYP1A2* and *NAT2* activity and colorectal cancer risk – results from the EPIC cohort study. *Int J Cancer*. 135(2):401–12. <http://dx.doi.org/10.1002/ijc.28655> PMID:24318358
- Dik VK, Murphy N, Siersema PD, Fedirko V, Jenab M, Kong SY, et al. (2014b). Prediagnostic intake of dairy products and dietary calcium and colorectal cancer survival – results from the EPIC cohort study. *Cancer Epidemiol Biomarkers Prev*. 23(9):1813–23. <http://dx.doi.org/10.1158/1055-9965.EPI-14-0172> PMID:24917183
- Dolman L, Sauvaget C, Muwonge R, Sankaranarayanan R (2014). Meta-analysis of the efficacy of cold coagulation as a treatment method for cervical intraepithelial neoplasia: a systematic review. *BJOG*. 121(8):929–42. <http://dx.doi.org/10.1111/1471-0528.12655> PMID:24597779
- Donà MG, Gheit T, Latini A, Benevolo M, Torres M, Smelov V, et al. (2015). Alpha, beta and gamma human papillomaviruses in the anal canal of HIV-infected and uninfected men who have sex with men. *J Infect*. 71(1):74–84. <http://dx.doi.org/10.1016/j.jinf.2015.02.001> PMID:25698067
- Donaire-Gonzalez D, Gimeno-Santos E, Balcells E, de Battle J, Ramon MA, Rodriguez E, et al.; PAC-COPD Study Group (2015). Benefits of physical activity on COPD hospitalisation depend on intensity. *Eur Respir J*. 46(5):1281–9. <http://dx.doi.org/10.1183/13993003.01699-2014> PMID:26206873
- Dondog B, Schnitzler P, Michael KM, Clifford G, Franceschi S, Pawlita M, et al. (2015). Hepatitis C virus seroprevalence in Mongolian women assessed by a novel multiplex antibody detection assay. *Cancer Epidemiol Biomarkers Prev*. 24(9):1360–5. <http://dx.doi.org/10.1158/1055-9965.EPI-15-0351> PMID:26169147
- Dorji T, Tshomo U, Phuntsho S, Tamang TD, Tshokey T, Baussano I, et al. (2015). Introduction of a national HPV vaccination program into Bhutan. *Vaccine*. 33(31):3726–30. <http://dx.doi.org/10.1016/j.vaccine.2015.05.078> PMID:26057136
- Dossus L, Boutron-Ruault MC, Kaaks R, Gram IT, Vilier A, Fervers B, et al. (2014a). Active and passive cigarette smoking and breast cancer risk: results from the EPIC cohort. *Int J Cancer*. 134(8):1871–88. <http://dx.doi.org/10.1002/ijc.28508> PMID:24590452
- Dossus L, Jimenez-Corona A, Romieu I, Boutron-Ruault MC, Boutten A, Dupré T, et al. (2014b). C-reactive protein and postmenopausal breast cancer risk: results from the E3N cohort study. *Cancer Causes Control*. 25(4):533–9. <http://dx.doi.org/10.1007/s10552-014-0355-9> PMID:24504436
- Duarte-Salles T, Fedirko V, Stepien M, Aleksandrova K, Bamia C, Lagiou P, et al. (2015). Dietary fat, fat subtypes and hepatocellular carcinoma in a large European cohort. *Int J Cancer*. 137(11):2715–28. <http://dx.doi.org/10.1002/ijc.29643> PMID:26081477
- Duarte-Salles T, Fedirko V, Stepien M, Trichopoulou A, Bamia C, Lagiou P, et al. (2014). Dairy products and risk of hepatocellular carcinoma: the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer*. 135(7):1662–72. <http://dx.doi.org/10.1002/ijc.28812> PMID:24615266
- Ducarroz S, Leon ME, Schott AM, Friis S, Johansen C, Schüz J (2015). Are male immigrants in Denmark at lower or higher risk of tobacco-related cancers? A Danish nationwide cohort study. *Acta Oncol*. 54(8):1128–35. <http://dx.doi.org/10.3109/0284186X.2015.1016626> PMID:25813476
- Duell EJ, Bonet C, Muñoz X, Lujan-Barroso L, Weiderpass E, Boutron-Ruault MC, et al. (2015). Variation at *ABO* histo-blood group and *FUT* loci and diffuse and intestinal gastric cancer risk in a European population. *Int J Cancer*. 136(4):880–93. <http://dx.doi.org/10.1002/ijc.29034> PMID:24947433
- Durães C, Muñoz X, Bonet C, García N, Venceslá A, Cameiro F, et al. (2014). Genetic variants in the *IL1A* gene region contribute to intestinal-type gastric carcinoma susceptibility in European populations. *Int J Cancer*. 135(6):1343–55. <http://dx.doi.org/10.1002/ijc.28776> PMID:24615437
- Ecsedi S, Hernandez-Vargas H, Lima SC, Vizkeleti L, Toth R, Lazar V, et al. (2014). DNA methylation characteristics of primary melanomas with distinct biological behaviour. *PLoS ONE*. 9(5):e96612. <http://dx.doi.org/10.1371/journal.pone.0096612> PMID:24832207
- Edmands WM, Barupal DK, Scalbert A (2015). MetMSLine: an automated and fully integrated pipeline for rapid processing of high-resolution LC-MS metabolomic datasets. *Bioinformatics*. 31(5):788–90. <http://dx.doi.org/10.1093/bioinformatics/btu705> PMID:25348215
- Edmands WM, Ferrari P, Rothwell JA, Rinaldi S, Slimani N, Barupal DK, et al. (2015). Polyphenol metabolome in human urine and its association with intake of polyphenol-rich foods across European countries. *Am J Clin Nutr*. 102(4):905–13. <http://dx.doi.org/10.3945/ajcn.114.101881> PMID:26269369
- Edmands WM, Ferrari P, Scalbert A (2014). Normalization to specific gravity prior to analysis improves information recovery from high resolution mass spectrometry metabolomic profiles of human urine. *Anal Chem*. 86(21):10925–31. <http://dx.doi.org/10.1021/ac503190m> PMID:25285402
- Ekelund U, Ward HA, Norat T, Luan J, May AM, Weiderpass E, et al. (2015). Physical activity and all-cause mortality across levels of overall and abdominal adiposity in European men and women: the European Prospective Investigation into Cancer and Nutrition Study (EPIC). *Am J Clin Nutr*. 101(3):613–21. <http://dx.doi.org/10.3945/ajcn.114.100065> PMID:25733647
- El-Zaemey S, Heyworth J, Fritschi L (2014). Qat consumption among women living in Yemen. *Int J Occup Environ Med*. 5(2):109–11. PMID:24748003
- El-Zaemey S, Schüz J, Leon ME (2015). Qat chewing and risk of potentially malignant and malignant oral disorders: a systematic review. *Int J Occup Environ Med*. 6(3):129–43. PMID:26174990
- Elfström KM, Arnheim-Dahlström L, von Karsa L, Dillner J (2015). Cervical cancer screening in Europe: quality assurance and organisation of programmes. *Eur J Cancer*. 51(8):950–68. <http://dx.doi.org/10.1016/j.ejca.2015.03.008> PMID:25817010
- Ellison-Loschmann L, Firestone R, Aquilina L, McKenzie F, Gray M, Jeffreys M (2015). Barriers to and delays in accessing breast cancer care among New Zealand women: disparities by ethnicity. *BMC Health Serv Res*. 15(1):394. <http://dx.doi.org/10.1186/s12913-015-1050-6> PMID:26385793
- Emaus MJ, van Gils CH, Bakker MF, Bisschop CN, Monninkhof EM, Bueno-de-Mesquita HB, et al. (2014). Weight change in middle adulthood and breast cancer risk in the EPIC-PANACEA study. *Int J Cancer*. 135(12):2887–99. <http://dx.doi.org/10.1002/ijc.28926> PMID:24771551
- Eng A, Gallant Z, Shepherd J, McCormack V, Li J, Dowsett M, et al. (2014a). Digital mammographic density and breast cancer risk: a case-control study of six alternative density assessment methods. *Breast Cancer Res*. 16(5):439. <http://dx.doi.org/10.1186/s13058-014-0439-1> PMID:25239205

- Eng A, McCormack V, dos-Santos-Silva I (2014b). Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis. *PLoS Med.* 11(9):e1001720. <http://dx.doi.org/10.1371/journal.pmed.1001720> PMID:25202974
- Engeset D, Braaten T, Teucher B, Kühn T, Bueno-de-Mesquita HB, Leenders M, et al. (2015). Fish consumption and mortality in the European Prospective Investigation into Cancer and Nutrition cohort. *Eur J Epidemiol.* 30(1):57–70. <http://dx.doi.org/10.1007/s10654-014-9966-4> PMID:25377533
- Erdmann F, Kaatsch P, Schüz J (2015b). Family circumstances and survival from childhood acute lymphoblastic leukaemia in West Germany. *Cancer Epidemiol.* 39(2):209–15. <http://dx.doi.org/10.1016/j.canep.2015.01.012> PMID:25698214
- Erdmann F, Kaatsch P, Zeeb H, Roman E, Lightfoot T, Schüz J (2014). Survival from childhood acute lymphoblastic leukaemia in West Germany: does socio-demographic background matter? *Eur J Cancer.* 50(7):1345–53. <http://dx.doi.org/10.1016/j.ejca.2014.01.028> PMID:24582913
- Erdmann F, Kielkowski D, Schonfeld SJ, Kellett P, Stanulla M, Dickens C, et al. (2015a). Childhood cancer incidence patterns by race, sex and age for 2000–2006: a report from the South African National Cancer Registry. *Int J Cancer.* 136(11):2628–39. <http://dx.doi.org/10.1002/ijc.29308> PMID:25363616
- Escamilla-Núñez MC, Barraza-Villarreal A, Hernández-Cadena L, Navarro-Olivos E, Sly PD, Romieu I (2014). Omega-3 fatty acid supplementation during pregnancy and respiratory symptoms in children. *Chest.* 146(2):373–82. <http://dx.doi.org/10.1378/chest.13-1432> PMID:24626819
- Espinosa-Parrilla Y, Muñoz X, Bonet C, Garcia N, Venceslá A, Yannakouris N, et al. (2014). Genetic association of gastric cancer with miRNA clusters including the cancer-related genes *MIR29*, *MIR25*, *MIR93* and *MIR106*: results from the EPIC-EURGAST study. *Int J Cancer.* 135(9):2065–76. <http://dx.doi.org/10.1002/ijc.28850> PMID:24643999
- Etemadi A, Abnet CC, Kamangar F, Islami F, Khademi H, Pourshams A, et al. (2014). Impact of body size and physical activity during adolescence and adult life on overall and cause-specific mortality in a large cohort study from Iran. *Eur J Epidemiol.* 29(2):95–109. <http://dx.doi.org/10.1007/s10654-014-9883-6> PMID:24557643
- Etemadi A, Kamangar F, Islami F, Poustchi H, Pourshams A, Brennan P, et al. (2015). Mortality and cancer in relation to ABO blood group phenotypes in the Golestan Cohort Study. *BMC Med.* 13(1):8. <http://dx.doi.org/10.1186/s12916-014-0237-8> PMID:25592833
- Fages A, Duarte-Salles T, Stepien M, Ferrari P, Fedirko V, Pontoizeau C, et al. (2015). Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort. *BMC Med.* 13(1):242. <http://dx.doi.org/10.1186/s12916-015-0462-9> PMID:26399231
- Fages A, Ferrari P, Monni S, Dossus L, Floegel A, Mode N, et al. (2014). Investigating sources of variability in metabolomic data in the EPIC study: the Principal Component Partial R-square (PC-PR2) method. *Metabolomics.* 10(6):1074–83. <http://dx.doi.org/10.1007/s11306-014-0647-9>
- Familiar I, Ortiz-Panozo E, Hall B, Vieitez I, Romieu I, Lopez-Ridaura R, et al. (2015). Factor structure of the Spanish version of the Patient Health Questionnaire-9 in Mexican women. *Int J Methods Psychiatr Res.* 24(1):74–82. <http://dx.doi.org/10.1002/mpr.1461> PMID:25524806
- Fanidi A, Relton C, Ueland PM, Midttun Ø, Vollset SE, Travis RC, et al. (2015). A prospective study of one-carbon metabolism biomarkers and cancer of the head and neck and esophagus. *Int J Cancer.* 136(4):915–27. <http://dx.doi.org/10.1002/ijc.29051> PMID:24975698
- Fedirko V, Duarte-Salles T, Bamia C, Trichopoulou A, Aleksandrova K, Trichopoulos D, et al. (2014b). Prediagnostic circulating vitamin D levels and risk of hepatocellular carcinoma in European populations: a nested case-control study. *Hepatology.* 60(4):1222–30. <http://dx.doi.org/10.1002/hep.27079> PMID:24644045
- Fedirko V, Romieu I, Aleksandrova K, Pischon T, Trichopoulos D, Peeters PH, et al. (2014a). Pre-diagnostic anthropometry and survival after colorectal cancer diagnosis in Western European populations. *Int J Cancer.* 135(8):1949–60. <http://dx.doi.org/10.1002/ijc.28841> PMID:24623514
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. (2015a). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer.* 136(5):E359–86. <http://dx.doi.org/10.1002/ijc.29210> PMID:25220842
- Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. (2015b). Reprint of: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur J Cancer.* 51(9):1201–2. <http://dx.doi.org/10.1016/j.ejca.2015.05.004>
- Fernández-Alvira JM, Bammann K, Pala V, Krogh V, Barba G, Eiben G, et al. (2014). Country-specific dietary patterns and associations with socioeconomic status in European children: the IDEFICS study. *Eur J Clin Nutr.* 68(7):811–21. <http://dx.doi.org/10.1038/ejcn.2014.78> PMID:24824009
- Fernández-Alvira JM, Böhnhorst C, Bammann K, Gwozdz W, Krogh V, Hebestreit A, et al. (2015). Prospective associations between socio-economic status and dietary patterns in European children: the Identification and Prevention of Dietary- and Lifestyle-induced Health Effects in Children and Infants (IDEFICS) Study. *Br J Nutr.* 113(3):517–25. <http://dx.doi.org/10.1017/S0007114514003663> PMID:25563904
- Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, et al. (2015). Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. *Genome Biol.* 16(1):7. <http://dx.doi.org/10.1186/s13059-014-0558-0> PMID:25650807
- Fernandez-Cuesta L, Thomas RK (2015). Molecular pathways: targeting *NRG1* fusions in lung cancer. *Clin Cancer Res.* 21(9):1989–94. <http://dx.doi.org/10.1158/1078-0432.CCR-14-0854> PMID:25501131
- Ferrari M, Cuenca-García M, Valtueña J, Moreno LA, Censi L, González-Gross M, et al.; HELENA Study Group (2015). Inflammation profile in overweight/obese adolescents in Europe: an analysis in relation to iron status. *Eur J Clin Nutr.* 69(2):247–55. <http://dx.doi.org/10.1038/ejcn.2014.154> PMID:25205319
- Ferrari P, Licaj I, Muller DC, Kragh Andersen P, Johansson M, Boeing H, et al. (2014). Lifetime alcohol use and overall and cause-specific mortality in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *BMJ Open.* 4(7):e005245. <http://dx.doi.org/10.1136/bmjopen-2014-005245> PMID:24993766
- Fiaschetti G, Abela L, Nonoguchi N, Dubuc AM, Remke M, Boro A, et al. (2014). Epigenetic silencing of miRNA-9 is associated with *HES1* oncogenic activity and poor prognosis of medulloblastoma. *Br J Cancer.* 110(3):636–47. <http://dx.doi.org/10.1038/bjc.2013.764> PMID:24346283

- Figueroa JD, Han SS, Garcia-Closas M, Baris D, Jacobs EJ, Kogevinas M, et al. (2014a). Genome-wide interaction study of smoking and bladder cancer risk. *Carcinogenesis*. 35(8):1737–44. <http://dx.doi.org/10.1093/carcin/bgu064> PMID:24662972
- Figueroa JD, Ye Y, Siddiq A, Garcia-Closas M, Chatterjee N, Prokunina-Olsson L, et al. (2014b). Genome-wide association study identifies multiple loci associated with bladder cancer risk. *Hum Mol Genet*. 23(5):1387–98. <http://dx.doi.org/10.1093/hmg/ddt519> PMID:24163127
- Flanagan L, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, et al. (2014). *Fusobacterium nucleatum* associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. *Eur J Clin Microbiol Infect Dis*. 33(8):1381–90. <http://dx.doi.org/10.1007/s10096-014-2081-3> PMID:24599709
- Foliaki S, Brewer N, Pearce N, Snijders PJ, Meijer CJ, Waqatakiwewa L, et al. (2014). Prevalence of HPV infection and other risk factors in a Fijian population. *Infect Agent Cancer*. 9(1):14. <http://dx.doi.org/10.1186/1750-9378-9-14> PMID:24891876
- Fonseca-Nunes A, Agudo A, Aranda N, Arija V, Cross AJ, Molina E, et al. (2015). Body iron status and gastric cancer risk in the EURGAST study. *Int J Cancer*. 137(12):2904–14. <http://dx.doi.org/10.1002/ijc.29669> PMID:26135329
- Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P (2014). *Helicobacter pylori* eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. *BMJ*. 348:g3174. <http://dx.doi.org/10.1136/bmj.g3174> PMID:24846275
- Forouhi NG, Koulman A, Sharp SJ, Imamura F, Kröger J, Schulze MB, et al. (2014). Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study. *Lancet Diabetes Endocrinol*. 2(10):810–8. [http://dx.doi.org/10.1016/S2213-8587\(14\)70146-9](http://dx.doi.org/10.1016/S2213-8587(14)70146-9) PMID:25107467
- Forstner AJ, Hofmann A, Maaser A, Sumer S, Khudayberdiev S, Mühleisen TW, et al. (2015). Genome-wide analysis implicates microRNAs and their target genes in the development of bipolar disorder. *Transl Psychiatry*. 5(11):e678. <http://dx.doi.org/10.1038/tp.2015.159> PMID:26556287
- Fortner RT, Ose J, Merritt MA, Schock H, Tjønneland A, Hansen L, et al. (2015). Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: results from the EPIC cohort. *Int J Cancer*. 137(5):1196–208. <http://dx.doi.org/10.1002/ijc.29471> PMID:25656413
- Fowke JH, McLerran DF, Gupta PC, He J, Shu XO, Ramadas K, et al. (2015). Associations of body mass index, smoking, and alcohol consumption with prostate cancer mortality in the Asia Cohort Consortium. *Am J Epidemiol*. 182(5):381–9. <http://dx.doi.org/10.1093/aje/kwv089> PMID:26243736
- Franceschi S (2014a). HPV and cancer: a unique opportunity for cancer prevention. *Bulletin Suisse du Cancer*. 3:191–2.
- Franceschi S (2014b). Intervention trials. In: Ahrens W, Pigeot I, editors. *Handbook of epidemiology*, 2nd edition. Berlin, Germany: Springer; pp. 365–88.
- Franceschi S (2015a). Past and future of prophylactic ablation of the cervical squamocolumnar junction. *Ecancermedicalscience*. 9:527. PMID:25987896
- Franceschi S (2015b). Embryonic cells in the squamous-columnar junction of the cervix: scope for prophylactic ablation? *Int J Cancer*. 136(5):989–90. <http://dx.doi.org/10.1002/ijc.29057> PMID:24990544
- Franceschi S, Baussano I (2014). Naturally acquired immunity against human papillomavirus (HPV): why it matters in the HPV vaccine era. *J Infect Dis*. 210(4):507–9. <http://dx.doi.org/10.1093/infdis/jiu143> PMID:24610878
- Franceschi S, Bray F (2014). Chronic conditions rising in low- and middle-income countries: the case of cancer control. In: Magrath I, editor. *Cancer Control 2014: Cancer care in emerging health systems*. Brussels, Belgium: International Network for Cancer Treatment and Research; pp. 17–23.
- Franceschi S, Combes JD, Dalstein V, Caudroy S, Clifford G, Gheit T, et al.; Study of Natural History of Human Papillomavirus Infection and Precancerous Lesions in the Tonsils (SPLIT) (2015). Deep brush-based cytology in tonsils resected for benign diseases. *Int J Cancer*. 137(12):2994–9. <http://dx.doi.org/10.1002/ijc.29660> PMID:26111735
- Franceschi S, Vaccarella S (2015). Thyroid cancer: an epidemic of disease or an epidemic of diagnosis? *Int J Cancer*. 136(11):2738–9. <http://dx.doi.org/10.1002/ijc.29311> PMID:25365909
- Frecha C, Chevalier SA, van Uden P, Rubio I, Siouda M, Saidj D, et al. (2015). Expression of the epidermodysplasia verruciformis-associated genes *EVER1* and *EVER2* is activated by exogenous DNA and inhibited by LMP1 oncoprotein from Epstein-Barr virus. *J Virol*. 89(2):1461–7. <http://dx.doi.org/10.1128/JVI.02936-14> PMID:25378492
- Freisling H, Ocké MC, Casagrande C, Nicolas G, Crispim SP, Niekerk M, et al. (2015). Comparison of two food record-based dietary assessment methods for a pan-European food consumption survey among infants, toddlers, and children using data quality indicators. *Eur J Nutr*. 54(3):437–45. <http://dx.doi.org/10.1007/s00394-014-0727-7> PMID:24916012
- Freisling H, Slimani N (2015). Challenges in estimating dietary acrylamide intake. In: Gökmen V, editor. *Acrylamide in food. Analysis, content and potential health effects*. Amsterdam, Netherlands: Elsevier; pp. 19–35.
- Fu YP, Kohaar I, Moore LE, Lenz P, Figueroa JD, Tang W, et al. (2014). The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease. *Cancer Res*. 74(20):5808–18. <http://dx.doi.org/10.1158/0008-5472.CAN-14-1531> PMID:25320178
- Gadgil A, Sauvaget C, Roy N, Grosse Frie K, Chakraborty A, Lucas E, et al. (2015). Breast cancer awareness among middle class urban women – a community-based study from Mumbai, India. *Asian Pac J Cancer Prev*. 16(15):6249–54. PMID:26434824
- Galanter JM, Gignoux CR, Torgerson DG, Roth LA, Eng C, Oh SS, et al. (2014). Genome-wide association study and admixture mapping identify different asthma-associated loci in Latinos: the Genes-environments & Admixture in Latino Americans study. *J Allergy Clin Immunol*. 134(2):295–305. <http://dx.doi.org/10.1016/j.jaci.2013.08.055> PMID:24406073
- Galeone C, Turati F, Zhang ZF, Guercio V, Tavani A, Serraino D, et al. (2015). Relation of allium vegetables intake with head and neck cancers: evidence from the INHANCE consortium. *Mol Nutr Food Res*. 59(9):1641–50. <http://dx.doi.org/10.1002/mnfr.201500042> PMID:26018663
- Gallus S, Lugo A, Fernandez E, Gilmore AB, Leon ME, Clancy L, et al. (2014a). Support for a tobacco endgame strategy in 18 European countries. *Prev Med*. 67:255–8. <http://dx.doi.org/10.1016/j.ypmed.2014.08.001> PMID:25117519

- Gallus S, Lugo A, La Vecchia C, Boffetta P, Chaloupka FJ, Colombo P, et al. (2014b). Pricing Policies And Control of Tobacco in Europe (PPACTE) project: cross-national comparison of smoking prevalence in 18 European countries. *Eur J Cancer Prev.* 23(3):177–85. <http://dx.doi.org/10.1097/CEJ.000000000000009> PMID: 24441832
- Gavin A, Rous B, Marcos-Gragera R, Middleton R, Steliarova-Foucher E, Maynadie M, et al.; European Network of Cancer Registries (2015). Towards optimal clinical and epidemiological registration of haematological malignancies: guidelines for recording progressions, transformations and multiple diagnoses. *Eur J Cancer.* 51(9):1109–22. <http://dx.doi.org/10.1016/j.ejca.2014.02.008> PMID: 24630945
- GBD 2013 Mortality and Causes of Death Collaborators (2015). Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet.* 385(9963):117–71. [http://dx.doi.org/10.1016/S0140-6736\(14\)61682-2](http://dx.doi.org/10.1016/S0140-6736(14)61682-2) PMID: 25530442
- Ghantous A, Hernandez-Vargas H, Byrnes G, Dwyer T, Herceg Z (2015). Characterising the epigenome as a key component of the fetal exposome in evaluating in utero exposures and childhood cancer risk. *Mutagenesis.* 30(6):733–42. <http://dx.doi.org/10.1093/mutage/gev010> PMID:25724893
- Ghantous A, Saffery R, Cros MP, Ponsonby AL, Hirschfeld S, Kasten C, et al. (2014). Optimized DNA extraction from neonatal dried blood spots: application in methylome profiling. *BMC Biotechnol.* 14(1):60. <http://dx.doi.org/10.1186/1472-6750-14-60> PMID:24980254
- Gheit T, Abedi-Ardekani B, Carreira C, Missad CG, Tommasino M, Torrente MC (2014). Comprehensive analysis of HPV expression in laryngeal squamous cell carcinoma. *J Med Virol.* 86(4):642–6. <http://dx.doi.org/10.1002/jmv.23866> PMID:24374907
- Ghittoni R, Accardi R, Chiocca S, Tommasino M (2015). Role of human papillomaviruses in carcinogenesis. *Ecancermedicalscience.* 9:526. <http://dx.doi.org/10.3332/ecancer.2015.526> PMID: 25987895
- Ghoussaini M, Edwards SL, Michailidou K, Nord S, Cowper-Sal Lari R, Desai K, et al.; Australian Ovarian Cancer Management Group (2014). Evidence that breast cancer risk at the 2q35 locus is mediated through *IGFBP5* regulation. *Nat Commun.* 4:4999. <http://dx.doi.org/10.1038/ncomms5999> PMID: 25248036
- Giacomazzi J, Graudenz MS, Osorio CA, Koehler-Santos P, Palmero EI, Zagonel-Oliveira M, et al. (2014). Prevalence of the *TP53* p.R337H mutation in breast cancer patients in Brazil. *PLoS ONE.* 9(6):e99893. <http://dx.doi.org/10.1371/journal.pone.0099893> PMID:24936644
- Gillison ML, Castellsagué X, Chaturvedi A, Goodman MT, Snijders P, Tommasino M, et al. (2014). Eurogin Roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. *Int J Cancer.* 134(3):497–507. <http://dx.doi.org/10.1002/ijc.28201> PMID:23568556
- Gimeno-Santos E, Frei A, Steurer-Stey C, de Batlle J, Rabinovich RA, Raste Y, et al.; PROactive Consortium (2014). Determinants and outcomes of physical activity in patients with COPD: a systematic review. *Thorax.* 69(8):731–9. <http://dx.doi.org/10.1136/thoraxjnl-2013-204763> PMID:24558112
- Giuliano AR, Nyitray AG, Kreimer AR, Pierce Campbell CM, Goodman MT, Sudenga SL, et al. (2015). EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. *Int J Cancer.* 136(12):2752–60. <http://dx.doi.org/10.1002/ijc.29082> PMID:25043222
- Glubb DM, Maranian MJ, Michailidou K, Pooley KA, Meyer KB, Kar S, et al.; GENICA Network; kConFab Investigators; Norwegian Breast Cancer Study (2015). Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating *MAP3K1*. *Am J Hum Genet.* 96(1):5–20. <http://dx.doi.org/10.1016/j.ajhg.2014.11.009> PMID:25529635
- Gonzalez P, Hildesheim A, Herrero R, Katki H, Wacholder S, Porras C, et al.; Costa Rica HPV Vaccine Trial (CVT) Group (2015). Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. *Vaccine.* 33(18):2141–51. <http://dx.doi.org/10.1016/j.vaccine.2015.03.015> PMID:25796338
- Gonzalez-Casanova I, Stein AD, Hao W, Garcia-Feregrino R, Barraza-Villarreal A, Romieu I, et al. (2015). Prenatal supplementation with docosahexaenoic acid has no effect on growth through 60 months of age. *J Nutr.* 145(6):1330–4. <http://dx.doi.org/10.3945/jn.114.203570> PMID: 25926416
- González-Horta C, Ballinas-Casarrubias L, Sánchez-Ramírez B, Ishida MC, Barrera-Hernández A, Gutiérrez-Torres D, et al. (2015). A concurrent exposure to arsenic and fluoride from drinking water in Chihuahua, Mexico. *Int J Environ Res Public Health.* 12(5):4587–601. <http://dx.doi.org/10.3390/ijerph120504587> PMID:25918912
- Govsig CF, Huusom LD, Deltour I, Andersen KK, Duun-Henriksen AK, Madsen EM, et al. (2015). Role of human papillomavirus testing and cytology in follow-up after conization. *Acta Obstet Gynecol Scand.* 94(4):405–11. <http://dx.doi.org/10.1111/aogs.12601> PMID:25645089
- Greenop KR, Miller M, Bailey HD, de Klerk NH, Attia J, Kellie SJ, et al. (2015a). Childhood folate, B6, B12, and food group intake and the risk of childhood brain tumors: results from an Australian case-control study. *Cancer Causes Control.* 26(6):871–9. <http://dx.doi.org/10.1007/s10552-015-0562-z> PMID:25791129
- Greenop KR, Miller M, Bailey HD, Scott RJ, Attia J, Bower C, et al. (2015b). Paternal dietary folate, B6 and B12 intake, and the risk of childhood brain tumors. *Nutr Cancer.* 67(2):224–30. <http://dx.doi.org/10.1080/01635581.2015.990571> PMID:25625505
- Greenop KR, Peters S, Fritschi L, Glass DC, Ashton LJ, Bailey HD, et al. (2014a). Exposure to household painting and floor treatments, and parental occupational paint exposure and risk of childhood brain tumors: results from an Australian case-control study. *Cancer Causes Control.* 25(3):283–91. <http://dx.doi.org/10.1007/s10552-013-0330-x> PMID: 24337771
- Greenop KR, Peters S, Fritschi L, Glass DC, Ashton LJ, Bailey HD, et al. (2014b). Erratum to: Exposure to household painting and floor treatments, and parental occupational paint exposure and risk of childhood brain tumors: results from an Australian case-control study. *Cancer Causes Control.* 25(9):1241–2. <http://dx.doi.org/10.1007/s10552-014-0419-x>
- Grell K, Diggle PJ, Frederiksen K, Schüz J, Cardis E, Andersen PK (2015). A three-dimensional point process model for the spatial distribution of disease occurrence in relation to an exposure source. *Stat Med.* 34(23):3170–80. <http://dx.doi.org/10.1002/sim.6538> PMID:26011698

- Grosse Y, Loomis D, Guyton KZ, Lauby-Secretan B, El Ghissassi F, Bouvard V, et al.; International Agency for Research on Cancer Monograph Working Group (2014). Carcinogenicity of fluorene, silicon carbide fibres and whiskers, and carbon nanotubes. *Lancet Oncol.* 15(13):1427–8. [http://dx.doi.org/10.1016/S1470-2045\(14\)71109-X](http://dx.doi.org/10.1016/S1470-2045(14)71109-X) PMID:25499275
- Guevara E, Baena A, Almonte M, Salaza JE, Gaviria A, Sanchez GI (2014). Reproducibilidad en la lectura de un set de placas de citología cérvico-uterinas en cuatro centros especializados de Medellín, Antioquia. *Revista Facultad Nacional de Salud Publica.* 32(2):54–60.
- Guha N, Baan RA, Straif K (2014a). Electromagnetic fields. In: Landrigan PJ, Etzel RA, editors. *Textbook of children's environmental health.* Oxford University Press USA; pp. 383–96.
- Guha N, Warnakulasuriya S, Vlaanderen J, Straif K (2014b). Betel quid chewing and the risk of oral and oropharyngeal cancers: a meta-analysis with implications for cancer control. *Int J Cancer.* 135(6):1433–43. <http://dx.doi.org/10.1002/ijc.28643> PMID:24302487
- Guillot C, Favaudon V, Herceg Z, Sagne C, Sauvaigo S, Merle P, et al. (2014a). PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in *in vitro* hepatocellular carcinoma models. *BMC Cancer.* 14(1):603. <http://dx.doi.org/10.1186/1471-2407-14-603> PMID:25139788
- Guillot C, Hall J, Herceg Z, Merle P, Chemin I (2014b). Update on hepatocellular carcinoma breakthroughs: poly(ADP-ribose) polymerase inhibitors as a promising therapeutic strategy. *Clin Res Hepatol Gastroenterol.* 38(2):137–42. <http://dx.doi.org/10.1016/j.clinre.2013.07.006> PMID:23953496
- Guo X, Long J, Zeng C, Michailidou K, Ghoussaini M, Bolla MK, et al.; kConFab Investigators (2015). Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk. *Cancer Epidemiol Biomarkers Prev.* 24(11):1680–91. <http://dx.doi.org/10.1158/1055-9965.EPI-15-0363> PMID:26354892
- Guyton KZ, Loomis D, Grosse Y, El Ghissassi F, Benbrahim-Tallaa L, Guha N, et al.; International Agency for Research on Cancer Monograph Working Group (2015). Carcinogenicity of tetrachlorvinphos, parathion, malathion, diazinon, and glyphosate. *Lancet Oncol.* 16(5):490–1. [http://dx.doi.org/10.1016/S1470-2045\(15\)70134-8](http://dx.doi.org/10.1016/S1470-2045(15)70134-8) PMID:25801782
- Hampras SS, Giuliano AR, Lin HY, Fisher KJ, Abrahamsen ME, McKay-Chopin S, et al. (2015). Natural history of polyomaviruses in men: the HPV infection in men (HIM) study. *J Infect Dis.* 211(9):1437–46. <http://dx.doi.org/10.1093/infdis/jiu626> PMID:25387582
- Hampras SS, Giuliano AR, Lin HY, Fisher KJ, Abrahamsen ME, Sirak BA, et al. (2014). Natural history of cutaneous human papillomavirus (HPV) infection in men: the HIM study. *PLoS ONE.* 9(9):e104843. <http://dx.doi.org/10.1371/journal.pone.0104843> PMID:25198694
- Hampras SS, Michel A, Schmitt M, Waterboer T, Kranz L, Gheit T, et al. (2015). Merkel cell polyomavirus (MCV) T-antigen seroreactivity, MCV DNA in eyebrow hairs, and squamous cell carcinoma. *Infect Agent Cancer.* 10(1):35. <http://dx.doi.org/10.1186/s13027-015-0030-0> PMID:26483848
- Hamra GB, Guha N, Cohen A, Laden F, Raaschou-Nielsen O, Samet JM, et al. (2014a). Outdoor particulate matter exposure and lung cancer: a systematic review and meta-analysis. *Environ Health Perspect.* 122(9):906–11. PMID:24911630
- Hamra GB, Laden F, Cohen AJ, Raaschou-Nielsen O, Brauer M, Loomis D (2015). Lung cancer and exposure to nitrogen dioxide and traffic: a systematic review and meta-analysis. *Environ Health Perspect.* 123(11):1107–12. <http://dx.doi.org/10.1289/ehp.1408882> PMID:25870974
- Hamra GB, Loomis D, Dement J (2014b). Examining the association of lung cancer and highly correlated fibre size-specific asbestos exposures with a hierarchical Bayesian model. *Occup Environ Med.* 71(5):353–7. <http://dx.doi.org/10.1136/oemed-2013-101965> PMID:24569623
- Hamra GB, MacLehose R, Richardson D, Bertke S, Daniels RD (2014c). Modelling complex mixtures in epidemiologic analysis: additive versus relative measures for differential effectiveness. *Occup Environ Med.* 71(2):141–6. <http://dx.doi.org/10.1136/oemed-2013-101665> PMID:24213566
- Hamra GB, Semelka RC, Burke LM, Pate V, Brookhart MA (2014d). Trends in diagnostic CT among fee-for-service enrollees, 2000–2011. *J Am Coll Radiol.* 11(2):125–30. <http://dx.doi.org/10.1016/j.jacr.2013.07.014> PMID:24035504
- Hansch RA, Cherne SL, Sow PS, Winer RL, Hughes JP, Feng Q, et al.; University of Washington-Dakar HIV and Cervical Cancer Study Group (2014). Human papillomavirus type 16 viral load in relation to HIV infection, cervical neoplasia and cancer in Senegal. *Cancer Epidemiol.* 38(4):369–75. <http://dx.doi.org/10.1016/j.canep.2014.04.005> PMID:24852136
- Hanly P, Soerjomataram I, Sharp L (2015). Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe. *Int J Cancer.* 136(4):E136–45. <http://dx.doi.org/10.1002/ijc.29105> PMID:25066804
- Hashemian M, Poustchi H, Abnet CC, Boffetta P, Dawsey SM, Brennan PJ, et al. (2015). Dietary intake of minerals and risk of esophageal squamous cell carcinoma: results from the Golestan Cohort Study. *Am J Clin Nutr.* 102(1):102–8. <http://dx.doi.org/10.3945/ajcn.115.107847> PMID:26016858
- Hebestreit A, Börnhorst C, Barba G, Siani A, Huybrechts I, Tognon G, et al. (2014). Associations between energy intake, daily food intake and energy density of foods and BMI z-score in 2–9-year-old European children. *Eur J Nutr.* 53(2):673–81. <http://dx.doi.org/10.1007/s00394-013-0575-x> PMID:24061347
- Hedley C, Sriraksa R, Showell R, Van Noorden S, El-Bahrawy M (2014). The frequency and significance of WT-1 expression in serous endometrial carcinoma. *Hum Pathol.* 45(9):1879–84. <http://dx.doi.org/10.1016/j.humpath.2014.05.009> PMID:25033726
- Henrickson MY, Purdum MP, Scelo G, Broderick P, Frampton M, Ritchie A, et al. (2015). Common variation at 1q24.1 (*ALDH9A1*) is a potential risk factor for renal cancer. *PLoS ONE.* 10(3):e0122589. <http://dx.doi.org/10.1371/journal.pone.0122589> PMID:25826619
- Herceg Z (2014). Cancer prevention potential of diet and dietary supplements in epigenome modulation. In: Mahabir S, Pathak YV, editors. *Nutraceuticals and health: review of human evidence.* Boca Raton (FL), USA: CRC Press; pp. 43–70.
- Hernandez C, Aibar J, de Battlle J, Gomez-Cabrero D, Soler N, Duran-Tauleria E, et al.; NEXES Consortium (2015). Assessment of health status and program performance in patients on long-term oxygen therapy. *Respir Med.* 109(4):500–9. <http://dx.doi.org/10.1016/j.rmed.2015.01.005> PMID:25771036



- Hernandez-Vargas H, Castelino J, Silver MJ, Dominguez-Salas P, Cros MP, Durand G, et al. (2015). Exposure to aflatoxin B<sub>1</sub> *in utero* is associated with DNA methylation in white blood cells of infants in The Gambia. *Int J Epidemiol*. 44(4):1238–48. <http://dx.doi.org/10.1093/ije/dyv027> PMID:25855716
- Herrero R, González P, Markowitz LE (2015). Present status of human papillomavirus vaccine development and implementation. *Lancet Oncol*. 16(5):e206–16. [http://dx.doi.org/10.1016/S1470-2045\(14\)70481-4](http://dx.doi.org/10.1016/S1470-2045(14)70481-4) PMID:25943065
- Herrero R, Park JY, Forman D (2014b). The fight against gastric cancer – the IARC Working Group report. *Best Pract Res Clin Gastroenterol*. 28(6):1107–14. <http://dx.doi.org/10.1016/j.bpg.2014.10.003> PMID:25439075
- Herrero R, Parsonnet J, Greenberg ER (2014a). Prevention of gastric cancer. *JAMA*. 312(12):1197–8. <http://dx.doi.org/10.1001/jama.2014.10498> PMID:25247512
- Hosnijeh FS, Lan Q, Rothman N, San Liu C, Cheng WL, Nieters A, et al. (2014a). Mitochondrial DNA copy number and future risk of B-cell lymphoma in a nested case-control study in the prospective EPIC cohort. *Blood*. 124(4):530–5. <http://dx.doi.org/10.1182/blood-2013-10-532085> PMID:24899624
- Hosnijeh FS, Matullo G, Russo A, Guarrera S, Modica F, Nieters A, et al. (2014b). Prediagnostic telomere length and risk of B-cell lymphoma – results from the EPIC cohort study. *Int J Cancer*. 135(12):2910–7. <http://dx.doi.org/10.1002/ijc.28934> PMID:24771230
- Huang YH, Zhang ZF, Tashkin DP, Feng B, Straif K, Hashibe M (2015). An epidemiologic review of marijuana and cancer: an update. *Cancer Epidemiol Biomarkers Prev*. 24(1):15–31. <http://dx.doi.org/10.1158/1055-9965.EPI-14-1026> PMID:25587109
- Hughes DJ, Fedirko V, Jenab M, Schomburg L, Méplan C, Freisling H, et al. (2015). Selenium status is associated with colorectal cancer risk in the European Prospective Investigation of Cancer and Nutrition cohort. *Int J Cancer*. 136(5):1149–61. <http://dx.doi.org/10.1002/ijc.29071> PMID:25042282
- Hung RJ, Ulrich CM, Goode EL, Brhane Y, Muir K, Chan AT, et al.; for GECCO; for FOCI; for CORECT; for DRIVE; GAME-ON Network (2015). Cross cancer genomic investigation of inflammation pathway for five common cancers: lung, ovary, prostate, breast, and colorectal cancer. *J Natl Cancer Inst*. 107(11):djv246. <http://dx.doi.org/10.1093/jnci/djv246> PMID:26319099
- Huoi C, Olsson A, Lightfoot T, Roman E, Clavel J, Lacour B, et al. (2014). Parental occupational exposure and risk of childhood central nervous system tumors: a pooled analysis of case-control studies from Germany, France, and the UK. *Cancer Causes Control*. 25(12):1603–13. <http://dx.doi.org/10.1007/s10552-014-0465-4> PMID:25281325
- Huybrechts I, Beirlaen C, De Vriendt T, Slimani N, Pisa PT, Schoupe E, et al. (2014a). Validity of instruction leaflets for parents to measure their child's weight and height at home: results obtained from a randomised controlled trial. *BMJ Open*. 4(2):e003768. <http://dx.doi.org/10.1136/bmjopen-2013-003768> PMID:24508849
- Huybrechts I, De Vriendt T, Breidenassel C, Rogiers J, Vanaelst B, Cuenca-García M, et al.; HELENA Study Group (2014b). Mechanisms of stress, energy homeostasis and insulin resistance in European adolescents – the HELENA study. *Nutr Metab Cardiovasc Dis*. 24(10):1082–9. <http://dx.doi.org/10.1016/j.numecd.2014.04.014> PMID:24907850
- Iannacone MR, Gheit T, Pfister H, Giuliano AR, Messina JL, Fenske NA, et al. (2014). Case-control study of genus-beta human papillomaviruses in plucked eyebrow hairs and cutaneous squamous cell carcinoma. *Int J Cancer*. 134(9):2231–44. <http://dx.doi.org/10.1002/ijc.28552> PMID:24136717
- Ichim G, Mola M, Finkbeiner MG, Cros MP, Herceg Z, Hernandez-Vargas H (2014). The histone acetyltransferase component TRRAP is targeted for destruction during the cell cycle. *Oncogene*. 33(2):181–92. <http://dx.doi.org/10.1038/onc.2012.570> PMID:23318449
- Igartua C, Myers RA, Mathias RA, Pino-Yanes M, Eng C, Graves PE, et al. (2015). Ethnic-specific associations of rare and low-frequency DNA sequence variants with asthma. *Nat Commun*. 6:5965. <http://dx.doi.org/10.1038/ncomms6965> PMID:25591454
- Iglesia I, Mouratidou T, González-Gross M, Novakovic R, Breidenassel C, Jiménez-Pavón D, et al.; HELENA Study Group (2014). Socioeconomic factors are associated with folate and vitamin B12 intakes and related biomarkers concentrations in European adolescents: the Healthy Lifestyle in Europe by Nutrition in Adolescence study. *Nutr Res*. 34(3):199–209. <http://dx.doi.org/10.1016/j.nutres.2014.01.006> PMID:24655486
- Illner AK, Lachat C, Slimani N (2014). Assessing food intake through a chest-worn camera device. *Public Health Nutr*. 17(8):1669–70. <http://dx.doi.org/10.1017/S136889001400130X> PMID:24983427
- Inamasu T, Schonfeld SJ, Abe M, Bidstrup PE, Deltour I, Ishida T, et al. (2015). Meeting report: suggestions for studies on future health risks following the Fukushima accident. *Environ Health*. 14(1):26. <http://dx.doi.org/10.1186/s12940-015-0013-z> PMID:25889395
- InterAct Consortium (2014). Adherence to predefined dietary patterns and incident type 2 diabetes in European populations: EPIC-InterAct Study. *Diabetologia*. 57(2):321–33. <http://dx.doi.org/10.1007/s00125-013-3092-9> PMID:24196190
- Iqbal B, Shah IA, Bhat GA, Bhat AB, Rafiq R, Nabi S, et al. (2015). Impediments in foreign collaboration and conducting a high throughput molecular epidemiology research in India, an assessment from a feasibility study. *Springerplus*. 4(1):287. <http://dx.doi.org/10.1186/s40064-015-1046-z> PMID:26120504
- Islami F, Nasseri-Moghaddam S, Pourshams A, Poustchi H, Semnani S, Kamangar F, et al. (2014a). Determinants of gastroesophageal reflux disease, including hookah smoking and opium use – a cross-sectional analysis of 50,000 individuals. *PLoS ONE*. 9(2):e89256. <http://dx.doi.org/10.1371/journal.pone.0089256> PMID:24586635
- Islami F, Pourshams A, Nasseri-Moghaddam S, Khademi H, Poustchi H, Khoshnia M, et al. (2014b). Gastroesophageal reflux disease and overall and cause-specific mortality: a prospective study of 50000 individuals. *Middle East J Dig Dis*. 6(2):65–80. PMID:24872865
- Izetti P, Hautefeuille A, Abujamra AL, de Farias CB, Giacomazzi J, Alemar B, et al. (2014). PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. *Invest New Drugs*. 32(5):783–94. <http://dx.doi.org/10.1007/s10637-014-0090-9> PMID:24838627
- Jacxsens L, Ibañez IC, Gómez-López VM, Fernandes JA, Allende A, Uyttendaele M, et al. (2015). Belgian and Spanish consumption data and consumer handling practices for fresh fruits and vegetables useful for further microbiological and chemical exposure assessment. *J Food Prot*. 78(4):784–95. <http://dx.doi.org/10.4315/0362-028X.JFP-14-376> PMID:25836406
- Jelaković B, Castells X, Tomić K, Ardin M, Karanović S, Zavadil J (2015). Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid. *Int J Cancer*. 136(12):2967–72. <http://dx.doi.org/10.1002/ijc.29338> PMID:25403517

- Jemal A, Lortet-Tieulent J, Bray F (2014). Reply from authors re: Lambertus A. Kiemeneij. The global risk of bladder cancer: let's just do something about it! *Eur Urol* 2014;66:74–5. <http://dx.doi.org/10.1016/j.eururo.2013.12.028> PMID:24411280
- Jemal A, Vineis P, Bray F, Torre L, Forman D (2015). The cancer atlas, 2nd edition. Atlanta (GA), USA: American Cancer Society.
- Jeumink SM, Ros MM, Leenders M, van Duijnhoven FJ, Siersema PD, Jansen EH, et al. (2015). Plasma carotenoids, vitamin C, retinol and tocopherols levels and pancreatic cancer risk within the European Prospective Investigation into Cancer and Nutrition: a nested case-control study: plasma micronutrients and pancreatic cancer risk. *Int J Cancer*. 136(6):E665–76. <http://dx.doi.org/10.1002/ijc.29175> PMID:25175624
- Jhuranya A, Velkova A, Johnson RC, Kessing B, Carvalho RS, Whitley P, et al.; Evidence-based Network for the Interpretation of Germline Mutant Alleles Consortium (2015). BRCA1 Circos: a visualisation resource for functional analysis of missense variants. *J Med Genet*. 52(4):224–30. <http://dx.doi.org/10.1136/jmedgenet-2014-102766> PMID:25643705
- Ji X, Gui J, Han Y, Brennan P, Li Y, McKay J, et al. (2015). The role of haplotype in 15q25.1 locus in lung cancer risk: results of scanning chromosome 15. *Carcinogenesis*. 36(11):1275–83. <http://dx.doi.org/10.1093/carcin/bgv118> PMID:26282330
- Jiron J, Sethi S, Ali-Fehmi R, Franceschi S, Struijk L, van Doorn LJ, et al. (2014). Racial disparities in human papillomavirus (HPV) associated head and neck cancer. *Am J Otolaryngol*. 35(2):147–53. <http://dx.doi.org/10.1016/j.amjoto.2013.09.004> PMID:24209992
- Johansson M, Fanidi A, Muller DC, Bassett JK, Midttun Ø, Vollset SE, et al. (2014). Circulating biomarkers of one-carbon metabolism in relation to renal cell carcinoma incidence and survival. *J Natl Cancer Inst*. 106(12):dju327. <http://dx.doi.org/10.1093/jnci/dju327> PMID:25376861
- Johnson N, Dudbridge F, Orr N, Gibson L, Jones ME, Schoemaker MJ, et al.; GENICA (Gene Environment Interaction and Breast Cancer in Germany) Network; kConFab Investigators; Australian Ovarian Cancer Study Group (2014). Genetic variation at *CYP3A* is associated with age at menarche and breast cancer risk: a case-control study. *Breast Cancer Res*. 16(3):R51. <http://dx.doi.org/10.1186/bcr3662> PMID:24887515
- Joshi S, Babu JM, Jayalakshmi D, Kulkarni V, Divate U, Muwonge R, et al. (2014). Human papillomavirus infection among human immunodeficiency virus-infected women in Maharashtra, India. *Vaccine*. 32(9):1079–85. <http://dx.doi.org/10.1016/j.vaccine.2013.12.060> PMID:24397900
- Julián-Almárcegui C, Gómez-Cabello A, Huybrechts I, González-Agüero A, Kaufman JM, Casajús JA, et al. (2015). Combined effects of interaction between physical activity and nutrition on bone health in children and adolescents: a systematic review. *Nutr Rev*. 73(3):127–39. <http://dx.doi.org/10.1093/nutrit/nuu065> PMID:26024536
- Julián Almárcegui C, Huybrechts I, Gómez Bruton A, Matute Llorente Á, González Agüero A, Gómez Cabello A, et al. (2015). Validity of a food-frequency questionnaire for estimating calcium intake in adolescent swimmers. *Nutr Hosp*. 32(04):1773–9. PMID:26545549
- Kaaks R, Johnson T, Tikk K, Sookthai D, Tjønneland A, Roswall N, et al. (2014a). Insulin-like growth factor I and risk of breast cancer by age and hormone receptor status – a prospective study within the EPIC cohort. *Int J Cancer*. 134(11):2683–90. <http://dx.doi.org/10.1002/ijc.28589> PMID:24248481
- Kaaks R, Sookthai D, Hemminki K, Krämer A, Boeing H, Wirfält E, et al. (2014b). Risk factors for cancers of unknown primary site: results from the prospective EPIC cohort. *Int J Cancer*. 135(10):2475–81. <http://dx.doi.org/10.1002/ijc.28874> PMID:24692151
- Kaaks R, Sookthai D, Łuczynska A, Oakes CC, Becker S, Johnson T, et al. (2015). Lag times between lymphoproliferative disorder and clinical diagnosis of chronic lymphocytic leukemia: a prospective analysis using plasma soluble CD23. *Cancer Epidemiol Biomarkers Prev*. 24(3):538–45. <http://dx.doi.org/10.1158/1055-9965.EPI-14-1107> PMID:25542829
- Kaaks R, Tikk K, Sookthai D, Schock H, Johnson T, Tjønneland A, et al. (2014c). Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status – results from the EPIC cohort. *Int J Cancer*. 134(8):1947–57. <http://dx.doi.org/10.1002/ijc.28528> PMID:24155248
- Karalexi MA, Papatoma P, Thomopoulos TP, Ryzhov A, Zborovskaya A, Dimitrova N, et al. (2015). Childhood central nervous system tumour mortality and survival in Southern and Eastern Europe (1983–2014): gaps persist across 14 cancer registries. *Eur J Cancer*. 51(17):2665–77. <http://dx.doi.org/10.1016/j.ejca.2015.08.018> PMID:26343313
- Karanović S, Tomić K, Dittrich D, Borovečki F, Zavadil J, Vuković-Lela I, et al. (2014). Endemic (Balkan) nephropathy is aristolochic acid nephropathy. *Prilozi*. 35(1):43–6. PMID:24798595
- Kay A, Melo da Silva E, Pedreira H, Negreiros S, Lobato C, Braga W, et al. (2014). HBV/HDV co-infection in the Western Brazilian Amazonia: an intriguing mutation among HDV genotype 3 carriers. *J Viral Hepat*. 21(12):921–4. <http://dx.doi.org/10.1111/jvh.12267> PMID:25040045
- Keeley BR, Islami F, Pourshams A, Poustchi H, Pak JS, Brennan P, et al. (2014). Prediagnostic serum levels of inflammatory biomarkers are correlated with future development of lung and esophageal cancer. *Cancer Sci*. 105(9):1205–11. <http://dx.doi.org/10.1111/cas.12485> PMID:25040886
- Kelly RS, Roulland S, Morgado E, Sungalee S, Jouve N, Tumino R, et al. (2015). Determinants of the t(14;18) translocation and their role in t(14;18)-positive follicular lymphoma. *Cancer Causes Control*. 26(12):1845–55. <http://dx.doi.org/10.1007/s10552-015-0677-2> PMID:26424368
- Kengne AP, Beulens JW, Peelen LM, Moons KG, van der Schouw YT, Schulze MB, et al. (2014). Non-invasive risk scores for prediction of type 2 diabetes (EPIC-InterAct): a validation of existing models. *Lancet Diabetes Endocrinol*. 2(1):19–29. [http://dx.doi.org/10.1016/S2213-8587\(13\)70103-7](http://dx.doi.org/10.1016/S2213-8587(13)70103-7) PMID:24622666
- Key TJ, Appleby PN, Reeves GK, Travis RC, Brinton LA, Helzlsouer KJ, et al.; Endogenous Hormones and Breast Cancer Collaborative Group (2015). Steroid hormone measurements from different types of assays in relation to body mass index and breast cancer risk in postmenopausal women: reanalysis of eighteen prospective studies. *Steroids*. 99 Pt A: 49–55. <http://dx.doi.org/10.1016/j.steroids.2014.09.001> PMID:25304359
- Key TJ, Appleby PN, Travis RC, Albanes D, Alberg AJ, Barricarte A, et al.; Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group (2015). Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies. *Am J Clin Nutr*. 102(5):1142–57. <http://dx.doi.org/10.3945/ajcn.115.114306> PMID:26447150
- Khuhaprema T, Sangrajrang S, Lalitwongsa S, Chokvanitphong V, Raunroadroong T, Ratanachu-Ek T, et al. (2014). Organised colorectal cancer screening in Lampang Province, Thailand: preliminary results from a pilot implementation programme. *BMJ Open*. 4(1):e003671. <http://dx.doi.org/10.1136/bmjopen-2013-003671> PMID:24435889

- Kim CH, Lee YC, Hung RJ, McNallan SR, Cote ML, Lim WY, et al. (2014b). Exposure to secondhand tobacco smoke and lung cancer by histological type: a pooled analysis of the International Lung Cancer Consortium (ILCCO). *Int J Cancer*. 135(8):1918–30. <http://dx.doi.org/10.1002/ijc.28835> PMID:24615328
- Kim YH, Ohta T, Oh JE, Le Calvez-Kelm F, McKay J, Voegelé C, et al. (2014a). *TP53*, *MSH4*, and *LATS1* germline mutations in a family with clustering of nervous system tumors. *Am J Pathol*. 184(9):2374–81. <http://dx.doi.org/10.1016/j.ajpath.2014.05.017> PMID:25041856
- Koester-Weber T, Valtueña J, Breidenassel C, Beghin L, Plada M, Moreno S, et al. (2014). Reference values for leptin, cortisol, insulin and glucose, among European adolescents and their association with adiposity: the HELENA study. *Nutr Hosp*. 30(5):1181–90. PMID:25365025
- Kracker S, Di Virgilio M, Schwartzentruber J, Cuenin C, Forveille M, Deau MC, et al. (2015). An inherited immunoglobulin class-switch recombination deficiency associated with a defect in the INO80 chromatin remodeling complex. *J Allergy Clin Immunol*. 135(4):998–1007.e6. <http://dx.doi.org/10.1016/j.jaci.2014.08.030> PMID:25312759
- Krais AM, Mühlbauer KR, Kucab JE, Chinbuah H, Cornelius MG, Wei QX, et al. (2015). Comparison of the metabolic activation of environmental carcinogens in mouse embryonic stem cells and mouse embryonic fibroblasts. *Toxicol In Vitro*. 29(1):34–43. <http://dx.doi.org/10.1016/j.tiv.2014.09.004> PMID:25230394
- Kreimer AR, Brennan P, Lang Kuhs KA, Waterboer T, Clifford G, Franceschi S, et al. (2015b). Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European Prospective Investigation into Cancer and Nutrition study. *J Clin Oncol*. 33(8):877–84. <http://dx.doi.org/10.1200/JCO.2014.57.8435> PMID:25667279
- Kreimer AR, Johansson M, Hildesheim A, Pawlita M, Brennan P (2014). Reply to P.E. Castle. *J Clin Oncol*. 32(4):361–2. <http://dx.doi.org/10.1200/JCO.2013.53.2697> PMID:24366940
- Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, et al.; Costa Rica Vaccine Trial and PATRICIA study groups (2015a). Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. *Lancet Oncol*. 16(7):775–86. [http://dx.doi.org/10.1016/S1470-2045\(15\)00047-9](http://dx.doi.org/10.1016/S1470-2045(15)00047-9) PMID:26071347
- Krille L, Dreger S, Schindel R, Albrecht T, Asmussen M, Barkhausen J, et al. (2015). Risk of cancer incidence before the age of 15 years after exposure to ionising radiation from computed tomography: results from a German cohort study. *Radiat Environ Biophys*. 54(1):1–12. <http://dx.doi.org/10.1007/s00411-014-0580-3> PMID:25567615
- Krishnan S, Dhillon PK, Bhadelia A, Schurmann A, Basu P, Bhatla N, et al. (2015). Report from a symposium on catalyzing primary and secondary prevention of cancer in India. *Cancer Causes Control*. 26(11):1671–84. <http://dx.doi.org/10.1007/s10552-015-0637-x> PMID:26335262
- Krishnan S, Sivaram S, Anderson BO, Basu P, Belinson JL, Bhatla N, et al. (2015). Using implementation science to advance cancer prevention in India. *Asian Pac J Cancer Prev*. 16(9):3639–44. <http://dx.doi.org/10.7314/APJCP.2015.16.9.3639> PMID:25987015
- Kuasas H, Cólus IM, Busso AF, Hernandez-Vargas H, Barros-Filho MC, Marchi FA, et al. (2015). Genome-wide methylation and transcriptome analysis in penile carcinoma: uncovering new molecular markers. *Clin Epigenetics*. 7(1):46. <http://dx.doi.org/10.1186/s13148-015-0082-4> PMID:25908946
- Kyrø C, Olsen A, Bueno-de-Mesquita HB, Skeie G, Loft S, Åman P, et al. (2014b). Plasma alkylresorcinol concentrations, biomarkers of whole-grain wheat and rye intake, in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. *Br J Nutr*. 111(10):1881–90. <http://dx.doi.org/10.1017/S0007114513004388> PMID:24521535
- Kyrø C, Olsen A, Landberg R, Skeie G, Loft S, Åman P, et al. (2014a). Plasma alkylresorcinols, biomarkers of whole-grain wheat and rye intake, and incidence of colorectal cancer. *J Natl Cancer Inst*. 106(1):djt352. <http://dx.doi.org/10.1093/jnci/djt352> PMID:24317181
- Kyrø C, Zamora-Ros R, Scalbert A, Tjønneland A, Dossus L, Johansen C, et al. (2015). Pre-diagnostic polyphenol intake and breast cancer survival: the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. *Breast Cancer Res Treat*. 154(2):389–401. <http://dx.doi.org/10.1007/s10549-015-3595-9> PMID:26531755
- Labayen I, Ruiz JR, Ortega FB, Huybrechts I, Rodríguez G, Jiménez-Pavón D, et al. (2014). High fat diets are associated with higher abdominal adiposity regardless of physical activity in adolescents; the HELENA study. *Clin Nutr*. 33(5):859–66. <http://dx.doi.org/10.1016/j.clnu.2013.10.008> PMID:24182766
- Lambert MP, Ancy PB, Esposti DD, Cros MP, Sklias A, Scoazec JY, et al. (2015). Aberrant DNA methylation of imprinted loci in hepatocellular carcinoma and after in vitro exposure to common risk factors. *Clin Epigenetics*. 7(1):15. <http://dx.doi.org/10.1186/s13148-015-0053-9> PMID:25755686
- Lang Kuhs KA, Anantharaman D, Waterboer T, Johansson M, Brennan P, Michel A, et al. (2015). Human papillomavirus 16 E6 antibodies in individuals without diagnosed cancer: a pooled analysis. *Cancer Epidemiol Biomarkers Prev*. 24(4):683–9. <http://dx.doi.org/10.1158/1055-9965.EPI-14-1217> PMID:25623733
- Lang Kuhs KA, Gonzalez P, Rodriguez AC, van Doorn LJ, Schiffman M, Struijk L, et al.; Costa Rica Vaccine Trial Group (2014a). Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial. *J Infect Dis*. 210(12):1890–9. <http://dx.doi.org/10.1093/infdis/jiu357> PMID:24958910
- Lang Kuhs KA, Porras C, Schiller JT, Rodriguez AC, Schiffman M, Gonzalez P, et al.; Costa Rica Vaccine Trial Group (2014b). Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. *Am J Epidemiol*. 180(6):599–607. <http://dx.doi.org/10.1093/aje/kwu168> PMID:25139208
- Langenberg C, Sharp SJ, Franks PW, Scott RA, Deloukas P, Forouhi NG, et al. (2014). Gene-lifestyle interaction and type 2 diabetes: the EPIC InterAct case-cohort study. *PLoS Med*. 11(5):e1001647. <http://dx.doi.org/10.1371/journal.pmed.1001647> PMID:24845081
- Lauby-Secretan B, Loomis D, Straif K (2015b). Breast-cancer screening – viewpoint of the IARC Working Group. *N Engl J Med*. 373(15):1479. PMID:26444742
- Lauby-Secretan B, Scoccianti C, Loomis D, Benbrahim-Tallaa L, Bouvard V, Bianchini F, et al.; International Agency for Research on Cancer Handbook Working Group (2015a). Breast-cancer screening – viewpoint of the IARC Working Group. *N Engl J Med*. 372(24):2353–8. <http://dx.doi.org/10.1056/NEJMs1504363> PMID:26039523
- Lazcano-Ponce E, Stanley M, Muñoz N, Torres L, Cruz-Valdez A, Salmerón J, et al. (2014). Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. *Vaccine*. 32(6):725–32. <http://dx.doi.org/10.1016/j.vaccine.2013.11.059> PMID:24355090

- Le Cornet C, Fervers B, Oksbjerg Dalton S, Feychting M, Pukkala E, Tynes T, et al. (2015). Testicular germ cell tumours and parental occupational exposure to pesticides: a register-based case-control study in the Nordic countries (NORD-TEST study). *Occup Environ Med.* 72(11):805–11. <http://dx.doi.org/10.1136/oemed-2015-102860> PMID:26304777
- Le Cornet C, Lortet-Tieulent J, Forman D, Béranger R, Flechon A, Fervers B, et al. (2014). Testicular cancer incidence to rise by 25% by 2025 in Europe? Model-based predictions in 40 countries using population-based registry data. *Eur J Cancer.* 50(4):831–9. <http://dx.doi.org/10.1016/j.ejca.2013.11.035> PMID:24369860
- Leclercq C, Charrodiere R, Bertazzi Levy R, Cannon G, Gibson R, Huybrechts I, et al. (2015). Guidelines on the collection of information on food processing through food consumption surveys. Rome, Italy: Food and Agriculture Organization of the United Nations.
- Leduc C, Chemin G, Puget N, Sawan C, Moutahir M, Herceg Z, et al. (2014). Tissue-specific inactivation of HAT cofactor TRRAP reveals its essential role in B cells. *Cell Cycle.* 13(10):1583–9. <http://dx.doi.org/10.4161/cc.28560> PMID:24675885
- Lee HS (2015). Impact of maternal diet on the epigenome during in utero life and the developmental programming of diseases in childhood and adulthood. *Nutrients.* 7(11):9492–507. <http://dx.doi.org/10.3390/nu7115467> PMID:26593940
- Lee HS, Barraza-Villarreal A, Biessy C, Duarte-Salles T, Sly PD, Ramakrishnan U, et al. (2014a). Dietary supplementation with polyunsaturated fatty acid during pregnancy modulates DNA methylation at *IGF2/H19* imprinted genes and growth of infants. *Physiol Genomics.* 46(23):851–7. <http://dx.doi.org/10.1152/physiolgenomics.00061.2014> PMID:25293351
- Lee HS, Herceg Z (2014). The epigenome and cancer prevention: a complex story of dietary supplementation. *Cancer Lett.* 342(2):275–84. <http://dx.doi.org/10.1016/j.canlet.2012.01.021> PMID:22266189
- Lee R, Mason A, Lee R, Mason A, Amporfu E, An C-B, et al.; NTA Network (2014b). Is low fertility really a problem? Population aging, dependency, and consumption. *Science.* 346(6206):229–34. <http://dx.doi.org/10.1126/science.1250542> PMID:25301626
- Leenders M, Boshuizen HC, Ferrari P, Siersema PD, Overvad K, Tjønneland A, et al. (2014a). Fruit and vegetable intake and cause-specific mortality in the EPIC study. *Eur J Epidemiol.* 29(9):639–52. <http://dx.doi.org/10.1007/s10654-014-9945-9> PMID:25154553
- Leenders M, Leufkens AM, Siersema PD, van Duijnhoven FJ, Vrieling A, Hulshof PJ, et al. (2014b). Plasma and dietary carotenoids and vitamins A, C and E and risk of colon and rectal cancer in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer.* 135(12):2930–9. <http://dx.doi.org/10.1002/ijc.28938> PMID:24771392
- Leenders M, Siersema PD, Overvad K, Tjønneland A, Olsen A, Boutron-Ruault MC, et al. (2015). Subtypes of fruit and vegetables, variety in consumption and risk of colon and rectal cancer in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer.* 137(11):2705–14. <http://dx.doi.org/10.1002/ijc.29640> PMID:26077137
- Lehtinen M, Apter D, Baussano I, Eriksson T, Natunen K, Paavonen J, et al. (2015). Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial. *Vaccine.* 33(10):1284–90. <http://dx.doi.org/10.1016/j.vaccine.2014.12.019> PMID:25593103
- Leitz J, Reuschenbach M, Lohrey C, Honegger A, Accardi R, Tommasino M, et al. (2014). Oncogenic human papillomaviruses activate the tumor-associated lens epithelial-derived growth factor (*LEDGF*) gene. *PLoS Pathog.* 10(3):e1003957. <http://dx.doi.org/10.1371/journal.ppat.1003957> PMID:24604027
- Leoncini E, Ricciardi W, Cadoni G, Arzani D, Petrelli L, Paludetti G, et al. (2014). Adult height and head and neck cancer: a pooled analysis within the IN-HANCE consortium. *Eur J Epidemiol.* 29(1):35–48. <http://dx.doi.org/10.1007/s10654-013-9863-2> PMID:24271556
- Leuraud K, Richardson DB, Cardis E, Daniels RD, Gillies M, O'Hagan JA, et al. (2015). Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study. *Lancet Haematol.* 2(7):e276–81. [http://dx.doi.org/10.1016/S2352-3026\(15\)00094-0](http://dx.doi.org/10.1016/S2352-3026(15)00094-0) PMID:26436129
- Li K, Hüsing A, Fortner RT, Tjønneland A, Hansen L, Dossus L, et al. (2015a). An epidemiologic risk prediction model for ovarian cancer in Europe: the EPIC study. *Br J Cancer.* 112(7):1257–65. <http://dx.doi.org/10.1038/bjc.2015.22> PMID:25742479
- Li P, Znaor A, Holcatova I, Fabianova E, Mates D, Wozniak MB, et al. (2015b). Regional geographic variations in kidney cancer incidence rates in European countries. *Eur Urol.* 67(6):1134–41. <http://dx.doi.org/10.1016/j.eururo.2014.11.001> PMID:25465966
- Lin WY, Camp NJ, Ghousaini M, Beesley J, Michailidou K, Hopper JL, et al.; GENICA Network; kConFab Investigators; Australian Ovarian Cancer Study Group; Breast and Ovarian Cancer Susceptibility (BOCS) Study (2015a). Identification and characterization of novel associations in the *CASP8/ALS2CR12* region on chromosome 2 with breast cancer risk. *Hum Mol Genet.* 24(1):285–98. <http://dx.doi.org/10.1093/hmg/ddu431> PMID:25168388
- Lin Y, Huybrechts I, Vereecken C, Mouratidou T, Valtueña J, Kersting M, et al. (2015b). Dietary fiber intake and its association with indicators of adiposity and serum biomarkers in European adolescents: the HELENA study. *Eur J Nutr.* 54(5):771–82. <http://dx.doi.org/10.1007/s00394-014-0756-2> PMID:25129656
- Lin Y, Mouratidou T, Vereecken C, Kersting M, Bolca S, de Moraes AC, et al.; HELENA Study Group (2015c). Dietary animal and plant protein intakes and their associations with obesity and cardio-metabolic indicators in European adolescents: the HELENA cross-sectional study. *Nutr J.* 14(1):10. <http://dx.doi.org/10.1186/1475-2891-14-10> PMID:25609179
- Loomis D, Guyton K, Grosse Y, El Ghissasi F, Bouvard V, Benbrahim-Tallaa L, et al.; International Agency for Research on Cancer Monograph Working Group (2015). Carcinogenicity of lindane, DDT, and 2,4-dichlorophenoxyacetic acid. *Lancet Oncol.* 16(8):891–2. [http://dx.doi.org/10.1016/S1470-2045\(15\)00081-9](http://dx.doi.org/10.1016/S1470-2045(15)00081-9) PMID:26111929
- Loomis D, Huang W, Chen G (2014). The International Agency for Research on Cancer (IARC) evaluation of the carcinogenicity of outdoor air pollution: focus on China. *Chin J Cancer.* 33(4):189–96. <http://dx.doi.org/10.5732/cjc.014.10028> PMID:24694836
- López RV, Levi JE, Eluf-Neto J, Koifman RJ, Koifman S, Curado MP, et al. (2014). Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection. *Cancer Causes Control.* 25(4):461–71. <http://dx.doi.org/10.1007/s10552-014-0348-8> PMID:24474236

- Lortet-Tieulent J, Renteria E, Sharp L, Weiderpass E, Comber H, Baas P, et al. (2015). Convergence of decreasing male and increasing female incidence rates in major tobacco-related cancers in Europe in 1988–2010. *Eur J Cancer*. 51(9):1144–63. <http://dx.doi.org/10.1016/j.ejca.2013.10.014> PMID: 24269041
- Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E, Bray F (2014). International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. *Lung Cancer*. 84(1):13–22. <http://dx.doi.org/10.1016/j.lungcan.2014.01.009> PMID:24524818
- Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, et al. (2014). International Society of Neuropathology–Haarlem consensus guidelines for nervous system tumor classification and grading. *Brain Pathol*. 24(5):429–35. <http://dx.doi.org/10.1111/bpa.12171> PMID:24990071
- Lowy DR, Herrero R, Hildesheim A; Participants in the IARC/NCI workshop on Primary Endpoints for Prophylactic HPV Vaccine Trials (2015). Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. *Lancet Oncol*. 16(5):e226–33. [http://dx.doi.org/10.1016/S1470-2045\(15\)70075-6](http://dx.doi.org/10.1016/S1470-2045(15)70075-6) PMID: 25943067
- Lubin JH, De Stefani E, Abnet CC, Acosta G, Boffetta P, Victora C, et al. (2014). Maté drinking and esophageal squamous cell carcinoma in South America: pooled results from two large multicenter case-control studies. *Cancer Epidemiol Biomarkers Prev*. 23(1):107–16. <http://dx.doi.org/10.1158/1055-9965.EPI-13-0796> PMID:24130226
- Lujan-Barroso L, González CA, Slimani N, Obón-Santacana M, Ferrari P, Freisling H, et al. (2014). Dietary intake of acrylamide and esophageal cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. *Cancer Causes Control*. 25(5):639–46. <http://dx.doi.org/10.1007/s10552-014-0359-5> PMID:24532026
- Lukanova A, Becker S, Hüsing A, Schock H, Fedirko V, Trepo E, et al. (2014). Prediagnostic plasma testosterone, sex hormone-binding globulin, IGF-I and hepatocellular carcinoma: etiological factors or risk markers? *Int J Cancer*. 134(1):164–73. <http://dx.doi.org/10.1002/ijc.28342> PMID:23801371
- Lunetta KL, Day FR, Sulem P, Ruth KS, Tung JY, Hinds DA, et al.; EPIC-InterAct Consortium; Generation Scotland (2015). Rare coding variants and X-linked loci associated with age at menarche. *Nat Commun*. 6:7756. <http://dx.doi.org/10.1038/ncomms8756> PMID:26239645
- Ma X, Rousseau V, Sun H, Lantuejoul S, Filipits M, Pirker R, et al.; IALT-Bio working group (2014). Significance of *TP53* mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer. *Mol Oncol*. 8(3):555–64. <http://dx.doi.org/10.1016/j.molonc.2013.12.015> PMID:24495481
- Machiela MJ, Zhou W, Sampson JN, Dean MC, Jacobs KB, Black A, et al. (2015). Characterization of large structural genetic mosaicism in human autosomes. *Am J Hum Genet*. 96(3):487–97. <http://dx.doi.org/10.1016/j.ajhg.2015.01.011> PMID: 25748358
- Maillard S, Damiola F, Clero E, Pertesi M, Robinot N, Rachédi F, et al. (2015). Common variants at 9q22.33, 14q13.3, and *ATM* loci, and risk of differentiated thyroid cancer in the French Polynesian population. *PLoS ONE*. 10(4):e0123700. <http://dx.doi.org/10.1371/journal.pone.0123700> PMID:25849217
- Malekzadeh MM, Khademi H, Malekzadeh R, Kamangar F (2014). Response to Lankarani. *Am J Gastroenterol*. 109(4):600–1. <http://dx.doi.org/10.1038/ajg.2014.16> PMID:24698869
- Malhotra J, Sartori S, Brennan P, Zaridze D, Szeszenia-Dabrowska N, Świątkowska B, et al. (2015). Effect of occupational exposures on lung cancer susceptibility: a study of gene-environment interaction analysis. *Cancer Epidemiol Biomarkers Prev*. 24(3):570–9. <http://dx.doi.org/10.1158/1055-9965.EPI-14-1143-T> PMID:25583949
- Mariga A, Zavadil J, Ginsberg SD, Chao MV (2015). Withdrawal of BDNF from hippocampal cultures leads to changes in genes involved in synaptic function. *Dev Neurobiol*. 75(2):173–92. <http://dx.doi.org/10.1002/dneu.22216> PMID:25059794
- Marks MA, Chaturvedi AK, Kelsey K, Straif K, Berthiller J, Schwartz SM, et al. (2014). Association of marijuana smoking with oropharyngeal and oral tongue cancers: pooled analysis from the INHANCE consortium. *Cancer Epidemiol Biomarkers Prev*. 23(1):160–71. <http://dx.doi.org/10.1158/1055-9965.EPI-13-0181> PMID:24351902
- Markt SC, Shui IM, Unger RH, Urun Y, Berg CD, Black A, et al. (2015). ABO blood group alleles and prostate cancer risk: results from the breast and prostate cancer cohort consortium (BPC3). *Prostate*. 75(15):1677–81. <http://dx.doi.org/10.1002/pros.23035> PMID:26268879
- Martin E, González-Horta C, Rager J, Bailey KA, Sánchez-Ramírez B, Ballinas-Casarrubias L, et al. (2015). Metabolomic characteristics of arsenic-associated diabetes in a prospective cohort in Chihuahua, Mexico. *Toxicol Sci*. 144(2):338–46. <http://dx.doi.org/10.1093/toxsci/ktu318> PMID: 25577196
- Martin M, Ancey PB, Cros MP, Durand G, Le Calvez-Kelm F, Hernandez-Vargas H, et al. (2014). Dynamic imbalance between cancer cell subpopulations induced by transforming growth factor beta (TGF-β) is associated with a DNA methylome switch. *BMC Genomics*. 15(1):435. <http://dx.doi.org/10.1186/1471-2164-15-435> PMID:24898317
- Mbaye HS, Gheit T, Dem A, McKay-Chopin S, Toure-Kane NC, Mboup S, et al. (2014). Human papillomavirus infection in women in four regions of Senegal. *J Med Virol*. 86(2):248–56. <http://dx.doi.org/10.1002/jmv.23719> PMID:24026804
- McCloskey K, Sun C, Pezic A, Cochrane J, Morley R, Vuillemin P, et al. (2014). The effect of known cardiovascular risk factors on carotid-femoral pulse wave velocity in school-aged children: a population based twin study. *J Dev Orig Health Dis*. 5(4):307–13. <http://dx.doi.org/10.1017/S2040174414000282> PMID:24965137
- McCormack V, Peto J, Byrnes G, Straif K, Boffetta P (2014). Corrigendum: Estimating the asbestos-related lung cancer burden from mesothelioma mortality. *Br J Cancer*. 111(12):2381. <http://dx.doi.org/10.1038/bjc.2014.616>
- McKenzie F, Ellison-Loschmann L, Jeffreys M, Firestone R, Pearce N, Romieu I (2014). Healthy lifestyle and risk of breast cancer for indigenous and non-indigenous women in New Zealand: a case control study. *BMC Cancer*. 14(1):12. <http://dx.doi.org/10.1186/1471-2407-14-12> PMID:24410858
- McKenzie F, Ferrari P, Freisling H, Chajès V, Rinaldi S, de Battle J, et al. (2015). Healthy lifestyle and risk of breast cancer among postmenopausal women in the European Prospective Investigation into Cancer and Nutrition cohort study. *Int J Cancer*. 136(11):2640–8. <http://dx.doi.org/10.1002/ijc.29315> PMID:25379993

- Mena M, Wiafe-Addai B, Sauvaget C, Ali IA, Wiafe SA, Dabis F, et al. (2014). Evaluation of the impact of a breast cancer awareness program in rural Ghana: a cross-sectional survey. *Int J Cancer*. 134(4):913–24. <http://dx.doi.org/10.1002/ijc.28412> PMID:23913595
- Mendy M, Caboux E, Sylla BS, Dillner J, Chinquee J, Wild C; BCNet survey participants (2014). Infrastructure and facilities for human biobanking in low- and middle-income countries: a situation analysis. *Pathobiology*. 81(5–6):252–60. <http://dx.doi.org/10.1159/000362093> PMID:25792214
- Merritt MA, Riboli E, Murphy N, Kadi M, Tjønneland A, Olsen A, et al. (2015). Reproductive factors and risk of mortality in the European Prospective Investigation into Cancer and Nutrition; a cohort study. *BMC Med*. 13(1):252. <http://dx.doi.org/10.1186/s12916-015-0484-3> PMID:26515238
- Merritt MA, Riboli E, Weiderpass E, Tsilidis KK, Overvad K, Tjønneland A, et al. (2014). Dietary fat intake and risk of epithelial ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiol*. 38(5):528–37. <http://dx.doi.org/10.1016/j.canep.2014.07.011> PMID:25155210
- Merritt MA, Tzoulaki I, Tworoger SS, De Vivo I, Hankinson SE, Fernandes J, et al. (2015). Investigation of dietary factors and endometrial cancer risk using a nutrient-wide association study approach in the EPIC and Nurses' Health Study (NHS) and NHSII. *Cancer Epidemiol Biomarkers Prev*. 24(2):466–71. <http://dx.doi.org/10.1158/1055-9965.EPI-14-0970> PMID:25662427
- Mertens E, Deforche B, Mullie P, Lefevre J, Charlier R, Knaeps S, et al. (2015). Longitudinal study on the association between three dietary indices, anthropometric parameters and blood lipids. *Nutr Metab (Lond)*. 12(1):47. <http://dx.doi.org/10.1186/s12986-015-0042-1> PMID:26594230
- Mertens E, Mullie P, Deforche B, Lefevre J, Charlier R, Huybrechts I, et al. (2014). Cross-sectional study on the relationship between the Mediterranean Diet Score and blood lipids. *Nutr J*. 13(1):88. <http://dx.doi.org/10.1186/1475-2891-13-88> PMID:25189183
- Metayer C, Milne E, Dockerty JD, Clavel J, Pombode-Oliveira MS, Wesseling C, et al. (2014). Maternal supplementation with folic acid and other vitamins and risk of leukemia in offspring: a Childhood Leukemia International Consortium study. *Epidemiology*. 25(6):811–22. <http://dx.doi.org/10.1097/EDE.0000000000000141> PMID:25207954
- Meulenijs E, Vyncke K, Labayen I, Meirhaeghe A, Béghin L, Breidenassel C, et al. (2015). Associations of early life and sociodemographic factors with menarcheal age in European adolescents. *Eur J Pediatr*. 174(2):271–8. <http://dx.doi.org/10.1007/s00431-014-2376-5> PMID:25070467
- Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, et al.; BOCS; kConFab Investigators; AOCs Group; NBCS; GENICA Network (2015). Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. *Nat Genet*. 47(4):373–80. <http://dx.doi.org/10.1038/ng.3242> PMID:25751625
- Michels N, Sioen I, Boone L, Braet C, Vanaelst B, Huybrechts I, et al. (2015a). Longitudinal association between child stress and lifestyle. *Health Psychol*. 34(1):40–50. <http://dx.doi.org/10.1037/hea0000108> PMID:25133838
- Michels N, Sioen I, Boone L, Clays E, Vanaelst B, Huybrechts I, et al. (2015b). Cross-lagged associations between children's stress and adiposity: the Children's Body Composition and Stress study. *Psychosom Med*. 77(1):50–8. <http://dx.doi.org/10.1097/PSY.0000000000000122> PMID:25341703
- Midttun O, Townsend MK, Nygård O, Tworoger SS, Brennan P, Johansson M, et al. (2014). Most blood biomarkers related to vitamin status, one-carbon metabolism, and the kynurenine pathway show adequate preanalytical stability and within-person reproducibility to allow assessment of exposure or nutritional status in healthy women and cardiovascular patients. *J Nutr*. 144(5):784–90. <http://dx.doi.org/10.3945/jn.113.189738> PMID:24647388
- Milne E, Greenop KR, Fritsch L, Attia J, Bailey HD, Scott RJ, et al. (2014a). Childhood and parental diagnostic radiological procedures and risk of childhood brain tumors. *Cancer Causes Control*. 25(3):375–83. <http://dx.doi.org/10.1007/s10552-014-0338-x> PMID:24445596
- Milne E, Greenop KR, Scott RJ, Haber M, Norris MD, Attia J, et al. (2015). Folate pathway gene polymorphisms, maternal folic acid use, and risk of childhood acute lymphoblastic leukemia. *Cancer Epidemiol Biomarkers Prev*. 24(1):48–56. <http://dx.doi.org/10.1158/1055-9965.EPI-14-0680> PMID:25395472
- Milne RL, Burwinkel B, Michailidou K, Arias-Perez JI, Zamora MP, Menéndez-Rodríguez P, et al.; GENICA Network; kConFab Investigators; Australian Ovarian Cancer Study Group; TNBCC (2014b). Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. *Hum Mol Genet*. 23(22):6096–111. <http://dx.doi.org/10.1093/hmg/ddu311> PMID:24943594
- Mimoso C, Lee DD, Zavadil J, Tomic-Canic M, Blumenberg M (2014). Analysis and meta-analysis of transcriptional profiling in human epidermis. *Methods Mol Biol*. 1195:61–97. [http://dx.doi.org/10.1007/7651\\_2013\\_60](http://dx.doi.org/10.1007/7651_2013_60) PMID:24297317
- Moore SP, Antoni S, Colquhoun A, Healy B, Ellison-Loschmann L, Potter JD, et al. (2015). Cancer incidence in indigenous people in Australia, New Zealand, Canada, and the USA: a comparative population-based study. *Lancet Oncol*. 16(15):1483–92. [http://dx.doi.org/10.1016/S1470-2045\(15\)00232-6](http://dx.doi.org/10.1016/S1470-2045(15)00232-6) PMID:26476758
- Moore SP, Forman D, Piñeros M, Fernández SM, de Oliveira Santos M, Bray F (2014a). Cancer in indigenous people in Latin America and the Caribbean: a review. *Cancer Med*. 3(1):70–80. <http://dx.doi.org/10.1002/cam4.134> PMID:24403278
- Moore SP, Green AC, Bray F, Garvey G, Coory M, Martin J, et al. (2014b). Survival disparities in Australia: an analysis of patterns of care and comorbidities among indigenous and non-indigenous cancer patients. *BMC Cancer*. 14(1):517. <http://dx.doi.org/10.1186/1471-2407-14-517> PMID:25037075
- Moreno LA, Gottrand F, Huybrechts I, Ruiz JR, González-Gross M, DeHenauw S; HELENA Study Group (2014). Nutrition and lifestyle in European adolescents: the HELENA (Healthy Lifestyle in Europe by Nutrition in Adolescence) study. *Adv Nutr*. 5(5):615S–23S. <http://dx.doi.org/10.3945/an.113.005678> PMID:25469407
- Moreno-Estrada A, Gignoux CR, Fernández-López JC, Zakharia F, Sikora M, Contreras AV, et al. (2014). Human genetics. The genetics of Mexico recapitulates Native American substructure and affects biomedical traits. *Science*. 344(6189):1280–5. <http://dx.doi.org/10.1126/science.1251688> PMID:24926019
- Moreno-Macias H, Romieu I (2014a). Reply: To PMID 24766873. *J Allergy Clin Immunol*. 134(5):1216. <http://dx.doi.org/10.1016/j.jaci.2014.08.033> PMID:25263232

- Moreno-Macias H, Romieu I (2014b). Effects of antioxidant supplements and nutrients on patients with asthma and allergies. *J Allergy Clin Immunol.* 133(5):1237–44, quiz 1245. <http://dx.doi.org/10.1016/j.jaci.2014.03.020> PMID:24766873
- Moreno-Macias H, Romieu I (2014c). Reply: To PMID 24766873. *J Allergy Clin Immunol.* 134(3):763–4. <http://dx.doi.org/10.1016/j.jaci.2014.06.012> PMID:25065722
- Morton LM, Sampson JN, Cerhan JR, Turner JJ, Vajdic CM, Wang SS, et al. (2014a). Rationale and design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. *J Natl Cancer Inst Monogr.* 2014(48):1–14. <http://dx.doi.org/10.1093/jncimonographs/igu005> PMID:25174022
- Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, et al. (2014b). Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. *J Natl Cancer Inst Monogr.* 2014(48):130–44. <http://dx.doi.org/10.1093/jncimonographs/igu013> PMID:25174034
- Moskal A, Pisa PT, Ferrari P, Byrnes G, Freisling H, Boutron-Ruault MC, et al. (2014). Nutrient patterns and their food sources in an international study setting: report from the EPIC study. *PLoS ONE.* 9(6):e98647. <http://dx.doi.org/10.1371/journal.pone.0098647> PMID:24901309
- Mühleisen TW, Leber M, Schulze TG, Strohmaier J, Degenhardt F, Treutlein J, et al. (2014). Genome-wide association study reveals two new risk loci for bipolar disorder. *Nat Commun.* 5:3339. <http://dx.doi.org/10.1038/ncomms4339> PMID:24618891
- Muller DC, Fanidi A, Midttun Ø, Steffen A, Dossus L, Boutron-Ruault MC, et al. (2014). Circulating 25-hydroxyvitamin D3 in relation to renal cell carcinoma incidence and survival in the EPIC cohort. *Am J Epidemiol.* 180(8):810–20. <http://dx.doi.org/10.1093/aje/kwu204> PMID:25205830
- Muller DC, Johansson M, Zaridze D, Moukieria A, Janout V, Holcatova I, et al. (2015). Circulating concentrations of vitamin B6 and kidney cancer prognosis: a prospective case-cohort study. *PLoS ONE.* 10(10):e0140677. <http://dx.doi.org/10.1371/journal.pone.0140677> PMID:26506437
- Muller DC, Scelo G, Zaridze D, Janout V, Holcatova I, Navratilova M, et al. (2015). Circulating 25-hydroxyvitamin D3 and survival after diagnosis with kidney cancer. *Cancer Epidemiol Biomarkers Prev.* 24(8):1277–81. <http://dx.doi.org/10.1158/1055-9965.EPI-14-1351> PMID:26021552
- Munishi MO, Hanisch R, Mapunda O, Ndyetabura T, Ndaro A, Schüz J, et al. (2015). Africa's oesophageal cancer corridor: do hot beverages contribute? *Cancer Causes Control.* 26(10):1477–86. <http://dx.doi.org/10.1007/s10552-015-0646-9> PMID:26245249
- Murugan N, Dickens C, McCormack V, Joffe M, Jacobson J, Cubasch H (2014). Down-staging of breast cancer in the pre-screening era: experiences from Chris Hani Baragwanath Academic Hospital, Soweto, South Africa. *S Afr Med J.* 104(5):380. <http://dx.doi.org/10.7196/samj.8243> PMID:25295329
- Muwonge R, Wesley RS, Nene BM, Shastri SS, Jayant K, Malvi SG, et al. (2014). Evaluation of cytology and visual triage of human papillomavirus-positive women in cervical cancer prevention in India. *Int J Cancer.* 134(12):2902–9. <http://dx.doi.org/10.1002/ijc.28627> PMID:24272364
- Myers RA, Scott NM, Gauderman WJ, Qiu W, Mathias RA, Romieu I, et al.; GRAAD (2014). Genome-wide interaction studies reveal sex-specific asthma risk alleles. *Hum Mol Genet.* 23(19):5251–9. <http://dx.doi.org/10.1093/hmg/ddu222> PMID:24824216
- Naska A, Katsoulis M, Orfanos P, Lachat C, Gedrich K, Rodrigues SS, et al.; HECTOR Consortium (2015). Eating out is different from eating at home among individuals who occasionally eat out. A cross-sectional study among middle-aged adults from eleven European countries. *Br J Nutr.* 113(12):1951–64. <http://dx.doi.org/10.1017/S0007114515000963> PMID:25907775
- Nasrollahzadeh D, Malekzadeh R, Ploner A, Shakeri R, Sotoudeh M, Fahimi S, et al. (2015a). Variations of gastric corpus microbiota are associated with early esophageal squamous cell carcinoma and squamous dysplasia. *Sci Rep.* 5:8820. <http://dx.doi.org/10.1038/srep08820> PMID:25743945
- Nasrollahzadeh D, Ye W, Shakeri R, Sotoudeh M, Merat S, Kamangar F, et al. (2015b). Contact with ruminants is associated with esophageal squamous cell carcinoma risk. *Int J Cancer.* 136(6):1468–74. <http://dx.doi.org/10.1002/ijc.29109> PMID:25082448
- NCD Risk Factor Collaboration (NCD-RisC) (2015). Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331,288 participants. *Lancet Diabetes Endocrinol.* 3(8):624–37. [http://dx.doi.org/10.1016/S2213-8587\(15\)00129-1](http://dx.doi.org/10.1016/S2213-8587(15)00129-1) PMID:26109024
- Newton R, Wakeham K, Bray F (2014). Cancer in the tropics. In: Farrar J, Hotez P, Junghanss T, Kang G, Lalloo D, White NJ, editors. *Manson's tropical infectious diseases*, 23rd edition. China: Elsevier; pp. 879–93.E1.
- Nieters A, Łucznińska A, Becker S, Becker N, Vermeulen R, Overvad K, et al. (2014). Prediagnostic immunoglobulin E levels and risk of chronic lymphocytic leukemia, other lymphomas and multiple myeloma – results of the European Prospective Investigation into Cancer and Nutrition. *Carcinogenesis.* 35(12):2716–22. <http://dx.doi.org/10.1093/carcin/bgu188> PMID:25269801
- Nimptsch K, Aleksandrova K, Boeing H, Janke J, Lee YA, Jenab M, et al. (2015a). Association of CRP genetic variants with blood concentrations of C-reactive protein and colorectal cancer risk. *Int J Cancer.* 136(5):1181–92. <http://dx.doi.org/10.1002/ijc.29086> PMID:25043606
- Nimptsch K, Aleksandrova K, Boeing H, Janke J, Lee YA, Jenab M, et al. (2015b). Plasma fetuin-A concentration, genetic variation in the AHSG gene and risk of colorectal cancer. *Int J Cancer.* 137(4):911–20. <http://dx.doi.org/10.1002/ijc.29448> PMID:25611809
- Nitter M, Norgård B, de Vogel S, Eussen SJ, Meyer K, Ulvik A, et al. (2014). Plasma methionine, choline, betaine, and dimethylglycine in relation to colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Ann Oncol.* 25(8):1609–15. <http://dx.doi.org/10.1093/annonc/mdu185> PMID:24827130
- Njai HF, Shimakawa Y, Sanneh B, Ferguson L, Ndow G, Mendy M, et al. (2015). Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa. *J Clin Microbiol.* 53(4):1156–63. <http://dx.doi.org/10.1128/JCM.02980-14> PMID:25631805
- Nysen R, Faes C, Ferrari P, Verger P, Aerts M (2015). Parametric and semi-nonparametric model strategies for the estimation of distributions of chemical contaminant data. *Environ Ecol Stat.* 22(2):423–44. <http://dx.doi.org/10.1007/s10651-014-0304-5>
- Obón-Santacana M, Kaaks R, Slimani N, Lujan-Barroso L, Freisling H, Ferrari P, et al. (2014). Dietary intake of acrylamide and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. *Br J Cancer.* 111(5):987–97. <http://dx.doi.org/10.1038/bjc.2014.328> PMID:24937665

- Obón-Santacana M, Peeters PH, Freisling H, Dossus L, Clavel-Chapelon F, Baglietto L, et al. (2015). Dietary intake of acrylamide and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. *Cancer Epidemiol Biomarkers Prev.* 24(1):291–7. <http://dx.doi.org/10.1158/1055-9965.EPI-14-0636> PMID:25300475
- Ocké M, Brants H, Dofkova M, Freisling H, van Rossum C, Ruprich J, et al. (2015). Feasibility of dietary assessment methods, other tools and procedures for a pan-European food consumption survey among infants, toddlers and children. *Eur J Nutr.* 54(5):721–32. <http://dx.doi.org/10.1007/s00394-014-0750-8> PMID:25108656
- Oh JE, Ohta T, Satomi K, Foll M, Durand G, McKay J, et al. (2015). Alterations in the NF2/LATS1/LATS2/YAP pathway in schwannomas. *J Neuropathol Exp Neurol.* 74(10):952–9. <http://dx.doi.org/10.1097/NEN.0000000000000238> PMID:26360373
- Ohgaki H, Burger P, Kleihues P (2014). Definition of primary and secondary glioblastoma – response. *Clin Cancer Res.* 20(7):2013. <http://dx.doi.org/10.1158/1078-0432.CCR-14-0238> PMID:24557936
- Ohta T, Kim YH, Oh JE, Satomi K, Nonoguchi N, Keyvani K, et al. (2014). Alterations of the *RRAS* and *ERCC1* genes at 19q13 in gemistocytic astrocytomas. *J Neuropathol Exp Neurol.* 73(10):908–15. <http://dx.doi.org/10.1097/EN.0000000000000110> PMID:25192052
- Olivier M, Weninger A, Ardin M, Huskova H, Castells X, Vallée MP, et al. (2014). Modelling mutational landscapes of human cancers in vitro. *Sci Rep.* 4:4482. <http://dx.doi.org/10.1038/srep04482> PMID:24670820
- Orr N, Dudbridge F, Dryden N, Maguire S, Novo D, Perrakis E, et al.; GENICA Network; kConFab Investigators; Australian Ovarian Cancer Study Group (2015). Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. *Hum Mol Genet.* 24(10):2966–84. <http://dx.doi.org/10.1093/hmg/ddv035> PMID:25652398
- Ose J, Fortner RT, Rinaldi S, Schock H, Overvad K, Tjønneland A, et al. (2015a). Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer.* 136(2):399–410. <http://dx.doi.org/10.1002/ijc.29000> PMID:24890047
- Ose J, Fortner RT, Schock H, Peeters PH, Onland-Moret NC, Bueno-de-Mesquita HB, et al. (2015b). Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort. *Br J Cancer.* 112(1):162–6. <http://dx.doi.org/10.1038/bjc.2014.566> PMID:25349976
- Ose J, Schock H, Tjønneland A, Hansen L, Overvad K, Dossus L, et al. (2015c). Inflammatory markers and risk of epithelial ovarian cancer by tumor subtypes: the EPIC cohort. *Cancer Epidemiol Biomarkers Prev.* 24(6):951–61. <http://dx.doi.org/10.1158/1055-9965.EPI-14-1279-T> PMID:25855626
- Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. (2014). The epidemiology of glioma in adults: a “state of the science” review. *Neuro Oncol.* 16(7):896–913. <http://dx.doi.org/10.1093/neuonc/nou087> PMID:24842956
- Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. (2015). Response to “The epidemiology of glioma in adults: a ‘state of the science’ review”. *Neuro Oncol.* 17(4):624–6. <http://dx.doi.org/10.1093/neuonc/nov022> PMID:25762697
- Pacini L, Savini C, Ghittoni R, Saidj D, Lamartine J, Hasan UA, et al. (2015). Downregulation of Toll-like receptor 9 expression by beta human papillomavirus 38 and implications for cell cycle control. *J Virol.* 89(22):11396–405. <http://dx.doi.org/10.1128/JVI.02151-15> PMID:26339055
- Paltiel O, Tikellis G, Linet M, Golding J, Lemeshow S, Phillips G, et al.; International Childhood Cancer Cohort Consortium (2015). Birthweight and childhood cancer: preliminary findings from the International Childhood Cancer Cohort Consortium (I4C). *Paediatr Perinat Epidemiol.* 29(4):335–45. <http://dx.doi.org/10.1111/ppe.12193> PMID:25989709
- Panagiotou OA, Befano BL, Gonzalez P, Rodríguez AC, Herrero R, Schiller JT, et al.; Costa Rica HPV Vaccine Trial (CVT) Group (2015). Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. *BMJ.* 351:h4358. <http://dx.doi.org/10.1136/bmj.h4358> PMID:26346155
- Papathoma P, Thomopoulos TP, Karalexi MA, Ryzhov A, Zborovskaya A, Dimitrova N, et al. (2015). Childhood central nervous system tumours: incidence and time trends in 13 Southern and Eastern European cancer registries. *Eur J Cancer.* 51(11):1444–55. <http://dx.doi.org/10.1016/j.ejca.2015.04.014> PMID:25971531
- Parham GP, Mwanahamuntu MH, Kapambwe S, Muwonge R, Bateman AC, Blevins M, et al. (2015). Population-level scale-up of cervical cancer prevention services in a low-resource setting: development, implementation, and evaluation of the cervical cancer prevention program in Zambia. *PLoS ONE.* 10(4):e0122169. <http://dx.doi.org/10.1371/journal.pone.0122169> PMID:25885821
- Park DJ, Tao K, Le Calvez-Kelm F, Nguyen-Dumont T, Robinot N, Hammet F, et al. (2014a). Rare mutations in *RINT1* predispose carriers to breast and Lynch syndrome-spectrum cancers. *Cancer Discov.* 4(7):804–15. <http://dx.doi.org/10.1158/2159-8290.CD-14-0212> PMID:25050558
- Park JY, von Karsa L, Herrero R (2014b). Prevention strategies for gastric cancer: a global perspective. *Clin Endosc.* 47(6):478–89. <http://dx.doi.org/10.5946/ce.2014.47.6.478> PMID:25505712
- Park MK, Park JY, Nicolas G, Paik HY, Kim J, Slimani N (2015). Adapting a standardised international 24 h dietary recall methodology (GloboDiet software) for research and dietary surveillance in Korea. *Br J Nutr.* 113(11):1810–8. <http://dx.doi.org/10.1017/S0007114515000987> PMID:25899045
- Park SL, Fesinmeyer MD, Timofeeva M, Caberto CP, Kocarnik JM, Han Y, et al. (2014c). Pleiotropic associations of risk variants identified for other cancers with lung cancer risk: the PAGE and TRICL consortia. *J Natl Cancer Inst.* 106(4):dju061. <http://dx.doi.org/10.1093/jnci/dju061> PMID:24681604
- Park WB, Cho JS, Shin SD, Kong SY, Kim JJ, Lim YS, et al. (2014d). Comparison of epidemiology, emergency care, and outcomes of acute ischemic stroke between young adults and elderly in Korean population: a multicenter observational study. *J Korean Med Sci.* 29(7):985–91. <http://dx.doi.org/10.3346/jkms.2014.29.7.985> PMID:25045232
- Parkin DM, Bray F, Ferlay J, Jemal A (2014). Cancer in Africa 2012. *Cancer Epidemiol Biomarkers Prev.* 23(6):953–66. <http://dx.doi.org/10.1158/1055-9965.EPI-14-0281> PMID:24700176
- Pathy S, Muwonge R, Chander S, Dadhwal V, Pandjatcharam J (2014). Predictors of tumor response in carcinoma of uterine cervix: data from tertiary cancer centre in India. *Bull Cancer.* 101(2):E13–8. PMID:24590357



- Pauwels S, Doperé I, Huybrechts I, Godderis L, Koppen G, Vansant G (2014). Validation of a food-frequency questionnaire assessment of methyl-group donors using estimated diet records and plasma biomarkers: the method of triads. *Int J Food Sci Nutr.* 65(6):768–73. <http://dx.doi.org/10.3109/09637486.2014.917149> PMID:24827748
- Pauwels S, Doperé I, Huybrechts I, Godderis L, Koppen G, Vansant G (2015). Reproducibility and validity of an FFQ to assess usual intake of methyl-group donors. *Public Health Nutr.* 18(14):2530–9. <http://dx.doi.org/10.1017/S1368980014003140> PMID:25585686
- Pearce A, Hanly P, Sharp L, Soerjomataram I (2015). The burden of cancer in emerging economies: productivity loss as an alternative perspective. *Value Health.* 18(7):A336. <http://dx.doi.org/10.1016/j.jval.2015.09.118> PMID:26531906
- Pearce N, Brennan P, Foliaki S, Ellison-Loschmann L, D'Souza W, Davey Smith G (2014). The Ikale collaboration: randomized trials of beer recognition. *Int J Epidemiol.* 43(1):81–2. <http://dx.doi.org/10.1093/ije/dyt258> PMID:24585855
- Pedersen C, Bräuner EV, Rod NH, Albiery V, Andersen CE, Ulbak K, et al. (2014a). Distance to high-voltage power lines and risk of childhood leukemia – an analysis of confounding by and interaction with other potential risk factors. *PLoS ONE.* 9(9):e107096. <http://dx.doi.org/10.1371/journal.pone.0107096> PMID:25259740
- Pedersen C, Johansen C, Schüz J, Olsen JH, Raaschou-Nielsen O (2015). Residential exposure to extremely low-frequency magnetic fields and risk of childhood leukaemia, CNS tumour and lymphoma in Denmark. *Br J Cancer.* 113(9):1370–4. <http://dx.doi.org/10.1038/bjc.2015.365> PMID:26484412
- Pedersen C, Raaschou-Nielsen O, Rod NH, Frei P, Poulsen AH, Johansen C, et al. (2014b). Distance from residence to power line and risk of childhood leukemia: a population-based case-control study in Denmark. *Cancer Causes Control.* 25(2):171–7. <http://dx.doi.org/10.1007/s10552-013-0319-5> PMID:24197706
- Pelucchi C, Galeone C, Polesel J, Manzari M, Zucchetto A, Talamini R, et al. (2014). Smoking and body mass index and survival in pancreatic cancer patients. *Pancreas.* 43(1):47–52. <http://dx.doi.org/10.1097/MPA.0b013e3182a7c74b> PMID:24177141
- Peng C, Deng Q, Li Z, Xiong C, Li C, Zheng F (2014). Risk-association of *DNMT1* gene polymorphisms with coronary artery disease in Chinese Han population. *Int J Mol Sci.* 15(12):22694–705. <http://dx.doi.org/10.3390/ijms151222694> PMID:25493477
- Pereda CM, Lesueur F, Pertesi M, Robinot N, Lence-Anta JJ, Turcios S, et al. (2015). Common variants at the 9q22.33, 14q13.3 and *ATM* loci, and risk of differentiated thyroid cancer in the Cuban population. *BMC Genet.* 16(1):22. <http://dx.doi.org/10.1186/s12863-015-0180-5> PMID:25879635
- Pérez de Heredia F, Garaulet M, Gómez-Martínez S, Díaz LE, Wärnberg J, Androutsos O, et al.; HELENA Study Group (2014). Self-reported sleep duration, white blood cell counts and cytokine profiles in European adolescents: the HELENA study. *Sleep Med.* 15(10):1251–8. <http://dx.doi.org/10.1016/j.sleep.2014.04.010> PMID:25156749
- Pérez-de-Heredia F, Gómez-Martínez S, Díaz LE, Veses AM, Nova E, Wärnberg J, et al.; HELENA Study Group (2015). Influence of sex, age, pubertal maturation and body mass index on circulating white blood cell counts in healthy European adolescents – the HELENA study. *Eur J Pediatr.* 174(8):999–1014. <http://dx.doi.org/10.1007/s00431-015-2497-5> PMID:25665972
- Pertesi M, Galia P, Nazaret N, Vallée M, Garderet L, Leleu X, et al. (2015). Rare circulating cells in familial Waldenström macroglobulinemia displaying the *MYD88* L265P mutation are enriched by Epstein-Barr virus immortalization. *PLoS ONE.* 10(9):e0136505. <http://dx.doi.org/10.1371/journal.pone.0136505> PMID:26352266
- Peto TJ, Mendy ME, Lowe Y, Webb EL, Whittle HC, Hall AJ (2014). Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986–90) and in the nationwide immunisation program. *BMC Infect Dis.* 14(1):7. <http://dx.doi.org/10.1186/1471-2334-14-7> PMID:24397793
- Pettersson A, Graff RE, Ursin G, Santos Silva ID, McCormack V, Baglietto L, et al. (2014). Mammographic density phenotypes and risk of breast cancer: a meta-analysis. *J Natl Cancer Inst.* 106(5):dju078. <http://dx.doi.org/10.1093/jnci/dju078> PMID:24816206
- Plummer M (2015). Cuts in Bayesian graphical models. *Stat Comput.* 25(1):37–43. <http://dx.doi.org/10.1007/s11222-014-9503-z>
- Plummer M, Franceschi S, Vignat J, Forman D, de Martel C (2015). Global burden of gastric cancer attributable to *Helicobacter pylori*. *Int J Cancer.* 136(2):487–90. <http://dx.doi.org/10.1002/ijc.28999> PMID:24889903
- Poirier JG, Brennan P, McKay JD, Spitz MR, Bickeböller H, Risch A, et al. (2015). Informed genome-wide association analysis with family history as a secondary phenotype identifies novel loci of lung cancer. *Genet Epidemiol.* 39(3):197–206. <http://dx.doi.org/10.1002/gepi.21882> PMID:25644374
- Ponsonby AL, Dwyer T (2014). Statistics: biomedicine must look beyond *P* values. *Nature.* 507(7491):169. <http://dx.doi.org/10.1038/507169b> PMID:24622193
- Porras C, Hildesheim A, González P, Schiffman M, Rodríguez AC, Wacholder S, et al.; CVT Vaccine Group (2015). Performance of self-collected cervical samples in screening for future precancer using human papillomavirus DNA testing. *J Natl Cancer Inst.* 107(1):400. <http://dx.doi.org/10.1093/jnci/dju400> PMID:25479804
- Portier CJ, Goldman LR, Goldstein BD (2014). Inconclusive findings: now you see them, now you don't! *Environ Health Perspect.* 122(2):A36. <http://dx.doi.org/10.1289/ehp.1408106> PMID:24486734
- Pouchieu C, Chajès V, Laporte F, Kesse-Guyot E, Galan P, Hercberg S, et al. (2014). Prospective associations between plasma saturated, monounsaturated and polyunsaturated fatty acids and overall and breast cancer risk – modulation by antioxidants: a nested case-control study. *PLoS ONE.* 9(2):e90442. <http://dx.doi.org/10.1371/journal.pone.0090442> PMID:24587366
- Quesada P, Whitby D, Benavente Y, Miley W, Labo N, Chichareon S, et al. (2015). Hepatitis C virus seroprevalence in the general female population from 8 countries. *J Clin Virol.* 68:89–93. <http://dx.doi.org/10.1016/j.jcv.2015.05.005> PMID:26071344
- Rabassa M, Cherubini A, Zamora-Ros R, Urpi-Sarda M, Bandinelli S, Ferrucci L, et al. (2015a). Low levels of a urinary biomarker of dietary polyphenol are associated with substantial cognitive decline over a 3-year period in older adults: the Invecchiare in Chianti study. *J Am Geriatr Soc.* 63(5):938–46. <http://dx.doi.org/10.1111/jgs.13379> PMID:25919574
- Rabassa M, Zamora-Ros R, Urpi-Sarda M, Andres-Lacueva C (2015b). Resveratrol metabolite profiling in clinical nutrition research – from diet to uncovering disease risk biomarkers: epidemiological evidence. *Ann N Y Acad Sci.* 1348(1):107–15. <http://dx.doi.org/10.1111/nyas.12851> PMID:26250997

- Rabassa M, Zamora-Ros R, Urpi-Sarda M, Bandinelli S, Ferrucci L, Andres-Lacueva C, et al. (2015). Association of habitual dietary resveratrol exposure with the development of frailty in older age: the Invecchiare in Chianti study. *Am J Clin Nutr.* 102(6):1534–42. <http://dx.doi.org/10.3945/ajcn.115.118976> PMID:26490492
- Rajaraman P, Anderson BO, Basu P, Belinson JL, Cruz AD, Dhilon PK, et al. (2015). Recommendations for screening and early detection of common cancers in India. *Lancet Oncol.* 16(7):e352–61. [http://dx.doi.org/10.1016/S1470-2045\(15\)00078-9](http://dx.doi.org/10.1016/S1470-2045(15)00078-9) PMID:26149887
- Ramirez-Silva I, Rivera JA, Trejo-Valdivia B, Martorell R, Stein AD, Romieu I, et al. (2015). Breastfeeding status at age 3 months is associated with adiposity and cardiometabolic markers at age 4 years in Mexican children. *J Nutr.* 145(6):1295–302. <http://dx.doi.org/10.3945/jn.114.198366> PMID:25926414
- Rappaport SM, Barupal DK, Wishart D, Vineis P, Scalbert A (2014). The blood exposome and its role in discovering causes of disease. *Environ Health Perspect.* 122(8):769–74. PMID:24659601
- Ravindran D, Hariharan I, Muwonge R, Kumar RR, Pillai MR, Ramadas K (2014). Efficacy of Varunadi Ghrita (polyherbal compound) in treated head and neck cancer cases as a biological response modifier. *Ayu.* 35(2):168–74. <http://dx.doi.org/10.4103/0974-8520.146236> PMID:25558162
- Ricceri F, Fasanelli F, Giraudo MT, Sieri S, Tumino R, Mattiello A, et al. (2015). Risk of second primary malignancies in women with breast cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer.* 137(4):940–8. <http://dx.doi.org/10.1002/ijc.29462> PMID:25650288
- Ricceri F, Trevisan M, Fiano V, Grasso C, Fasanelli F, Scoccianti C, et al. (2014). Seasonality modifies methylation profiles in healthy people. *PLoS ONE.* 9(9):e106846. <http://dx.doi.org/10.1371/journal.pone.0106846> PMID:25210735
- Rice MS, Bertrand KA, Lajous M, Tamimi RM, Torres G, López-Ridaura R, et al. (2015). Reproductive and lifestyle risk factors and mammographic density in Mexican women. *Ann Epidemiol.* 25(11):868–73. <http://dx.doi.org/10.1016/j.annepidem.2015.08.006> PMID:26475982
- Richardson DB, Cardis E, Daniels RD, Gillies M, O'Hagan JA, Hamra GB, et al. (2015). Risk of cancer from occupational exposure to ionising radiation: retrospective cohort study of workers in France, the United Kingdom, and the United States (INWORKS). *BMJ.* 351:h5359. <http://dx.doi.org/10.1136/bmj.h5359> PMID:26487649
- Riegman PH, de Jong B, Daidone MG, Söderström T, Thompson J, Hall JA, et al. (2015). Optimizing sharing of hospital biobank samples. *Sci Transl Med.* 7(297):297fs31. <http://dx.doi.org/10.1126/scitranslmed.3009279> PMID:26203078
- Rinaldi S, Biessy C, de la Luz Hernandez M, Lajous M, Ortiz-Panozo E, Yunes E, et al. (2015). Endogenous hormones, inflammation, and body size in premenopausal Mexican women: results from the Mexican Teachers' Cohort (MTC, ESMAestras). *Cancer Causes Control.* 26(3):475–86. <http://dx.doi.org/10.1007/s10552-015-0527-2> PMID:25665532
- Rinaldi S, Biessy C, Hernandez M, Lesueur F, dos-Santos-Silva I, Rice MS, et al. (2014a). Circulating concentrations of insulin-like growth factor-I, insulin-like growth factor-binding protein-3, genetic polymorphisms and mammographic density in premenopausal Mexican women: results from the ESMAestras cohort. *Int J Cancer.* 134(6):1436–44. <http://dx.doi.org/10.1002/ijc.28469> PMID:24037648
- Rinaldi S, Kaaks R, Friedenreich CM, Key TJ, Travis R, Biessy C, et al. (2014b). Physical activity, sex steroid, and growth factor concentrations in pre- and post-menopausal women: a cross-sectional study within the EPIC cohort. *Cancer Causes Control.* 25(1):111–24. <http://dx.doi.org/10.1007/s10552-013-0314-x> PMID:24173534
- Rinaldi S, Plummer M, Biessy C, Tsilidis KK, Østergaard JN, Overvad K, et al. (2014c). Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study. *J Natl Cancer Inst.* 106(6):dju097. <http://dx.doi.org/10.1093/jnci/dju097> PMID:24824312
- Ro YS, Shin SD, Song KJ, Lee EJ, Lee YJ, Kim JY, et al. (2015). Interaction effects between hypothermia and diabetes mellitus on survival outcomes after out-of-hospital cardiac arrest. *Resuscitation.* 90:35–41. <http://dx.doi.org/10.1016/j.resuscitation.2015.02.006> PMID:25725296
- Robbins HA, Kemp TJ, Porras C, Rodriguez AC, Schiffman M, Wacholder S, et al. (2014a). Comparison of antibody responses to human papillomavirus vaccination as measured by three assays. *Front Oncol.* 3:328. <http://dx.doi.org/10.3389/fonc.2013.00328> PMID:24455487
- Robbins HA, Li Y, Porras C, Pawlita M, Ghosh A, Rodriguez AC, et al. (2014b). Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. *BMC Infect Dis.* 14(1):120. <http://dx.doi.org/10.1186/1471-2334-14-120> PMID:24588945
- Robbins HA, Waterboer T, Porras C, Kemp TJ, Pawlita M, Rodriguez AC, et al. (2014c). Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay. *Hum Vaccin Immunother.* 10(10):2965–74. <http://dx.doi.org/10.4161/21645515.2014.972811> PMID:25483632
- Rodríguez H, Levican J, Muñoz JP, Carrillo D, Acevedo ML, Gaggero A, et al. (2015). Viral infections in prostate carcinomas in Chilean patients. *Infect Agent Cancer.* 10(1):27. <http://dx.doi.org/10.1186/s13027-015-0024-y> PMID:26330890
- Rohrmann S, Linseisen J, Overvad K, Lund Würtz AM, Roswall N, Tjønneland A, et al. (2015). Meat and fish consumption and the risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer.* 136(5):E423–31. <http://dx.doi.org/10.1002/ijc.29236> PMID:25258006
- Rollan A, Arab JP, Camargo MC, Candia R, Harris P, Ferreccio C, et al. (2014). Management of *Helicobacter pylori* infection in Latin America: a Delphi technique-based consensus. *World J Gastroenterol.* 20(31):10969–83. <http://dx.doi.org/10.3748/wjg.v20.i31.10969> PMID:25152601
- Romaguera D, Ward H, Wark PA, Vergnaud AC, Peeters PH, van Gils CH, et al. (2015). Pre-diagnostic concordance with the WCRF/AICR guidelines and survival in European colorectal cancer patients: a cohort study. *BMC Med.* 13(1):107. <http://dx.doi.org/10.1186/s12916-015-0332-5> PMID:25948112
- Romieu I, Scoccianti C, Chajès V, de Batlle J, Biessy C, Dossus L, et al. (2015). Alcohol intake and breast cancer in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer.* 137(8):1921–30. <http://dx.doi.org/10.1002/ijc.29469> PMID:25677034
- Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al.; International HPV screening working group (2014). Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. *Lancet.* 383(9916):524–32. [http://dx.doi.org/10.1016/S0140-6736\(13\)62218-7](http://dx.doi.org/10.1016/S0140-6736(13)62218-7) PMID:24192252

- Rosenberger A, Friedrichs S, Amos CI, Brennan P, Fehring G, Heinrich J, et al. (2015). META-GSA: combining findings from gene-set analyses across several genome-wide association studies. *PLoS ONE*. 10(10):e0140179. <http://dx.doi.org/10.1371/journal.pone.0140179> PMID:26501144
- Ross H, Kostova D, Stoklosa M, Leon M (2014). The impact of cigarette excise taxes on smoking cessation rates from 1994 to 2010 in Poland, Russia, and Ukraine. *Nicotine Tob Res*. 16 Suppl 1:S37–43. <http://dx.doi.org/10.1093/ntr/ntt024> PMID:24343956
- Roswall N, Freisling H, Bueno-de-Mesquita HB, Ros M, Christensen J, Overvad K, et al. (2014). Anthropometric measures and bladder cancer risk: a prospective study in the EPIC cohort. *Int J Cancer*. 135(12):2918–29. <http://dx.doi.org/10.1002/ijc.28936> PMID:24771290
- Rothwell JA, Medina-Remón A, Pérez-Jiménez J, Neveu V, Knaze V, Slimani N, et al. (2015). Effects of food processing on polyphenol contents: a systematic analysis using Phenol-Explorer data. *Mol Nutr Food Res*. 59(1):160–70. <http://dx.doi.org/10.1002/mnfr.201400494> PMID:25338821
- Roulland S, Kelly RS, Morgado E, Sungalee S, Solal-Celigny P, Colombat P, et al. (2014). t(14;18) Translocation: a predictive blood biomarker for follicular lymphoma. *J Clin Oncol*. 32(13):1347–55. <http://dx.doi.org/10.1200/JCO.2013.52.8190> PMID:24687831
- Roura E, Castellsagué X, Pawlita M, Travier N, Waterboer T, Margall N, et al. (2014). Smoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohort. *Int J Cancer*. 135(2):453–66. <http://dx.doi.org/10.1002/ijc.28666> PMID:24338632
- Routledge MN, Kimanya ME, Shirima CP, Wild CP, Gong YY (2014). Quantitative correlation of aflatoxin biomarker with dietary intake of aflatoxin in Tanzanian children. *Biomarkers*. 19(5):430–5. <http://dx.doi.org/10.3109/1354750X.2014.924998> PMID:24902045
- Ruiz JR, Huybrechts I, Cuenca-García M, Artero EG, Labayen I, Meirhaeghe A, et al.; HELENA Study Group (2015). Cardiorespiratory fitness and ideal cardiovascular health in European adolescents. *Heart*. 101(10):766–73. <http://dx.doi.org/10.1136/heartjnl-2014-306750> PMID:25489050
- Rushton L, Hutchings SJ, Straif K (2014). Occupational cancer burden. In: Anttila S, Boffetta P, editors. *Occupational cancers*. London, UK: Springer-Verlag London; pp. 531–50.
- Saberi Hosnijeh F, Peeters P, Romieu I, Kelly R, Riboli E, Olsen A, et al. (2014). Dietary intakes and risk of lymphoid and myeloid leukemia in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Nutr Cancer*. 66(1):14–28. <http://dx.doi.org/10.1080/01635581.2014.847471> PMID:24279598
- Sagne C, Marcel V, Bota M, Martel-Planche G, Nobrega A, Palmero EI, et al. (2014). Age at cancer onset in germline *TP53* mutation carriers: association with polymorphisms in predicted G-quadruplex structures. *Carcinogenesis*. 35(4):807–15. <http://dx.doi.org/10.1093/carcin/bgt381> PMID:24336192
- Sahay D, Leblanc R, Grunewald TG, Ambatipudi S, Ribeiro J, Clézardin P, et al. (2015). The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer. *Oncotarget*. 6(24):20604–20. <http://dx.doi.org/10.18632/oncotarget.3774> PMID:26098771
- Samet JM, Straif K, Schüz J, Saracci R (2014a). Commentary: mobile phones and cancer: next steps after the 2011 IARC review. *Epidemiology*. 25(1):23–7. <http://dx.doi.org/10.1097/EDE.0000000000000028> PMID:24296926
- Samet JM, Straif K, Schüz J, Saracci R (2014b). The authors respond. *Epidemiology*. 25(4):618. <http://dx.doi.org/10.1097/EDE.0000000000000109> PMID:24887168
- Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, et al. (2015). Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types. *J Natl Cancer Inst*. 107(12):djv279. <http://dx.doi.org/10.1093/jnci/djv279> PMID:26464424
- Sanikini H, Dik VK, Siersema PD, Bhoo-Pathy N, Uiterwaal CS, Peeters PH, et al. (2015). Total, caffeinated and decaffeinated coffee and tea intake and gastric cancer risk: results from the EPIC cohort study. *Int J Cancer*. 136(6):E720–30. <http://dx.doi.org/10.1002/ijc.29223> PMID:25236393
- Sankaranarayanan R (2014a). Magnivisualizer in the early detection of cervical neoplasia. *J Gynecol Oncol*. 25(4):263–4. <http://dx.doi.org/10.3802/jgo.2014.25.4.263> PMID:25310029
- Sankaranarayanan R (2014b). Treatment of precancerous cervical lesions. In: Grigsby PW, editor. *Advances in cervical cancer management*. London, UK: Future Medicine Ltd; pp. 101–21.
- Sankaranarayanan R (2014c). Cancer prevention and care in India: an unfinished agenda. *Lancet Oncol*. 15(6):554–5. [http://dx.doi.org/10.1016/S1470-2045\(14\)70140-8](http://dx.doi.org/10.1016/S1470-2045(14)70140-8) PMID:24731886
- Sankaranarayanan R (2014d). Screening for cancer in low- and middle-income countries. *Ann Glob Health*. 80(5):412–7. <http://dx.doi.org/10.1016/j.aogh.2014.09.014> PMID:25512156
- Sankaranarayanan R (2015). HPV vaccination: the most pragmatic cervical cancer primary prevention strategy. *Int J Gynaecol Obstet*. 131 Suppl 1:S33–5. <http://dx.doi.org/10.1016/j.ijgo.2015.02.014> PMID:26433502
- Sankaranarayanan R, Esmey PO, Rajkumar R, Muwonge R, Swaminathan R (2014d). Cervical cancer mortality in India – Authors' reply. *Lancet*. 383(9931):1804–5. [http://dx.doi.org/10.1016/S0140-6736\(14\)60878-3](http://dx.doi.org/10.1016/S0140-6736(14)60878-3) PMID:24856024
- Sankaranarayanan R, Jivarajani PJ, Qiao YL (2014b). Early detection of colorectal cancer at primary care level health services. In: Magrath I, editor. *Cancer Control 2014: Cancer care in emerging health systems*. Brussels, Belgium: International Network for Cancer Treatment and Research; pp. 67–71.
- Sankaranarayanan R, Nene BM, Shastri S, Esmey PE, Rajkumar R, Muwonge R, et al. (2014c). Response to article titled "US-funded measurements of cervical cancer death rates in India: scientific and ethical concerns" by Eric J Suba. *Indian J Med Ethics*. 11(3):175–8. PMID:25101550
- Sankaranarayanan R, Qiao YL, Keita N (2015). The next steps in cervical screening. *Women's Health (Lond Engl)*. 11(2):201–12. <http://dx.doi.org/10.2217/whe.14.70> PMID:25776294
- Sankaranarayanan R, Ramadas K, Qiao YL (2014a). Managing the changing burden of cancer in Asia. *BMC Med*. 12(1):3. <http://dx.doi.org/10.1186/1741-7015-12-3> PMID:24400922
- Santaliestra-Pasías AM, Mouratidou T, Huybrechts I, Beghin L, Cuenca-García M, Castillo MJ, et al. (2014). Increased sedentary behaviour is associated with unhealthy dietary patterns in European adolescents participating in the HELENA study. *Eur J Clin Nutr*. 68(3):300–8. <http://dx.doi.org/10.1038/ejcn.2013.170> PMID:24045790
- Saracci R (2015). Erionite and cancer in a Mexican village. *Occup Environ Med*. 72(3):163–4. <http://dx.doi.org/10.1136/oemed-2014-102544> PMID:25406477

- Scalbert A, Brennan L, Manach C, Andres-Lacueva C, Dragsted LO, Draper J, et al. (2014). The food metabolome: a window over dietary exposure. *Am J Clin Nutr.* 99(6):1286–308. <http://dx.doi.org/10.3945/ajcn.113.076133> PMID:24760973
- Scalbert A, Zamora-Ros R (2015). Bridging evidence from observational and intervention studies to identify flavonoids most protective for human health. *Am J Clin Nutr.* 101(5):897–8. <http://dx.doi.org/10.3945/ajcn.115.110205> PMID:25832341
- Scelo G, Riazalhosseini Y, Greger L, Letourneau L, González-Porta M, Wozniak MB, et al. (2014). Variation in genomic landscape of clear cell renal cell carcinoma across Europe. *Nat Commun.* 5:5135. <http://dx.doi.org/10.1038/ncomms6135> PMID:25351205
- Schaafsma T, Wakefield J, Hanisch R, Bray F, Schüz J, Joy EJ, et al. (2015). Africa's oesophageal cancer corridor: geographic variations in incidence correlate with certain micronutrient deficiencies. *PLoS ONE.* 10(10):e0140107. <http://dx.doi.org/10.1371/journal.pone.0140107> PMID:26448405
- Schinasi L, Leon ME (2014). Non-Hodgkin lymphoma and occupational exposure to agricultural pesticide chemical groups and active ingredients: a systematic review and meta-analysis. *Int J Environ Res Public Health.* 11(4):4449–527. <http://dx.doi.org/10.3390/ijerph110404449> PMID:24762670
- Schmidt JA, Allen NE, Almquist M, Franceschi S, Rinaldi S, Tipper SJ, et al. (2014). Insulin-like growth factor-I and risk of differentiated thyroid carcinoma in the European Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiol Biomarkers Prev.* 23(6):976–85. <http://dx.doi.org/10.1158/1055-9965.EPI-13-1210-T> PMID:24646451
- Schmidt JA, Rinaldi S, Ferrari P, Carayol M, Achaintre D, Scalbert A, et al. (2015). Metabolic profiles of male meat eaters, fish eaters, vegetarians, and vegans from the EPIC-Oxford cohort. *Am J Clin Nutr.* 102(6):1518–26. <http://dx.doi.org/10.3945/ajcn.115.111989> PMID:26511225
- Schonfeld SJ, McCormack V, Rutherford MJ, Schüz J (2014a). Regional variations in German mesothelioma mortality rates: 2000–2010. *Cancer Causes Control.* 25(5):615–24. <http://dx.doi.org/10.1007/s10552-014-0368-4> PMID:24658968
- Schonfeld SJ, Winde F, Albrecht C, Kielkowski D, Liefferink M, Patel M, et al.; workshop participants (2014b). Health effects in populations living around the uraniferous gold mine tailings in South Africa: gaps and opportunities for research. *Cancer Epidemiol.* 38(5):628–32. <http://dx.doi.org/10.1016/j.canep.2014.06.003> PMID:25023081
- Schüz J (2014). Airline crew cohorts: is there more to learn regarding their cancer risk? *Occup Environ Med.* 71(5):307. <http://dx.doi.org/10.1136/oemed-2013-102026> PMID:24627305
- Schüz J, Luta G, Erdmann F, Ferro G, Bautz A, Simony SB, et al. (2015). Birth order and risk of childhood cancer in the Danish birth cohort of 1973–2010. *Cancer Causes Control.* 26(11):1575–82. <http://dx.doi.org/10.1007/s10552-015-0651-z> PMID:26259524
- Scoccianti C, Lauby-Secretan B (2014). L'exposition aux perturbateurs endocriniens induit-elle un risque d'obésité chez l'enfant ? *Bulletin de veille Scientifique* (25):67–70.
- Scoccianti C, Lauby-Secretan B, Bello PY, Chajes V, Romieu I (2014). Female breast cancer and alcohol consumption: a review of the literature. *Am J Prev Med.* 46(3 Suppl 1):S16–25. <http://dx.doi.org/10.1016/j.amepre.2013.10.031> PMID:24512927
- Scott RA, Fall T, Pasko D, Barker A, Sharp SJ, Arriola L, et al.; RISC Study Group; EPIC-InterAct Consortium (2014). Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity. *Diabetes.* 63(12):4378–87. <http://dx.doi.org/10.2337/db14-0319> PMID:24947364
- Scott S, van der Sande M, Faye-Joof T, Mendy M, Sanneh B, Barry Jallow F, et al. (2015). Seroprevalence of pertussis in the Gambia: evidence for continued circulation of *Bordetella pertussis* despite high vaccination rates. *Pediatr Infect Dis J.* 34(4):333–8. <http://dx.doi.org/10.1097/INF.0000000000000576> PMID:25764094
- Seidler A, Brüning T, Taeger D, Möhner M, Gawrych K, Bergmann A, et al. (2014a). Cancer incidence among workers occupationally exposed to dinitrotoluene in the copper mining industry. *Int Arch Occup Environ Health.* 87(2):117–24. <http://dx.doi.org/10.1007/s00420-012-0842-9> PMID:23274286
- Seidler A, Harth V, Taeger D, Möhner M, Gawrych K, Bergmann A, et al. (2014b). Dinitrotoluene exposure in the copper mining industry and renal cancer: a case-cohort study. *Occup Environ Med.* 71(4):259–65. <http://dx.doi.org/10.1136/oemed-2013-101850> PMID:24486554
- Seitz H, Canali E, Ribeiro-Müller L, Pálfi A, Bolchi A, Tommasino M, et al. (2014). A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses. *Vaccine.* 32(22):2610–7. <http://dx.doi.org/10.1016/j.vaccine.2014.03.033> PMID:24662712
- Seitz H, Ribeiro-Müller L, Canali E, Bolchi A, Tommasino M, Ottonello S, et al. (2015). Robust in vitro and in vivo neutralization against multiple high-risk HPV types induced by a thermostable thioredoxin-L2 vaccine. *Cancer Prev Res (Phila).* 8(10):932–41. <http://dx.doi.org/10.1158/1940-6207.CAPR-15-0164> PMID:26170394
- Sen A, Tsilidis KK, Allen NE, Rinaldi S, Appleby PN, Almquist M, et al. (2015). Baseline and lifetime alcohol consumption and risk of differentiated thyroid carcinoma in the EPIC study. *Br J Cancer.* 113(5):840–7. <http://dx.doi.org/10.1038/bjc.2015.280> PMID:26313664
- Sevanlou SG, Malekzadeh R, Poustchi H, Sharafkhan M, Ghodsi S, Malekzadeh F, et al. (2015a). The clinical performance of an office-based risk scoring system for fatal cardiovascular diseases in North-East of Iran. *PLoS ONE.* 10(5):e0126779. <http://dx.doi.org/10.1371/journal.pone.0126779> PMID:26011607
- Sevanlou SG, Newson RB, Poustchi H, Malekzadeh MM, Rezanejad Asl P, Etemadi A, et al. (2015b). Cardiovascular disease mortality and years of life lost attributable to non-optimal systolic blood pressure and hypertension in northeastern Iran. *Arch Iran Med.* 18(3):144–52. PMID:25773687
- Sera F, Ferrari P (2015). A multilevel model to estimate the within- and the between-center components of the exposure/disease association in the EPIC study. *PLoS ONE.* 10(3):e0117815. <http://dx.doi.org/10.1371/journal.pone.0117815> PMID:25785729
- Serrano B, Alemany L, Ruiz PA, Tous S, Lima MA, Bruni L, et al. (2014). Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China). *Cancer Epidemiol.* 38(6):748–56. <http://dx.doi.org/10.1016/j.canep.2014.09.003> PMID:25305098
- Shakeri R, Malekzadeh R, Nasrollahzadeh D, Pawlita M, Murphy G, Islami F, et al. (2015). Multiplex *H. pylori* serology and risk of gastric cardia and noncardia adenocarcinomas. *Cancer Res.* 75(22):4876–83. <http://dx.doi.org/10.1158/0008-5472.CAN-15-0556> PMID:26383162

- Shimakawa Y, Bottomley C, Njie R, Mendy M (2014a). The association between maternal hepatitis B e antigen status, as a proxy for perinatal transmission, and the risk of hepatitis B e antigenaemia in Gambian children. *BMC Public Health*. 14(1):532. <http://dx.doi.org/10.1186/1471-2458-14-532> PMID:24885392
- Shimakawa Y, Lemoine M, Bottomley C, Njai HF, Ndow G, Jatta A, et al. (2015). Birth order and risk of hepatocellular carcinoma in chronic carriers of hepatitis B virus: a case-control study in The Gambia. *Liver Int*. 35(10):2318–26. <http://dx.doi.org/10.1111/liv.12814> PMID:25728498
- Shimakawa Y, Lemoine M, Mendy M, Njai HF, D'Alessandro U, Hall A, et al. (2014b). Population-based interventions to reduce the public health burden related with hepatitis B virus infection in the Gambia, West Africa. *Trop Med Health*. 42(2 Suppl):59–64. <http://dx.doi.org/10.2149/tmh.2014-S08> PMID:25425952
- Shirima CP, Kimanya ME, Routledge MN, Srey C, Kinabo JL, Humpf HU, et al. (2015). A prospective study of growth and biomarkers of exposure to aflatoxin and fumonisin during early childhood in Tanzania. *Environ Health Perspect*. 123(2):173–8. PMID:25325363
- Shivappa N, Hébert JR, Rietzschel ER, De Buyzere ML, Langlois M, Debruyne E, et al. (2015). Associations between dietary inflammatory index and inflammatory markers in the Asklepios Study. *Br J Nutr*. 113(4):665–71. <http://dx.doi.org/10.1017/S000711451400395X> PMID:25639781
- Shterzer N, Heyman D, Shapiro B, Yaniv A, Jackman A, Serour F, et al. (2014). Human papillomavirus types detected in skin warts and cancer differ in their transforming properties but commonly counteract UVB induced protective responses in human keratinocytes. *Virology*. 468–470:647–59. <http://dx.doi.org/10.1016/j.virol.2014.09.015> PMID:25443667
- Shu X, Prochazka M, Lannering B, Schüz J, Rööslö M, Tynes T, et al. (2014). Atopic conditions and brain tumor risk in children and adolescents – an international case-control study (CEFALO). *Ann Oncol*. 25(4):902–8. <http://dx.doi.org/10.1093/annonc/mdu048> PMID:24608192
- Shui IM, Lindström S, Kibel AS, Berndt SI, Campa D, Gerke T, et al. (2014). Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. *Eur Urol*. 65(6):1069–75. <http://dx.doi.org/10.1016/j.eururo.2013.12.058> PMID:24411283
- Shui IM, Mondul AM, Lindström S, Tsilidis KK, Travis RC, Gerke T, et al.; Breast and Prostate Cancer Cohort Consortium Group (2015). Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. *Cancer*. 121(12):1949–56. <http://dx.doi.org/10.1002/cncr.29320> PMID:25731953
- Sieri S, Chiodini P, Agnoli C, Pala V, Berrino F, Trichopoulou A, et al. (2014). Dietary fat intake and development of specific breast cancer subtypes. *J Natl Cancer Inst*. 106(5):dju068. <http://dx.doi.org/10.1093/jnci/dju068> PMID:24718872
- Siesling S, Louwman WJ, Kwast A, van den Hurk C, O'Callaghan M, Rosso S, et al. (2015). Uses of cancer registries for public health and clinical research in Europe: results of the European Network of Cancer Registries survey among 161 population-based cancer registries during 2010–2012. *Eur J Cancer*. 51(9):1039–49. <http://dx.doi.org/10.1016/j.ejca.2014.07.016> PMID:25131265
- Silver MJ, Kessler NJ, Hennig BJ, Dominguez-Salas P, Laritsky E, Baker MS, et al. (2015). Independent genomewide screens identify the tumor suppressor *VTRNA2-1* as a human epiallele responsive to periconceptual environment. *Genome Biol*. 16(1):118. <http://dx.doi.org/10.1186/s13059-015-0660-y> PMID:26062908
- Simbiri KO, Biddle J, Kinyera T, Were PA, Tenge C, Kawira E, et al. (2014). Burkitt lymphoma research in East Africa: highlights from the 9th African Organization for Research and Training in Cancer conference held in Durban, South Africa in 2013. *Infect Agent Cancer*. 9(32):1–8. <http://dx.doi.org/10.1186/1750-9378-9-32> PMID:25686906
- Siouda M, Frecha C, Accardi R, Yue J, Cuenin C, Gruffat H, et al. (2014). Epstein-Barr virus down-regulates tumor suppressor *DOK1* expression. *PLoS Pathog*. 10(5):e1004125. <http://dx.doi.org/10.1371/journal.ppat.1004125> PMID:24809689
- Skibola CF, Berndt SI, Vijai J, Conde L, Wang Z, Yeager M, et al. (2014). Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. *Am J Hum Genet*. 95(4):462–71. <http://dx.doi.org/10.1016/j.ajhg.2014.09.004> PMID:25279986
- Skyrud KD, Bray F, Møller B (2014). A comparison of relative and cause-specific survival by cancer site, age and time since diagnosis. *Int J Cancer*. 135(1):196–203. <http://dx.doi.org/10.1002/ijc.28645> PMID:24302538
- Slimani N, Freisling H, Illner AK, Huybrechts I (2015). Methods to determine dietary intake. In: Lovegrove JA, Hodson L, Sharma S, Lanham-New SA, editors. *Nutrition research methodologies*. Chichester, UK: Wiley-Blackwell; pp. 48–70. <http://dx.doi.org/10.1002/9781119180425.ch4>
- Sluijs I, Holmes MV, van der Schouw YT, Beulens JW, Asselbergs FW, Huerta JM, et al.; InterAct Consortium (2015). A Mendelian randomization study of circulating uric acid and type 2 diabetes. *Diabetes*. 64(8):3028–36. <http://dx.doi.org/10.2337/db14-0742> PMID:25918230
- Smith KR, Bruce N, Balakrishnan K, Adair-Rohani H, Balmes J, Chafe Z, et al.; HAP CRA Risk Expert Group (2014). Millions dead: how do we know and what does it mean? Methods used in the comparative risk assessment of household air pollution. *Annu Rev Public Health*. 35(1):185–206. <http://dx.doi.org/10.1146/annurev-publhealth-032013-182356> PMID:24641558
- Sokolnikov M, Preston D, Gilbert E, Schonfeld S, Koshurnikova N (2015). Radiation effects on mortality from solid cancers other than lung, liver, and bone cancer in the Mayak worker cohort: 1948–2008. *PLoS ONE*. 10(2):e0117784. <http://dx.doi.org/10.1371/journal.pone.0117784> PMID:25719381
- Sovio U, Li J, Aitken Z, Humphreys K, Czene K, Moss S, et al. (2014). Comparison of fully and semi-automated area-based methods for measuring mammographic density and predicting breast cancer risk. *Br J Cancer*. 110(7):1908–16. <http://dx.doi.org/10.1038/bjc.2014.82> PMID:24556624
- Spijkerman AM, van der A DL, Nilsson PM, Ardanaz E, Gavrilu D, Agudo A, et al.; InterAct Consortium (2014). Smoking and long-term risk of type 2 diabetes: the EPIC-InterAct study in European populations. *Diabetes Care*. 37(12):3164–71. <http://dx.doi.org/10.2337/dc14-1020> PMID:25336749
- Stang A, Bray F, Dieckmann KP, Lortet-Tieulent J, Rusner C (2015). Mortality of testicular cancer in East and West Germany 20 years after reunification: a gap not closed yet. *Urol Int*. 95(2):160–6. <http://dx.doi.org/10.1159/000381883> PMID:25966659
- Startsev N, Dimov P, Grosche B, Tretyakov F, Schüz J, Akleyev A (2015). Methods for ensuring high quality of coding of cause of death: the mortality register to follow Southern Urals populations exposed to radiation. *Methods Inf Med*. 54(4):359–63. <http://dx.doi.org/10.3414/ME14-01-0101> PMID:25731905

- Stattin P, Vickers AJ, Sjöberg DD, Johansson R, Granfors T, Johansson M, et al. (2015). Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: a nested case-control study. *Eur Urol.* 68(2):207–13. <http://dx.doi.org/10.1016/j.eururo.2015.01.009> PMID:25682340
- Stefan DC, Stones DK, Wainwright D, Kruger M, Davidson A, Poole J, et al. (2015). Childhood cancer incidence in South Africa, 1987 – 2007. *S Afr Med J.* 105(11):939–47. <http://dx.doi.org/10.7196/SAMJ.2015.v105i11.9780> PMID:26632323
- Steffen A, Huerta JM, Weiderpass E, Bueno-de-Mesquita HB, May AM, Siersema PD, et al. (2015). General and abdominal obesity and risk of esophageal and gastric adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer.* 137(3):646–57. <http://dx.doi.org/10.1002/ijc.29432> PMID:25598323
- Steins Bisschop CN, van Gils CH, Emaus MJ, Bueno-de-Mesquita HB, Monninkhof EM, Boeing H, et al. (2014). Weight change later in life and colon and rectal cancer risk in participants in the EPIC-PANACEA study. *Am J Clin Nutr.* 99(1):139–47. <http://dx.doi.org/10.3945/ajcn.113.066530> PMID:24225355
- Steliarova-Foucher E, O'Callaghan M, Ferlay J, Masuyer E, Rosso S, Forman D, et al. (2015b). The European Cancer Observatory: a new data resource. *Eur J Cancer.* 51(9):1131–43. <http://dx.doi.org/10.1016/j.ejca.2014.01.027> PMID:24569102
- Steliarova-Foucher E, Stiller C, Colombet M, Kaatsch P, Zanetti R, Peris-Bonet R (2015a). Registration of childhood cancer: moving towards pan-European coverage? *Eur J Cancer.* 51(9):1064–79. <http://dx.doi.org/10.1016/j.ejca.2015.03.009> PMID:25899984
- Straif K, Loomis D, Guyton K, Grosse Y, Lauby-Secretan B, El Ghissassi F, et al. (2014). Future priorities for the IARC Monographs. *Lancet Oncol.* 15(7):683–4. [http://dx.doi.org/10.1016/S1470-2045\(14\)70168-8](http://dx.doi.org/10.1016/S1470-2045(14)70168-8)
- Stronach EA, Cunnea P, Turner C, Guney T, Aiyappa R, Jayapalan S, et al. (2015). The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma. *Oncotarget.* 6(31):31593–603. PMID:26267317
- Su Z, Labaj PP, Li S, Thierry-Mieg J, Thierry-Mieg D, Shi W, et al.; SEQC/MAQC-III Consortium (2014). A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium. *Nat Biotechnol.* 32(9):903–14. <http://dx.doi.org/10.1038/nbt.2957> PMID:25150838
- Suzuki A, Nobusawa S, Natsume A, Suzuki H, Kim YH, Yokoo H, et al. (2014). Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas. *J Neurooncol.* 120(2):283–91. <http://dx.doi.org/10.1007/s11060-014-1568-1> PMID:25085214
- Svensson A, Larsson C, Eiben G, Lanfer A, Pala V, Hebestreit A, et al.; IDEFICS Consortium (2014). European children's sugar intake on weekdays versus weekends: the IDEFICS study. *Eur J Clin Nutr.* 68(7):822–8. <http://dx.doi.org/10.1038/ejcn.2014.87> PMID:24824016
- Taeger D, Pesch B, Kendzia B, Behrens T, Jöckel KH, Dahmann D, et al. (2015). Lung cancer among coal miners, ore miners and quarrymen: smoking-adjusted risk estimates from the SYNERGY pooled analysis of case-control studies. *Scand J Work Environ Health.* 41(5):467–77. PMID:26153779
- Tang H, Wei P, Duell EJ, Risch HA, Olson SH, Bueno-de-Mesquita HB, et al. (2014a). Axonal guidance signaling pathway interacting with smoking in modifying the risk of pancreatic cancer: a gene- and pathway-based interaction analysis of GWAS data. *Carcinogenesis.* 35(5):1039–45. <http://dx.doi.org/10.1093/carcin/bgu010> PMID:24419231
- Tang H, Wei P, Duell EJ, Risch HA, Olson SH, Bueno-de-Mesquita HB, et al. (2014b). Genes-environment interactions in obesity- and diabetes-associated pancreatic cancer: a GWAS data analysis. *Cancer Epidemiol Biomarkers Prev.* 23(1):98–106. <http://dx.doi.org/10.1158/1055-9965.EPI-13-0437-T> PMID:24136929
- Tao MH, Zhou J, Rialdi AP, Martinez R, Dabek J, Scelo G, et al. (2014). Indoor air pollution from solid fuels and peripheral blood DNA methylation: findings from a population study in Warsaw, Poland. *Environ Res.* 134:325–30. <http://dx.doi.org/10.1016/j.envres.2014.08.017> PMID:25199973
- Tapias A, Zhou ZW, Shi Y, Chong Z, Wang P, Groth M, et al. (2014). Trpap-dependent histone acetylation specifically regulates cell-cycle gene transcription to control neural progenitor fate decisions. *Cell Stem Cell.* 14(5):632–43. <http://dx.doi.org/10.1016/j.stem.2014.04.001> PMID:24792116
- Tchounga BK, Jaquet A, Coffie PA, Horo A, Sauvaget C, Adoubi I, et al. (2014). Cervical cancer prevention in reproductive health services: knowledge, attitudes and practices of midwives in Côte d'Ivoire, West Africa. *BMC Health Serv Res.* 14(1):165. <http://dx.doi.org/10.1186/1472-6963-14-165> PMID:24721621
- Thierry-Chef I, Richardson DB, Daniels RD, Gillies M, Hamra GB, Haylock R, et al.; INWORKS Consortium (2015). Dose estimation for a study of nuclear workers in France, the United Kingdom and the United States of America: methods for the International Nuclear Workers Study (INWORKS). *Radiat Res.* 183(6):632–42. <http://dx.doi.org/10.1667/RR14006.1> PMID:26010707
- Thomas NE, Krickler A, Waxweiler WT, Dillon PM, Busman KJ, From L, et al.; Genes, Environment, and Melanoma (GEM) Study Group (2014). Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study. *JAMA Dermatol.* 150(12):1306–14. <http://dx.doi.org/10.1001/jamadermatol.2014.1348> PMID:25162299
- Thulaseedharan JV, Malila N, Esmey PO, Muwonge R, Hakama M, Sankaranarayanan R (2015a). Risk of invasive cancer among women visually screened and colposcopy triaged by trained nurses in rural South India. *Int J Gynaecol Obstet.* 129(2):104–8. <http://dx.doi.org/10.1016/j.ijgo.2014.11.019> PMID:25661324
- Thulaseedharan JV, Malila N, Swaminathan R, Esmey PO, Cherian M, Hakama M, et al. (2015b). Effect of screening on variation in cervical cancer survival by socioeconomic determinants – a study from rural South India. *Asian Pac J Cancer Prev.* 16(13):5237–42. <http://dx.doi.org/10.7314/APJCP.2015.16.13.5237> PMID:26225659
- Tikk K, Sookthai D, Fortner RT, Johnson T, Rinaldi S, Romieu I, et al. (2015). Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study. *Breast Cancer Res.* 17(1):49. <http://dx.doi.org/10.1186/s13058-015-0563-6> PMID:25887963
- Tikk K, Sookthai D, Johnson T, Dossus L, Clavel-Chapelon F, Tjønneland A, et al. (2014a). Prolactin determinants in healthy women: a large cross-sectional study within the EPIC cohort. *Cancer Epidemiol Biomarkers Prev.* 23(11):2532–42. <http://dx.doi.org/10.1158/1055-9965.EPI-14-0613> PMID:25143360

- Tikk K, Sookthai D, Johnson T, Rinaldi S, Romieu I, Tjønneland A, et al. (2014b). Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort. *Ann Oncol.* 25(7): 1422–8. <http://dx.doi.org/10.1093/annonc/mdu150> PMID:24718887
- Timofeeva MN, Kinnersley B, Farrington SM, Whiffin N, Palles C, Svinti V, et al. (2015). Recurrent coding sequence variation explains only a small fraction of the genetic architecture of colorectal cancer. *Sci Rep.* 5:16286. <http://dx.doi.org/10.1038/srep16286> PMID:26553438
- Tissot C, Toffart AC, Villar S, Souquet PJ, Merle P, Moro-Sibilot D, et al. (2015). Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. *Eur Respir J.* 46(6):1773–80. <http://dx.doi.org/10.1183/13993003.00676-2015> PMID:26493785
- Toll A, Lloerbas B, Masferrer E, Ferrández-Pulido C, García-Patos V, Gheit T, et al. (2014). Human beta papillomavirus DNA study in primary cutaneous squamous cell carcinomas and their corresponding metastases. *Arch Dermatol Res.* 306(1):93–5. <http://dx.doi.org/10.1007/s00403-013-1424-8> PMID:24173126
- Tommasino M (2014). The human papillomavirus family and its role in carcinogenesis. *Semin Cancer Biol.* 26:13–21. <http://dx.doi.org/10.1016/j.semcancer.2013.11.002> PMID:24316445
- Toporcov TN, Znaor A, Zhang ZF, Yu GP, Winn DM, Wei Q, et al. (2015). Risk factors for head and neck cancer in young adults: a pooled analysis in the INHANCE consortium. *Int J Epidemiol.* 44(1):169–85. <http://dx.doi.org/10.1093/ije/dyu255> PMID:25613428
- Torabi K, Miró R, Fernández-Jiménez N, Quintanilla I, Ramos L, Prat E, et al. (2015). Patterns of somatic uniparental disomy identify novel tumor suppressor genes in colorectal cancer. *Carcinogenesis.* 36(10):1103–10. <http://dx.doi.org/10.1093/carcin/bgv115> PMID:26243311
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015). Global cancer statistics, 2012. *CA Cancer J Clin.* 65(2):87–108. <http://dx.doi.org/10.3322/caac.21262> PMID:25651787
- Torres M, Gheit T, McKay-Chopin S, Rodríguez C, Romero JD, Filotico R, et al. (2015). Prevalence of beta and gamma human papillomaviruses in the anal canal of men who have sex with men is influenced by HIV status. *J Clin Virol.* 67:47–51. <http://dx.doi.org/10.1016/j.jcv.2015.04.005> PMID:25959158
- Trabert B, Chen J, Devesa SS, Bray F, McGlynn KA (2015). International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973–2007. *Andrology.* 3(1):4–12. <http://dx.doi.org/10.1111/andr.293> PMID:25331326
- Traoré F, Gormally E, Villar S, Friesen MD, Groopman JD, Vernet G, et al. (2015). Molecular characteristics of hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali. *BMC Infect Dis.* 15(1):180. <http://dx.doi.org/10.1186/s12879-015-0916-x> PMID:25886382
- Tshomo U, Franceschi S, Dorji D, Baussano I, Tenet V, Snijders PJ, et al. (2014). Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme. *BMC Infect Dis.* 14(1):408. <http://dx.doi.org/10.1186/1471-2334-14-408> PMID:25047665
- Tsilidis KK, Allen NE, Appleby PN, Rohmann S, Nöthlings U, Arriola L, et al. (2015). Diabetes mellitus and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer.* 136(2):372–81. <http://dx.doi.org/10.1002/ijc.28989> PMID:24862312
- Turati F, Trichopoulos D, Polesel J, Bravi F, Rossi M, Talamini R, et al. (2014). Mediterranean diet and hepatocellular carcinoma. *J Hepatol.* 60(3):606–11. <http://dx.doi.org/10.1016/j.jhep.2013.10.034> PMID:24240052
- Turner MC, Benke G, Bowman JD, Figuerola J, Fleming S, Hours M, et al. (2014). Occupational exposure to extremely low-frequency magnetic fields and brain tumor risks in the INTEROCC study. *Cancer Epidemiol Biomarkers Prev.* 23(9):1863–72. <http://dx.doi.org/10.1158/1055-9965.EPI-14-0102> PMID:24935666
- Urpi-Sarda M, Andres-Lacueva C, Rabassa M, Ruggiero C, Zamora-Ros R, Bandinelli S, et al. (2015). The relationship between urinary total polyphenols and the frailty phenotype in a community-dwelling older population: the InCHIANTI study. *J Gerontol A Biol Sci Med Sci.* 70(9):1141–7. <http://dx.doi.org/10.1093/gerona/glv026> PMID:25838546
- Vaca-Paniagua F, Alvarez-Gomez RM, Maldonado-Martínez HA, Pérez-Plasencia C, Fragozo-Ontiveros V, Lasa-Gonsebatt F, et al. (2015b). Revealing the molecular portrait of triple negative breast tumors in an understudied population through omics analysis of formalin-fixed and paraffin-embedded tissues. *PLoS ONE.* 10(5):e0126762. <http://dx.doi.org/10.1371/journal.pone.0126762> PMID:25961742
- Vaca-Paniagua F, Oliver J, Nogueira da Costa A, Merle P, McKay J, Herceg Z, et al. (2015a). Targeted deep DNA methylation analysis of circulating cell-free DNA in plasma using massively parallel semiconductor sequencing. *Epigenomics.* 7(3):353–62. <http://dx.doi.org/10.2217/epi.14.94> PMID:26077425
- Vaccarella S, Bray F (2015). Epidemiology and burden of disease associated with HPV infection. *Curr Obstet Gynecol Rep.* 4(4):181–8. <http://dx.doi.org/10.1007/s13669-015-0137-8>
- Vaccarella S, Dal Maso L, Laversanne M, Bray F, Plummer M, Franceschi S (2015). The impact of diagnostic changes on the rise in thyroid cancer incidence: a population-based study in selected high-resource countries. *Thyroid.* 25(10):1127–36. <http://dx.doi.org/10.1089/thy.2015.0116> PMID:26133012
- Vaccarella S, Franceschi S, Engholm G, Lönnberg S, Khan S, Bray F (2014). 50 Years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. *Br J Cancer.* 111(5):965–9. <http://dx.doi.org/10.1038/bjc.2014.362> PMID:24992581
- Valery PC, Laversanne M, Bray F (2015). Bone cancer incidence by morphological subtype: a global assessment. *Cancer Causes Control.* 26(8): 1127–39. <http://dx.doi.org/10.1007/s10552-015-0607-3> PMID:26054913
- Valery PC, Moore SP, Meiklejohn J, Bray F (2014). International variations in childhood cancer in indigenous populations: a systematic review. *Lancet Oncol.* 15(2):e90–103. [http://dx.doi.org/10.1016/S1470-2045\(13\)70553-9](http://dx.doi.org/10.1016/S1470-2045(13)70553-9) PMID:24480559
- van den Broek EC, Liu L, Posthuma EF, Janssen-Heijnen ML, Coebergh JW, Soerjomataram I (2014). Increased risk of chronic lymphocytic leukaemia among cancer survivors in the Netherlands: increased detection, causal factors or both? *Ann Hematol.* 93(1):157–62. <http://dx.doi.org/10.1007/s00277-013-1929-4> PMID:24381068
- van Nielen M, Feskens EJ, Mensink M, Sluijs I, Molina E, Amiano P, et al.; InterAct Consortium (2014). Dietary protein intake and incidence of type 2 diabetes in Europe: the EPIC-InterAct case-cohort study. *Diabetes Care.* 37(7):1854–62. <http://dx.doi.org/10.2337/dc13-2627> PMID:24722499
- Vanaelst B, Michels N, Clays E, Herrmann D, Huybrechts I, Sioen I, et al. (2014). The association between childhood stress and body composition, and the role of stress-related lifestyle factors – cross-sectional findings from the baseline ChiBSD survey. *Int J Behav Med.* 21(2):292–301. <http://dx.doi.org/10.1007/s12529-013-9294-1> PMID:23377786

- Vandevoorde C, Gomolka M, Roessler U, Samaga D, Lindholm C, Fernet M, et al. (2015). EPI-CT: in vitro assessment of the applicability of the  $\gamma$ -H2AX-foci assay as cellular biomarker for exposure in a multicentre study of children in diagnostic radiology. *Int J Radiat Biol.* 91(8):653–63. <http://dx.doi.org/10.3109/09553002.2015.1047987> PMID:25968559
- Vehmas T, Sauni R, Miller AB, Straif K, Malila N, Smith RA (2014). Screening for asbestos-related lung cancer. In: Oksa P, Wolff H, Vehmas T, Pallasaho P, Frilander H, editors. *Asbestos, asbestosis, and cancer – Helsinki criteria for diagnosis and attribution 2014*. Helsinki, Finland: Finnish Institute of Occupational Health; pp. 11–35.
- Vereecken C, Covents M, Huybrechts I, Kelly C, Maes L (2014). Changes in children's food group intake from age 3 to 7 years: comparison of a FFQ with an online food record. *Br J Nutr.* 112(2):269–76. <http://dx.doi.org/10.1017/S0007114514000762> PMID:24780104
- Vermeulen R, Silverman DT, Garshick E, Vlaanderen J, Portengen L, Steenland K (2014). Exposure-response estimates for diesel engine exhaust and lung cancer mortality based on data from three occupational cohorts. *Environ Health Perspect.* 122(2):172–7. PMID:24273233
- Vijai J, Wang Z, Berndt SI, Skibola CF, Slager SL, de Sanjose S, et al. (2015). A genome-wide association study of marginal zone lymphoma shows association to the HLA region. *Nat Commun.* 6:5751. <http://dx.doi.org/10.1038/ncomms6751> PMID:25569183
- Villeneuve PJ, Jerrett M, Brenner D, Su J, Chen H, McLaughlin JR (2014a). Villeneuve et al. respond to "Impact of air pollution on lung cancer". *Am J Epidemiol.* 179(4):455–6. <http://dx.doi.org/10.1093/aje/kwt291> PMID:24287469
- Villeneuve PJ, Jerrett M, Brenner D, Su J, Chen H, McLaughlin JR (2014b). A case-control study of long-term exposure to ambient volatile organic compounds and lung cancer in Toronto, Ontario, Canada. *Am J Epidemiol.* 179(4):443–51. <http://dx.doi.org/10.1093/aje/kwt289> PMID:24287467
- Vineis P, Saracci R (2015). Conflicts of interest matter and awareness is needed. *J Epidemiol Community Health.* 69(10):1018–20. <http://dx.doi.org/10.1136/jech-2014-205012> PMID:25636323
- Vineis P, Wild CP (2014). Global cancer patterns: causes and prevention. *Lancet.* 383(9916):549–57. [http://dx.doi.org/10.1016/S0140-6736\(13\)62224-2](http://dx.doi.org/10.1016/S0140-6736(13)62224-2) PMID:24351322
- Vlaanderen J, Portengen L, Schüz J, Olsson A, Pesch B, Kendzia B, et al. (2014). Effect modification of the association of cumulative exposure and cancer risk by intensity of exposure and time since exposure cessation: a flexible method applied to cigarette smoking and lung cancer in the SYNERGY study. *Am J Epidemiol.* 179(3):290–8. <http://dx.doi.org/10.1093/aje/kwt273> PMID:24355332
- Vlaanderen J, Straif K, Ruder A, Blair A, Hansen J, Lyng E, et al. (2014). Tetrachloroethylene exposure and bladder cancer risk: a meta-analysis of dry-cleaning-worker studies. *Environ Health Perspect.* 122(7):661–6. PMID:24659585
- Vlachopoulos D, Gracia-Marco L, Barker-Collo S, Huybrechts I, Moreno Aznar L, Mouratidou T (2015). Bone health: the independent and combined effects of calcium, vitamin D and exercise in children and adolescents. In: Preedy VR, editor. *Calcium: chemistry, analysis, function and effects*. Cambridge, UK: Royal Society of Chemistry; pp. 530–46. <http://dx.doi.org/10.1039/9781782622130-00530>
- von Karsa L, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, et al. (2015). European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. *Papillomavirus Res.* 1:22–31. <http://dx.doi.org/10.1016/j.pvr.2015.06.006>
- Vorsters A, Van Damme P, Clifford G (2014). Urine testing for HPV: rationale for using first void. *BMJ.* 349:g6252. <http://dx.doi.org/10.1136/bmj.g6252> PMID:25319476
- Vyncke K, Huybrechts I, Van Winckel M, Cuenca Garcia M, Labayen I, Gottrand F, et al. (2014). Dietary lipid intake only partially influences variance in serum phospholipid fatty acid composition in adolescents: impact of other dietary factors. *Lipids.* 49(9):881–93. <http://dx.doi.org/10.1007/s11745-014-3935-2> PMID:25119486
- Walsh L, Zhang W, Shore RE, Auvinen A, Laurier D, Wakeford R, et al. (2014). A framework for estimating radiation-related cancer risks in Japan from the 2011 Fukushima nuclear accident. *Radiat Res.* 182(5):556–72. <http://dx.doi.org/10.1667/RR13779.1> PMID:25251702
- Wang N, Tikellis G, Sun C, Pezic A, Wang L, Wells JC, et al. (2014b). The effect of maternal prenatal smoking and alcohol consumption on the placenta-to-birth weight ratio. *Placenta.* 35(7):437–41. <http://dx.doi.org/10.1016/j.placenta.2014.04.006> PMID:24816479
- Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, et al. (2014a). Rare variants of large effect in *BRCA2* and *CHEK2* affect risk of lung cancer. *Nat Genet.* 46(7):736–41. <http://dx.doi.org/10.1038/ng.3002> PMID:24880342
- Wang Y, Wei Y, Gaborieau V, Shi J, Han Y, Timofeeva MN, et al. (2015). Deciphering associations for lung cancer risk through imputation and analysis of 12 316 cases and 16 831 controls. *Eur J Hum Genet.* 23(12):1723–8. <http://dx.doi.org/10.1038/ejhg.2015.48> PMID:25804397
- Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, et al. (2014c). Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the *TERT-CLPTM1L* region on chromosome 5p15.33. *Hum Mol Genet.* 23(24):6616–33. <http://dx.doi.org/10.1093/hmg/ddu363> PMID:25027329
- Weiderpass E, Antoine J, Bray FI, Oh JK, Arbyn M (2014). Trends in corpus uteri cancer mortality in member states of the European Union. *Eur J Cancer.* 50(9):1675–84. <http://dx.doi.org/10.1016/j.ejca.2014.02.020> PMID:24656568
- Wessel J, Chu AY, Willems SM, Wang S, Yaghootkar H, Brody JA, et al.; EPIC-InterAct Consortium (2015). Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. *Nat Commun.* 6:5897. <http://dx.doi.org/10.1038/ncomms6897> PMID:25631608
- Wild C, Brennan P, Plummer M, Bray F, Straif K, Zavadil J (2015a). Cancer risk: role of chance overstated. *Science.* 347(6223):728. <http://dx.doi.org/10.1126/science.aaa6799> PMID:25656657
- Wild CP (2014). Cancer control: a reminder of the need for a balanced approach between prevention and treatment. *East Mediterr Health J.* 20(6):360–2. PMID:24960511
- Wild CP, Bray F, Forman D, Franceschi S, Sankaranarayanan R, Straif K (2014). Cancer in the 25×25 non-communicable disease targets. *Lancet.* 384(9953):1502–3. [http://dx.doi.org/10.1016/S0140-6736\(14\)61918-8](http://dx.doi.org/10.1016/S0140-6736(14)61918-8) PMID:25390574
- Wild CP, Bucher JR, de Jong BW, Dillner J, von Gertten C, Groopman JD, et al. (2015b). Translational cancer research: balancing prevention and treatment to combat cancer globally. *J Natl Cancer Inst.* 107(1):353. <http://dx.doi.org/10.1093/jnci/dju353> PMID:25515230



- Wolpin BM, Rizzato C, Kraft P, Kooperberg C, Petersen GM, Wang Z, et al. (2014). Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. *Nat Genet.* 46(9):994–1000. <http://dx.doi.org/10.1038/ng.3052> PMID:25086665
- Wozniak MB, Brennan P, Brenner DR, Overvad K, Olsen A, Tjønneland A, et al. (2015a). Alcohol consumption and the risk of renal cancers in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer.* 137(8):1953–66. <http://dx.doi.org/10.1002/ijc.29559> PMID:25866035
- Wozniak MB, Scelo G, Muller DC, Mukeria A, Zaridze D, Brennan P (2015b). Circulating microRNAs as non-invasive biomarkers for early detection of non-small-cell lung cancer. *PLoS ONE.* 10(5):e0125026. <http://dx.doi.org/10.1371/journal.pone.0125026> PMID:25965386
- Wu C, Kraft P, Stolzenberg-Solomon R, Stepulowsk E, Brotzman M, Xu M, et al. (2014). Genome-wide association study of survival in patients with pancreatic adenocarcinoma. *Gut.* 63(1):152–60. <http://dx.doi.org/10.1136/gutjnl-2012-303477> PMID:23180869
- Xu QF, Pan YW, Li LC, Zhou Z, Huang QL, Pang JC, et al. (2014). MiR-22 is frequently downregulated in medulloblastomas and inhibits cell proliferation via the novel target *PAPST1*. *Brain Pathol.* 24(6):568–83. <http://dx.doi.org/10.1111/bpa.12136> PMID:24576181
- Yang Y, Sun JW, Zhao LG, Bray F, Xiang YB (2015). Quantitative evaluation of hepatitis B virus mutations and hepatocellular carcinoma risk: a meta-analysis of prospective studies. *Chin J Cancer Res.* 27(5):497–508. PMID:26543337
- Zamora-Ros R, Forouhi NG, Sharp SJ, González CA, Buijsse B, Guevara M, et al. (2014a). Dietary intakes of individual flavanols and flavonols are inversely associated with incident type 2 diabetes in European populations. *J Nutr.* 144(3):335–43. <http://dx.doi.org/10.3945/jn.113.184945> PMID:24368432
- Zamora-Ros R, Guinó E, Henar Alonso M, Vidal C, Barenys M, Soriano A, et al. (2015b). Dietary flavonoids, lignans and colorectal cancer prognosis. *Sci Rep.* 5:14148. <http://dx.doi.org/10.1038/srep14148> PMID:26369380
- Zamora-Ros R, Luján-Barroso L, Bueno-de-Mesquita HB, Dik VK, Boeing H, Steffen A, et al. (2014b). Tea and coffee consumption and risk of esophageal cancer: the European Prospective Investigation into Cancer and Nutrition study. *Int J Cancer.* 135(6):1470–9. <http://dx.doi.org/10.1002/ijc.28789> PMID:24535727
- Zamora-Ros R, Rinaldi S, Biessi C, Tjønneland A, Halkjaer J, Fournier A, et al. (2015a). Reproductive and menstrual factors and risk of differentiated thyroid carcinoma: the EPIC study. *Int J Cancer.* 136(5):1218–27. <http://dx.doi.org/10.1002/ijc.29067> PMID:25041790
- Zamora-Ros R, Sacerdote C, Ricceri F, Weiderpass E, Roswall N, Buckland G, et al. (2014c). Flavonoid and lignan intake in relation to bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Br J Cancer.* 111(9):1870–80. <http://dx.doi.org/10.1038/bjc.2014.459> PMID:25121955
- Zamora-Ros R, Shivappa N, Steck SE, Canzian F, Landi S, Alonso MH, et al. (2015c). Dietary inflammatory index and inflammatory gene interactions in relation to colorectal cancer risk in the Bellvitge colorectal cancer case-control study. *Genes Nutr.* 10(1):447. <http://dx.doi.org/10.1007/s12263-014-0447-x> PMID:25488145
- Zamora-Ros R, Touillaud M, Rothwell JA, Romieu I, Scalbert A (2014d). Measuring exposure to the polyphenol metabolome in observational epidemiologic studies: current tools and applications and their limits. *Am J Clin Nutr.* 100(1):11–26. <http://dx.doi.org/10.3945/ajcn.113.077743> PMID:24787490
- Zaridze D, Lewington S, Boroda A, Scélo G, Karpov R, Lazarev A, et al. (2014). Alcohol and mortality in Russia: prospective observational study of 151,000 adults. *Lancet.* 383(9927):1465–73. [http://dx.doi.org/10.1016/S0140-6736\(13\)62247-3](http://dx.doi.org/10.1016/S0140-6736(13)62247-3) PMID:24486187
- Zhang C, Doherty JA, Burgess S, Hung RJ, Lindström S, Kraft P, et al.; GECCO and the GAME-ON Network: CORECT, DRIVE, ELLIPSE, FOCI, and TRICL (2015a). Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study. *Hum Mol Genet.* 24(18):5356–66. <http://dx.doi.org/10.1093/hmg/ddv252> PMID:26138067
- Zhang L, Samad A, Pombo-de-Oliveira MS, Scelo G, Smith MT, Feusner J, et al. (2015b). Global characteristics of childhood acute promyelocytic leukemia. *Blood Rev.* 29(2):101–25. <http://dx.doi.org/10.1016/j.blre.2014.09.013> PMID:25445717
- Zheng W, McLerran DF, Rolland BA, Fu Z, Boffetta P, He J, et al. (2014). Burden of total and cause-specific mortality related to tobacco smoking among adults aged  $\geq 45$  years in Asia: a pooled analysis of 21 cohorts. *PLoS Med.* 11(4):e1001631. <http://dx.doi.org/10.1371/journal.pmed.1001631> PMID:24756146
- Znaor A, Lortet-Tieulent J, Jemal A, Bray F (2014). International variations and trends in testicular cancer incidence and mortality. *Eur Urol.* 65(6):1095–106. <http://dx.doi.org/10.1016/j.eururo.2013.11.004> PMID:24268506
- Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F (2015a). International testicular cancer incidence trends: generational transitions in 38 countries 1900–1990. *Cancer Causes Control.* 26(1):151–8. <http://dx.doi.org/10.1007/s10552-014-0486-z> PMID:25388800
- Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F (2015b). International variations and trends in renal cell carcinoma incidence and mortality. *Eur Urol.* 67(3):519–30. <http://dx.doi.org/10.1016/j.eururo.2014.10.002> PMID:25449206
- Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F (2015c). Reply from authors re: Mehrad Adibi, Jose A. Karam, Christopher G. Wood. Reporting geographic and temporal trends in renal cell carcinoma: why is this important? *Eur Urol* 2015;67:531–2: Tackling inequalities in renal cell carcinoma. *Eur Urol.* 67(3):532–3. <http://dx.doi.org/10.1016/j.eururo.2014.11.008> PMID:25465971
- Znaor A, van den Hurk C, Primic-Zakelj M, Agius D, Coza D, Demetriou A, et al. (2015d). Reprint of: Cancer incidence and mortality patterns in South Eastern Europe in the last decade: gaps persist compared with the rest of Europe. *Eur J Cancer.* 51(9):1199–200. <http://dx.doi.org/10.1016/j.ejca.2015.05.003>